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Agonists of inhibitory serotonin 1A receptors (5-HT1AR) may have therapeutic potential 
for their ability to enhance and stabilize respiration These effects are suggested to be 
mediated by inhibition of inhibitory interneurons of the respiratory control network. 
However, precise effects of selective 5-HT1AR agonism on this network are poorly 
understood. The main aim of the thesis was to establish the effects of systemic 5-HT1AR 
transmission on respiratory motor drives, during rest and homeostatic respiratory 
reflexes, as generated by the intact respiratory control network in rats.  
Systemic administration of selective 5-HT1AR agonist NLX-101 in rats in situ resulted in: 
enhanced respiratory rate due to shortening of the expiratory phase; promoted late-
expiratory abdominal activity; and enhanced respiratory patterns in phrenic and 
abdominal, but not hypoglossal and vagal nerve motor outputs. Homeostatic respiratory 
reflex responses were not altered by systemic NLX-101. Fluorescent in situ hybridization 
indicated that 5-HT1AR RNA is present in SLC32A1-positive (i.e. glycinergic and/or 
GABAergic) neurones and SLC32A1-negative neurones, broadly distributed across key 
regions of the respiratory control network. Extracellular recordings of functionally 
identified respiratory neurones in the ventral respiratory column, combined with juxta-
cellular pico-ejection of NLX-101, indicated that 5-HT1A R expressing neurones are also 
broadly distributed across functional subpopulations of respiratory neurones.  
The broad expression of 5-HT1AR across anatomical regions and functional subpopulations 
of respiratory neurones indicates that the observed enhanced respiratory drive after 
systemic 5-HT1A transmission is likely an emergent network effect mediated by action at 
multiple neurone populations and mechanisms throughout the respiratory network. 
Based on the signature of functional effects of systemic NLX-101, I propose several 
candidate contributing mechanisms.  
The thesis contributes to establishing the role of 5-HT1AR in respiratory control, and 
ultimately, the therapeutic potential of 5-HT1AR transmission in the reversal of opioid 
induced respiratory depression and the treatment of respiratory control disorders such 
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Chapter 1: GENERAL INTRODUCTION 
1.1 GENERAL OVERVIEW 
Oxygen and carbon dioxide homeostasis are essential to life for two reasons. First, every 
cell in your body requires O2 for the formation of adenosine triphosphate through aerobic 
metabolism. Second, the CO2 produced in this process promotes hypercapnic acidosis. 
Acidosis, too, influences cellular functions throughout the body, and only a limited pH 
range is compatible with life. Respiration, along with blood circulation, is one of two 
principle processes though which O2 enters, and CO2 exits the bloodstream, and blood gas 
homeostasis is maintained (Davies and Moores, 2010).  
Central control of respiration involves a semi-autonomous neural network in the 
brainstem known as a central pattern generator (CPG). The generation of respiratory 
rhythm in this network involves dynamic modulation from other brainstem regions in the 
medulla and pons, and from central and peripheral chemo-, and mechanoreceptor 
afferents in order to continuously adapt respiratory activity to changing metabolism and 
maintain blood-gas-, and acid-base homeostasis. Optimal homeostasis requires dynamic 
pulmonary gas exchange, with matched control of blood perfusion. Therefore, not 
surprisingly, respiratory control is coupled to sympathetic cardiovascular control. The 
various neural network interactions involved in sympathetic and respiratory control are 
modulated by a variety of neurotransmitters. Serotonergic transmission has been of 
interest for its apparent role in respiratory control in health and disease. This thesis 
concerns the role serotonin 1A receptor (5-HT1AR) transmission in eupnoeic (healthy, 
resting state) respiratory control and chemoreceptor-mediated respiratory and 
sympathetic reflexes from a systems neuroscience perspective.  
The present ‘General Introduction’ addresses the current understanding of the brainstem 
network interactions underlying respiratory and sympathetic control which are relevant 
to the aims of this thesis. Section 1.2 describes the phases of the respiratory cycle as 
categorised by neural and motor activity patterns, and it discusses the core CPG neural 
network interactions thought to underlie these patterns. Subsequent sections describe 
modulation of respiratory CPG activity through mechanisms that affect respiratory phase 
transitioning (section 1.3), and through feedback from central chemoreceptors (section 
1.4) and peripheral chemoreceptors (section 1.5). Section 1.6 describes neural 
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mechanisms by which respiratory control is coupled to sympathetic control. Modulation 
of respiratory activity by serotonergic transmission, specifically by 5-HT1AR transmission, 
is addressed in section 1.7. Section 1.8 addresses therapeutic potential of 5-HT1A 
transmission in the treatment of respiratory control disorders. Ultimately, thesis aims and 
hypotheses are outlined in section 1.9. 
1.2 GENERATION OF THE RESPIRATORY RHYTHM 
1.2.1 Phases of the respiratory cycle, cognate peripheral nerve outputs, and their 
physiological significance 
The eupnoeic respiratory cycle consists of three phases.  
Eupnoea, or normal restful breathing is typically described as a cyclic sequence that can 
be divided into three phases: inspiration (I); post-inspiration (Post-I), which is the first 
stage of expiration; and a second expiratory phase (E2). Each of these phases is marked 
by distinct activity patterns of respiratory control centres in the brainstem, and of cranial 
and spinal nerves (Smith et al., 2013, Dhingra et al., 2020).  
 
Motor patterns of the respiratory cycle and their physiological significance. 
Cranial and spinal nerves drive activity of two functionally distinct groups of muscles: 
those controlling thoracic pressure and those controlling upper airway resistance. An 
overview of motor and sympathetic nerve activity patterns over the course of the various 
phases of the respiratory cycle is presented in figure 1-1A. During eupnoea in mammals, 
the main pump muscle activated with every single inspiration is the diaphragm, which is 
innervated by the phrenic nerve (PN). Activity in the PN can be recorded as an appropriate 
surrogate for the determination of the neural phase of inspiration (Dutschmann et al., 
2014b). Upper airway resistance is largely determined by laryngeal adductor and abductor 
muscles, and by the genioglossus muscle. The former two are innervated by the recurrent 
laryngeal nerve (RLN), which is a branch of the cervical vagus nerve (cVN). The 
genioglossus muscle is innervated by the hypoglossal nerve (HN). An increase in HN 
activity immediately prior to, and during, inspiration results in a stabilization of the airway, 
thereby preventing its collapse under negative inspiratory pressure (Bailey, 2011). In 
eupnoeic breathing, expiratory airflow is driven by release of the potential energy stored 
in the contracted diaphragm as it returns to its former position, as well as by recoil of the 
expanded lung tissue and chest wall. Post-I is an early expiratory phase that spans the 
transition between inspiration and E2 phases. During post-I phase, laryngeal adductor 
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muscles contract to counteract passive expiratory airflow and thereby control its pattern 
and duration. This activity slows the release of air during early stages of expiration and 
controls time for gas exchange in the lungs. Post-I activity is usually determined from 
recordings of the cervical vagal nerve (cVN) or the recurrent laryngeal nerve (Dutschmann 
et al., 2014b). During post-I, low amplitude discharge is also observed in the lower 
branches of thoraco-abdominal nerves (T13-L1, hencerforth referred to as AbN), including 
the iliohypogastric, which innervate the transverse abdominal muscles (Abdala et al., 
2009). The second stage of expiration (E2) is largely a passive process at rest. However, in 
conditions of high metabolic demand, e.g. during exercise, abdominal expiratory 
contraction emerges during the E2 phase, in association with reduced upper airway 
resistance and increased sympathetic outflow (Abdala et al., 2009, de Britto and Moraes, 
2017, Molkov et al., 2011). This activity, referred to as late expiration (Late-E),  decreases 
lung volume below functional residual capacity so that the inspiratory volume of the 
subsequent breathing cycle can be increased (Abdala et al., 2009). Late-E motor activity, 
like abdominal post-I activity, can be recorded from the lower branches of thoraco-
abdominal nerves (T13-L1). Late-E sympathetic activity can be recorded at nerves of the 
thoracic sympathetic trunk (tSN).  
Respiratory neurones are named based on their discharge patterns relative to the 
respiratory cycle 
Extracellular and single cell recordings reveal that the above respiratory phases and motor 
outputs are reflected in rhythmic activity patterns of distinct functional subpopulations of 
respiratory neurones in the brainstem (Segers et al., 2008, Alheid and McCrimmon, 2008, 
Smith et al., 2007, Schwarzacher et al., 1991, Ezure, 1990). These respiratory 
subpopulations are typically named based on the respiratory phase during which they 
display peak activity, as well as the patterning of their discharge (e.g. incrementing or 
decrementing). The following functional subpopulations can be identified among 
neurones involved in respiratory control: pre-inspiratory and inspiratory (pre-I/I) phase 
spanning neurones, whose discharge starts shortly prior to inspiration and proceeds into 
early phases of inspiration; early-inspiratory (Early-I) neurones; incrementing, or ramping 
inspiratory (Ramp-I) neurones; post-inspiratory (Post-I) neurones, which have a 
decrementing discharge pattern that spans the Post-I phase only; decrementing 
expiratory (Dec-E) neurones, which are similar to Post-I neurones but their discharge 
spans the Post-I and E2 phases; incrementing, or augmenting expiratory (Aug-E) 
neurones, which show peak activity during E2; and late-expiratory (late-E) neurones. A 
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schematic representation of burst patterns of respiratory subpopulations relative to 
phases of the respiratory cycle is provided in Figure 1-1B. It should be noted that whether 
Post-I neurones (Richter, 1982) and Dec-E neurones (Manabe and Ezure, 1988) are indeed 
distinct populations is not clear, and the two populations are often pooled under the term 
‘Post-I neurones’ in the respiratory literature. In the same vein, although categorization 
by discharge pattern can facilitate intuitive understanding of neural network dynamics, it 
is important to always be aware that ‘populations’ of a shared functional phenotype 
should not be presumed homogenous. Neurones with a common discharge pattern can 





(A) Schematic representation of the eupnoeic respiratory and sympatho-respiratory pattern 
and rhythm as recorded from cranial and spinal motor nerves and the thoracic sympathetic 
trunk. Dotted lines represent late-E activity, which is absent in eupnoeic respiration, but 
emerges in conditions of high respiratory drive  (adapted from Dutschmann and Dick (2012)) 
(B) Schematic representation of discharge patterns relative to the respiratory cycle of various 
functional subtypes of respiratory neurones (adapted from Smith et al. (2013)). See text in 
section 1.2.1.for further detail. Abbreviations: HN = hypoglossal nerve; PN = phrenic nerve; cVN 
= cervical vagus nerve; RLN = recurrent laryngeal nerve; AbN = abdominal nerve; tSN = thoracic 
sympathetic nerve; Post-I = post-inspiratory neurones (or phase); Aug-E = augmenting 
expiratory neurones; Pre-I/I =  pre-inspiratory/inspiratory phase spanning neurones; Early-I = 
early inspiratory neurones; Ramp-I = ramping inspiratory neurones. 
Figure 1-1: Eupnoeic respiratory and sympatho-respiratory activity patterns in peripheral nerves 
and in respiratory neurone populations. 
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1.2.2 Principle mechanisms of rhythm generating neural networks 
The respiratory motor outputs associated with each respiratory phase are generated by a 
central pattern generator (CPG). CPG’s are neural networks that generate a behaviourally 
relevant rhythmic pattern of activity, even when isolated from all other central and 
peripheral rhythmic inputs (Bucher et al., 2015). CPGs exist for most, if not all, rhythmic 
motor behaviors in invertebrates and vertebrates (e.g. walking, flying, swimming, feeding 
behaviours, enteric rhythms, respiration) (Bucher et al., 2015, Marder and Bucher, 2001). 
Despite the diversity of animals and behaviours in which CPGs are involved, it appears 
CPG networks commonly adhere to either or both of two principal mechanisms for rhythm 
generation. Firstly, many CPGs rely on so called ‘pacemaker neurones’ to drive 
autorhythmic activity. Such pacemaker neurones have intrinsic properties by which they 
produce oscillations of the membrane potential that usually result in action potentials. 
Often, such pacemaker neurones are co-active with non-pacemaker neurones through 
excitatory synapses or gap junctions, giving rise to so called ‘pacemaker groups’ (Bucher 
et al., 2015). A second common mechanism is that rhythmicity can emerge from synaptic 
interactions of neurones that do not necessarily show oscillatory properties in isolation. 
Such emergent network rhythmicity is often a function of reciprocal synaptic inhibition 
between neurones, combined with post-inhibitory rebound properties of CPG neurones 
and/or excitatory drives, which results in alternating bouts of activity and suppression 
(Bucher et al., 2015). Over a century ago, Brown (1911) suggested that the alternate 
flexion and extension of leg muscles in walking could be produced by rhythmic central 
circuits in which the antagonistic muscles were driven by neurones that inhibited each 
other. This concept was later developed into the notion of ‘inhibitory half-centre 
oscillators’, i.e. two or more neurones, or synchronized neurone populations, that make 
reciprocally inhibitory synaptic connections and produce out-of-phase rhythmic 
oscillations. Both pacemaker driven CPGs and inhibitory half-centre oscillators are capable 
of generating rhythmic activity independently, but it is important to note that the two 
mechanisms are not mutually exclusive, and both can contribute to rhythm generation in 
a CPG network. 
1.2.3 The respiratory central pattern generator (CPG) 
The mechanistic underpinnings of rhythm generation in the respiratory CPG is a topic of 
ongoing debate. Most current evidence suggests that rhythmic activity in the respiratory 
CPG is likely shaped by a combination of both pacemaker neurones, as well as emergent 
network properties.  
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Auto-rhythmic populations in the respiratory CPG 
The core circuitry of the mammalian respiratory CPG is located in a bilateral ventral 
respiratory column (VRC) in the ventrolateral medulla. The VRC is a collection of brainstem 
nuclei involved in respiratory control organized in a rostral-to-caudal orientation (see 
figure 1-2A). Expiratory populations involved in rhythm generation are concentrated in 
rostral regions of the VRC: the parafacial respiratory group (pFRG, contains late-E 
neurones) (Abdala et al., 2009, Moraes et al., 2013, Silva et al., 2016, Pagliardini et al., 
2011); the post-inspiratory complex (PiCo, contains Post-I neurones) (Anderson et al., 
2016); and the Bötzinger Complex (BötC, contains Post-I and Aug-E neurones) (Alheid and 
McCrimmon, 2008, Segers et al., 2008, Tian et al., 1999, Ezure et al., 1988). Inspiratory 
rhythmogenic VRC populations (Pre-I/I and Early-I) are concentrated in the pre-Bötzinger 
complex (pre-BötC) (Smith et al., 1991, Guyenet and Wang, 2001, Sun et al., 1998, Alheid 
and McCrimmon, 2008, Ezure et al., 1988). Most caudally, the rostral-, and caudal ventral 
respiratory group (RVRG and CVRG) contain transmission circuitry which relays inputs 
from rhythmogenic populations to various (pre-)motor neurones (Ezure et al., 1988, 
Alheid and McCrimmon, 2008). In rats and mice, three of the above VRC regions – the 
pFRG, the PiCo, and the pre-BötC – are reported to contain neurone populations with 
autonomous rhythm generating properties. The pFRG contains auto-rhythmic 
glutamatergic neurones that are thought to be suppressed during eupnoeic breathing, but 
that generate rhythmic activity in conjunction with AbN late-E activity under specific 
conditions (e.g. conditions of high respiratory drive (Pagliardini et al., 2011, Abdala et al., 
2009, Huckstepp et al., 2015). The PiCo is a region with auto-rhythmic glutamatergic-
cholinergic neurones that fire in phase with Post-I motor output (Anderson et al., 2016). 
Lastly, the pre-BötC contains auto-rhythmic glutamatergic neurones derived from 
developing brain homeobox protein 1 (Dbx1) expressing progenitor cells that are essential 
for inspiratory rhythm generation (Smith et al., 1991, Gray et al., 2010).  
By far the most research on putative mechanisms underlying autorhythmic populations 
in the respiratory CPG has focused on the pre-BötC. Nonetheless, the mechanisms 
underlying auto-rhythmic inspiratory activity in the pre-BötC remains subject of debate 
(Del Negro et al., 2018, Ramirez and Baertsch, 2018b, Phillips et al., 2019) Pacemaker 
theories (Del Negro et al., 2010, Toporikova and Butera, 2011, Phillips et al., 2019) assume 
that persistent sodium currents (INaP) and calcium activated nonselective cation currents 
(ICAN), drive slow-wave oscillations of the membrane potential of excitatory pacemaker 
neurones in the pre-BötC, resulting in their endogenous rhythmic bursting. These 
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pacemaker neurones, combined with recruitment of additional excitatory neurones, are 
believed to form a pacemaker group with a pre-I/I discharge pattern that provides the 
principal auto-rhythmic excitatory drive for inspiratory rhythm generation. Alternatively, 
the ‘burstlet theory’ (Kam et al., 2013a, Feldman and Kam, 2015) posits that burst 
associated conductances are important for robust inspiratory activity, but that Pre-I/I 
bursts are not themselves auto-rhythmic. Rather, the principle auto-rhythmic mechanism 
underlying inspiration is reflected in low frequency Pre-I burstlets observed through field 
potential recordings of the pre-BötC in rhythmic brain slice preparations of mice and in 
rats in vivo, which may or may not develop into higher frequency pre-I/I bursts that 
propagate to other regions in the CPG (Kam et al., 2013a, Kam et al., 2013b). The 
mechanisms underlying burstlet generation, as well as those underlying development of 
burstlets into bursts remain to be determined. It has been suggested that burstlets are 
generated by synchronization of convergent subsets of excitatory neurones through 
emergent network properties in the pre-BötC microcircuitry (Kam et al., 2013b, Feldman 
and Kam, 2015). Development of burstlets into bursts is suggested to be a threshold 
process involving INaP and ICAN and the recruitment of additional neurones (Feldman and 
Kam, 2015, Del Negro et al., 2018). Thus, burstlet theory posits that pre-I burstlets and 
bursts are separable components. Inspiratory bursts are triggered by burstlets, and only 
the latter is a true auto-rhtyhmic activity. 
Current theories on the coordination of multiphasic respiratory activity  
Despite being important rhythmogenic microcircuits, neither the pFRG, the PiCo, nor the 
pre-BötC can generate multiphasic respiratory activity in isolation. To generate 
multiphasic respiratory activity, the respiratory CPG must coordinate rhythmic alternation 
of the respiratory phases and activities (I, Post-I, E2 or late-E) within each respiratory 
cycle. The two prevailing theories on the coordination of multiphasic respiratory activity 
are the inhibitory ring model (Rybak et al., 2004, Rybak et al., 2007, Smith et al., 2007, 
Smith et al., 2009, Smith et al., 2013), and the triple oscillator theory (Anderson et al., 
2016, Anderson and Ramirez, 2017, Ramirez and Baertsch, 2018a). 
The inhibitory ring model posits that the coordination of alternating inspiratory and 
expiratory activities in eupnoeic breathing is mediated by antagonistic interactions 
between specific functional subpopulations of respiratory neurones in the fashion of an 
inhibitory half-centre oscillator. This model hypothesises that the minimal network 
architecture of the VRC rhythmogenic circuitry can be described as an auto-rhythmic Pre-
I/I population of glutamatergic neurones observed in the pre-BötC (Gray et al., 2010, 
Chapter 1: General Introduction 
8 
 
Bouvier et al., 2010), which is interconnected to three GABA-ergic and glycinergic 
respiratory subpopulations that form a ring of mutually inhibiting neurones comprising 
Post-I and Aug-E neurones in the BötC (Alheid and McCrimmon, 2008, Burke et al., 2010, 
Smith et al., 2007), and Early-I neurones in the pre-BötC (Winter et al., 2009, Morgado-
Valle et al., 2010, Kuwana et al., 2006, Koizumi et al., 2013) (see Figure 1.2B). The three 
phases of eupnoeic respiration (I, Post-I, E2) are marked by predominant activity of either 
of the three neurone populations in the inhibitory ring (Early-I, Post-I, and Aug-E, 
respectively). Inhibitory neurones of the BötC and pre-BötC (notably Post-I and Early-I 
neurones) are suggested to also contribute to the suppression of the pFRG auto-rhythmic 
late-E activity during eupnoeic breathing (Barnett et al., 2018, Flor et al., 2020) (via 
mechanisms discussed in section 1.4.4). Onset of inspiration is suggested to be mediated, 
in part, by the interplay between glutamatergic (auto-rhythmic and other) populations in 
the pre-BötC and inhibitory drive to the pre-BötC from expiratory populations in the BötC 
(Smith et al., 2013, Marchenko et al., 2016) . Rhythmic excitatory drive from the pontine 
parabrachial complex to Post-I neurones in the VRC is suggested to play an important role 
in inspiratory to expiratory phase transitioning (Dutschmann and Dick, 2012, Molkov et 
al., 2013) (via mechanisms discussed in section 1.3).  
Multi-level computational simulations of the inhibitory ring model are able to generate 
rhythmic activity patterns at the level of individual neurones and at the network level 
(motor outputs) that are consistent with experimentally observed eupnoeic respiratory 
activity patterns (Smith et al., 2007), respiratory reflex responses (Barnett et al., 2017, 
Molkov et al., 2013), and responses to various experimental manipulations of the CPG 
(Shevtsova et al., 2011, Shevtsova et al., 2014, Richter and Smith, 2014, Smith et al., 2007, 
Dhingra et al., 2019) in rats and mice in vivo, and in in situ working heart-brainstem 
preparations (WHBP) of mice and rat. In situ WHBP are decerebrated, pO2 and pCO2 
clamped preparations of rats and mice on cardio-pulmonary bypass which allow 
simultaneous recordings of brainstem neurones and of multiple cranial and spinal nerve 
outputs generated by the intact, unanaesthetised respiratory CPG (Paton, 1996b). The 
model’s assumptions on how distinct populations in various pontine and medullary 
anatomical regions contribute to the coordination of respiratory phases is also consistent 
with the spatio-temporal activity pattern observed in field potential recordings with multi-
electrode arrays spanning the entire respiratory CPG network in in situ WHBP (Dhingra et 
al., 2020). Experiments to test the role of inhibition in the VRC as postulated in the 
inhibitory ring model have predominantly employed pharmacological and optogenetic 
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manipulations of glycinergic and/or GABAergic transmission, or activity of glycinergic 
and/or GABAergic neurones in either the BötC or the pre-BötC in rats and mice in vivo or 
in in situ WHBP. Generally, the hypothesis in such experiments is that inhibitory 
transmission in the pre-BötC and/or activity of inhibitory neurones in the BötC each 
promote expiratory (Post-I and E2) activity and supress inspiratory activity. Conversely, 
inhibitory transmission in the BötC, and activity of inhibitory neurones in the pre-BötC are 
hypothesised to promote inspiratory activity and suppress expiratory activity. Multiple 
such pharmacological (Bongianni et al., 2010, Pierrefiche et al., 1998, Marchenko et al., 
2016) and optogenetic (Ausborn et al., 2018, Sherman et al., 2015, Alsahafi et al., 2015) 
studies report findings in rats, mice, cats, and rabbits in vivo and in situ that are consistent 
with the above hypothesis. Nonetheless, the role of inhibitory transmission in the 
coordination of respiratory phases is disputed. Marchenko et al. (2016) and Janczewski et 
al. (2013) performed identical manipulations of pharmacological excitation, inhibition, 
and blockade of inhibition in either the BötC or the pre-BötC in anesthetised rats in vivo 
in which peripheral feedback to the respiratory CPG was removed through 
vagotomisation. Whereas findings of the former study are consistent with the general 
hypothesis described above, Janczewski et al. (2013) report that disruption of inhibitory 
transmission has no significant effect on respiratory rhythm generation in the absence of 
peripheral feedback. This discrepancy is not readily resolved and remains to be further 
explored in future studies. Perhaps the greatest obstacle in the verification of the 
inhibitory ring model, however, is that the hypothesised connectivity of functional 
subpopulations in the VRC remains to be mapped experimentally. This is partly because 
the relevant functional subpopulations are, as yet, not exclusively associated with specific 
biochemical markers that can be utilized in connectivity studies.  
An alternative model of the respiratory CPG, although with a similar principal network 
structure, is the triple oscillator theory. The triple oscillator theory (Anderson and 
Ramirez, 2017) was proposed in response to the recent discovery of auto-rhtyhmic 
excitatory Post-I neurones in the PiCo (Anderson et al., 2016). This theory assumes that 
the three autorhythmic populations in the respiratory CPG – the pre-BötC, the PiCo, and 
the pFRG - each provide excitatory drive for I, Post-I and late-E activity, respectively. 
Similar to the inhibitory ring model, each of these respiratory phases and activities are 
marked by dominance of its cognate rhythmogenic populations, which is suggested to be 
coordinated through reciprocal inhibitory connections between the three oscillators (see 
figure 1-2C). In conditions of eupnoeic respiratory drive, activity of the pFRG remains 
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suppressed by inhibition from both inspiratory and Post-I neurone populations. 
Optogenetic activation of cholinergic (ChAT-positive) PiCo neurones delays the onset of 
the subsequent inspiratory burst in vivo in mice (Anderson et al., 2016). Conversely, in in 
vitro horizontal slice preparations that encompass the VRC of mice, inspiratory Dbx1-
positive pre-BötC neurones simultaneously inhibit and excite PiCo neurones via 
GABAergic and glutamatergic transmission, with inhibitory drive being dominant 
(Anderson et al., 2016). These findings are consistent with the theory’s hypothesis that 
temporal coordination of inspiratory and expiratory activity is mediated by mutually 
inhibitory interactions between PiCo and pre-BötC populations. The mutually inhibitory 
interactions between PiCo and the pFRG, as proposed in the triple oscillator theory, 
remain to be experimentally verified. 
The triple oscillator theory and the inhibitory ring model both emphasise the role of 
reciprocal inhibitory connections between inspiratory and expiratory populations in the 
coordination of multiphasic respiratory activity. Despite their shared features, there are 
also notable contrasts between the inhibitory ring model and the triple oscillator theory. 
A key difference is that the triple oscillator theory emphasizes the role of auto-rhythmic 
PiCo neurones as an independent source of excitatory drive for Post-I activity. In contrast, 
current iterations of the inhibitory ring model do not incorporate the PiCo, but emphasize 
the role of ponto-medullary interactions as a source of excitatory drive to BötC Post-I 
neurones. Furthermore, the triple oscillator theory does not account for the E2 
respiratory phase or its neurophysiological correlates (Aug-E neurone activity). 
Nonetheless, the two theories are theoretically reconcilable. The existence of auto-
rhythmic excitatory Post-I neurones is not principally incompatible with the inhibitory ring 
model. PiCo neurones could hypothetically contribute to inspiratory-to-expiratory phase 
transitioning through excitatory drive to inhibitory BötC post-I interneurones, directly or 
via pontine circuitry. Likewise, the network structure of the triple oscillator theory does 
not preclude implementation of mutually inhibitory interactions between Post-I and Aug-
E neurones that could account for the experimentally observed antagonistic activity 
patterns of these respiratory subpopulations (Tian et al., 1999). Further exploring the role 
of the PiCo in respiratory control will be important in determining the mechanisms 
underlying coordination of multiphase respiratory activity, and in exploring if the 
inhibitory ring model and the triple oscillator theory can be integrated.  
To conclude, the mechanisms underlying respiratory rhythmogenesis are a topic of 
ongoing debate. Primary components of respiratory rhythms likely originate from an 
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interplay of glutamatergic autorhythmic populations and emergent network properties. 
Phasic synaptic inhibition appears to be critically involved in coordinating these drives and 
shaping the three-phase pattern of respiratory activity during normal breathing by 
controlling which populations are active and inactive during each phase. 
  
Schematic representations of: (A) key neuroanatomical regions of the respiratory CPG; (B) 
principal network interactions involved in the coordination multiphase respiratory activity 
according to the inhibitory ring model; or (C) according to the triple oscillator theory. See text in 
section 1.2.3 for a description of the anatomy and postulated network interactions. 
Abbreviations: PBc = parabrachial complex; KF = Kölliker-Fuse nucleus; pFRG = parafacial 
respiratory group; RTN = retrotrapezoid nucleus; VII = facial nucleus; PiCo = post-inspiratory 
complex; BötC = Bötzinger Complex; pre-BötC = pre-Bötzinger complex; RVRG = rostral ventral 
respiratory group; CVRG = caudal ventral respiratory complex; VRC = ventral respiratory column; 
NTS = nucleus tractus solitarius; Post-I = post-Inspiratory neurons; Pre-I/I = pre-
inspiratory/inspiratory phase spanning neurones; Early-I = early-inspiratory neurons; Aug-E 
=augmenting expiratory neurons; late-E = late-expiratory neurones. 
Figure 1-2: key brainstem regions of the respiratory CGP, and principle respiratory CPG network 
architecture according to the inhibitory ring model and the triple oscillator theory.  
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1.3 CONTROL OF RESPIRATORY PHASE TRANSITION 
The respiratory rhythm continuously adapts to changes in environment (informed by 
sensory input from e.g. chemoreceptors, mechanoreceptors, and nociceptors) and 
behaviour (e.g. mastication, swallowing, vocalization, coughing, sneezing, and diving 
reflex). One mechanism by which such adaptation occurs is through control of respiratory 
phase transitioning. The importance of mechanisms of phase transitioning is clearly 
illustrated in the case of Rett syndrome, a neurological disorder in which disruptions of 
phase transitioning mechanisms can promote potentially lethal forms of respiratory 
dysrhythmia (Abdala et al., 2014a, Ramirez et al., 2013) (discussed further in section 
1.8.2). The current section describes the Herring-Breuer reflex and interactions between 
the VRC and regions in the pontine parabrachial complex. These are two mechanisms 
which provide input to the core rhythmogenic circuitry in the VRC and act complementary 
to mediate the inspiratory-to-expiratory phase transition, and the duration of 
inspiratory-, and expiratory phases. 
1.3.1 The Hering-Breuer Reflex 
The Hering-Breuer reflex (HBR) is a lung inflation induced activation of pulmonary stretch 
(mechano-) receptors (PSR) that elicits termination of inspiration, facilitation of the post-
inspiratory respiratory phase, and prolongation of expiration (Clark and von Euler, 1972, 
Luck, 1970, Kubin et al., 2006). Simply put, the HBR acts to prevent over-inflation of the 
lungs. In rats, cats, and dogs PSR axons travel via the cVN to form excitatory synapses with 
excitatory and inhibitory pump cells in the nucleus tractus solitarius (NTS), which then 
relay PSR feedback to respiratory regions in the VRC and the pontine parabrachial 
complex. Experimental studies (reviewed in (Kubin et al., 2006, Dutschmann and Dick, 
2012)) and computational simulations based on the inhibitory ring model (Molkov et al., 
2013), suggest that PSR feedback promotes inspiratory-to-expiratory phase transition 
through NTS pump cell mediated excitation of Post-I neurones in the BötC, and inhibition 
of Early-I neurones in the pre-BötC. 
1.3.2 Pontine control of phase transition 
The pontine parabrachial complex (PBc) contains respiratory neurones that have been 
implicated in shaping the eupnoeic respiratory pattern and rhythm through the 
promotion of inspiratory-to-expiratory phase transition, much like the HBR. In in situ 
WHBP of rats, despite the lack of HBR feedback due to removal of the lungs and of vagal 
afferent inputs, a normal three-phase pattern of respiratory activity can be observed in 
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electrophysiological recordings of respiratory neurones and the cranial and spinal nerves 
relevant for respiratory motor activity. Neurones of the PBc were reported to 
demonstrate phase modulation of their firing patterns, and a substantial amount of these 
neurones showed activity patterns centred around inspiratory-to-expiratory phase 
transitions (Dhingra et al., 2020, Alheid et al., 2004). Further, transection of the PBc, which 
constitutes removal of pontine input to the medullary rhythmogenic circuitry, results in 
apneustic breathing in vagotomised in situ WHBP of neonatal (Dutschmann et al., 2000) 
or juvenile (Smith et al., 2007) rats.  
The PBc is a term used to describe the collective parabrachial nuclei (medial parabrachial 
nucleus; internal-, central-, and external parts of the lateral parabrachial nucleus) and the 
Kölliker-Fuse (KF) nucleus in the dorsolateral pons. The KF, in particular, plays an essential 
role in the suppression of inspiration and providing drive for Post-I activity. 
Pharmacological excitation or disinhibition of neurones in the KF parenchyma in the 
absence of pulmonary feedback, promotes tonic excitation of post-I activity in the cVN 
and/or the RLN, promotes premature termination of inspiration and inspiratory-to-
expiratory phase transitioning, and prolongs expiratory phase duration (Abdala et al., 
2016, Dutschmann and Herbert, 2006, Bonis et al., 2013, Barnett et al., 2018). 
Pharmacological inhibition of the KF in the absence of pulmonary feedback, on the other 
hand, prolongs inspiration and eliminates the post-I component of cVN activity 
(Dutschmann and Herbert, 2006, Levitt et al., 2015, Jenkin et al., 2017).  Tract tracing 
studies show that neurones in the KF and select nearby parabrachial nuclei (medial 
parabrachial nucleus, external part of the lateral parabrachial nucleus, and internal part 
of the lateral parabrachial nucleus) collectively are reciprocally connected to a multitude 
of respiratory areas such as the rhythmogenic areas in the VRC (BötC, pre-BötC, rVRG, and 
cVRG), and the NTS (Dutschmann and Dick, 2012, Ezure and Tanaka, 2006, Song et al., 
2015). Projections from the KF, specifically, to rhythmogenic VRC regions are thought to 
be mainly excitatory (Ezure and Tanaka, 2006, Geerling et al., 2017, Rosin et al., 2006). 
Based on the anatomy and functional interactions as described above, computational 
models based on the inhibitory ring model suggested that inputs from the PBc, and 
notably the KF, shape respiratory phase durations and inspiratory-to-expiratory phase 
transitioning through the activation of post-I and Aug-E neurones in the BötC, and 
inhibition of Early-I neurones in the pre-BötC (Molkov et al., 2013) (see figure 1-3). This 
was later supported by cross-correlational analysis of timing specific and response specific 
discharge patterns in response to electrical stimulation and/or pharmacological inhibition 
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performed among pairs of KF and BötC neuronal pools. The experiments confirmed an 
excitatory functional connection between neurones in the KF with an early expiratory 
(Early-E) discharge pattern that project to glycinergic Post-I neurones in the BötC (Song et 
al., 2015).  
  
  
Figure 1-3: Ponto-medullary interactions that mediate inspiratory-to-expiratory phase 
transitioning.  
Schematic representation projections from the KF to regions in the medullary VRC that mediate 
inspiratory-to-expiratory phase transitioning as suggested in a computational simulation based 
on the inhibitory ring model (Molkov et al., 2013). The schematics do not show the complete 
model but highlight selected elements of it for the sake of visual clarity.  See text of section 
1.3.2 for further details. Abbreviations: KF = Kölliker-Fuse; BötC = Bötzinger Complex, Pre-BötC 
= pre-Bötzinger Complex, Pre-I/I = pre-inspiratory/inspiratory phase spanning neurones; Early-
I = early inspiratory neurones; Aug-E = augmenting expiratory neurones; Post-I = post-
inspiratory neurones. 
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1.3.3 Interactions between peripheral feedback and PBc control 
Both peripheral and pontine controls described above appear to mediate the duration of 
respiratory phases and inspiratory-to-expiratory phase transitions via the same 
mechanisms: excitation of Post-I neurones in the BötC, and inhibition of Early-I neurones 
in the pre-BötC. The two mechanisms appear to interact. This notion is supported by the 
finding that activity of respiratory phase spanning neurones in the PBc is found to be 
increased in vagotomized animals or preparations (Feldman and Gautier, 1976, Dick et al., 
2008). Further, tract tracing studies that show the NTS and the parabrachial complex are 
reciprocally connected (reviewed in (Dutschmann and Dick, 2012)), and that GABAergic 
neurones of NTS are in contact with KF neurones projecting to the VRC in rats (Yokota et 
al., 2008). Computational simulations suggest that respiratory-modulated activity in the 
PBc may be suppressed by inhibitory pump cells in the NTS projecting to the pons (Molkov 
et al., 2013).  
Suppression of the ponto-medullary control loop by NTS pump cells suggests that the HBR 
may be the dominant mechanism to mediate respiratory phase transitions. However, 
experiments with vagal stimulation in in situ WHBP of rats across different stages of 
postnatal development show that, while neonates exhibit HBR stimulus-dependent 
prolongation of expiration, significant habituation occurs following repetitive vagal 
stimulation in preparations of juvenile rats (PND >16) (Dutschmann et al., 2014a, 
Dutschmann et al., 2009a). In light of this, it has been suggested that the HBR habituates 
during early development and that control of inspiratory-to-expiratory phase 
transitioning shifts from the HBR to ponto-medullary mechanisms during postnatal 
development (Dutschmann et al., 2014a, Dutschmann et al., 2009a). 
.  
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1.4 CENTRAL CHEMORECEPTOR FEEDBACK MECHANISMS IN RESPIRATORY CONTROL 
Respiratory pattern and rhythm generation is to a large extent controlled by feedback 
mechanisms in which chemoreceptor cells relay information regarding levels of O2, CO2 
and pH to brainstem regions of respiratory control. There are central and peripheral 
components to ventilatory chemoreflexes. The current section addresses the former and 
section 1.5, the latter.  
The respiratory central chemoreflex is defined as the process by which CO2, or 
hypercapnic acidification, in cerebrospinal fluid interacts with chemoreceptor cells in the 
brainstem and promotes augmented respiratory drive and enhanced sympathetic activity. 
Hypercapnic acidification is the result of the interconversion of CO2 and water into 
carbonic acid, protons, and bicarbonate ions. Enhanced respiratory drive in response to 
CO2 promotes an increase in lung ventilation, which contributes to the maintenance of 
O2/CO2/pH equilibrium through a wash out of CO2 and influx of O2. This increased lung 
ventilation occurs in conjunction with an increase in sympathetic activity that promotes 
vasoconstriction and enhanced cardiac output, which results in increased blood perfusion 
(this will be discussed in detail in section 1.6). Additionally, enhanced sympathetic activity 
can promote arousal, which can act to stimulate breathing (Kaur et al., 2013). Large, acute 
increases in partial pressure of arterial CO2 (paCO2) can lead to high arousal/panic 
responses, some of which are adaptive behaviours in the case of airway blockade (e.g. 
arousal from sleep, postural changes) (Taugher et al., 2014).  
The currently prevailing view is that the brainstem mediators of the respiratory central 
chemoreflex are concentrated in - though not exclusively to - the retrotrapezoid nucleus 
(RTN), and serotonergic (5-HT) neurones in the raphe nuclei. It should be noted that there 
are other CO2 chemosensitive cell populations that may modulate the hypercapnic 
respiratory response: noradrenergic neurones in the Locus Coeruleus (reviewed in 
Guyenet (2014)); Orexigenic neurones (reviewed in Carrive and Kuwaki (2017); and 
stimulation of respiratory neurones by CO2 dependent astrocyte activities (Beltran-
Castillo et al., 2017, Howarth et al., 2017, Wenker et al., 2010). This section will focus on 
the role of the RTN and of chemoreceptive serotonergic neurones in the hypercapnic 
respiratory response, which have been described in most detail and appear to provide a 
greater contribution to the overall ventilatory response to hypercapnia and/or low pH.   
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1.4.1 Central chemoreceptors in the RTN 
Anatomical location, phenotype, and connectivity of RTN chemoreceptor neurones 
The retrotrapezoid nucleus (RTN) is historically defined as a cluster of chemoreceptive 
cells in the region ventral and caudal to the facial nucleus (the ventral parafacial nucleus, 
pFV) . Recent phenotyping studies of the cells responsive to changes in CO2 in this region 
have helped more specifically define the RTN as a group of cells that express vesicular 
glutamate transporter 2 (VGluT2), transcription factor paired-like homeobox 2b (Phox2B), 
and neurokinin 1 (NK-1) receptors. They contain RNA transcripts for pituitary adenylate 
cyclase-activating peptide (PACAP) and Neuromedin B, and the majority of RTN neurones 
(>80%) also contain transcripts for TASK-2 and G-protein coupled receptor 4 (GPR4), 
proteins that contribute to their pH sensitivity. Furthermore, RTN neurones lack the 
defining markers of catecholaminergic, serotonergic, cholinergic, GABAergic, and 
glycinergic neurones. Axons of RTN neurones spread out to innervate various brainstem 
regions involved in respiratory rhythm generation, such as: the BötC, pre-BötC, RVRG, 
CVRG, NTS, and the KF (for review, see: Guyenet et al. (2019)). 
Physiological role of RTN neurones in the central chemoreflex respiratory response. 
The physiological role of RTN neurones as mediators of the respiratory hypercapnic 
response is well established and reviewed in Guyenet et al. (2019) and Guyenet and 
Bayliss (2015). This section provides a brief summary of some findings that demonstrate 
RTN chemosensitivity, and that RTN neurones drive breathing in proportion to paCO2.  
Single unit electrophysiological recordings of RTN neurones in anaesthetized rats show 
that the RTN neurone discharge pattern tracks the end-expiratory CO2 concentration (a 
proxy measure for paCO2), with higher firing frequencies as the CO2 concentrations of 
expired air increase. This effect is maintained after intracerebral administration of 
glutamate receptor antagonist (kynurenate) to eliminate excitatory input from other 
putative central and peripheral chemoreceptor sites (Mulkey et al., 2004).  Also, acute 
brain slices with RTN neurones from neonatal mice respond to acidification in the 
presence of synaptic blockers, and these neurones maintain pH sensitivity after acute 
dissociation (Mulkey et al., 2004, Onimaru et al., 2014). These findings suggest that RTN 
neurones respond to local brain pCO2, and likely have intrinsic CO2/pH sensitivity.  
Unilateral optogenetic stimulation of RTN neurones with Channelrhodopsin-2 (ChR2), a 
light sensitive depolarizing cation channel, expressed under a promoter selective of 
Phox2B expressing neurones (PRSx8) results in enhanced lung ventilation as observed in 
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plethysmography recordings of anesthetized rats (Burke et al., 2015). Conversely, bilateral 
inhibition of RTN neurones through optic stimulation of Arch2.0, a light-sensitive 
hyperpolarizing proton pump, of which expression was driven by the PRSx8 promotor, 
resulted in reduction of breathing when arterial pH was 7.44, but not when arterial pH is 
7.59. Arterial pH was manipulated by changing the fraction of inspired O2 (FiO2) or by 
systemic administration of acetazolamide, an inhibitor of carbonic anhydrase, an enzyme 
that assists interconversion of carbonic acid into water and carbon dioxide (Basting et al., 
2015). Transgenic Phox2b knockout mice (Phox2b27alacki;;Egr-2Cre mice) hypoventilate at 
rest and do not increase breathing rate when exposed to high concentrations of CO2 
(Ramanantsoa et al., 2011). Similarly, lesioning of RTN neurones in rats, via local injections 
of SSP-saporin (a toxin that eliminates cells expressing the NK-1 receptor, of which 
expression in the RTN/pFV region is unique to RTN neurones), leads to hypoventilation at 
rest, and a reduction in the hypercapnic ventilatory response in accordance with the 
percentage RTN neurones lesioned (Souza et al., 2018). Together, these findings indicate 
that RTN neurones mediate the central chemoreflex respiratory response.  
1.4.2 Central chemoreceptors in the raphe nuclei 
Serotonergic neurones are located in following anatomical regions in the mature rodent 
brain: the raphe pallidus (RPa); the raphe obscurus (ROb); the raphe magnus (RMg); 
periaqueductal grey structures; the pontine raphe; the dorsal raphe; the median raphe; 
and the medial lemniscus (Harding et al., 2004).  
Physiological role of serotonergic raphe neurones in the central chemoreflex respiratory 
response. 
The above regions are derived from several embryonic rhombomeres of the neural tube. 
Brust et al. (2014) performed a series of pharmacogenetic experiments in which various 
5-HT populations defined by embryonic origin, were each selectively inhibited in mice 
through activation of hyperpolarizing ‘designer receptors exclusively activated by 
designer drugs’ (DREADD) hM4Di (a Gi/o protein-coupled receptor with selectivity for a 
biologically inert synthetic ligand), upon which the hypercapnic response was queried in 
vivo via plethysmography recordings in room air (0% FiCO2) vs. hypercapnic air (5% FiCO2). 
The authors demonstrated that exclusively Egr2-, and Pet1-positive (Egr2-Pet1) 
serotonergic neurones derived from rhombomeres 3 and 5 (r3/r5) were necessary for the 
full hypercapnic response in vivo in awake adult mice. Patch clamp recordings in acute 
brain slices in the presence of synaptic blockers revealed that Egr2-Pet1 serotonergic 
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neurones had intrinsic CO2/pH chemosensitivity (Brust et al., 2014). The anatomical 
locations of this subset of serotonergic neurones correspond to the caudal end of the 
medial lemniscus and median raphe nucleus (for r3 derived Egr2-Pet1 neurones), and the 
rostral end of the raphe magnus and raphe pallidus (for r5 derived Egr2-Pet1 neurones) 
(figure 1-4). Rhombomeric lineage also appears to determine the innervation patterns of 
serotonergic neurones. Serotonergic neurones derived from r3/r5 selectively innervated 
brainstem nuclei involved in chemosensory processing, but not various respiratory 
(pre)motor nuclei (figure 1-4). The findings by Brust et al. (2014) are in line with earlier 
findings that indicate that, in rodents, serotonergic neurones in the raphe magnus can be 
activated by CO2, whereas serotonergic neurones in the raphe obscurus are less 
responsive to changes in CO2/pH (Depuy et al., 2011, Mulkey et al., 2004, Hodges et al., 
2005, Iceman et al., 2013).  
Using an experimental protocol similar to Brust et al. (2014), Hennessy et al. (2017) found 
that pharmacogenetic (hM4Di-mediated) inhibition of Tachykinin positive and Pet1 
positive (Tac1-Pet1) serotonergic neurones blunted the in vivo hypercapnic respiratory 
response to 5% piCO2 vs. 0% piCO2 in mice. The authors did not report any experiments 
to confirm whether Tac1-Pet1 neurones lacked intrinsic chemosensitivity, as would be 
expected from the findings of Brust et al. (2014). Tac1-Pet1 neurones populated the raphe 
obscurus and raphe pallidus (Okaty et al., 2015, Hennessy et al., 2017). Tac1-Pet1 axonal 
boutons were found sparsely in respiratory control areas (e.g. pre-BötC), but densely in 
respiratory motor regions (Hennessy et al., 2017). Hennessy et al. (2017) suggest Tac1-
Pet1 neurones may act downstream of Egr2-Pet1 serotonergic neurones, which do not 
innervate respiratory motor nuclei. Thus, intrinsic CO2/pH sensitivity in serotonergic 
neurones appears specific to the Egr2-Pet1 neurones derived from r3/r5, but serotonergic 
transmission by other raphe neurones may facilitate a respiratory reflex initiated by 
CO2/pH sensors elsewhere. 
1.4.3 Molecular mechanisms of CO2 chemosensitivity 
RTN neurones and a subset of serotonergic neurones are thought to have intrinsic CO2/H+ 
sensitivity. The mechanism underlying Erg2-Pet1 neurone CO2/H+ sensitivity is currently 
not yet identified. However, in RTN neurones, double knockout of two proton detectors, 
potassium channel TASK-2 and G protein coupled receptor 4 (GPR4), nearly eliminates the 
hypercapnic respiratory response in mice in vivo  (Wang et al., 2013, Kumar et al., 2015) , 
whereas mice in which either TASK-2 or GPR4 is knocked out separately show a 65% 
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reduction of the hypercapnic respiratory response (Guyenet et al., 2016, Kumar et al., 
2015, Gestreau et al., 2010). In acute brain slices of wild type mice, incubation of GRP4 
antagonists reduced the proportion of pH sensitive RTN neurones (Kumar et al., 2015, 
Dong et al., 2017), and systemic administration of a GPR4 antagonist (NE 52-QQ57) 
attenuated the respiratory response to CO2 in unanaesthetised waking rats and mice 
(Hosford et al., 2018). Conversely, selective reintroduction of GPR4 expression in RTN 
neurones of GPR4 KO mice restores the respiratory chemoreflex in vivo and the ability of 
hypercapnia to elicit Fos expression (a metabolic marker) in RTN neurones (Kumar et al., 
2015). These findings indicate that intrinsic CO2 chemosensitivity in the RTN is mediated 
by proton pump TASK-2 and GPR4, in response to hypercapnic acidification. Although 
TASK-2 and GPR4 are present in high levels in RTN neurones, it should be noted that 
TASK-2 expression is also reported outside the RTN (Gestreau et al., 2010), and GPR4 may 
be expressed in low levels by subsets of serotonergic neurones and the brain vascular 
endothelium (Hosford et al., 2018, Shi et al., 2017, Kumar et al., 2015).   
  
Schematic representation of anatomical location and projections of Egr2-Pet1 serotonergic 
neurones derived from embryonic rhombomeres r3 and r5 that are found be unique among 
5-HT neurones to have intrinsic CO2 sensitivity. (A) raphe (grey) and r3-Egr2-Pet1 and r5-Egr2-
Pet1 5-HT neurones (green) with intrinsic CO2 sensitivity map onto the caudal parts of the 
median lemniscus and the median raphe, and onto the rostral parts of the caudal raphe (raphe 
magnus and raphe pallidus). Egr2-Pet1 5-HT neurones derived from r3/r5 selectively innervate 
brainstem nuclei involved in chemosensory processing (orange), but not various analysed 
respiratory (pre)motor nuclei (B, blue regions). Abbreviations: DRN = dorsal raphe nucleus; 
MRN = median raphe nucleus; LC/PB = locus corealeus/parabrachial nucleus; NTS nucleus 
tractus solitarius; RTN = retrotrapezoid nucleus; PBC = pre-Botzinger Complex; DH = dorsal 
horn; NA = nucleus ambiguous; 12N = Vagal nucleus; VMN = ventral spinal motor neurones; 
IML = intermediolateral cell column of the spinal cord. Figures adapted from Brust et al. (2014). 
Figure 1-4: Anatomical location and projection sites of CO2 sensitive serotonergic neurones. 
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1.4.4 Contributions of the RTN to emergence of late-E activity in hypercapnic 
conditions. 
Under conditions of high metabolic demand, such as hypercapnia, late-E activity can 
emerge as a result of activity of a conditional expiratory oscillator located in the pFRG (see 
section 1.2) (Huckstepp et al., 2015, Zoccal et al., 2018). The pFRG houses a population of 
neurones, named ‘late-E neurones’, that fire exclusively in phase with late-E activity 
recorded in the AbN and have been identified as a critical source of late-E AbN activity 
under hypercapnic conditions (Abdala et al., 2009, Moraes et al., 2013, Silva et al., 2016, 
Pagliardini et al., 2011). The respiratory network interactions that - in response to CO2 
chemoreceptor activation – lead to the emergence of late-E burst of abdominal nerve 
activity are suggested to constitute combined excitation and disinhibition of late-E 
neurones. Under resting conditions, late-E neurone activity is thought to be suppressed 
by inhibitory synaptic inputs from glycinergic Post-I neurones in the BötC, and Early-I 
neurones in the pre-BötC (Molkov et al., 2010).  
Optogenetic inhibition via selective expression of a light-sensitive inhibitory Cl- channel 
(eNpHR3.0) in glycinergic neurones of the BötC during the post-I phase evoked generation 
of late-E abdominal nerve activity in in situ WHBP of rats. In contrast, optogenetic 
excitation of glycinergic BötC neurones via a light-sensitive cation channel (ChETA) during 
the post-I phase suppressed late-E abdominal nerve activity in hypercapnic conditions 
(Moraes et al., 2014a). In the same in situ preparations, intracellular recordings of pFRG 
late-E neurones confirmed that inhibitory input during the post-I phase prevents 
generation of late-E neurone activity under eucapnic conditions (Moraes et al., 2014a). 
Excitatory drive to late-E neurones, on the other hand, may come from glutamatergic CO2-
sensitive RTN neurones. Late-E activity emerges in hypercapnic conditions, when CO2 
sensitive drive to late-E neurones is increased beyond the threshold value to overcome 
their inhibitory input. Optogenetic stimulation of Phox2B expressing RTN neurones with 
pacing stimulation of ChR2 elicits late-expiratory airflow in conscious rats under 
normocapnic conditions (Abbott et al., 2011). Conversely, pharmacogenetic inhibition of 
Phox2B expressing RTN neurones with G-protein-coupled Drosophila allatostatin receptor 
prevents the development of late-E abdominal activity under hypercapnic conditions in 
anesthetised rats and in in situ WHBP of rats (Marina et al., 2010, Abbott et al., 2011). 
Thus, emergence of late-E AbN activity is suggested to be the result of interplay between 
inhibitory- (from BötC post-I neurones) and excitatory (from RTN glutamatergic CO2 
chemosensitive neurones) inputs to pFRG late-E neurones (see figure 1-5). Late-E activity 
Chapter 1: General Introduction 
22 
 
is inhibited in resting conditions, but can emerge as a result of enhanced excitatory 
chemoreceptor drive to late-E neurones, or as a result of reduced inhibition of late-E 
neurones from Post-I neurones. 
The Kölliker-Fuse nucleus modulates late-E motor output.  
Given that activity of BötC post-I neurones inhibits late-E activity, and given that the 
pontine KF plays an important role in the emergence of post-I activity (see section 1.3.2), 
it is possible that the KF plays an indirect role in the control of late-E activity. Recent 
pharmacological experiments with focal micro-injections in the KF confirm that 
disinhibition of the KF with GABAA antagonist gabazine increases cVN post-I activity and 
attenuates the emergence of AbN late-E bursts in hypercapnic conditions (Barnett et al., 
2018). Conversely, augmented inhibition of the KF via micro-injection in the KF of GABAA 
receptor agonist isoguvacine resulted in reduced cVN post-I activity and advanced the 
onset of late-E abdominal bursts in hypercapnic conditions (Jenkin et al., 2017). Based on 
computational modeling simulations it was suggested that excitatory neurones in the KF 
stimulate post-I neurones in the BötC, which in their turn inhibit late-E neurones in the 
pFRG (see figure 1-5). Via reduction of excitatory input from KF neurones to VRC post-I 
neurones, inhibition of the KF is suggested to indirectly disinhibit late-E neurones (Barnett 
et al., 2018). Thus, late-E activity is thought to stem from interactions between the KF, the 
BötC and pre-BötC, the pFRG, and CO2 chemosensitive neurones of the RTN. The pFRG 
houses an expiratory oscillator that is suppressed under eupnoeic conditions. Emergence 
and timing of late-E activity is a function of inhibitory inputs to the pFRG from the VRC 
Post-I and Early-I neurones – which in their turn are modulated by KF efferents – and 
excitatory drive from central chemoreceptors in the RTN. 
 
 




Figure 1-5: Pathways suggested to mediate emergence of late-E activity 
Schematic representation of interactions between the pontine KF, the VRC, and CO2 
chemosensitive neurones that are thought to affect the emergence and timing of late-E activity. 
The interactions displayed in figure are as suggested in the computational model by (Barnett et 
al., 2018). The schematic does not show the complete model but highlight selected elements of 
it for the sake of visual clarity. Justification for all suggested projections and an explanation of 
the interactions is provided in section 1.4.4. Abbreviations: KF = Kölliker-Fuse; BötC = Bötzinger 
Complex, Pre-BötC = pre-Bötzinger Complex, RTN = retrotrapezoid nucleus; pFRG = parafacial 
respiratory group. 
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1.5 PERIPHERAL CHEMORECEPTOR FEEDBACK MECHANISMS IN RESPIRATORY 
CONTROL 
1.5.1 Oxygen sensing in the Carotid Bodies.  
Multisensory chemoreceptors in the carotid-, and aortic bodies mediate the peripheral 
chemoreflex response. 
The peripheral chemoreflex is the sympathetic and respiratory response activated by 
chemosensory cells located in the carotid bodies, and to a lesser extent, the aortic bodies 
(reviewed in Costa et al. (2014)). The carotid bodies are located bilaterally in the 
bifurcation of the common carotid artery, whereas the aortic bodies are located along the 
aortic arch. Both carotid and aortic bodies are multifunctional receptors that sense 
multiple modalities (e.g. blood gases, arterial pressure, blood pH, glucose and circulating 
signalling molecules), and can evoke multiple reflex responses, likely via distinct signalling 
pathways (reviewed in Zera et al. (2019)). Stimulation of peripheral chemoreceptors 
results in increased respiratory rate and tidal volume (or physiological surrogates 
thereof), combined with enhanced post-I activity (observed in AbN, HN, and cVN), 
sympathetic and respiratory late-E activity (observed in AbN and thoracic sympathetic 
nerve activity), overall sympatho-activation, and bradycardia followed by tachycardia 
(Lindsey et al., 2018, Dick et al., 2004, Moraes et al., 2012a, Barnett et al., 2017, Abdala 
et al., 2009). Carotid bodies (CB) are the main peripheral sites for chemoreceptor cells 
that sense low paO2 and high paCO2/pH. Only a sparse number of chemoreceptor cells 
have been identified in the aortic arch region of rats (Easton and Howe, 1983), and they 
may be entirely absent from mice (Chalmers et al., 1967). The remainder of this section 
will focus on carotid body chemoreceptors and their downstream neural architecture as 
the main mediators of the peripheral chemoreflex. 
Molecular mechanisms of O2 and CO2 sensing in the carotid bodies 
The carotid bodies are uniquely sensitive to even modest changes in paO2 (e.g. from ~100 
to 80 mmHg) (Prabhakar et al., 2006). The CB are made up of a dense network of 
capillaries that supply blood to clusters of chemoreceptor glomus cells, also known as type 
1 cells, and supportive sustentacular type 2 cells. The glomus cells can be directly sensitive 
to both low O2 and high CO2/pH (Lahiri et al., 2006) and, upon stimulation, secrete 
neurotransmitters (e.g. ATP, acetylcholine, dopamine, 5-HT, and substance-P) that excite 
adjacent afferent terminals of petrosal ganglia neurones (Vicario et al., 2000, Costa et al., 
2014) with axons that project via the carotid nerve to the NTS. Type 2 cells, although 
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electrophysiologicaly unresponsive to hypoxia or hypercapnic acidosis, are purported to 
have a glia-like paracrine role in the CB (Kumar and Prabhakar, 2012). The exact molecular 
mechanisms by which glomus cells may sense a decline in O2 is still a matter of debate. 
Most theories rely on the integration of mitochondrial O2 sensing with transduction 
mechanisms that interact with membrane ion channels (reviewed in Rakoczy and Wyatt 
(2018)). There is consensus that acute O2 sensing by glomus cells is mediated by several 
types of outward rectifying K+ channels that are reversibly inhibited by decreases in pO2. 
Closure of these K+ channels results in the membrane depolarization that opens Ca2+ 
channels to trigger exocytosis of synaptic vesicles. (reviewed in Teppema and Dahan 
(2010), Lopez-Barneo et al. (2016)). Sensitivity of glomus cells to hypercapnic acidosis is 
dependent on acid-sensing ion channel 3 (ASIC3) (Lu et al., 2013, Tan et al., 2010). 
Interestingly, ASIC3 mediated sensitivity to low pH is reciprocally related to sensitivity to 
hypoxia. That is, with increasing expression of ASIC3 or increasing sensitivity to low pH, 
the response magnitude to low pO2 decreases (Lu et al., 2013). This suggests the existence 
of distinct O2 vs. CO2 ‘sensitivity profiles’ among various glomus cells.  
1.5.2 Respiratory peripheral chemoreflex mechanisms: interactions between the 
Nucleus Tractus Solitarius and the Ventral Respiratory Column.  
Anatomical studies suggest the peripheral chemoreflex response is mediated, at least in 
part, by interactions between NTS and VRC neurones. Retrograde labelling with wheat 
germ agglutinin and horseradish peroxidase conjugates injected into vascularly isolated 
CB in situ in rats revealed most CB afferents first synapse in the commissural and medial 
subnuclei of the NTS, with some fibres projecting to areas in the ventral and ventrolateral 
medulla (e.g. area postrema,  the dorsal motor nucleus of the vagus nerve, the caudal 
ventrolateral medulla, and the nucleus ambiguus) (Mifflin, 1992). These findings are in 
line with those of immunohistochemical labelling of Fos protein after hypoxia or electrical 
stimulation of the carotid sinus nerve in rat (Erickson and Millhorn, 1994, Erickson and 
Millhorn, 1991). Through projections to various brainstem circuits, second order neurones 
in the NTS form multiple pathways to modulate respiratory rhythm and pattern and, 
concurrently, the sympathetic and parasympathetic outflows that mediate cardiac output 
and vascular tone (sympathetic reflexes will be discussed in section 1.6). The respiratory 
response to CB activation is likely reliant on second order NTS neurones that project 
directly to various respiratory regions in the VRC. The majority of such NTS neurones 
innervate the RTN/pFRG area, the RVRG, the CVRG, the RVLM, and to a lesser extent the 
BötC and pre-BötC regions (Alheid et al., 2011, Yang et al., 2020).  
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In addition to anatomical studies, functional studies provide further support for the 
notion that the peripheral chemoreflex respiratory response is mediated by interactions 
between NTS and VRC neurones. In vivo single unit recordings in rats show that 
stimulation of peripheral chemoreceptors through brief periods of normocapnic hypoxia 
or through intravenous injection of sodium cyanide (NaCN) results in the activation of RTN 
neurones (Takakura et al., 2006). This activation requires the integrity of the carotid sinus 
nerves and the NTS (Takakura et al., 2006, Guyenet et al., 2018). NTS neurones with 
projections to the RTN/pFRG area show Fos expression after hypoxia, and ninety percent 
of these NTS neurones are glutamatergic (contain VGLUT2 mRNA) (Takakura et al., 2006). 
Inhibition of the pre-BötC and RVRG, through local injections of GABAA receptor agonist 
(muscimol) until complete loss of PN activity, had no effect on the excitatory response of 
RTN neurones to peripheral chemoreceptor activation in anaesthetised rats (Takakura et 
al., 2006). Local pharmacological inhibition of the RTN, on the other hand, abolished the 
late-E sympathetic and respiratory components of the peripheral chemoreflex upon CB 
stimulation, but did not affect the Post-I respiratory response (Moraes et al., 2012a). 
Based on these findings it has been suggested that the late-E response to peripheral 
chemoreceptor activation is independent from VRC circuits underlying eupnoeic 
respiratory activity and is likely mediated by projections from NTS neurones to the 
RTN/pFRG regions, resulting in excitation of late-E neurones (see figure 1-6) (Barnett et 
al., 2017). Furthermore, late-E activity and post-I activity in response to peripheral 
chemoreceptor activation are thought to be mediated by distinct pathways. 
Computational simulations based on the inhibitory ring model suggest that excitatory 
projections of second order peripheral chemoreceptor neurones in the NTS to post-I 
neurones in CVRG transmission circuitry may contribute to the peripheral chemoreceptor 
induced motor activity during Post-I phase (see figure 1-6) (Barnett et al., 2017). 
1.5.3 Pontine contribution to the respiratory peripheral chemoreflex.  
Besides respiratory regions in the ventrolateral medulla, the KF and parabrachial nuclei of 
the pons, too, have been found to receive inputs from NTS neurones that relay signals 
from CB afferents. This innervation originates in part from commissural NTS neurones that 
express Fos after hypoxia (Herbert et al., 1990, Song et al., 2011). The KF and parabrachial 
nuclei are known to be involved in respiratory phase transitioning, control of the duration 
of the respiratory cycle (see section 1.3), and the promotion of late-E activity through 
disinhibition of RTN neurones (see section 1.4.4). Transverse sectioning at the ponto-
medullary junction to remove inputs from the pons resulted in a loss of AbN post-I and 
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late-E activity, and of cVN post-I activity that could not be reinstated by hypercapnia, 
hypoxia, anoxia, or peripheral chemoreceptor activation with NaCN in in situ WHBP of rats 
(Abdala et al., 2009). KF neurones are activated during hypoxia and carotid sinus nerve 
stimulation (Erickson and Millhorn, 1994), and pharmacological inhibition through local 
muscimol injections in the KF attenuated the sympathetic and respiratory responses to 
intra-arterial KCN injections or to hypoxia in anaesthetized, and unanaesthetised rats, 
respectively  (Damasceno et al., 2014, Damasceno et al., 2015). Furthermore, the lateral 
parabrachial nucleus is suggested to mediate shortening of expiratory phase duration in 
response to hypoxia, as uni-, or bilateral lesion of this region resulted in an attenuation of 
this expiratory phase shortening in anesthetized rats (Song and Poon, 2009). Taken 
together, these findings indicate that respiratory regions in the parabrachial complex 
mediate the respiratory response to peripheral chemoreceptor activation. This could be 
via a pathway in which NTS neurones relay peripheral chemoreceptor afferents to the 
parabrachial complex, which then interacts with rhythmogenic circuitry in the VRC as 
described in section 1.3 (see figure 1-6). 
To summarize, the respiratory late-E component of the peripheral chemoreflex is 
dependent on RTN and pFRG function and is likely mediated by excitatory projections 
from the NTS to the RTN/pFRG regions. The post-I respiratory response and tachypnoea 
in response to peripheral chemoreceptor activation is mediated by a separate pathway, 
which is hypothesised to involve excitatory projections from NTS neurones to 
transmission circuitry of the CVRG. This latter pathway remains to be experimentally 
verified. The respiratory response to peripheral chemoreceptor activation is also found to 
be dependent on intact ponto-medullary interactions.   






Schematic representation of interactions between the NTS, the VRC, and the pFRG 
(thick lines) that mediate the emergence of late-E activity and Post-I activity in 
response to peripheral chemoreceptor activation as suggested in the computational 
inhibitory ring model by Barnett et al. (2017). The schematics do not show the 
complete model but highlight selected elements of it for the sake of visual clarity.  
Late-E and post-I activity in response to peripheral chemoreceptor activation are 
suggested to be mediated by separate pathways. Justification for all suggested 
projections and an explanation of the interactions is provided in sections 1.5.2 and 
1.5.3. Abbreviations: NTS = Nucleus tractus solitarius; KF = Kölliker-Fuse; VRC = ventral 
respiratory column, BötC = Bötzinger Complex, Pre-BötC = pre-Bötzinger Complex, 
CVRG = caudal ventral respiratory group, pFRG = parafacial respiratory group. 
Figure 1-6: Pathways suggested to mediate respiratory responses to peripheral 
chemoreceptor activation 
Chapter 1: General Introduction 
29 
 
1.6 ENTRAINMENT OF RESPIRATORY AND SYMPATHETIC ACTIVITY 
Blood circulation and pulmonary ventilation are modulated in a coordinated fashion to 
optimally maintain oxygen-, and pH homeostasis in bodily tissues under continuously 
changing conditions of metabolic demand. Not surprisingly, central mechanisms of 
cardiovascular and respiratory control interact. Central cardiovascular control is largely 
mediated via sympathetic outflow to the heart and vasculature, where it modulates 
cardiac output and vasoconstriction. 
1.6.1 Distinct patterns of sympatho-respiratory coupling occur depending on 
metabolic state  
Under eupnoeic conditions, sympathetic nerve activity in mammals exhibits positive 
modulation during I and Post-I phases of the respiratory cycle (Dick et al., 2014, Baekey et 
al., 2008, Malpas, 1998, Malpas, 2010, Zoccal et al., 2008, Zoccal et al., 2009a, Zoccal et 
al., 2009b). This results in respiratory-rhythm-entrained oscillations in baseline heart rate 
(known as respiratory sinus arrhythmia) and in arterial pressure levels (known as 
Traube-Hering waves) (figure 1-7) (Moraes et al., 2012b, Bazilio et al., 2019). 
The pattern of sympathetic output changes with alterations in respiratory rhythm and 
pattern. Suppression of respiratory activity via exposure to hypocapnia reversibly reduces 
sympathetic outlflow, heart rate, baseline levels of arterial pressure, and Traube-Hering 
waves in in situ WHBP of rats (Simms et al., 2009). Conversely, in conditions of high 
respiratory drive (hypoxia and/or hypercapnia), the emergence of AbN late-E bursts 
(addressed in sections 1.4.4 and 1.5) is coupled with concomitant sympathetic late-E 
activity, which contributes to an overall increase in sympathetic drive (Zoccal et al., 2008, 
Dick et al., 2004, Mandel and Schreihofer, 2009, Molkov et al., 2011).  
Stimulation of peripheral chemoreceptors by short periods of hypoxia or intra-arterial 
cyanide administration in anesthetized rats (Dick et al., 2004, Mandel and Schreihofer, 
2006) or in in situ WHBP of rats (Costa-Silva et al., 2010, Moraes et al., 2012a) gives rise 
to yet another distinct pattern of sympatho-respiratory coupling. Section 1.5 mentions 
that the respiratory response to peripheral chemoreceptor activation includes enhanced 
post-I activity observed in AbN, HN, and cVN in in situ preparations of rats. This response 
to peripheral chemoreceptor activation is coupled with high amplitude sympathetic 
bursts during post-I followed by inhibition of sympathetic output during early inspiration. 
(Dick et al., 2004, Costa-Silva et al., 2010, Mandel and Schreihofer, 2009, Moraes et al., 
2012a, Barnett et al., 2017, Braga et al., 2007). 




Sympathetic ganglionic efferents control long- and short term blood pressure regulation. 
Sympathetic control of circulation operates via three main classes of sympathetic 
ganglionic neurone efferents: thermosensitive, glucosensitive, and barosensitive 
(Guyenet, 2006). Thermosensitive sympathetic efferents consist primarily of 
hypothermia-activated cutaneous vasoconstrictors (Janig and Habler, 2003, Vallbo et al., 
2004). Glucosensitive sympathetic efferents are activated by hypoglycaemia and physical 
exercise, and mediate adrenaline release from the adrenal glands (Cao and Morrison, 
2001). Activity of barosensitive sympathetic ganglionic efferents can be mediated by 
arterial baroreceptors located in the aortic arch and the carotid sinus, of which vagal 
efferents project to the NTS (Guyenet, 2006). The group of barosensitive neurones is the 
largest group of sympathetic efferents, and is thought to play a dominant role in both 
short-, and long term blood pressure regulation (Janig and Habler, 2003, Guyenet, 2006). 
Sympathetic activity is entrained with the respiratory cycle. Specifically, during eupnoeic 
breathing sympathetic activity is upregulated during late stages of the inspiratory phase. This 
results in respiratory sinus arrhthmia, and a delayed peak in perfusion pressure (Traube-Hering 
waves). From top to bottom, traces show perfusion pressure (PP), sympathetic nerve activity, 
RVLM pre-sympathetic neurone activity, phrenic nerve activity, and heart rate. Figure is 
adapted from Machado et al. (2017) 
Figure 1-7: Example traces of sympathetic activity entrained with the respiratory cycle. 
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They control cardiac output, vasoconstriction (except for cutaneous arteriole 
constriction), the kidneys (renin secretion, renal sodium reabsorption, and renal blood 
flow (DiBona and Kopp, 1997)), and noradrenaline release from a subset of adrenal gland 
chromaffin cells (Janig and Habler, 2003). These sympathetic efferents show ongoing 
activity at rest (sympathetic tone), and their discharge patterns are highly synchronised 
with respiratory rhythm (Janig and Habler, 2003, Vallbo et al., 2004, Dempsey et al., 2002). 
Excitatory pre-sympathetic neurones in the rostral ventrolateral medulla drive activity of 
sympathetic efferents 
A nodal point for respiratory reflexes mediated by barosensitive sympathetic efferents is 
found in the rostral ventrolateral medulla (RVLM), which houses two major populations 
of pre-sympathetic neurones. The first is a population of catecholaminergic neurones, 
denoted C1, which express all the enzymes required for synthesizing adrenaline, and the 
second is a population of non-catecholaminergic (non-C1) neurones (Ross et al., 1984, 
Schreihofer and Guyenet, 1997, Schreihofer et al., 2000). RVLM C1 and non-C1 pre-
sympathetic neurones are glutamatergic, as evidenced by expression of vesicular 
glutamate transporter-2 (VGLUT2) RNA (Stornetta et al., 2002b, Stornetta et al., 2002a). 
They lack markers of inhibitory neurones such as glycine transporter 2 (GlyT2) and 
glutamic acid decarboxylase (GAD) (Comer et al., 1999, Schreihofer et al., 1999, Stornetta 
and Guyenet, 1999, Stornetta et al., 2002b, Stornetta et al., 2002a). C1 Pre-sympathetic 
neurones are the major source of monosynaptic excitatory input to sympathetic 
preganglionic neurones in the intermediolateral column of the spinal cord (Guyenet et al., 
2013, Stornetta et al., 2016, Stornetta, 2009, Stornetta et al., 2002b, Moraes et al., 2017, 
Marina et al., 2011) which, in their turn, drive the barosensitive sympathetic ganglionic 
efferents described above (Guyenet et al., 2013). 
Contributions of RVLM C1 pre-sympahtetic neurones to sympatho-respiratory coupling 
In pioneering studies on the role of RVLM neurones on cardiovascular control, micro-
injection of L-glutamate in the RVLM resulted in increased arterial pressure in rodents 
(Dampney, 1981, Dampney et al., 1982, Ross et al., 1984).  Catecholaminergic brainstem 
neurones express transcription factor Phox2B, which allows for their genetic targeting via 
Phox2B selective artificial promoter PRSx8 (Marina et al., 2011, Hwang et al., 2001, Duale 
et al., 2007). Optogenetic gain of function experiments have targeted RVLM C1 neurones 
via focal viral vector delivery of a transgene that drives expression of ChR2 under control 
of the PRSx8 promoter. These studies showed that selective stimulation of RVLM C1 
neurones increased sympathetic activity, heart rate, and arterial pressure under resting 
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conditions in anesthetised (Abbott et al., 2009), and unanaesthetised (Abbott et al., 2013, 
Burke et al., 2014, Kanbar et al., 2010) rats, and in in situ preparations of rats (Menuet et 
al., 2014). The sympathetic responses evoked by C1 photo-stimulation in anesthetized 
rats (a rise in blood pressure and reflex bradycardia) were similar to those evoked by 
hypoxia, and were also occluded by hypoxia, while they persisted under hypercapnia 
(Burke et al., 2014). Conversely, loss of function studies show that blocking glutamatergic 
transmission via local micro-injection of glutamate receptor antagonist (kynurenic acid) 
in the RVLM results in the elimination of sympathetic reflex responses to brief hypoxia in 
urethane anesthetized rats (Koshiya et al., 1993).  
Pharmacogenetic loss of function studies have utilised the PRSx8 promoter to target 
RVLM C1 neurones for expression of the inhibitory drosophila allatostatin receptor, which 
can be activated by administration of exogenous allatostatin peptide (Tan et al., 2006). 
Pharmacogenetic inhibition of RVLM C1 cells with allatostatin resulted in large reductions 
of eucapnic sympathetic nerve activity and arterial pressure in urethane anesthetized rats 
(Marina et al., 2011), in freely moving unanaesthetised rats (Moraes et al., 2017), and in 
in situ WHBP of rats (Marina et al., 2011, Moraes et al., 2017). In anesthetized and 
peripheral chemoreceptor denervated rats, systemic hypercapnia still evoked vigorous 
sympathetic and cardiovascular chemoreflex responses after allatostatin induced 
inhibition of RVLM C1 neurones (Marina et al., 2011). In line with this, allatostatin-
mediated inhibition did not reduce late-E sympathetic activity, but did inhibit I/Post-I 
sympathetic activity after exposure to hypercapnia in in situ WHBP of rats (Moraes et al., 
2017). Allatostatin-mediated inhibition also significantly reduced the inspiratory 
sympathetic, but not the late-E sympathetic responses to peripheral chemoreflex 
activation in situ (Moraes et al., 2017). Findings of a recent optogenetic inhibition study 
also point towards a role of RVLM C1 neurones in cardiovascular control under conditions 
of peripheral chemoreceptor activation, but not under conditions of central 
chemoreceptor activation. Light-stimulation of inhibitory proton pump 
ArchaeorhodopsinT-3.0, expressed in the RVLM under the PRSx8 promoter, resulted in a 
large decrease in blood pressure under conditions of brief hypoxia, but had little effect 
under hypercapnic- or resting conditions in unanaesthetised rats (Wenker et al., 2017). 
Furthermore, the authors report that under the effect of isoflurane anaesthesia, C1 
inhibition did result in a significant drop in blood pressure under resting conditions. They 
suggest that the contribution of C1 activity to cardiovascular control under resting 
conditions may have been overestimated by experiments using anaesthesia. 
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Nevertheless, the lack of a significant hypotensive effect of optogenetic C1 inhibition 
under resting conditions in unanaesthetised rats contrasts with the earlier-mentioned 
large reductions in sympathetic activity and arterial pressure observed after allatostatin-
mediated inhibition of C1 neurones under similar conditions (Moraes et al., 2017).  
To summarize, the above findings of RVLM C1 gain- or loss of function studies collectively 
suggest that the (I/Post-I) sympathetic activity in response to peripheral and/or central 
chemoreceptor activation is dependent on RVLM C1 neurone function, but that late-E 
sympathethic activity in response to central chemoreceptor activation is not. 
Interestingly, pharmacogenetic (allatostatin) inhibition (Moraes et al., 2017) and 
optogenetic (archaeorhodopsinT3.0) inhibition (Wenker et al., 2017) experiments in 
unanaesthetised rats in vivo suggest differing degrees of contribution of RVLM C1 
neurones to cardiovascular control under resting conditions. This discrepancy calls for 
further experimental validation of the contribution of C1 neurone activity to 
cardiovascular control under resting conditions in unanaesthetised rats in vivo.  
1.6.2 Sympatho-respiratory coupling is the result of interactions between brainstem 
networks of sympathetic and respiratory control 
Respiratory modulation of sympathetic activity was found to persist after vagotomy and 
decerebration (reviewed in Molkov et al. (2014b). This suggests that 
sympatho-respiratory coupling occurs through interactions between brainstem circuits of 
sympathetic and respiratory control. The exact neural mechanisms that give rise to the 
various patterns of sympatho-respiratory coupling addressed in section 1.6.1 are not fully 
understood. The distinct patterns of sympatho-respiratory coupling under the various 
states of respiratory drive conditions (normoxia/eucapnia, hypoxia, hypercapnia), along 
with the differing contributions of C1 pre-sympathetic neurones to these patterns, 
suggests that there are multiple pathways along which sympatho-respiratory coupling can 
occur.  
Functional and anatomical connectivity underlying eupnoeic sympatho-respiratory 
coupling. 
RVLM C1 and non-C1 pre-sympathetic neurones exhibit distinct respiratory modulation. 
Extracellular recordings in combination with peripheral nerve recordings showed that 
RVLM neurone activity patterns were phase-locked with the respiratory cycle (Haselton 
and Guyenet, 1989). Intracellular recordings in in situ WHBP of rats combined with 
peripheral nerve recordings showed that all recorded RVLM C1 and non-C1 pre-
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sympathetic neurones presented INaP intrinsic pacemaker activity, and confirmed that 
many cells also exhibit spontaneous excitatory post-synaptic potentials and synaptic 
inhibition in different phases of the respiratory cycle (Moraes et al., 2013, Moraes et al., 
2017). Specifically, 3 groups of pre-sympathetic neurones were identified that showed 
distinct patterns of respiratory modulation, which corresponded to the sympathetic 
activity recorded at various sympathetic nerves. A fourth group showed no respiratory 
modulation (Moraes et al., 2013).  IHC labelling for tyrosine hydroxylase (TH) after 
intracellular recordings in in situ WHBP of rat showed that all recorded inspiratory 
modulated RVLM cells were C1 (TH positive, and positive for a transgene expressed under 
the PRSx8 promoter), and that all recorded Post-I modulated RVLM cells were non-C1 (TH 
negative, and negative for a transgene expressed under the PRSx8 promoter) (Moraes et 
al., 2017). These findings indicate that: (1) RVLM pre-sympathetic cells receive input from 
respiratory neurones; (2) RVLM C1 pre-sympathetic neurones contribute specifically to 
inspiratory modulation of sympathetic activity; and (3) RVLM non-C1 pre-sympathetic 
neurones may contribute specifically to post-I modulation of sympathetic activity. 
The RVLM lies immediately dorsal to the ventral respiratory column in close proximity to, 
and even partly intermingled with, neurones of the rythmogenic BötC region (Stornetta 
et al., 2016, Stornetta et al., 2002a, Stornetta et al., 2002b, Guyenet et al., 2013). Due to 
this anatomical proximity, it has been suggested that the respiratory modulation of pre-
sympathetic RVLM neurones may be in part mediated by direct synaptic connections with 
rhythmogenic respiratory neurones of the ventral respiratory column (Zoccal et al., 2008, 
Zoccal et al., 2014). Indeed, anatomical studies have reported BötC neurone axon 
varicosities in close apposition to RVLM neurones, suggesting synaptic contacts between 
both regions (Sun et al., 1997).   
Another source of respiratory modulation to RVLM neurone activity is introduced by a 
population of GABA-ergic neurones in the caudal ventrolateral medulla (CVLM), a region 
immediately caudal to the RVLM at the level of the pre-BötC. CVLM GABA-ergic neurones 
establish synaptic inputs with RVLM neurones (Schreihofer and Guyenet, 2003). Micro-
injection of L-glutamic acid in the CVLM (Willette et al., 1983), or GABAA receptor 
antagonist bicuculine in the RVLM (Monnier et al., 2003, Guyenet et al., 1990) results in 
inhibition of sympathetic output and a drop in arterial pressure. CVLM GABA-ergic input 
to the RVLM is crucial to negative feedback control of sympathetic activity via the 
sympathetic baroreflex (Schreihofer and Guyenet, 2003). Afferents of arterial 
baroreceptors synapse at 2nd order baroreceptor neurones in the NTS, which project 
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(directly or indirectly) to CVLM GABA-ergic neurones (Schreihofer and Guyenet, 2002, 
Molkov et al., 2014b), that, in turn, inhibit the pre-sympathetic neurones of the RVLM 
(Dampney, 1994a, Molkov et al., 2014b). Among CVLM GABA-ergic neurones, 4 groups of 
neurones were identified that exhibit distinct patterns of respiratory modulation (Mandel 
and Schreihofer, 2006). This suggests that respiratory-phase-locked inhibition from CVLM 
neurones can contribute to the respiratory modulation of RVLM neurone activity.  
Sympatho-respiratory coupling is dependent on pontine input, directly and/or via VRC 
respiratory populations. Experiments in in situ WHBP of rats showed that pontomedullary 
transection, which constitutes removal of pontine input to medullary respiratory and 
sympathetic circuitry, eliminated eupneic respiratory modulation of sympathetic activity 
and its cardiovascular derivatives (Traube-Hering waves, and respiratory sinus cardiac 
arrhythmia), and it attenuated the cardiovascular response to stimulation of peripheral 
chemoreceptors with cyanide (Baekey et al., 2008). This suggests that input from pontine 
respiratory neurones contributes to sympatho-respiratory coupling.  Anatomical studies 
have indicated the existence of pontine projections to medullary VRC neurones (see 
section 1.3), that, in turn, may interact with pre-sympathetic neurones of the RVLM 
(Stornetta et al., 2016). Tracing experiments have reported direct projections between 
the pontine KF and parabrachial nuclei and RVLM C1 pre-sympathetic neurones (Stornetta 
et al., 2016). Computational models based on the inhibitory ring model suggest that 
pontine inspiratory-expiratory phase spanning respiratory neurones projecting to the 
RVLM may contribute to the enhanced I/Post-I sympathetic activity observed under 
eupnoeic conditions (Barnett et al., 2017).  
Besides GABA-ergic and glutamatergic input from respiratory neurones, it should be 
noted that RVLM pre-sympathetic neurones are also reported to receive inputs from the 
hypothalamus (orexinergic and oxytocinergic), from the medullary raphe (serotonergic 
and substance P), and cholinergic inputs (Dampney, 1994a, Dampney, 1994b, Guyenet, 
2006). It is possible that the function of such inputs relates to the regulation of 
sympathetic activity in accordance to wakefulness and vigilance (hypothalamic orexigenic 
input), and central chemoreflex activation (medullary raphe serotonergic input), but their 
role is currently not well understood. 
To summarize, converging evidence of anatomical, functional, and computational studies 
suggest that sympatho-respriatory coupling occurs, at least in part, through interactions 
of rhythmogenic respiratory neurones of the VRC and of respiratory neurones of the 
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dorsolateral pons with RVLM pre-sympahtetic neurones. Furthermore, RVLM pre-
sympathetic neurones receive respiratory rhythm-entrained inhibitory input from GABA-
ergic neurones in the CVLM. (see figure 1-8A) Besides GABA-ergic and glutamatergic 
inputs, RVLM pre-sympathetic neurone activity is possibly regulated by a host of other 
transmitters (e.g. orexin, substance P, serotonin) of which the contribution and function 
in sympatho-respiratory interactions is currently poorly understood.  
Late-E sympatho-respiratory coupling in response to hypercapnia and peripheral 
chemoreceptor activation likely share common pathways.  
RVLM C1 gain/loss of function studies and single cell recordings of RVLM C1 neurones, 
both discussed in section 1.6.2, suggest that sympathetic Late-E activity and sympathetic 
I/Post-I activity are mediated by distinct pathways. Sympathetic late-E activity is likely not 
mediated by C1 pre-sympathetic neurones, but may be mediated by RVLM non-C1 pre-
sympathetic neurones. Respiratory (AbN) Late-E activity in response to peripheral and 
central chemoreceptor activation is thought to have its origin in activity of late-E neurones 
in the pFRG region (see sections 1.4.4 and 1.5.2). Because sympathetic late-E activity 
appears in conjunction with respiratory late-E activity, it has been suggested that late-E 
sympathetic activity is likely a consequence of excitatory projections from pFRG late-E 
neurones to pre-sympathetic neurones in the RVLM which lies adjacent (Baekey et al., 
2010, Molkov et al., 2011, Molkov et al., 2014a). The notion of a common pFRG drive for 
late-E sympathetic and respiratory activity, that is distinct from the drive of sympathetic 
I/Post-I activity, is supported by the finding that local injection of GABAA receptor agonist 
muscimol in the RTN/pFRG inhibited both the late-E respiratory and sympathetic 
responses, but did not affect the post-I sympathetic response to peripheral 
chemoreceptor activation (Moraes et al., 2012a). Carotid body stimulation was found to 
activate neurones in the RTN/pFRG region via direct projections from glutamatergic 2nd 
order peripheral chemoreceptor neurones of the NTS in rats (Takakura et al., 2006). 
Computational models based on the inhibitory ring model were able to reproduce 
sympathetic and respiratory reflex responses to peripheral chemoreflex stimulation and 
hypercapnia with a model that assumes that enhanced excitatory drive from central 
chemoreceptors to pFRG late-E neurones drives the hypercapnic late-E sympathetic and 
respiratory response, and that excitation of pFRG late-E neurones via a direct excitatory 
projection from peripheral chemoreceptor neurones of the NTS drives the late-E 
sympathetic and respiratory response to peripheral chemoreceptor activation (see figure 
1-8B) (Barnett et al., 2017).   
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Functional connectivity underlying sympatho-respiratory coupling observed during 
peripheral chemoreceptor stimulation. 
The phasic post-I sympathetic activity pattern observed after peripheral chemoreceptor 
activation likely originates from 2nd order NTS peripheral chemoreceptor neurones that 
project to pontomedullary respiratory circuitry, of which output is projected to RVLM pre-
sympathetic neurones. Section 1.5.2 addressed a computational modelling study which 
suggests that projections from excitatory second order peripheral chemoreceptor 
neurones in the NTS  to post-I neurones in CVRG transmission circuitry may contribute to 
respiratory post-I bursts observed in the AbN, cVN, and HN after peripheral 
chemoreceptor activation  (Barnett et al., 2017). This modelling study also assumes tSN 
post-I activity in response to peripheral chemoreceptor activation originates from 
excitatory drive of these CVRG post-I neurones to RVLM pre-sympathetic neurones (see 
figure 1-8C). These assumptions still require experimental verification. Nevertheless, they 
are plausible given that the model was comprised of minimal additions to a well validated 
framework, and the model allowed for in silico reproduction of experimentally observed 
sympathetic and respiratory activity under eucapnic/normoxic, hypercapnic, and hypoxic 
conditions. The RVLM C1 neurone loss-, and gain of function studies and single cell 
recordings addressed in section 1.6.2 suggest that the sympathetic peripheral 
chemoreflex is mediated by RVLM C1 pre-sympathetic neurones. Thus, one putative 
pathway via which Post-I sympathetic activity may occur is via excitatory drive from a 
population of Post-I neurones in cVRC transmission circuitry to C1 neurones in the RVLM.  
Finally, there is support for a second source of tSN drive in response to peripheral 
chemoreceptor activation. This pathway is rather straightforward, and is comprised of a 
direct projection from commissural NTS neurones that receive input from CB afferents 
and have a direct glutamatergic projection to C1 pre-sympathetic neurones of the RVLM. 
This projection could be considered to underlie sympatho-respiratory coupling, as it 
involves sympathetic activity in response to peripheral chemoreceptor activation. 
However, it is thought to drive tonic, respiratory-independent, sympathetic excitation 
(Koshiya and Guyenet, 1996, Koshiya et al., 1993, Mandel and Schreihofer, 2009, Moraes 
et al., 2012b, Barnett et al., 2017).  
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Figure 1-8: pathways mediating 
sympatho-respiratory coupling 
 
Schematic representation of 
interactions thought to underlie 
sympatho-respiratory coupling 
(A) during eupnoeic late 
inspiration, (B), during late-E 
activity; (C) and during Post-I 
activity in the peripheral 
chemoreflex response. This 
figure legend is continued on the 
next page. 





Figure 1-8 caption, continued from previous page: All interactions are originally proposed in a 
computational model by Barnett et al. (2017), which is an expansion of the inhibitory ring model. The 
schematics do not show the complete model but highlight selected elements of it for the sake of visual 
clarity. (A) Excitatory projections from inspiratory-to-expiratory phase spanning neurones of the KF to RVLM 
pre-sympathetic neurones are suggested to mediate eupnoeic sympatho-respiratory activity during late 
stages of inspiration. (B) Excitatory projections from pFRG late-E neurones to RVLM pre-sympathetic 
neurones are suggested to underlie late-E sympathetic activity. Excitatory projections from NTS 2nd order 
peripheral chemoreceptor neurones to the pFRG are suggested to mediate late-E sympathetic activity in 
response to peripheral chemoreceptor activation. (C) Excitatory projections from a hypothetical cVRG Post-
I population are suggested to underlie Post-I sympatho-respiratory coupling in response to peripheral 
chemoreflex activation. Justification for all suggested projections and an explanation of the interactions is 
provided in section 1.6.2. Abbreviations: RVLM = rostral ventrolateral medulla; CVLM = caudal ventrolateral 
medulla; NTS = Nucleus tractus solitarius; KF = Kölliker-Fuse; VRC = ventral respiratory column, BötC = 
Bötzinger Complex, Pre-BötC = pre-Bötzinger Complex, RVRG = rostral ventral respiratory group, CVRG = 
caudal ventral respiratory group, pFRG = parafacial respiratory group.  
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1.7 SEROTONERGIC MODULATION OF RESPIRATORY CONTROL 
The review of central chemoreflex mechanisms in respiratory control (section 1.4) 
addressed evidence for a role of raphe serotonergic (5-HT) neurones in respiratory 
control. The present section will further explore the role of 5-HT transmission in general, 
and 5-HT1A transmission in particular, in respiratory control. 
1.7.1 Serotonergic transmission: a brief overview of cellular and physiological 
functions 
When considering the role of 5-HT transmission in respiratory control, it is important to 
be aware of its wide range of effects on cellular and physiological mechanisms. Before 
addressing the role of 5-HT transmission in respiratory control specifically, this section will 
briefly address some general properties of the serotonergic system that contribute to a 
better understanding of its role in respiratory control.  
Serotonergic transmission has been implicated in the regulation of respiratory-, 
(Cummings and Hodges, 2019, Hodges and Richerson, 2008) and cardiovascular control 
(Watts et al., 2012), along with a wide range of other behaviours and physiological 
functions (i.e. the regulation of sleep, memory, feeding, mood regulation, sexual 
behaviour, temperature regulation, and pain signalling (Sahu et al., 2018). In addition, 
during development and in adult mammals, 5-HT signalling mediates trophic effects (e.g. 
cell proliferation, migration, differentiation, synaptogenesis, neurogenesis, cortical 
network organization) and influences synaptic plasticity (Sahu et al., 2018). The wide 
range of processes in which the serotonergic system is involved can be partly explained 
by a high variability and heterogeneity in terms of neuronal properties and receptor 
subtypes, and the serotonergic system’s extensive connections with other brain regions.  
To date, fifteen 5-HT receptor subtypes have been identified (5-HT1A-F, 5-HT2A-B, 5-HT3, 
5-HT4, 5-HT5A-B, 5-HT6, and 5-HT7). All 5-HT receptors are G-protein coupled receptors 
(GPCRs), with the exception of 5-HT3 receptors, which are depolarizing ligand gated Na+ 
and K+ channels. 5-HT1A,B,D-F, 5-HT4B, and 5-HT5 receptors classically couple with Gi-o 
proteins, 5-HT2A-C receptors couple with Gq proteins, and receptors 5-HT4A, 5-HT6, and 5-
HT7 couple with Gs (Hannon and Hoyer, 2008). Through activation of various distinct G-
protein-activated intracellular signalling cascades, 5-HT signalling can mediate a wide 
range of cellular functions. Grossly simplified, 5-HT1 and 5-HT5 signalling acts to inhibit 
neuronal activity via a decrease in cellular levels of cAMP, whereas 5-HT2,4,6,7 signalling 
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typically results in neuronal excitation via increasing cellular cAMP (Hannon and Hoyer, 
2008, Hodges and Richerson, 2008). 
5-HT belong to a class of signalling molecules known as neuromodulators. That is, by 
driving biochemical changes (e.g. cAMP production, intracellular Ca2+ levels, 
phosphorylation), 5-HT transmission has the ability to alter ion channel properties in 
target neurones and change their response to traditional neurotransmitters (Hodges and 
Richerson, 2008).  
Within the central nervous system, serotonin is synthesized by raphe neurones in the 
midbrain, pons, and medulla which have extensive projections throughout the brain and 
spinal cord. This includes projections to regions of respiratory and sympathetic control in 
the medulla and pons (Richter et al., 2003). Raphe neurones have a tonic activity pattern 
which can be modulated by sleep state, environmental cooling, repetitive motor activities 
(e.g. locomotion or mastication), and changes in pCO2/pH (see section 1.4) (Richter et al., 
2003). Peripherally, serotonin acts as a hormone, or auto- or paracrine factor, and is 
synthesized by both enteric neurones and enterochromaffin cells located in the 
gastrointestinal system (Jenkins et al., 2016). Systemic and central serotonin pools are 
separated by the blood brain barrier.  
1.7.2 Broad serotonergic transmission in respiratory control  
The role of the serotonergic system in respiratory control: evidence from complete loss of 
serotonergic function studies. 
5-HT knockout mouse models have been developed to assess the role of 5-HT 
transmission in respiratory control in vivo. One such 5-HT KO mouse model is derived from 
deletion of transcription factor Pet-1, which is uniquely expressed in all 5-HT neurones 
(Hendricks et al., 2003, Cheng et al., 2003). Pet-1-/- mice lack ˜70% of their brainstem 5-
HT neurones, and function of the residual 5-HT neurones is compromised (Hendricks et 
al., 2003). Pet-1-/- mice show prolonged apnoea (cessation of breathing), and a reduced 
respiratory frequency, both of which improve after the first 2 weeks of life (Erickson et 
al., 2007). More complete loss of 5-HT neurones was achieved in Lmx1bf/f/p mice which 
had conditional knockout of the LIM homeobox transcription factor (Lmx1b) gene 
exclusively in Pet-1 expressing cells. Lmx1bf/f/p mice have complete (~99%) and specific 
loss of central 5-HT neurones, and have severely reduced levels of central 5-HT (Zhao et 
al., 2006). They, too, show frequent apnoea and breathing arrhythmias that improve with 
age (after the first 2 weeks of life) (Hodges et al., 2009). In both Pet-1-/- and Lmx1bf/f/p 
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mice, respiratory dysrhythmias could be reverted to a more regular respiratory pattern 
by central administration of 5-HT2A receptor agonist 2,5-dimethoxy-iodoamphetamine 
(DOI), substance P (SP) (alone or in combination with DOI), or 5-HT (Hodges et al., 2009). 
Despite normalization of baseline respiratory activity with age, both Pet-1-/- and Lmx1bf/f/p 
mice have significantly reduced ventilatory responses to hypercapnia as adults (Hodges 
et al., 2008, Cerpa et al., 2017). Intracerebroventricular infusion of 5-HT in Lmx1bf/f/p mice 
is reported to restore the hypercapnic ventilatory response to near control levels (Hodges 
et al., 2008).  
Large scale genetic KO of all serotonergic neurones is a multifaceted manipulation of the 
central nervous system, and one cannot exclude developmental effects and/or 
compensatory mechanisms to occur. In an effort to overcome these caveats, acute loss of 
function studies have been performed utilizing inhibitory DREADD hM4Di receptors 
expressed in all 5-HT neurones (targeted by serotonin transporter SLC6A4 gene 
expression) in adult mice (Ray et al., 2011). Similar to the effect of 5-HT KO in adult mice, 
acute pharmacogenetic inhibition of 5-HT activity had no effect on baseline respiratory 
activity, but did reduce the central chemoreflex in adult mice in vivo. 
To conclude, 5-HT KO mouse studies suggest that broad 5-HT transmission is involved in 
the central chemoreflex, but also in baseline respiratory control, at least during neonatal 
development. The ability to normalize baseline respiratory activity and the central 
chemoreflex by simply replacing missing neurotransmitters suggests the dysrhythmias in 
5-HT KO mice are not due to trophic effects (e.g. altered developmental network 
formation). Acute loss of function of the serotonergic system via activation of DREADD 
hM4Di expressed in all 5-HT neurones in adult mice resulted in a similar respiratory 
pattern as seen in adult 5-HT KO mice: normal baseline activity but a reduced hypercapnic 
response. This suggests that the normalization of baseline respiratory activity observed in 
KO mice is likely not the result of a compensatory mechanism. These findings have been 
interpreted to suggest that the general function of the serotonergic system as a whole in 
respiratory control switches from providing tonic respiratory drive during the neonatal 
period, to providing CO2 chemosensitive drive past neonatal age (Cerpa et al., 2017).  
Evidence for a role of serotonergic transmission in respiratory drive via mechanisms 
distinct from central chemoreceptor drive in rodents past neonatal age. 
The net effect of loss of function of the complete serotonergic system appears to affect 
central chemoreception, but not baseline respiratory activity. Nevertheless, more 
Chapter 1: General Introduction 
43 
 
selective manipulations of specific 5-HT receptor subtypes have been found to affect 
baseline respiratory activity in rats past neonatal age.  
In in situ WHBP of juvenile rats, systemic administration of 5-HT4 (GR113808) or 5-HT2A 
antagonist (MDL 11399) significantly reduced or completely eliminated the amplitude of 
integrated HN and PN burst activity, yet did not significantly affect HN and PN burst 
frequency (i.e. respiratory rate). In contrast, systemic administration of 5-HT2C antagonist 
(RS 102221) significantly decreased HN and PN burst frequency, and decreased their 
integrated burst amplitude. All three antagonists reduced population potential 
amplitudes and burst frequencies of pre-BötC inspiratory neurones in accordance with 
cognate effects observed in peripheral nerves (Ptak et al., 2009). In the same study, 
electrophysiological and IHC experiments indicate that direct 5-HT release from 
spontaneously active raphe obscurus neurones acts on 5-HT2A/2C/4  receptors in the 
pre-BötC and HN motor nucleus in rhythmically active acute slices (Ptak et al., 2009). The 
rhythmically active slices were of neonatal rats, but the pharmacology in these slices is in 
line with that in the in situ preparations of juvenile rats. It is therefore possible that the 
mechanisms observed in slices of neonates are also preserved in the in situ preparations 
of juvenile rats. Together, these findings indicate that respiratory activity in rats is 
dependent on endogenous 5-HT transmission, with distinct effects mediated by various 
5-HT receptor subtypes. 
Gain of function via ChR2-mediated rhythmic stimulation of Pet-1 expressing 5-HT 
neurones of the raphe obscurus showed an increase in respiratory frequency and 
diaphragmatic EMG amplitude in adult mice in vivo (Depuy et al., 2011). This breathing 
stimulation was attenuated, but not abolished (-55%) by methysergide (an antagonist for 
all 5-HT receptors except 5-HT1A/4). The residual potentiation may be dependent on 
5-HT1A/4 receptor transmission. Elevated FiCO2 (8%) was still able to potentiate further 
(+16%) respiratory activity. Extracellular single unit recordings of ChR2 expressing 5-HT 
neurones in the raphe obscurus showed that these did not respond to hypercapnia (up to 
10% CO2) in anesthetized rats in vivo. Correspondingly, ChR2 stimulation of Pet-1 5-HT 
neurones in the raphe obscurus did not potentiate the hypercapnic (8% CO2) respiratory 
response in vivo. Thus, serotonergic raphe obscurus neurones enhance respiratory drive 
via a mechanism distinct from that underlying respiratory central chemoreflex responses. 
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1.7.3 Serotonin 1A receptor transmission in respiratory control  
The subtype of 5-HT receptor that is most extensively expressed in the respiratory 
network is 5-HT1A (Richter et al., 2003). There is increasing interest in 5-HT1A receptor 
transmission for its ability to stabilize respiratory dysrhythmia, presumably through 
depression of inhibitory neurones in the network. The current section will review the 
evidence for the effect of 5-HT1A transmission on respiratory activity, and the mechanisms 
thought to underlie this effect.  
Molecular mechanisms by which 5-HT1A R transmission exerts inhibition of neurones. 
The primary signalling cascade by which 5-HT1A agonism affects intracellular processes is 
via an exchange of GDP for GTP on the α subunit of the inhibitory Gi/o protein, which 
results in inhibition of adenylyl cyclase (AC), which then results in a decrease of cyclic 
adenosine monophosphate (cAMP) production, and ultimately, reduced protein kinase A 
(PKA) activity (Cooper and Londos, 1982). 5-HT1A receptors are also able to activate G 
protein-coupled inwardly rectifying potassium channels (GIRKs) (reviewed in Polter and Li 
(2010)). GIRK activation profoundly hyperpolarizes neurones and inhibits neuronal firing. 
GIRK activation is primarily mediated by G protein βγ subunits (Clarke et al., 1987). Also 
mediated by the G protein βγ subunit in response to 5-HT1A receptor activation, is the 
inhibition of voltage-gated Ca2+ channel activity (Chen and Penington, 1996, Bayliss et al., 
1997a). This results in a reduction of calcium entry. Thus, Giα / Goα activity in response to 
5-HT1A receptor binding results in inhibition of intracellular mechanisms that are mediated 
by the AC-cAMP-PKA pathway. In addition, activation of G protein βγ subunits in response 
to 5-HT1A receptor activation results in activation of GIRK channels and inhibition of 
voltage gated Ca2+ channels which results in direct inhibition of neuronal firing. A 
schematic representation of these signalling mechanisms in response to 5-HT1A receptor 
activation is provided in figure 1-9. 
It should be noted that these are not the only mechanisms by which 5-HT1A receptors 
affect their host cells. In fact, 5-HT1A receptors are coupled to the broadest range of 
second messengers of all serotonergic receptors. Other intracellular pathways regulated 
by regulated by 5-HT1A receptors include, but are not limited to: the mitogen-activated 
protein kinases (MAPK/ERK) pathway; and the phosphoinositide 3-kinase (PI3K) and 
protein kinase B/Akt pathway (reviewed in Chilmonczyk et al. (2015)). Given their 
relevance to neural excitability, emphasis in the present thesis is on 5-HT1A mediated 
inhibition of the AC-cAMP-PKA pathway, activation of GIRKs, and inhibition of voltage 
gated Ca2+ channels.  






Figure 1-9: Signalling pathways regulated by the 5-HT1A receptor. 
Giα/Goα activity in response to 5-HT1AR binding results in inhibition of 
intracellular mechanisms that are mediated by the AC-cAMP-PKA pathway 
(left). In addition, activation of G protein βγ subunits in response to 5-HT1A 
receptor activation results in activation of GIRK channels and inhibition of 
voltage gated Ca2+ channels which results in direct inhibition of neuronal firing 
(right). Figure adapted from Richter et al. (2003). 
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Many studies report augmented respiratory activity in response to 5-HT1A R agonist 
treatment 
The majority of studies performed to investigate the effect of 5-HT1A receptors on 
respiratory activity has utilized the drug (R)-(+)-8-hydroxy-2-(di-n-propylamino) tetralin 
hydrobromide (8-OH-DPAT). This drug has high affinitiy for 5-HT1A receptors, but it is also 
reported to have moderate affinity for 5-HT7 receptors in both rat (Hedlund et al., 2004) 
and human receptors (in human, 5-HT1A R pKi ranges from 8.4-9.4, and 5-HT7 R pKi ranges 
from 6.3-7.6 (guidetopharmacology.org, ligand ID: 7)). Systemic or central administration 
of 8-OH-DPAT results in augmented amplitude and/or frequency of integrated respiratory 
muscle and/or motor nerve activity and in spontaneously breathing anesthetized adult 
rats and cats (Szereda-Przestaszewska and Kaczynska, 2007, Valic et al., 2008, Besnard et 
al., 2012, Besnard et al., 2009, Manzke et al., 2009) or in in situ WHBP of rats and mice 
(Manzke et al., 2009, Manzke et al., 2010). Subsequent administration of 5-HT1AR 
antagonist and dopamine receptor D4 agonist WAY-100635 (Chemel et al., 2006, Martel 
et al., 2007) abolished these effects (Szereda-Przestaszewska and Kaczynska, 2007, Valic 
et al., 2008). Administration of WAY-100635 without any prior administration of 8-OH-
DPAT reduced upper airway muscle respiratory activity in anesthetized rats (Besnard et 
al., 2012, Besnard et al., 2007), and phrenic nerve activity in in situ WHBP of rats (Manzke 
et al., 2009) to below baseline levels. Thus, 5-HT1A receptors are endogenously active 
under baseline conditions and have an excitatory role in resting respiratory activity in in 
vivo and in in situ in rodents. The net effect of activation of 5-HT1A/7 receptors with 8-OH-
DPAT is also enhanced respiratory drive. 
In an effort to get an impression of the relative contributions of 5-HT1A transmission and 
5-HT7 transmission to the effects on respiratory activity of 8-OH-DPAT administration, 
(Manzke et al., 2009) recorded phrenic nerve activity before and after administering 5-
HT1A R or 5-HT7 R agonists or antagonists in in situ WHBP of rats. Application of 5-HT7R 
agonist (5-CT) significantly reduced minute respiratory activity derived from phrenic nerve 
activity. Respiratory activity was suppressed further after additional block of 5-HT1A 
receptor transmission with antagonist WAY-100635. Conversely, minute respiratory 
activity was enhanced when 8-OH-DPAT was administered after initial administration of 
5-HT7R antagonist (SB269970). Thus, while the net effect of 5-HT1A/7 receptor activation 
with 8-OH-DPAT is a stimulation of respiratory activity, the effect of 5-HT7 activation 
appears to be a reduction of respiratory drive. The increased respiratory activity observed 
after administration of 8-OH-DPAT appears attributable to activation of 5-HT1A receptors.  
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The effects of 8-OH-DPAT administration on resting respiratory activity in anaesthetised 
rats persisted after vagotomization, but carotid body denervation prevented the increase 
in breathing rate (Szereda-Przestaszewska and Kaczynska, 2007). Comparison of Fos 
expression in 8-OH-DPAT treated rats versus controls revealed significant increases in Fos 
expression after 8-OH-DPAT administration in the nucleus tractus solitarius, nucleus 
raphe pallidus, retrotrapezoid nucleus, lateral parabrachial, and Kölliker-Fuse nuclei 
(Besnard et al., 2012). 5-HT1A Receptors are expressed in the BötC, and pre-BötC (Manzke 
et al. 2009; Manzke et al. 2010), and commissural NTS of rats (Vantrease et al., 2015). 
Together, these findings suggest that key components of peripheral chemoreflex 
respiratory response circuitry (carotid bodies and NTS) are involved in the respiratory 
response to 8-OH-DPAT. By extension of the above findings, the peripheral chemoreflex 
response may be affected by 8-OH-DPAT. However, possible effects of 5-HT1A 
transmission on the peripheral respiratory chemoreflex remain unexplored to date. The 
central chemoreflex, on the other hand, is reported to be significantly attenuated (22% 
reduction) by microdialysis of 8-OH-DPAT in the proximity of the rostral raphe pallidus 
and raphe magnus regions in conscious rats (Li et al., 2006). Systemic administration of 
8-OH-DPAT in in situ WHBP of juvenile rats results in a loss of the hypercapnic respiratory 
response (Corcoran et al. 2013). Finally, administration (i.v.) of 8-OH-DPAT resulted in a 
fall of arterial pressure in anesthetized rats (Szereda-Przestaszewska and Kaczynska, 
2007). The mechanisms underlying this effect are currently unknown. 
5-HT1A autoreceptors and 5-HT1A heteroreceptors have opposing effects on respiratory 
control 
Serotonin 1A receptors can be found post-synaptically in various brainstem regions 
involved in respiratory control (BötC and pre-BötC (Manzke et al., 2009, Manzke et al., 
2010), but they are also found in high numbers pre-synaptically in serotonergic raphe 
neurone somata and dendrites (Beaudoin-Gobert and Sgambato-Faure, 2014, Sotelo et 
al., 1990). The pre-synaptic 5-HT1A receptors are referred to as 5-HT1A autoreceptors, 
whereas post-synaptic 5-HT1A receptors on non-serotonergic neurones are denoted 
hetero-receptors. From a network perspective, 5-HT1A hetero-receptors and 
auto-receptor transmission have inverse effects.  5-HT1A auto-receptor activation 
decreases serotonergic tone and inhibits further 5-HT release, and thereby constitutes a 
negative feedback loop that inhibits the entire 5-HT system. This means that 5-HT1A auto-
receptor activation can result in reduction of 5-HT1A heteroreceptor activation 
(Chilmonczyk et al., 2015).  
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Until recently, little was known about the relative contribution of both populations of 
receptors to the net effect of 5-HT1A agonism on respiratory control. In order to 
differentiate auto-receptor versus hetero-receptor effects of 8-OH-DPAT on respiratory 
drive, Corcoran et al. (2014) used rhythmically active medullary slices with HN rootlets 
from WT mice and from Lmx1bf/f/p neonatal mice which had a complete absence of 
central 5-HT neurones (i.e. no 5-HT1a auto-receptors, only hetero-receptors) and 
recorded the HN respiratory output in response to 8-OH-DPAT in vitro. 8-OH-DPAT bath 
application promoted increased hypoglossal nerve burst frequency in slices from 
Lmx1bf/f/p mice, but not in slices from WT mice. This effect was abolished by blockade of 
synaptic inhibition via bath co-administration of GABAA-, and glycine receptor antagonists 
(gabazine, CPG 55845, and strychnine). Interestingly, after 10 minutes of 8-OH-DPAT 
administration, HN burst frequency returned to baseline levels in slices from Lmx1bf/f/p 
mice, but was depressed in slices from WT rats. The authors concluded that 5-HT1A hetero-
receptors and auto-receptors may have physiologically competing effects: fast-onset 
stimulation of breathing due to hetero-receptor mediated inhibition of glycinergic and 
GABAergic respiratory interneurones (disinhibition), and slow-onset inhibition due to 
auto-receptor agonism. 
5-HT1A transmission may enhance respiratory drive through suppression of inhibitory 
respiratory interneurones. 
5-HT1A receptor transmission inhibits its host neurones, yet the effect of 8-OH-DPAT 
administration on the respiratory network is stimulatory. The augmented respiratory 
drive has been postulated to be the result of augmented glycinergic transmission in 
inhibitory respiratory interneurones, leading to disinhibition of their post-synaptic targets 
(Shevtsova et al., 2011, Manzke et al., 2009, Manzke et al., 2010).  
In vivo patch clamp recordings of Post-I neurones in the BötC, combined with 
simultaneous recordings of the phrenic nerve in anesthetised cats revealed that systemic 
administration of 8-OH-DPAT increases excitability of these neurones. This effect was 
most pronounced in post-I neurones, which are putatively glycinergic (Ezure et al., 2003, 
Schmid et al., 1991). The recorded Post-I neurones exhibited a release from inspiratory 
inhibitory input, causing them to advance the onset of their bursting activity far into the 
preceding inspiratory phase of the respiratory cycle. At higher concentrations of 8-OH-
DPAT, this release of inspiratory inhibition was combined with a hyperpolarizing K+ 
current that suppressed action potentials of these post-I neurones throughout most of 
the respiratory cycle (low levels of late inspiratory activity persisted, coincident with 
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depolarizing post-synaptic currents). At the network level, the authors also observed a 
shortening of both the inspiratory and expiratory phase, which resulted in an increase in 
PN burst frequency, after administration 8-OH-DPAT. The responses to systemic 
8-OH-DPAT at the network level (PN output) and at the cellular level (Post-I neurone 
activity) observed by Manzke et al. (2009) were reproduced in silico in computational 
simulations based on extensions of the inhibitory ring model (Shevtsova et al., 2011). This 
computational model hypothesises that systemic administration of 8-OH-DPAT at low 
concentrations results in 5-HT1AR mediated augmentation of glycine α3 receptor (Glyα3R) 
inhibitory currents in Early-I and Aug-E neurones. This was suggested to contribute to the 
shortening of inspiratory and expiratory phase durations observed in PN activity. 
Additionally, suppression of Early-I neurones was hypothesised to result in a release from 
post-synaptic inhibition of Post-I neurones during inspiration. This release from 
inspiratory inhibition is suggested to underlie the advancement of Post-I neurone activity 
into the inspiratory phase. The near-complete silencing of Post-I neurones through 
hyperpolarizing K+ currents, which was observed at higher concentrations of 8-OH-DPAT, 
was suggested to be the result of 5-HT1A R mediated activation of GIRK channels in Post-I 
neurones.  
The notion that the augmented respiratory drive is mediated by modulation of glycinergic 
transmission is inspired by the finding that 8-OH-DPAT directly induced 
dephosphorylation of Glyα3R’s, which augmented glycine-activated inhibitory Cl- currents 
in HEK293 cells co-expressing 5-HT1A and Glyα3R’s (Manzke et al., 2010). Further, 
8-OH-DPAT mediated enhancement of PNA frequency was abolished when glycine 
receptors were blocked by systemic application of strychnine before or after 
administration of 8-OH-DPAT in situ and in vivo in rats (Manzke et al., 2010, Manzke et al., 
2009). The latter findings, however, are difficult to interpret, as systemic blockade of 
glycinergic transmission likely has confounding effects on respiratory CPG network 
interactions. With regard to the computational model by Shevtsova et al. (2011), it should 
be noted that the assumed distribution of Glyα3R and 5-HT1A Receptor (co)expression in 
various VRC respiratory neurone functional subpopulations is not experimentally verified. 
Furthermore, potential effects of 5-HT7 transmission on the respiratory network, or 
potential 5-HT1A-mediated modulation of receptors other than Glyα3R’s are not taken into 
account. Nonetheless, the model is able to reproduce experimental findings at both the 
cellular and network level, and it provides testable hypotheses on putative mechanisms 
by which systemic 5-HT1A transmission may affect respiratory activity.  
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1.8 THERAPEUTIC RELEVANCE OF 5-HT1A TRANSMISSION 
Recently, there is increased interest in the therapeutic potential of 5-HT1A receptor 
agonists for treatment of breathing abnormalities. This section will discuss the potential 
of 5-HT1A agonists in the in the treatment of opioid induced respiratory depression, and 
in symptomatic treatment of respiratory dysrhythmia in Rett syndrome. 
1.8.1 Therapeutic relevance of 5-HT1A transmission in averting opioid induced 
respiratory depression. 
Opioid-based analgesics are the most often used therapeutic drugs for the relief of 
moderate to severe nociceptive pain that may occur following surgical operation or major 
trauma, or for the management of chronic nociceptive pain. An opioid-related adverse 
effect is respiratory depression due to inhibitory μ-opioid receptor (μOR) activation in 
brainstem regions of respiratory control (Dahan et al., 2018). This is of particular concern 
to clinicians as respiratory depression is potentially lethal. Outside the clinic, too, 
overdose of prescription or illicit opioids, or co-administration of opioids with central 
nervous system depressants may evoke respiratory depression. One strategy to mitigate 
opioid induced depression is to counteract it through co-treatment with respiratory 
stimulants. To be effective, the respiratory stimulants should prevent respiratory 
depression, without affecting the analgesic effect of opioids.  
The augmented respiratory drive in response to 5-HT1A receptor agonists reveals a 
potential strategy to avert opioid-induced respiratory depression. 5-HT1A/7 agonist 8-OH-
DPAT has been postulated to enhance respiratory drive via augmented glycinergic 
(Shevtsova et al., 2011, Manzke et al., 2009, Manzke et al., 2010) transmission in inhibitory 
respiratory interneurones, leading to disinhibition of their post-synaptic targets (see 
section 1.7.3). Systemic administration 8-OH-DPAT is reported to also counteract 
respiratory depression in response to fentanyl (μOR agonist) in in situ WHBP of juvenile 
rates in in vivo rats (Manzke et al., 2009, Shevtsova et al., 2011, Dutschmann et al., 2009b, 
Guenther et al., 2009), without antagonising anti-nociception (Guenther et al., 2009). 
Enhancement of respiratory drive in response to 8-OH-DPAT administration is suggested 
to be mediated by 5-HT1A transmission induced dephosphorylation of Glyα3 receptors, 
which resulted in augmented glycinergic inhibition (Shevtsova et al., 2011, Manzke et al., 
2009, Manzke et al., 2010) (see section 1.7.3). This notion is consistent with the finding 
that 5-HT1A receptor activation with 8-OH-DPAT failed to counteract opioid reduced 
respiratory depression in Glyα3 receptor deficient mice (Manzke et al., 2010). Since 5-HT1A 
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R mediated potentiation of glycinergic currents is a pathway distinct from opioid receptor 
activation, it is plausible that 5-HT1A transmission can enhance respiratory drive without 
interfering with opioid analgesic effects. Therefore, 5-HT1A receptor agonists may have 
potential for clinical use in prevention of opioid-induced depression.  
The problem with most available 5-HT1A receptor agonists today is insufficient selectivity 
(Dahan et al., 2018). Sufficient efficacy is also important, as the selective, but partial 
5-HT1A receptor agonist buspirone was found not effective to reverse morphine induced 
respiratory depression in humans (Oertel et al., 2007). 8-OH-DPAT is not available for 
clinical use and has moderate affinity for 5-HT7 receptors. A recently developed highly 
selective 5-HT1A full agonist NLX-112 (also known as befiradol or F13640) was reported to 
induce robust reduction of fentanyl induced respiratory depression in rats. However, in 
contrast to earlier findings with 8-OH-DPAT by Guenther et al. (2009), the authors also 
report concomitant decreases in fentanyl-induced analgesia, and altered nociception (Ren 
et al., 2015). The underlying mechanisms for the latter are as yet unclear.  
1.8.2 Therapeutic relevance of 5-HT1A transmission in rescue from respiratory 
dysrhythmia symptoms in Rett syndrome. 
Rett syndrome (RTT) is a neurological disorder most often caused by loss of function of 
transcriptional regulator methyl-CpG-binding protein 2 (MeCP2) (Chahrour et al., 2008, 
Percy, 2016, Young et al., 2005). RTT is most often linked to mutations in the X linked gene 
that encodes MeCP2, and it affects 1 in ~10,000 live female births (Chahrour and Zoghbi, 
2007). RTT in males is rare, as most boys with MECP2 mutations die in utero or early 
infancy (Jiang et al., 2017). Symptoms in humans start at 6-18 months after birth, and 
include severe mental disability, epilepsy (Dolce et al., 2013), and dystonia, and dyskinesia 
(Chahrour and Zoghbi, 2007). An additional, life-threatening symptom of RTT is breathing 
abnormalities as a result of brainstem dysfunction. Breathing abnormalities account for 
~26% of sudden and unexpected deaths in RTT patients (Weese-Mayer et al., 2006, 
Bissonnette and Knopp, 2006). The severity and development of clinical symptoms in RTT 
are variable, putatively as a result of random X-chromosome inactivation (Nagarajan et 
al., 2008), but respiratory abnormalities typically include: apneusis (abnormally prolonged 
inspiration producing breath-holding, followed by inadequate expiration) or episodic 
apnoea (cessation of breathing); Valsalva breathing (active expiration against a closed 
glottis);  air swallowing; gasping; and Cheyne-Stokes breathing (alternating hyper- and 
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hypoventilation) (Ramirez et al., 2013, Bissonnette and Knopp, 2006, Weese-Mayer et al., 
2006) 
The symptoms of respiratory dysrhythmia in humans with RTT can be reliably mimicked 
by knockout or loss-of-function mutations of the MeCP2 gene in female (MeCP2 -/+) or 
male (MeCP2-/Y) mice (reviewed in Jiang et al. (2017)). Even though complete loss of 
MeCP2 is lethal in human males, hemizygous MeCP2-/Y male mice can survive up to twelve 
weeks. MeCP-/Y mice develop breathing abnormalities from 2-3 weeks of age, and 
experience phenotypic regression which ultimately becomes lethal. Female Mecp+/- mice, 
on the other hand, have a normal lifespan and develop breathing abnormalities after 6-7 
months of age (Abdala et al., 2010, Levitt et al., 2013, Samaco et al., 2013, Schmid et al., 
2012). Male Mecp-/Y mouse models present a relatively homogenous pathological 
phenotype compared to humans with RTT (Chao et al., 2007), which is useful for 
systematic dissection of the mechanisms underlying the symptoms in this mouse model. 
However, as RTT occurs primarily in human females, Mecp2-/Y mice provide limited 
translational applicability. Therefore, therapeutic strategies derived from experiments 
with Mecp-/y mice need to be validated in Mecp2+/- females.   
 
Chemoreflex function disturbances are thought to underlie frequent apnoea in mouse and 
human 
Two known contributing factors to the respiratory symptoms in RTT mouse models and 
humans with RTT are reduced CO2 sensitivity, and a disruption of interactions between 
pontine and medullary regions of respiratory control. The current section will address the 
reduced CO2 sensitivity, the section thereafter will address the disruption of ponto-
medullary interactions. 
The prevalence of breathing dysrhythmia in humans and RTT mice appears negatively 
correlated with the CO2 sensitivity of the respiratory network. Both male Mecp2-/Y (Zhang 
et al., 2011b) and female Mecp2+/- mice (Bissonnette et al., 2014) show reduced CO2 
sensitivity. Specifically, Mecp2-/Y mice fail to increase ventilation in response to moderate 
hypercapnia (1-3% PCO2), and only respond with increased tidal volume and respiratory 
rate to severe hypercapnia (6-9% PCO2) (Zhang et al., 2011b). Crucially, enhanced 
respiratory drive in response to high pCO2 was coupled with a drastic inhibition of 
breathing irregularity in male Mecp2-/Y mice (Zhang et al., 2011b). Consistent with these 
findings, brainstem expression of multiple CO2/pH sensitive ion channels is altered in a 
way that results in reduced pH sensitivity of their host neurones in male Mecp2-/Y mice 
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(Zhang et al., 2011b). In humans (Smeets et al., 2006, Halbach et al., 2012) as well as 
Mecp2+/- mice (Bissonnette and Knopp, 2006), periods of hyperventilation and forceful 
breathing often alternate with periods of hypoventilation and apnoea. The repeated 
alternation between hyper- and hypoventilation is thought to be exacerbated by reduced 
CO2 sensitivity. Episodes of forceful breathing and hyperventilation result in hypocapnia. 
This, in combination with an upwards-shifted apnoeic threshold due to reduced CO2 
sensitivity then promotes episodes of apnoea (Bissonnette and Knopp, 2006, Toward et 
al., 2013), which leads to oxygen desaturation (Southall et al., 1988) and likely contributes 
to repetition of hyperventilation. Thus, in both humans with RTT, and in male and female 
Mecp2 deficient mice, reduced CO2 sensitivity leads to an increased apnoeic threshold. 
This can promote apnoea and contribute to repeated alternation of hyper- and 
hypoventilation. 
Pontine contributions to respiratory dysrhythmia in Rett syndrome 
In in situ WHBP of Mecp2-/Y male mice, and Mecp2+/- female mice, apnoea are 
characterized by enhanced activity and duration of Post-I activity in the cVN during the 
initial portion of the apnoea (Stettner et al., 2007, Abdala et al., 2010), combined with 
tonic discharge of the HN throughout the apnoea (Abdala et al., 2010). As addressed in 
section 1.1.2 Post-I cVN activity is linked to contraction of the laryngeal adductors that 
control expiratory airflow via closure of the glottis.  
Section 1.3.2, describes how Post-I activity is mediated by excitatory drive from the 
pontine KF to post-I neurones in the BötC. Active breath-hold, apnoea, and Valsalva 
manoeuvres through laryngeal adductor contraction, common features of disordered 
breathing in RTT, are suggested to be the result of disrupted ponto-medullary gating of 
Post-I activity (Abdala et al., 2014a, Ramirez et al., 2013). Ponto-medullary gating of Post-
I activity is also thought to control inspiratory to expiratory phase transitioning and the 
duration of inspiratory and expiratory phases (Barnett et al., 2018) (see section 1.3.2). 
Disruption of pontomedullary mechanisms for inspiratory-to-expiratory phase 
transitioning can result in the respiratory dysrhythmia often observed in the RTT 
respiratory phenotype, as it leads to disrupted timing of termination of the inspiratory 
phase, and expiratory phase duration irregularity.  Thus, disruptions in the rhythm and 
pattern of excitatory drive from KF neurones projecting to BötC Post-I neurones are 
thought to contribute to RTT respiratory symptoms related to control of laryngeal 
contraction and disruptions in respiratory phase transitioning. 
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Excitatory drive from the KF to post-I BötC neurones can be mediated by inhibitory 
transmission in the parabrachial complex. Previous sections (section 1.4.4) reviewed 
evidence that modulation of inhibitory transmission in the KF via focal administration of 
GABAA agonist or antagonist inhibits and enhances, respectively, Post-I activity in in situ 
WHBP of rats (Jenkin et al., 2017, Abdala et al., 2016). Mecp2+/- mice show deficiency of 
GABA perisomatic bouton-like puncta in the KF (Abdala et al., 2016). It is therefore 
plausible that deficits in synaptic inhibition in the KF underlie the exacerbation in Post-I 
activity which contributes to the breathing abnormalities in RTT. Indeed, systemic 
administration of GABA reuptake blocker (NO-711 hydrochloride) markedly reduced 
occurrence of central apnoea in Mecp2 deficient mice (Abdala et al., 2010). This effect 
was recapitulated with focal micro-injections of NO-711 in the KF of Mecp2+/- mice (Abdala 
et al., 2016). Conversely, blockade of GABAA receptors in the KF of WT rats with micro-
injections of GABAA antagonist bicuculline mimicked the RTT respiratory phenotype of 
recurrent central apnoea and prolonged Post-I activity (Abdala et al., 2016). Therefore, 
pharmacotherapeutic enhancement of synaptic inhibition in the KF may be an effective 
strategy for reversal of respiratory abnormalities in Rett syndrome.   
Therapeutic potential of 5-HT1A agonists in symptomatic treatment of abnormal breathing 
in Rett syndrome 
Deficits in inhibitory transmission could be treated with drugs that augment GABAergic 
transmission. Benzodiazepines, positive modulators of GABAA receptors, can be effective 
in reversing respiratory dysrhythmia (Abdala et al., 2010), yet they are suboptimal for 
clinical application due to their addictive and sedative properties. Moreover, GABA is one 
of the main inhibitory neurotransmitters and it has an important role in the generation of 
respiratory rhythm (and many other functions in the brain), it is therefore not a suitable 
therapeutical target for selective stabilization of respiratory rhythm. Indeed, although 
augmented GABAergic transmission can reduce isolated apnoea and periodic breathing in 
Mecp2+/- mice, it also results in a distorted respiratory pattern relative to that of naive WT 
mice (Abdala et al., 2010). This prompted the search for alternative inhibitory 
neurotransmitters that might be of clinical relevance to reverse abnormal breathing 
patterns in RTT. 
Deficiencies of 5-HT neurotransmission have been found in Mecp2 deficient mice, and in 
humans with RTT. In humans suffering from RTT, deficiency of 5-hydroxyindoleacetic acid 
(5-HIAA), a 5-HT metabolite, was found in spinal fluid (Samaco et al., 2009). Similarly, low 
brain concentrations of 5-HT were found in Mecp2-/Y male mice, and this deficiency 
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progressed with age (Ide et al., 2005, Viemari et al., 2005). In Mecp2-/Y mice, brain 
concentrations of 5-HT precursor tryptophan were comparable to WT mice, which 
suggests 5-HT deficiencies in these mice are due to a failure in 5-HT biosynthesis (Ide et 
al., 2005, Viemari et al., 2005). Systemic administration of citalopram, a selective 
serotonin reuptake inhibiter, was found to reverse reduced CO2 sensitivity in Mecp2 
deficient conscious mice (Toward et al., 2013). Further, systemic administration (Abdala 
et al., 2010) or focal micro-injection in the KF (Abdala et al., 2014b) of 5-HT1A/7 receptor 
agonist (8-OH-DPAT) can depress respiratory apnoea in Mecp2-/+ conscious mice and in 
situ WHBP of Mecp2+/- mice, respectively. It is, therefore, suggested that restoration of KF 
inhibitory transmission can also be mediated by augmented transmission of inhibitory 
5-HT1A receptors, resulting in a clinically relevant stabilization of the respiratory pattern 
in mouse models of RTT (Abdala et al., 2014a, Wittman et al., 2019). Together, these 
findings suggest that manipulation of 5-HT transmission may be an effective strategy for 
symptomatic treatment of breathing abnormalities in RTT. 
The search for 5-HT1A R agonists with clinical potential to stabilize respiratory activity and 
enhance respiratory drive is still ongoing. Sarizotan is a clinically approved 5-HT and 
D2-Like receptor agonist previously tested for L-dopa induced dyskinesia in the treatment 
of Parkinson’s disease (Goetz et al., 2007). In separate 7 day and 14 day studies, sarizotan 
reduced the incidence of apnoea (to 15% of pre-treatment level) and irregular breathing 
in three different female mouse models of RTT in conscious animals (Abdala et al., 2014b). 
This indicates that sarizotan is a viable candidate for clinical treatment of abnormal 
breathing in RTT. However, a phase 2/3 clinical trial with sarizotan for the symptomatic 
treatment of respiratory dysrhythmia in Rett syndrome has recently been terminated due 
to lack of efficacy (ClinicalTrials.gov Identifier: NCT02790034).  
A second family of 5-HT1A receptor agonists that may have clinical potential are 1-(1-
benzoylpiperidin-4-yl)methanamine derivates, of which drug discovery and clinical 
development is an ongoing process (Sniecikowska et al., 2019a, Sniecikowska et al., 
2019b). One 1-(1-benzoylpiperidin-4-yl)methanamine derivate of note is the selective 
5-HT1AR agonist NLX-101 (formerly named F15599). In rat cortex, striatum, and 
hippocampal tissue, NLX-101 showed 1000-fold higher binding affinity for 5-HT1A 
receptors over other 5-HT receptors, and over dopamine-, and adrenoreceptors in vitro. 
In addition, NLX-101 did not interact with a wide range of other receptors, ion channels, 
or monoamine transporters (Newman-Tancredi et al., 2009). Given its high selectivity for 
5-HT1A receptors, this novel compound may also have therapeutic potential for treatment 
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of respiratory symptoms in Rett syndrome. Systemic administration of NLX-101 was found 
to reduce apnoea and improve breath irregularity in unanaesthetised male Mecp2-/Y and 
female Mecp2-/+ mice in vivo in a dose dependent manner (Levitt et al., 2013). 
Interestingly, NLX-101 is reported to preferentially activate Gαi subunits over Gαo 
subunits at 5-HT1A receptors in vitro (Newman-Tancredi et al., 2009). Differences in host 
cell environment can determine which G-proteins interact with a G-protein coupled 
receptor (GPCR). This can result in differential recruitment of intracellular responses in 
response to GPCR agonism across neural subpopulations. In vivo and ex vivo experiments 
in rats reveal that NLX-101 induces hetero-receptor mediated responses with greater 
potency than it induces auto-receptor mediated responses (Llado-Pelfort et al., 2010). 
Similarly, pharmacological magnetic resonance imaging (phMRI) and positron emission 
tomography (PET) studies in cats and rats reveal that systemic administration of NLX-101 
results in anatomical patterns of energy metabolism that suggest preferential activation 
of cortical regions over raphe regions (Becker et al., 2016, Levigoureux et al., 2019, Vidal 
et al., 2018, Vidal et al., 2020). Based on these findings, it has been suggested that the 
preferential activation of Gαi subunits over Gαo subunits at 5-HT1A receptors may 
translate to a functional bias of NLX-101 for hetero-receptors over auto-receptors (Llado-
Pelfort et al., 2010). It should be noted that, from a clinical perspective, functional bias of 
a drug is only relevant when one can achieve clinical efficacy at the desired cell population 
without also saturating the response of the less responsive populations. To illustrate, in 
the above-mentioned experiments by Levitt et al. (2013), despite putative selectivity for 
hetero-receptors, the experimental dose (1μM) of NLX-101 was sufficient to activate 5-
HT1A auto-receptor mediated G protein-coupled inwardly rectifying potassium channels 
(GIRK) conductance in all recorded (n=7) dorsal raphe neurones. Whether the suggested 
functional bias for hetero-receptor activation of NLX-101 is clinically relevant, remains to 
be established.      
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1.9 THESIS AIMS 
The previous sections of this general introduction outlined how eupnoeic breathing and 
respiratory reflex responses are the result of an interplay between medullary 
rhythmogenic circuitry, pontine inputs, inputs from central chemoreceptor neurones in 
the RTN and raphe nuclei, and CB peripheral chemoreceptor input relayed via the NTS. 
Furthermore, interactions between the respiratory CPG, the CVLM, and RVLM pre-
sympathetic neurones mediate the coupling of respiratory activity to sympathetic activity. 
5-HT1A R transmission is thought to modulate the respiratory control network. However, 
the precise effects of selective 5-HT1AR transmission on respiratory and respiratory-
entrained sympathetic output, and the putative mechanisms from which such effects 
arise, are poorly understood.  
1.9.1 5-HT1A transmission in respiratory control: current knowledge of its effects 
and mechanisms, and the gaps in understanding. 
Systemic administration of 5-HT1A R agonists is reported to enhance respiratory drive 
(Szereda-Przestaszewska and Kaczynska, 2007, Valic et al., 2008, Besnard et al., 2012, 
Besnard et al., 2009, Manzke et al., 2009, Manzke et al., 2010) (see section 1.7.3) and 
stabilize the respiratory rhythm (Abdala et al., 2010, Abdala et al., 2014b, Abdala et al., 
2014a, Levitt et al., 2013) (see section 1.8.2). Pharmacological therapies targeting 5-HT1A 
transmission are therefore thought to have therapeutic potential for the treatment of 
respiratory depression or respiratory dysrhythmia. Various mechanisms have been 
proposed to explain these effects, many of which rely on 5-HT1A R mediated inhibition of 
inhibitory neurones, resulting in disinhibition of inspiratory populations (Shevtsova et al., 
2011). A feature that the mechanisms suggested to underlie 5-HT1A mediated 
enhancement of respiratory drive and stabilization of respiratory rhythm have in 
common, is that they are linked to activity at 5-HT1A heteroreceptors, i.e. 5-HT1A receptors 
expressed on non-serotonergic neurones. Moreover, activity at auto-receptors, i.e. those 
expressed on serotonergic neurones, could have negative effects on ventilation thwarting 
some of the expected therapeutic benefit. For instance, 5-HT1A transmission at the rostral 
raphe pallidus and raphe magnus is reported to affect the respiratory central chemoreflex 
response in rats (Li et al., 2006) (see section 1.7.3). It has been proposed that activation 
of 5-HT1A auto-receptors at chemosensitive raphe neurones, would reduce 5-HT release 
at their target sites, thereby reducing central chemoreceptor tonus and reflex responses 
(Corcoran et al., 2014). Activity at these pathways is expected to produce negative effects 
on ventilation, since activity of central chemosensory neurones provides an essential tonic 
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drive to inspiratory neurones (see section 1.4). The simultaneous recruitment of 
physiologically antagonistic pathways by 5-HT1A agonists imposes significant limitations 
on the interpretation of literature data, especially since the most commonly used 
pharmacological tools had a less than ideal selectivity profile and no evidence of 
heteroreceptor bias. 
Previously, effects of 5-HT1A transmission on respiratory drive have predominantly been 
assessed with the use of a non-selective 5-HT1A/7 agonist (8-OH-DPAT). Some studies have 
used cocktails of 5-HT1A/7R agonist and 5-HT7 antagonist, or selective 5-HT7R agonists to 
establish the relative contributions of each receptor type to the effect of 8-OH-DPAT 
(Manzke et al., 2009). However, the suppression of 5-HT7 transmission itself in such 
experiments introduces confounding manipulations of the respiratory network, and one 
should be cautious to interpret the effects of 5-HT7 antagonism combined with 5-HT1A/7 
agonism as if it were a selective manipulation of 5-HT1A transmission. Thus, direct 
experimental evidence of the effect of selective 5-HT1A R agonism on resting breathing, 
central and peripheral chemosensory control, and sympatho-respiratory coupling 
remains to be established. Such information would be relevant to assess the therapeutic 
potential and potential adverse effects of 5-HT1A agonists in the treatment of respiratory 
rhythm disorders.  Further, proposed theories on putative mechanisms underlying the 
effect of 5-HT1A transmission on respiratory control assume an important role for 5-HT1A 
mediated inhibition of inhibitory neurones in the respiratory CPG. However, the 5-HT1A R 
expression profile throughout key brainstem regions of the respiratory CPG, and the 
further phenotype of neurones expressing 5-HT1A receptors (e.g. whether they are 
inhibitory neurones), is currently largely unknown. Finally, the current model describing 
putative network interactions suggested to underlie the effect of 5-HT1A transmission on 
respiratory control assumes expression of 5-HT1A R (and Glyα3 R) at specific respiratory 
neurone subpopulations (e.g. Pre-I/I-, Early-I-, Ramp-I-, Post-I/Dec-E, and Aug-E neurones) 
(Manzke et al., 2009, Manzke et al., 2010, Shevtsova et al., 2011) (see section 1.7.3). 
However, the distribution of 5-HT1AR among these functional respiratory neurone 
subtypes is yet to be experimentally established.  
1.9.2 Thesis aim and general hypothesis 
The overarching aim of this thesis is to establish the effects of systemic administration of 
selective 5-HT1A R agonist (NLX-101) on respiratory motor outputs and respiratory 
modulation of sympathetic activity, during rest and homeostatic respiratory reflexes, as 
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generated by the intact respiratory CPG network in in situ WHBP of juvenile rats. NLX-101 
is a highly selective 5-HT1A R full agonist with suggested biased agonism properties that 
are thought to translate to preferential activation of 5-HT1A hetero-receptors over auto-
receptors (Llado-Pelfort et al., 2010, Newman-Tancredi et al., 2009) (see section 1.8.2). 
Whether NLX-101’s pharmacology involves biased agonism or another mechanism is yet 
uncertain, but its reported effects are consistent with selective activity at of 5-HT1A 
heteroreceptors in other brain regions, with reduced recruitment of auto-receptors.  
The overarching hypothesis is that systemic administration of this selective 5-HT1AR 
agonist will result in net enhanced respiratory drives that are determinant of enhanced 
ventilation. 
1.9.3 Chapter aims  
The general thesis aim is addressed through experiments that are presented in chapters 
3, 4, and 5. Experiments in these chapters have the following aims: 
• Experiments in Chapter 3 aim to assess effects of systemic administration of 
selective 5-HT1A receptor agonist (NLX-101) on eupnoeic respiratory activity 
(recorded at PN, HN, cVN, and AbN) and the respiratory and sympathetic 
responses (recorded at PN, cVN, AbN, and tSN) to peripheral chemoreceptor 
stimulation and to hypercapnia in situ WHBP of juvenile rats.  
• Experiments in Chapter 4 aim to map key anatomical components of the 
respiratory system that (co-)express 5-HT1A receptor RNA and SLC32A1 RNA. The 
SLC32A1 gene encodes for vesicular inhibitory amino acid transporter, which is a 
marker of inhibitory GABA-ergic and/or glycinergic neurones 
• Experiments in Chapter 5 aim to identify which functional subtypes of respiratory 
neurones in the VRC are responsive to juxta-cellular pico-ejection of 5-HT1A R 





Chapter 2: GENERAL METHODS 
To avoid repetitions in the methods sections of results chapters, this general methods 
section will address elements of the experimental methods that apply to multiple 
chapters. 
2.1 ANIMALS AND ETHICAL APPROVAL 
All experimental procedures conformed to the UK Animals (Home Office Scientific 
Procedures) Act 1986 and were approved by the University of Bristol Animal Welfare and 
Ethics Review Body (AWERB). 
The experiments in this thesis involve use of male Wistar rats, and they include 
procedures carried out on animals that are covered under Dr. Ana Abdala’s Home Office 
license. The highest severity procedures carried out on animals in the studies reported 
here are ‘mild’. The system and interactions under study in this thesis involves 
interactions of elements along various levels of organization: i.e. circuit-level dynamics, 
modulated by peripheral cues (central-, and peripheral chemoreceptor activation) and 
serotonergic transmission, that control whole-organism physiological states. Such 
interactions, and their net outcome, can only truly be probed in a system in which these 
interactions still function, i.e. animals and in situ preparations derived from animals. A 
large body of research leading up to the aims and hypotheses in this thesis is based on 
computational modelling of known, and putative brainstem network interactions. 
Verification of the hypotheses supported by these computational models requires the use 
of animals as proposed in the current studies. Our data is shared with a collaborating 
group of computational modellers to optimally utilize the data acquired through the 
experimental procedures. The use of rats is most appropriate for these studies as for this 
species we can utilize a well-established in situ preparation that enables comprehensive 
monitoring of respiratory activities in each experiment, and it allows us to capitalize on a 
large body of existing experimental data obtained in the same species. The use of in situ 
preparations of rats ensures a relatively high level of refinement and reduction of the use 




2.2 IN SITU WORKING HEART BRAINSTEM PREPARATIONS (WHBP) 
2.2.1 In Situ WHBP background and justification. 
All electrophysiological recordings reported in chapters 3 and 5 were performed using the 
in situ perfused working heart-brainstem preparation (WHBP) of juvenile rats (Paton, 
1996b). This is a transcardially perfused preparation of a decerebrate rat with an 
otherwise intact rostral neuraxis, and an intact brainstem respiratory network. The in situ 
WHBP allows simultaneous electrophysiological recording of respiratory and sympathetic 
nerves: the PN, the cVN, the HN, the AbN, and the SN without the requirement of 
anaesthetics. Simultaneous recording of multiple peripheral nerves provides a 
comprehensive image of respiratory network activity and of potential changes in 
respiratory network function induced by experimental manipulations. Absence of 
anaesthesia is important as some anaesthetics are known to dampen respiratory (Dahan 
et al., 2018) and sympathetic (Wenker et al., 2017) network activity. The brainstem was 
exposed for electrophysiological recordings (field potential, extracellular single unit 
recordings) and focal micro-ejections or pico-ejections of drugs directly in the brain. Drugs 
can also be administered systemically via the perfusate. The metabolic state of 
preparations was controlled by changing CO2 and O2 levels in the perfusate. Peripheral 
chemoreceptors were stimulated via intra-arterial bolus injections of cyanide salt solution 
(see Figure 2-1). 
2.2.2 Anaesthesia, euthanasia, and surgical procedures for in situ WHBP. 
Male Wistar juvenile (50-90g, PND 21-29) rats received an I.P. injection of heparin sodium 
salt (1000 I.U.) and were subsequently deeply anesthetised with isoflurane until loss of 
paw withdrawal reflex. The rats were killed through exsanguination via a cut in the 
descending aorta and bisected below the L1 spinal region. Anaesthesia was subsequently 
withdrawn and the head and thorax was placed in ice-chilled carbogenated Ringer 
solution (for composition, see section 2.2.3). The preparation was de-cerebrated, skinned, 
and visceral organs were removed. Thoracic phrenic (PN), cervical vagus (cVN), 
hypoglossal (HN), thoraco-lumbar (T12–L1) abdominal iliohypogastric (AbN), and thoracic 
(T9-T10) sympathetic trunk (tSN) nerves were exposed and distally cut. The preparation 
was then transferred to a recording chamber, where a double lumen catheter (DLR-4, 
Braintree Scientific, Braintree, USA) was inserted into the descending aorta for retrograde 
transcardiac perfusion. One lumen of the catheter was used for transcardiac perfusion 




polyethylene glycol (PEG) 20,000 oncotic agent (Fisher Scientific UK Ltd. Loughborough, 
UK) at a temperature of 31°C. The other lumen was attached to a pressure transducer for 
continuous measurement of perfusion pressure simultaneously with perfusion. Perfusate 
flow was controlled with a peristaltic pump (Watson-Marlow 505D, Falmouth, Cornwall, 
UK) and drawn from a reservoir flask, via a heat exchanger, through a particulate filter (25 
μm polypropylene screen filter, Merck Millipore Ltd., Burlington, U.S.A) and a bubble trap 
before entering the preparation. Circulated perfusate was recycled from the preparation 
chamber back to the reservoir. The volume of perfusate circulated through the setup was 
200mL. To ensure adequate brain perfusion, vasopressin (Tocris, Bristol, UK) stock 
solution (5mM) in saline was added to the perfusate to make up 0.5-3nM vasopressin in 
perfusate (200mL), and perfusion pressure was maintained between 50-90 mmHg. 500μL 
Vecuronium Bromide (Abcam, Cambridge, UK) stock solution (2mg/mL) was added to the 
perfusate (200mL) to block neuromuscular transmission. From the moment of 
exsanguination to the onset of perfusion, the surgical procedure was performed in under 
20 minutes. To optimise access to the desired nerves or to the brainstem for extracellular 
Schematic representation of the in situ WHBP, a decerebrate transcardially perfused 
preparation which allows simultaneous electrophysiological recording of output from the 
intact respiratory network via multiple cranial, and spinal motor nerves and of the 
sympathetic trunk without the requirement of anaesthetics. The brainstem can be exposed 
for electrophysiological recordings (patch-clamp, field potential, extracellular single unit 
recordings) and focal micro-ejections or pico-ejections of drugs directly in the brain. Drugs 
can also be administered systemically via the perfusate. The metabolic state of preparations 
can be controlled by changing CO2 and O2 levels in the perfusate. Peripheral chemoreceptors 
can be stimulated via intra-arterial bolus injections of cyanide salt solution.  




recordings, the animal was placed in lateral position (for experiments in Chapter 3), or 
prone with their head fixed using ear bars and a snout clamp to ensure the brainstem was 
orientated similarly in all preparations (for experiments in chapter 5).  
2.2.3 Solutions and pharmacological agents. 
The composition of Ringer solution is as follows: 1.25 mM MgSO4.7H2O; 1.25 mM KH2PO4 
(ACROS organics, Geel, Belgium); 3.95 mM KCl; 25 mM NaHCO3; 125 mM NaCl; 2.5 mM 
CaCl2.H2O; 10 mM D-Glucose. All reagents were from Fisher Scientific UK Ltd. 
(Loughborough, UK) unless stated otherwise. Perfusate was made by adding 1.25% 
Oncotic agent PEG 20.000 (Fisher Scientific UK Ltd., Loughborough, UK) to freshly made 
Ringer solution, then filtering it (5-13μm pore size general purpose filter paper, 
FisherbrandTM,  Pittsburg, U.S.A).  
2.2.4 Electrodes, Apparatus and software used for in situ WHBP peripheral nerve 
recordings. 
Custom made bipolar suction electrodes were positioned to record from each cut and 
exposed nerve. These electrodes were pulled from borosilicate glass (GC150-F10, Harvard 
Apparatus), broken back and fire-polished to the appropriate diameter for a tight seal 
around the recorded nerve. The recording electrodes were bipolar. That is, a silver 
recording wire (AG005130, Goodfellow Cambridge Ltd., Huntingdon, United Kingdom) 
was placed inside the glass capillary, and a reference insulated silver wire (AG005842, 
Goodfellow Cambridge Ltd., Huntingdon, United Kingdom) was fitted to the outside of the 
glass capillary in such a manner that the wire end, bared of insulator, could be placed in 
close apposition to the nerve. The use of a reference wire, along with a tight seal around 
the nerve, improved the signal-to-noise ratio obtained with the electrodes. Electrodes 
were mounted on separate mechanical 3-D micromanipulators (U31CF micromanipulator, 
Narishige International LTD., London, United Kingdom). Electrophysiological recordings of 
peripheral nerves were x10k amplified (A-M systems Model 1700, Sequim, USA), 
bandwidth filtered (PN, VN, AbN, tSN at 300-5000 Hz, and HN 100-5000 Hz). A-D 
conversion was performed using a Micro 1401 data-acquisition unit (Cambridge Electronic 
Design, Cambridge, UK) and Spike2 data acquisition software (Cambridge Electronic 
Design Ltd., Cambridge, UK). Raw recording data was converted to integrated nerve traces 
through the following online processing steps: direct current (DC) offset removal (τ= 10 




performed with Spike2 with the use of a custom script (Abdala Sheikh, 2020) and will be 
addressed in further detail in methods section of Chapter 3. 
2.3 JUSTIFICATION FOR THE USE OF 5-HT1A RECEPTOR AGONIST  NLX-101. 
As addressed in the general introduction, the majority of studies performed to investigate 
the role of 5-HT1A receptor agonism in respiratory and sympathetic control has utilized 
the drug (R)-(+)-8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT). This 
drug has high affinity for 5-HT1A receptors, but it is also reported to have moderate affinity 
for 5-HT7 receptors (See General Introduction, section 1.7.3) Experiments with co-
administration of 8-OH-DPAT with 5-HT7 agonist (5-CT), 5-HT7 antagonist (SB269970), or 
5-HT1A receptor antagonist (WAY-100635) have provided indications of the role of 5-HT1A 
in respiratory control, but effects on sympathetic and respiratory control of selective 5-
HT1A activation without confounding factors from other pharmacological manipulations 
are currently not yet established. The proprietary selective 5-HT1A receptor agonist NLX-
101 (formerly named F15599) facilitates investigation of the effect of 5-HT1A receptor 
activation on respiratory control with a specificity that was hitherto not possible 
(proprietor of NLX-101 is Neurolixis Inc. Dana Point, USA). NLX-101 is a highly selective 5-
HT1AR agonist. In rat cortex, striatum, and hippocampal tissue, NLX-101 showed 1000-fold 
higher binding affinity for 5-HT1A receptors over other 5-HT receptors, and over 
dopamine-, and adrenoreceptors in vitro. In addition, NLX-101 did not interact with a wide 
range of other receptors, ion channels, or monoamine transporters (Newman-Tancredi et 
al., 2009). Additionally, NLX-101 is suggested to have functional selectivity for 5-HT1A 
hetero-receptors (Llado-Pelfort et al., 2010). This may be of clinical relevance as 5-HT1A 
auto-receptor and hetero-receptor activation are reported to have opposing effects: fast 
onset stimulation of respiratory activity in response to hetero-receptor activation, and 
slow onset inhibition of respiratory activity in response to auto-receptor activation (see 
General introduction section 1.7.3). Thus, NLX-101 enables the hitherto limited 
investigation of the role of highly selective 5-HT1A activation in respiratory and 
sympathetic control.  
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Chapter 3: EFFECTS OF 5-HT1A TRANSMISSION ON 
RESPIRATORY MOTOR AND SYMPATHETIC NETWORK OUTPUT 
IN RAT IN SITU  
3.1 CHAPTER INTRODUCTION  
The present chapter presents a series of experiments performed to assess the role of 
5-HT1A transmission in eupnoeic respiratory control and in the respiratory and 
sympathetic responses to chemoreceptor activation in the in situ WHBP. The subsections 
in this chapter introduction will present a brief review of relevant literature to outline the 
present understanding, and gaps therein, regarding the role of 5-HT1A transmission in 
eupnoeic respiratory activity (section 3.1.1), in the respiratory responses to hypercapnia 
(3.1.2) and to peripheral chemoreceptor activation (section 3.1.3), and in the coupling of 
sympathetic and respiratory activity (section 3.1.4). Section 3.1.5 addresses the chapter 
aims and hypotheses based on the findings addressed in the preceding sections.  
3.1.1 5-HT1A transmission in eupnoeic respiratory control 
Effects of 5-HT1A transmission on eupnoeic respiratory activity 
Systemic or central administration of 5-HT1A/7 agonist (8-OH-DPAT) results in augmented 
amplitude and/or frequency of integrated bursts of the PN in mice, rats, cats, and dogs in 
vivo (Valic et al., 2008, Szereda-Przestaszewska and Kaczynska, 2007, Radocaj et al., 2015), 
or in in situ WHBP of rats and mice (Manzke et al., 2009, Manzke et al., 2010). In line with 
these findings, plethysmography recordings in anesthetized vagotomised rats in vivo 
revealed increases in breathing rate and tidal volume after systemic administration of 8-
OH-DPAT (Szereda-Przestaszewska and Kaczynska, 2007). Systemic administration of 
8-OH-DPAT is also reported to result in augmented electromyographic activity of upper 
airway muscles in anesthetized rats in vivo (Besnard et al., 2012, Besnard et al., 2007). In 
a subset of these experiments, 8-OH-DPAT induced stimulation of respiratory activity was 
reported to be abolished by subsequent administration of 5-HT1AR antagonist and 
dopamine receptor D4 agonist WAY-100635 (Szereda-Przestaszewska and Kaczynska, 
2007, Valic et al., 2008). Administration of WAY-100635 without any prior administration 
of 8-OH-DPAT reduced upper airway muscle respiratory activity in anesthetized rats 
(Besnard et al., 2012, Besnard et al., 2007), and phrenic nerve activity in in situ WHBP of 
rats (Manzke et al., 2009) to below baseline levels. Systemic administration 8-OH-DPAT is 
reported to also counteract respiratory depression in response to fentanyl (μ-opioid 
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receptor agonist) in in situ WHBP and in in vivo rats (Manzke et al., 2009, Shevtsova et al., 
2011, Dutschmann et al., 2009b, Guenther et al., 2009). Comparisons of the effect of 
8-OH-DPAT in rhythmically active acute brainstem slices from WT and from Lmx1bf/f/p 
neonatal mice, which had a complete absence of Raphe serotonergic neurons (i.e. no 5-
HT1A auto-receptors), suggest that pre-synaptic 5-HT1A auto-receptors and post-synaptic 
hetero-receptors may have physiologically competing effects. That is, 8-OH-DPAT 
transiently increased burst frequency from the HN nerve rootlet, a measure of respiratory 
drive, in slices from Lmx1bf/f/p neonatal mice, but not in WT slices. This excitation was 
abolished when synaptic inhibition was blocked by bath administration of a mixture of 
GABAA-, and glycine receptor antagonists (gabazine, CPG 55845, and strychnine). 
Conversely, after 10 min of application, respiratory frequency in Lmx1bf/f/p slices had 
returned to baseline levels, whereas it was significantly depressed in WT slices. This 
pattern of activity was interpreted to be reflective of rapid stimulation of breathing due 
to hetero-receptor mediated inhibition of glycinergic and GABA-ergic respiratory 
interneurons (disinhibition), and delayed inhibition due to auto-receptor agonism 
(Corcoran et al., 2014) (see section 1.7.3).  
To summarize, 5-HT1A receptors are endogenously active under baseline conditions and 
have an excitatory role in resting respiratory activity. The net effect of stimulation of 5-
HT1A/7 transmission with 8-OH-DPAT was enhanced respiratory drive. 5-HT1A auto-
receptors and hetero-receptors are suggested to have physiologically competing effects: 
rapid onset stimulation of breathing due to hetero-receptor mediated inhibition of 
inhibitory interneurons (disinhibition), and delayed inhibition due to auto-receptor 
agonism. 
Gaps in understanding with regard to the effect of systemic 5-HT1A transmission on the 
eupnoeic respiratory rhythm and pattern  
There are multiple sites and mechanisms in the respiratory CPG at which 5-HT1A 
transmission can affect eupnoeic respiratory rhythm and pattern (e.g. inhibition in the KF, 
inhibition of rhythmogenic subpopulations in the VRC). Previous experiments describing 
the effect of systemic 5-HT1AR agonism on respiratory activity have focused on specific 
elements of respiratory rhythm and pattern (e.g. respiratory rate and pattern derived 
from PN discharge recordings, upper airway resistance derived from upper airway muscle 
tonus recordings, etc.), often recorded from distinct animal models, preparations, and 
experimental conditions, and have typically used a non-selective 5-HT1A agonist. What is 
currently still lacking, is a comprehensive assessment of the effect of selective 5-HT1A 
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agonism on the intact respiratory CPG, free from possible confounds introduced by 
anaesthesia or the requirement to translate findings between various animal models, 
recording techniques, and experimental conditions. Such assessment can be obtained 
from experiments with simultaneous recordings of all relevant motor nerve outputs (i.e. 
the PN, HN, cVN, and AbN) combined with systemic administration of a selective 5-HT1A 
agonist, NLX-101, in the in situ WHBP. Because the various recorded nerve outputs are 
interdependent and shaped by network interactions relatively well described in the 
inhibitory ring model, and because all nerve recordings are simultaneously obtained 
under identical experimental conditions, such a dataset could be interpreted in the 
context of the inhibitory ring model to inform hypotheses regarding putative mechanisms 
by which 5-HT1A transmission affects the respiratory CPG. Furthermore, the 
physiologically antagonistic effects of 5-HT1A auto-receptor vs. hetero-receptor activation 
complicate interpretations of effects of 5-HT1AR agonists. The use of the proposed hetero-
receptor biased 5-HT1AR agonist NLX-101 facilitates assessment of the effect of hetero-
receptor activation on respiratory activity with reduced interference from auto-receptor 
activation.  
3.1.2 5-HT1A transmission in the hypercapnic respiratory response 
Serotonergic transmission affects central CO2 chemoreceptor function in respiratory 
control 
The respiratory central chemoreflex is primarily mediated by populations of RTN neurones 
(see section 1.4.1), and raphe serotonergic neurones (see section 1.4.2) both thought to 
have intrinsic CO2/pH sensitivity. Genetic KO mouse models with near complete loss of 
5-HT neurones show reduced CO2 sensitivity persisting into adult age (Hodges et al., 2008, 
Cerpa et al., 2017). Similarly, acute pharmacogenetic inhibition of 5-HT (SLC6A4-
expressing) neurones with DREADD hM4Di activation has no effect on baseline respiratory 
activity, but attenuates the hypercapnic respiratory response in vivo in adult mice (Ray et 
al., 2011) (see section 1.7.2). Selective pharmacogenetic inhibition of 5-HT neurone 
subpopulations, targeted by genetic markers of rhombomeric lineage, identified Raphe 
serotonergic neurones derived from embryonic rhombomeres 3 (r3 Egr2-Pet1 neurones) 
and 5 (r5 Egr2-Pet1 neurones) exclusively to have intrinsic CO2/pH chemosensitive 
properties. The anatomical locations of these subpopulations of Raphe serotonergic 
neurones correspond to the caudal end of the medial lemniscus and median Raphe 
nucleus (for r3 Egr2-Pet1 neurones), and the rostral end of the caudal Raphe nuclei, i.e. 
Raphe magnus and Raphe pallidus (for r5 Egr2-Pet1 neurones). These serotonergic 
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neurones derived from r3/r5 selectively innervated brainstem nuclei involved in 
chemosensory processing, but not various respiratory (pre-)motor nuclei (Brust et al., 
2014) (see section 1.4.2).  
A second subpopulation of serotonergic raphe neurones reported to contribute to the 
central chemoreflex respiratory response is made up of tachykinin (tac1) positive raphe 
serotonergic neurones (Tac1-Pet1 neurones). The anatomical location of the Tac1-Pet1 
population maps primarily onto the raphe obscurus and caudal raphe pallidus. Whether 
these neurones have intrinsic CO2 chemosensitive properties is not directly established, 
but the findings by Brust et al. (2014) suggest they are not. Pharmacogenetic inhibition of 
this population, however, resulted in blunted respiratory rate and tidal volume 
components of the hypercapnic ventilatory response in mice in vivo. These neurones were 
observed to project to the pre-BötC, to various (pre-)motor nuclei within in the brainstem, 
and to pre-sympathetic C1 neurones in the RVLM. The authors suggest that Tac1-Pet1 
raphe serotonergic neurones act downstream of r3/r5 Egr2-Pet1 neurones to modulate 
respiratory (pre-)motor output in response to hypercapnic acidosis (Hennessy et al., 2017) 
(see section 1.4.2).  
Late-E activity appears to also be mediated by serotonergic transmission in the RTN/pFRG 
region. Episodic micro-injections of 5-HT in the RTN/pFRG region resulted in a lasting (30 
min) stimulation of abdominal expiratory activity under resting conditions, and a 
potentiation of abdominal late-E activity in response to hypercapnia in anesthetised rats 
(Lemes et al., 2016b). This effect was blocked when antagonist to excitatory 5-HT2 
receptors (ketanserin) was administered to the RTN/pFRG region prior to the 5-HT micro-
injections. It is currently not established whether this excitatory serotonergic drive to the 
pFRG stems from intrinsically chemosensitive serotonergic neurones. However, late-E 
activity emerges under hypercapnic conditions which also stimulate serotonergic 
chemoreceptor neurones, and late-E activity appears to be promoted by excitatory 
serotonergic transmission in the RTN/pFRG. It is conceivable that the promotion of late-E 
activity via stimulation of post-synaptic 5-HT2 receptors in the RTN/pFRG may be 
mediated by serotonin release from intrinsically chemosensitive serotonergic neurones. 
Thus, serotonergic mechanisms thought to contribute to the central chemoreflex 
response include: CO2/pH chemosensory input to the CPG from r3/r5 Egr2-Pet1 raphe 
serotonergic neurones; modulation of respiratory motor output during the hypercapnic 
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ventilatory response by Tac1-Pet1 Raphe neurons; and promotion of late-E activity 
mediated by excitatory 5-HT2R transmission in the RTN/pFRG.  
5-HT1A mediated modulation of the central chemoreflex respiratory response 
5-HT1A auto-receptors are widely expressed in Raphe neurones, and the central 
chemoreflex is significantly attenuated (22% reduction) by microdialysis of 5-HT1A/7 
receptor agonist (8-OH-DPAT) in the proximity of the rostral raphe pallidus and raphe 
magnus regions in conscious rats (Li et al., 2006) (section 1.7.3). However, the effect of 5-
HT1A transmission can differ across brainstem regions. For example, blockade of 5-HT1A 
transmission in the LC through focal administration of 5-HT1AR antagonist and dopamine 
receptor D4 agonist (WAY-100635) attenuates the hypercapnic response in anesthetised 
rats. Activity of noradrenergic neurones in the locus coeruleus (LC) is thought to stimulate 
the hypercapnic response (reviewed in Guyenet (2014)), but 5-HT release in the LC is 
thought to attenuate the hypercapnic response (de Souza Moreno et al., 2010). The 
observed attenuation of the hypercapnic response observed after administration of 
WAY-100635 in the LC is suggested to be caused by blockade of local 5-HT1A auto-
receptors of serotonergic neurones that synapse in the LC, and the resulting disinhibition 
of 5-HT release in the locus coeruleus (de Souza Moreno et al., 2010). Thus, local 
pharmacological manipulations of 5-HT1A transmission indicate that 5-HT1A transmission 
can have opposing effects on the respiratory hypercapnic response, depending on the 
regions and mechanisms affected. Despite the above, systemic administration of 
5-HT1A/7R agonist 8-OH-DPAT in in situ WHBP of juvenile rats results in a loss of the 
hypercapnic respiratory response (Corcoran et al. 2013). This suggests that the net effect 
of systemic 5-HT1A transmission is an attenuation of the hypercapnic response.  
To conclude, 5-HT1AR transmission (and blockade thereof) appears to differentially 
contribute to the hypercapnic response in distinct regions. The net effect of systemic 
administration of a selective 5-HT1AR agonist or antagonist on the central chemoreflex 
respiratory response remains, to the best of my knowledge, unexplored. However, 
systemic 5-HT1A/7R agonism results in attenuation of the hypercapnic response. Current 
evidence suggests that effects of 5-HT1A transmission on the hypercapnic response are 
chiefly mediated by action at 5-HT1A auto-receptors. Candidate contributors to the 
observed effects of systemic 5-HT1A/7R agonism are 5-HT1A auto-receptor mediated 
inhibition of CO2 chemosensitive r5-Egr2-Pet1 raphe serotonergic neurones and/or 5-HT1A 
auto-receptor mediated inhibition of Tac1-Pet1 neurones in the caudal raphe pallidus or 
raphe obscurus. A further mechanism that could hypothetically contribute to the 
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attenuation of the hypercapnic response observed after systemic 5-HT1A/7R agonism, is 
5-HT1A auto-receptor mediated reduction of 5-HT release in the RTN. Despite evidence of 
attenuation of the hypercapnic response after local administration of WAY-100635 in the 
LC, it is possible that the net effect of systemic administration of 5-HT1A antagonist results 
in potentiation of the hypercapnic response through auto-receptor mediated disinhibition 
of raphe neurones. 
3.1.3 5-HT1A transmission in the peripheral chemoreflex respiratory response 
Peripheral chemoreflex function is dependent on O2 and CO2 sensitive glomus cells in the 
carotid bodies (CB), which can be stimulated by intra-arterial bolus injections of cyanide 
salt (NaCN or KCN) solution (reviewed in Lahiri et al. (2006)). Stimulation of peripheral 
chemoreceptors results in increased respiratory rate and tidal volume, large post-I bursts 
(in HN, cVN, and AbN) without elongation of the post-I phase, and late-E activity (in AbN 
and tSN) (see section 1.5.1). 
Key brainstem components of the peripheral chemoreflex respiratory response 
CB afferents project to the NTS (Mifflin, 1992, Erickson and Millhorn, 1994, Erickson and 
Millhorn, 1991), from which second order peripheral chemoreceptor neurones relay 
information to key regions of the respiratory CPG (predominantly to the RTN/pFRG region, 
the rVRG and cVRG, and the RVLM) (Alheid et al., 2011, Yang et al., 2020). Ablation or 
inhibition of CB and/or NTS eliminates the chemoreflex response to hypoxia or intra-
arterial cyanide altogether (Takakura et al., 2006, Guyenet et al., 2018, Mulkey et al., 
2004). Late-E activity in response to peripheral chemoreceptor activation is thought to be 
mediated by direct glutamatergic projections from NTS second order chemoreceptor 
neurones to the RTN (Takakura et al., 2006, Moraes et al., 2012a, Barnett et al., 2017). 
The late-E response, but not the Post-I response, to CB activation is dependent on RTN 
function (Moraes et al., 2012a). The Post-I response has been suggested to be mediated 
by direct projections from second order chemoreceptor neurones to post-I neurones in 
pre-motor transmission circuitry in the VRC (Barnett et al., 2017). Recordings of 
respiratory motor output after ponto-medullary transections in in situ WHBP of juvenile 
rats indicate that both post-I and late-E activity in response to peripheral chemoreceptor 
activation with NaCN bolus administrations are dependent on intact ponto-medullary 
interactions (Gandini et al., 2009). In summary, pharmacological inhibition studies and 
lesioning/transection studies indicate that the CB, NTS, RTN/pFRG, VRC, and pontine 
regions provide contributions necessary for distinct elements of the respiratory response 
to peripheral chemoreceptor activation. 
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Potential involvement of 5-HT1A transmission in the peripheral chemoreflex respiratory 
response 
Comparison of Fos expression (a metabolic marker) in 5-HT1A/7 agonist (8-OH-DPAT) 
treated rats versus controls revealed significant increases in Fos expression after 8-OH-
DPAT administration in the NTS, RTN, and lateral parabrachial and KF nuclei (Besnard et 
al., 2012). 5-HT1A Receptors are expressed in the commissural NTS of rats (Vantrease et 
al., 2015), and RT-PCR indicates that 5-HT1AR RNA is present in the cytosol of O2 
chemosensitive isolated glomus cells from rats (Yokoyama et al., 2015). To the best of my 
knowledge, effects of 5-HT1A transmission on the peripheral chemoreflex respiratory 
response have never been established. In light of the findings above, however, it is 
plausible that systemic administration of 5-HT1A agonist could result in suppression of 
neurones involved in the peripheral chemoreflex, and thereby attenuate the respiratory 
responses to peripheral chemoreceptor challenges.  
3.1.4 5-HT1A transmission in control of sympatho-respiratory coupling 
Distinct patterns of sympatho-respiratory coupling occur during different respiratory 
behaviours 
Sympathetic activity drives cardiac output and vasoconstriction, and it thereby acts to 
upregulate arterial perfusion. Sympathetic output exhibits entrainment with the 
respiratory cycle and the pattern of this sympatho-respiratory coupling changes with 
alterations in metabolic state, and respiratory rhythm and pattern. Under eupnoeic 
conditions, sympathetic nerve activity in mammals exhibits positive modulation during 
late-I and early Post-I phases of the respiratory cycle (Bazilio et al., 2019, Moraes et al., 
2012a) (see section 1.6.1). In in situ WHBP of juvenile rats, hypercapnia leads to 
augmented sympathetic drive via the emergence of late-E activity in the tSN which occurs 
concomitantly with AbN late-E bursts. (Zoccal et al., 2008, Dick et al., 2004, Mandel and 
Schreihofer, 2009, Molkov et al., 2011). Peripheral chemoreceptor activation also 
promotes AbN and tSN late-E activity, along with high amplitude sympathetic bursts 
during post-I followed by inhibition of sympathetic output during early inspiration. The 
Post-I tSN response to peripheral chemoreceptor activation occurs concomitantly with 
the augmented Post-I respiratory motor activity observed in the cVN, HN, and AbN (Dick 
et al., 2004, Costa-Silva et al., 2010, Mandel and Schreihofer, 2009, Moraes et al., 2012a, 
Barnett et al., 2017, Braga et al., 2007).   
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Mechanisms underlying sympatho-respiratory modulation 
A nodal point for sympathetic efferents is the RVLM, a region in which catecholaminergic 
(C1) and non-catecholaminergic pre-sympathetic neurones exhibit respiratory 
modulation through excitatory and inhibitory inputs from various sources in the 
respiratory CPG. Converging evidence of anatomical, functional, and computational 
studies suggest that sympatho-respiratory coupling occurs, at least in part, through 
interactions of rhythmogenic respiratory neurones of the VRC (Zoccal et al., 2008, Zoccal 
et al., 2014) and of respiratory neurones of the dorsolateral pons with RVLM pre-
sympathetic neurones (Baekey et al., 2008, Stornetta et al., 2016, Barnett et al., 2017). In 
addition, RVLM pre-sympathetic neurones receive respiratory rhythm-entrained 
inhibitory input from GABA-ergic neurones in the CVLM (Schreihofer and Guyenet, 2003, 
Willette et al., 1983, Guyenet et al., 1990, Monnier et al., 2003), which in turn receive 
excitatory input from the NTS (Schreihofer and Guyenet, 2002, Molkov et al., 2014b). (see 
section 1.6.2, figure 1-8A). Late-E and Post-I sympathetic activities in response to 
chemoreceptor activation appear mediated by distinct pathways. Late-E sympathetic 
activity is likely a consequence of excitatory projections from pFRG late-E neurones to 
non-C1 pre-sympathetic neurones in the RVLM (Baekey et al., 2010, Molkov et al., 2010, 
Molkov et al., 2011). Converging evidence from anatomical, pharmacological, 
pharmacogenetic, optogenetic, and computational modelling studies suggests that 
enhanced excitatory drive from central chemoreceptors to pFRG late-E neurones drives 
the hypercapnic late-E sympathetic and respiratory response, and that excitation of pFRG 
late-E neurones via an excitatory projection from 2nd order peripheral chemoreceptor 
neurones of the NTS drives the late-E sympathetic and respiratory response to peripheral 
chemoreceptor activation (Barnett et al., 2017) (see section 1.6.2, figure 1-8B). Post-I 
sympathetic activity in response to peripheral chemoreceptor activation, on the other 
hand, has been hypothesized to be mediated by excitatory drive from Post-I neurones in 
VRC transmission circuitry to C1 neurones in the RVLM (Barnett et al., 2017). The RVLM 
Post-I neurones were suggested to receive peripheral chemoreceptor drive from the NTS 
(see section 1.6.2, figure 1-8C). Finally, commissural NTS neurones that receive input from 
the CB provide direct glutamatergic drive to C1 pre-sympathetic neurones in the RVLM. 
This pathway is thought to underlie a tonic, non-respiratory dependent, component of 
augmented sympathetic activity in response to peripheral chemoreceptor activation (see 
section 1.6.2).  
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Putative role of 5-HT1A transmission in sympatho-respiratory coupling 
Respiratory regions thought to be critical components of various pathways for sympatho-
respiratory coupling are: the PBc, the NTS, the pFRG/RTN region, and various regions of 
the VRC (see section 1.6.2). Histological-, in situ hybridization-, and PCR experiments 
indicate that 5-HT1AR are expressed in the BötC and pre-BötC (Manzke et al., 2009, 
Manzke et al., 2010), and the NTS (Vantrease et al., 2015). Further, the NTS, RTN, lateral 
parabrachial nucleus, and the KF showed increased fos expression in 5-HT1A/7 agonist (8-
OH-DPAT) treated rats versus controls revealed (Besnard et al., 2012). This suggests 
modulation of activity in these regions in response to systemic 5-HT1AR transmission. 
Intravenous administration of 8-OH-DPAT resulted in a fall of arterial pressure in 
anesthetized rats (Szereda-Przestaszewska and Kaczynska, 2007). However, there is 
currently little known about the effects of 5-HT1A transmission on sympatho-respiratory 
coupling. Given the above findings, it is conceivable that 5-HT1A transmission influences 
respiratory rhythm entrained patterns of sympathetic activity. 
3.1.5 Chapter aims and hypotheses 
Chapter aim: The aim this chapter is to assess effects of systemic administration of 
selective 5-HT1A receptor agonist NLX-101 on restful eupnoeic respiratory activity 
(recorded at PN, HN, cVN, and AbN) in in situ WHBP of rats. I also aim to evaluate the 
effects of 5-HT1A transmission on respiratory and respiratory-entrained sympathetic 
responses (recorded at PN, cVN, AbN, and the tSN) to hypercapnia and to peripheral 
chemoreceptor activation in in situ WHBP of rats. 
Experiments: To assess the effects of 5-HT1A transmission on eupneic respiratory activity, 
we systemically administered selective 5-HT1AR full agonist NLX-101 or vehicle while 
performing a comprehensive assessment of respiratory motor output through 
simultaneous recordings of PN, HN, cVN, and AbN discharge in in situ WHBP of juvenile 
rats. NLX-101 or vehicle was administrated in a concentration-response experiment, and 
respiratory motor output patterns after NLX-101 administration were compared to those 
of vehicle controls.  
Effects of 5-HT1A transmission on the hypercapnic respiratory and sympathetic responses 
were assessed through recordings of the hypercapnic respiratory and sympathetic 
response in the PN, cVN, AbN, and tSN to normoxic hypercapnia (8% CO2, O2-balanced) 
before and after systemic administration of 5-HT1A agonist NLX-101, 5-HT1A R antagonist 
WAY-100635, or vehicle in in situ WHBP of rats. Any effects of drugs (WAY-100635 or NLX-
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101) on the hypercapnic response were expected to be revealed as a significant effect of 
drug versus vehicle.  
Effects of 5-HT1A transmission on the peripheral chemoreflex were evaluated through 
recordings of the respiratory and sympathetic responses in the PN, cVN, AbN, and tSN to 
intra-arterial bolus adminitration of NaCN solution before and after systemic 
administration of 5-HT1A agonist NLX-101, or vehicle in in situ WHBP of rats. Any effects 
of NLX-101 on the respiratory and sympathetic responses to peripheral chemoreceptor 
activation were expected to be revealed as a significant effect of NLX-101 versus vehicle 
post-treatment. 
Hypotheses: The hypothesis of this chapter is that systemic administration of 5-HT1AR 
agonist increases the respiratory drive, reflected in an augmented respiratory rate. 
Sympathetic and respiratory responses to peripheral chemoreceptor activation are 
hypothesized to be attenuated through inhibition of peripheral chemoreceptors and/or 
excitatory neurones downstream of chemoreceptors (e.g. in the NTS). Current evidence 
for a role of 5-HT1A transmission in the hypercapnic respiratory response suggests that 
systemic 5-HT1AR agonism attenuates the hypercapnic response, chiefly through 
activation of 5-HT1A auto-receptors at raphe neurones (see section 3.1.2). Because 
NLX-101 is believed to act as a 5-HT1A hetero-receptor biased agonist, we expect low-level 
activation of raphe neurone 5-HT1A auto-receptors. Therefore, sympathetic and 
respiratory responses to hypercapnia are hypothesized to be unaffected by systemic 
administration of NLX-101. We hypothesised that the net effect of systemic 
administration of WAY-100635 is an augmented respiratory and sympathetic hypercapnic 
response due to disinhibition of raphe chemoreceptor neurones and disinhibition of 5-HT 
mediated chemosensitive mechanisms downstream of raphe neurones (see section 
3.1.2).  
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3.2 CHAPTER METHODS 
This chapter describes three experiments with the in situ working heart-brainstem 
preparation (WHBP). The first experiment consists of simultaneous recordings of the PN, 
cVN, HN, and AbN while performing a concentration-response experiment with systemic 
administration via the perfusate of selective 5-HT1A receptor agonist NLX-101 or vehicle. 
The second and third experiments consist of simultaneous recordings of the PN, cVN, AbN, 
and tSN during hypercapnia or peripheral chemoreflex stimulation, respectively, before 
and after systemic administration via the perfusate of NLX-101 or vehicle. This section 
describes: methods of central and peripheral chemoreceptor activation (3.2.1); solutions 
and pharmacological agents specific to experiments in this chapter (3.2.2); respiratory and 
sympathetic output parameters analysed (3.2.3), experimental procedures, data 
processing, and analysis for the NLX-101 concentration response curve experiment 
(3.2.4); experimental procedures, data processing, and analysis for the NLX-101 
hypercapnic response experiment (3.2.5),  and experimental procedures, data processing, 
and analysis for the NLX-101 peripheral chemoreflex experiment (3.2.6). 
3.2.1 CO2 chemoreceptor and Peripheral chemoreceptor activation 
CO2 chemoreceptor activation 
CO2 chemoreceptors were stimulated through a change in the partial pressures of CO2 in 
the perfusate. Two perfusate solutions were prepared, stored in separate reservoir flasks, 
and pumped through parallel recirculating perfusion circuits that could be alternated to 
feed into the preparation with the use of a 4-way stopcock switch at the level of the aortic 
catheter. One reservoir was bubbled with 5% CO2 (O2 balanced), whereas the other was 
bubbled with 8% CO2 (O2 balanced). CO2 concentrations of the gas mixture were 
determined with the use of a CO2 gas sensor (P.K. Morgan Ltd., Kent, U.K.). Beyond 
differing partial pressures of CO2 and O2, both volumes of perfusate were kept identical 
in composition (i.e. if drugs were added to one volume, they were also added to the 
other), and were controlled by the same peristaltic pump (i.e. perfusion flow rates were 
identical). This setup facilitated selective and reversible manipulation of CO2 
chemosensitive drive through acute alternation between normocapnic (5% CO2, O2 
balanced) and hypercapnic (8% CO2, O2 balanced) perfusate flowing into the preparation. 
 
Peripheral chemoreceptor activation 
Peripheral chemoreceptors were stimulated with the use of intra-arterial boluses of 
sodium cyanide (0.03%) dissolved in saline (0.9% NaCl, pH = 7.3).  
Chapter 3: Effects of 5-HT1A Transmission on Respiratory Motor and Sympathetic Network Output 
in Rat In Situ 
76 
 
The peripheral chemoreflex is mediated through stimulation of neurosecretory type 1 
glomus cells in the carotid body and aortic bodies that sense hypoxia or hypercapnic 
acidosis. A decline in PaO2 is thought to result in membrane depolarization and synaptic 
vesicle release in Type 1 glomus cells through inhibition of K+ channels that is mediated by 
mitochondrial O2-sensing mechanisms (see section 1.5.1). Sensitivity of glomus cells to 
hypercapnic acidosis is mediated by acid-sensing ion channel 3 (ASIC3) (see section 1.5.1). 
Cyanide inhibits mitochondrial electron transport through the inhibition of mitochondrial 
enzyme cytochrome c-oxidase. As a result, intracellular oxygen utilization (oxidative 
phosphorylation), and production of ATP, is inhibited. This causes acute inhibition of O2 
regulated K+ channels in a manner similar to that observed in conditions of oxidative 
stress. Additionally, inhibition of oxidative phosphorylation forces cells into anaerobic 
metabolism, creating lactic acid and leading to acid-base imbalances and metabolic 
acidosis (reviewed in Lu et al. (2013) and Leavesley et al. (2008)). The latter can stimulate 
ASIC3 acid sensing channels. Intra-arterial bolus injections of small volumes (25-75μL) of 
cyanide salt solution (0.03%) results in acute stimulation of peripheral chemoreceptors 
with immediate washout. It is therefore a suitable method for repeated peripheral 
chemoreceptor stimulation.  
3.2.2 Solutions and Pharmacological Agents 
NLX-101 fumarate (Neurolixis Inc. Dana Point, USA) was dissolved in saline to make a 
100μM (free base) working solution from which to add to the perfusate in in situ WHBP 
experiments. WAY-100635 maleate (Abcam Biochemical, Cambridge, United Kingdom) 
was dissolved in H2O to make a 10mM working solution from which to add to the 
perfusate in in situ WHBP experiments. Intra-arterial cyanide boluses were performed 
with the use of NaCN (Sigma-Aldrich, Steinham, Germany) solution (0.03%) in 0.9% 
sodium chloride (Hameln Pharmaceuticals Ltd, Gloucester, UK).  
3.2.3 Descriptions of sympatho-respiratory, and respiratory motor output parameters  
Offline data processing and analysis was performed with Spike2 (version 8.16) with the 
use of a custom script (Abdala Sheikh, 2020). Parameters describing respiratory rhythm 
(phase durations, AbN late-E and PN discharge rates (bpm), and latencies to peak burst 
amplitude (s)) were obtained from integrated discharge patterns from all respiratory 
motor nerves (∫PN, ∫HN, ∫cVN, ∫AbN). Additionally, respiratory and sympathetic waveform 
patterns (area under the curve, and/or peak and trough amplitude values) were obtained 
per respiratory phase for ∫PN, ∫HN, ∫cVN, ∫AbN, and ∫tSN discharge patterns. The current 
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section provides a description of how each respiratory and sympathetic output parameter 
is obtained from integrated nerve activity traces.  
Phrenic nerve respiratory parameters 
For each respiratory cycle, the start and end of ∫PN inspiratory bursts were detected 
through marking the points at which ∫PN rises above (‘PN-start’, see figure 3-1A) or falls 
below (‘PN-end’, see figure 3-1A) an amplitude (μV) threshold value (PN-threshold, see 
figure 3-1A) manually set just above noise levels. The interval between ‘PN-start’ to ‘PN-
end’ is the duration of the inspiratory phase of the respiratory cycle (PN dur. I (s)). The 
end of the respiratory cycle was marked by the onset of the next ∫PN inspiratory burst 
(‘cycle-end’, see figure 3-1A). The interval between ‘PN-end’ to ‘cycle-end’ is the duration 
of the expiratory phase (PN dur. E(s), comprising both Post-I and E2). The interval between 
‘PN-start’ and ‘end-cycle’ marks was the total duration of the respiratory cycle, and is used 
to calculate the respiratory rate (PN rate (bpm). The latency between the ‘PN-start’ and 
the timepoint at which ∫PN reached its peak amplitude (relative to ‘PN-expiratory trough’) 
during the inspiratory phase was denoted PN Tpeak (s). The peak amplitude (PN 
amplitude I (μV)) and area under the curve (AUC) of ∫PN inspiratory bursts, were obtained 
relative to ‘PN expiratory trough’. The AUC of the PN burst is normalised by inspiratory 
phase duration to generate PN normalised AUC I. 
Hypoglossal nerve respiratory parameters 
In the ∫HN trace, trough and peak amplitudes were measured relative to a running 
minimum ∫HN amplitude (HN zero), measured per respiratory cycle in the expiratory 
phase of the preceding respiratory cycle. The maximum amplitude of ∫HN activity relative 
to ‘HN zero’ (HN amplitude (μV), see figure 3-1A) was obtained within the time period 
from 0.3 seconds prior to ‘PN-start’ to 0.2 seconds later than ‘PN-end’. In the eupnoeic 
respiratory rhythm, the onset of HN bursts slightly precedes that of PN bursts. HN burst 
onset (HN-start, see figure 3-1A) was defined as the timepoint of 97% repolarization from 
‘HN amplitude (μV)’to ‘HN zero (μV)’ occurring in the expiratory phase of the preceding 
respiratory cycle (i.e. between the preceding cycle’s ‘PN-end’ and the present cycle’s ‘PN-
start’). The duration of pre-inspiratory HN discharge (HN dur. Pre-I (s)) was defined as the 
interval between ‘HN-start’ and ‘PN-start’. In addition to the absolute duration of HN pre-
I activity, it was also expressed relative to inspiratory phase duration by dividing ‘HN dur. 
Pre-I (s)’ by ‘PN dur. I (s)’ (HN dur.pre-I : dur.I (%)).The latency between onset of the HN 
burst (HN-start) and the timepoint at which the maximum HN amplitude (HN amplitude 
(μV)) was measured is referred to as ‘HN Tpeak (s)’. ∫HN AUC was obtained in the interval 
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from ‘HN-start’ to ‘PN end’, and measured relative to ‘HN zero’. ∫HN AUC was normalised 
over inspiratory phase duration to generate HN normalised AUC I.  
Cervical vagus nerve respiratory parameters 
In the ∫cVN trace, a baseline amplitude value (cVN-zero) was obtained by measuring the 
minimum value in a manually selected 10-minute epoch of eupnoeic respiratory activity 
during baseline. In each respiratory cycle analysed, the maximum amplitude of ∫cVN 
activity and the minimum amplitude (see figure 3-1B) during the expiratory phase are 
measured relative to cVN zero to obtain ‘cVN amplitude PI (μV)’ and cVN Trough (μV), 
respectively (see figure 3-1B). The end of the Post-I phase (PI-end, see figure x) was 
defined as the timepoint at which ∫cVN reaches 97% repolarisation from ‘cVN amplitude 
PI’ (μV) relative to the ‘cVN-trough’ amplitude (μV) (see figure 3-1B). Post-inspiratory 
phase duration (cVN dur. PI (s)) was defined as the interval between ‘PN-end’ and ‘PI-end’ 
(see figure 3-1B). 
In addition to obtaining the absolute duration (s) of the post-I phase, it’s duration was also 
expressed relative to expiratory phase duration as a whole by dividing ‘cVN dur. PI (s)’ by 
‘PN dur. E (s)’, this parameter was denoted ‘cVN dur.PI : dur.E (%)’. The ∫cVN AUC during 
the inspiratory phase (from ‘PN-start’ till ‘PN-end’ timepoints) was obtained relative to 
‘cVN-zero’, and normalised by ‘PN dur. I (s)’ to obtain the cVN normalised AUC during the 
inspiratory phase (cVN normalised AUC I) (see figure 3-1B). Similarly, ∫cVN AUC during the 
post-inspiratory phase was obtained relative to ‘cVN-zero’, and normalised by ‘cVN dur. 
PI (s)’ to get the cVN normalised AUC during the post-inspiratory phase (cVN normalised 
AUC PI). 
Iliohypogastric (abdominal) nerve respiratory parameters 
To measure parameters derived from ∫AbN and tSN discharge, the expiratory phase was 
divided at two-third of its duration (2/3-expiration, see fig-3-1C). This division provided 
estimates of E1 phase duration (the first 2/3rd of the expiratory phase) and of E2 phase 
duration (the latter 1/3rd of the expiratory phase) centrally. Inspiratory and expiratory 
phase durations are derived from simultaneous recordings of the PN. The arithmetic 
estimation of the E1 and E2 phases based on PN discharge patterns allowed for the 
calculation of respiratory and sympathetic rhythm and pattern parameters independent 
of changes in cVN cycle duty. These definitions for the respiratory phases were used to 
obtain the following AbN pattern parameters per respiratory phase: ∫AbN peak amplitude 
values (AbN amplitude I (μV), AbN amplitude PI (μV), AbN amplitude E2 (μV)); AbN trough 
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amplitude values (AbN trough I (μV), AbN trough PI (μV), AbN trough E2 (μV)); and AbN 
normalised AUC values (AbN normalised AUC I, AbN normalised AUC PI, AbN normalised 
AUC E2). All amplitude, trough, and AUC values are measured relative to the minimum 
amplitude recorded in ∫AbN (AbN-zero) during a manually selected 10-minute epoch 
during baseline of eupnoeic respiratory activity. The occurrence of late-E bursts was also 
detected by the rise of ∫AbN discharge amplitude above a threshold amplitude value (AbN 
late-E threshold, see figure 3-1C) during the interval between final ‘1/3-expiration’ and 
the subsequent ‘PN-start’ + 0.2s. The late-E threshold value was manually set at a constant 
value, above baseline noise and below late-E peak amplitudes, for the duration of the 
whole recording. Identified AbN Late-E bursts were used to calculate the late-E rate over 
the duration of the recording sample selected for analysis (AbN late-E rate (bpm)). In 
respiratory cycles where late-E activity was detected, the AbN late-E amplitude (μV) 
(relative to ‘AbN-zero’) was also obtained. 
Sympatho-respiratory parameters obtained from thoraco-sympathetic nerve recordings 
From the ∫tSN trace, peak amplitude, trough amplitude, and normalised AUC parameters 
were obtained per respiratory phase in a fashion identical to that described for AbN 
parameters (see figure 3D). Definitions for respiratory phase durations were identical to 
those used to obtain AbN parameters. All AbN amplitude, trough, and AUC values were 
measured relative to the minimum amplitude recorded in ∫tSN (tSN-zero) during a 
manually selected 10-minute epoch of eupnoeic respiratory and sympathetic activity 
during baseline. The following tSN parameters were obtained: tSN amplitude I (μV), tSN 
amplitude PI (μV), tSNN amplitude E2 (μV)); tSN trough I (μV), tSN trough PI (μV), tSN 
trough E2 (μV)); tSN normalised AUC I, tSN normalised AUC PI, and tSN normalised AUC 
E2.  
 




Figures show integrated nerve traces annotated with amplitude or timepoint measurements (letters) of events relevant for the calculation of respiratory and 
sympathetic activity parameters from ∫PN (A, green), ∫HN (A, red), ∫cVN (B, purple), ∫AbN (C, orange), and ∫tSN (D, blue) traces. See text (section 3.2.3) for a 
detailed description of respiratory and sympatho-respiratory parameters, and how they are calculated with measurements depicted in this figure. I = inspiratory 
phase, AUC = area under the curve. 
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3.2.4 Experimental procedures, data acquisition, processing, and analysis for the 
NLX-101 concentration response curve experiment 
Experimental procedures 
For experiments concerning the effect of 5-HT1AR agonism on eupnoeic respiratory 
activity, rats were randomly allocated to one of two treatment groups: exposure to NLX-
101 fumarate, or to 0.9% NaCl (vehicle). In situ WHBP of male juvenile rats (50-90g) for 
simultaneous recordings of PN, HN, cVN, and AbN were prepared as described in the 
General Methods (section 2.2.2). Once a stable eupnoeic respiratory pattern was 
established, a 15-minute baseline recording was made. In preparations of the NLX-101 
exposure group, the baseline recording was followed by cumulative additions of NLX-101 
working solution (100μM in Saline) to the circulating perfusate (200mL) to achieve 
perfusate concentrations of 1nM, 10nM, 100nM, 500nM, and 1μM in succession. At each 
concentration, a 15-minute recording was performed before proceeding to the next 
concentration. In the control group, 0.9 % NaCl (Hameln pharmaceuticals Ltd., Gloucester, 
UK) was added in volumes that corresponded to the volumes added in the NLX-101 
concentration response curve and the same recording times were allowed. 
Data acquisition, processing and analysis  
Data acquisition parameters and the hardware and software used are described in the 
General Methods (section 2.2.4). Offline data processing and analysis was performed with 
Spike2 with the use of a custom script. With this script respiratory parameter values were 
obtained per respiratory cycle (see section 3.2.3). A 5-minute epoch, 10 minutes after 
each drug addition to the reservoir, was selected for analysis. For each respiratory 
parameter analysed, an average of all respiratory cycles in the sample was taken. Plots 
and statistical analysis were performed with Graphpad Prism (GraphPad Sotfware, Inc., La 
Jolla, USA). Recordings were excluded from statistical analysis if stability of respiratory 
output was inadequate from the onset of recording (e.g. displaying a biphasic respiratory 
pattern) or if general stability of the preparation deteriorated (usually indicated by a loss 
of perfusion pressure). Individual nerve recordings could be selectively excluded from a 
recording in the case of a loss of signal due to mechanical disconnection of a nerve from 
the suction electrode. These exclusion criteria apply for all in situ WHBP experiments 
described in this chapter (details on excluded recordings are provided in results sections 
3.3.1-3.3.2). Statistical analysis was done with Two-Way Repeated Measures 2-Way 
ANOVA (α = 0.05) with a Holm-Sidak correction for multiple comparisons of drug vs saline 
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at each step in the concentration-response relationship. The saline experiments served as 
a temporal control. This approach was chosen instead of comparison of NLX-101 at each 
concentration vs NLX-101 at the pre-treatment condition, in order to control for potential 
deterioration of the preparation over the course of the experiment. 
3.2.5 Experimental procedures, data processing, and analysis for experiments 
assessing effects of NLX-101  on the hypercapnic response. 
Experimental procedures 
For experiments concerning the effect of 5-HT1A transmission on the hypercapnic 
sympathetic and respiratory responses, rats were allocated to one of three treatment 
groups: exposure to NLX-101 (10nM), to WAY-100635 (300nM), or to 0.9% NaCl (vehicle, 
equivalent volume to NLX-101 concentration). In situ WHBP of male juvenile rats (50-90g) 
for simultaneous recordings of PN, cVN, AbN, and tSN were prepared as described in the 
General Methods (section 2.2.2). In experiments with administration of WAY-100635, 
only the PN and AbN were recorded. For each hypercapnic response experiment, 
perfusate was prepared in duplicate: one reservoir of eucapnic/normoxic perfusate (5% 
CO2, O2 balanced; 200mL); and one of hypercapnic perfusate (8% CO2, O2 
balanced;200mL) (see section 3.1.1). Accordingly, drugs additions were made to both 
reservoirs (see section 3.1.1). After establishing stable eupnoeic outputs from all recorded 
nerves under perfusion with eucapnic/normoxic perfusate, a 5-minute recording of 
baseline respiratory and sympathetic activity was obtained. This was followed by an acute 
switch from normocapnic to hypercapnic (8% CO2; 92 % O2) perfusion, with hypercapnic 
perfusion maintained for 5 minutes before acute reversion to normocapnic perfusate, 
after which another 5-minute recovery period was recorded. Then, depending on the 
treatment group, either NLX-101 (10nM), WAY-100635 (300nM), or saline was added to 
the arterial perfusate, in the equivalent volumes. Ten minutes were allowed to reach 
steady-state after drug or vehicle administration. Then, the hypercapnic state switch 
sequence was repeated post-treatment: 5-minute baseline recording; followed by 5-
minute hypercapnic perfusion; followed by recovery to eucapnic/normoxic perfusate and 
an additional 5-minute recording. Figure 3-2 provides a schematic representation of this 
experimental protocol. 
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Data acquisition, processing and analysis 
Data acquisition parameters and the hardware and software used are described in the 
General Methods (section 2.2.4). Data processing and analysis of sympatho-respiratory 
parameters was performed in Spike2 with the same custom script as described in section 
3.1.3. The last 3 minutes from each 5-minute recording block (pre-treatment 
normocapnic; pre-treatment hypercapnic; NLX-101 normocapnic; NLX-101 hypercapnic) 
were selected to calculate state averages for sympatho-respiratory parameters for 
statistical analysis (see figure 3-2). For each sympatho-respiratory parameter, the 
hypercapnic responses were expressed as the change from the immediately preceding 
baseline sample (i.e. pre-treatment hypercapnic response = pre-treatment hypercapnic 
sample average - pre-treatment baseline sample average, and post-treatment 
hypercapnic response = post-treatment hypercapnic sample average - post-treatment 
baseline sample average). Statistical analysis was performed with repeated measures 
ANOVA (α =.05), with holm-Sidak comparison of drug (NLX-101 or WAY-100635) groups 
versus the vehicle group per treatment condition (pre-treatment or post-treatment). Any 
effects of drugs (WAY-100635 or NLX-101) on the hypercapnic response were expected 
to be revealed as a significant effect of drug versus vehicle in the post-treatment 
condition. As a supplementary analysis, the pre-treatment hypercapnic response in all 
recordings (irrespective of drug treatment group) was quantified by comparison of pre-
treatment baseline sample averages versus pre-treatment hypercapnic sample averages 
with a repeated measures t-test (α =.05).  
Figure 3-2: Recording protocol to assess effects of 5HT1AR agonism and antagonism respiratory 
and sympatho-respriatory hypercapnic responses. 
Recordings consisted of two normocapnia-hypercapnia sequences: the first during pre-
treatment conditions, and a second after administration of NLX-101 (10nM), WAY100635 
(300nM), or vehicle to the perfusate. For every respiratory/sympathetic output parameter, the 
response to hypercapnia was defined per treatment condition (pre-treatment vs. post-
treatment) by subtracting the average of a 3-minute normocapnic sample (yellow line) from 
the average of the corresponding 3-minute hypercapnic sample (red line). The blue line 
represents the CO2 concentration in the perfusate.  
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3.2.6 Experimental procedures, data processing, and analysis for analysis for 
experiments assessing effects of NLX-101  on the peripheral chemoreflex 
response 
Experimental procedures 
For experiments concerning the effect of 5-HT1A transmission on the sympatho-
respiratory response to peripheral chemoreflex activation, rats were allocated to one of 
three treatment groups: exposure to low concentration NLX-101 (10nM), exposure to 
high concentration NLX-101 (100nM); and exposure to NaCl (vehicle, in equivalent 
volume). In situ WHBP of male juvenile rats (50-90g) for simultaneous recordings of PN,  
cVN, AbN, and tSN were prepared as described in the General Methods (section 2.2.2). 
After establishing stable eupnoeic outputs from all recorded nerves, recordings 
commenced with a 7.5-minute baseline recording followed by a series of three pre-
treatment intra-arterial bolus injections of 25, 50, and 75μL NaCN (0.03%) in saline (0.9% 
NaCl) solution. The bolus injections were interspersed with a 7.5-minute interval. After 
the final bolus injection of the pre-treatment series, a 5-minute interval followed. 
Depending on treatment conditions, low concentration NLX-101 (10nM), high 
concentration NLX-101 (100nM), or saline (0.9% NaCl) was then administrated and 
another 10-minute interval followed to establish a post-treatment steady-state. The 
series of three intra-arterial bolus injections (25, 50, and 75 μL) was performed again post-
treatment. A schematic representation of this experimental protocol is provided in Figure 
3-3.   
Figure 3-3: Recording protocol to assess effects of 5HT1AR agonism on respiratory and 
sympatho-respriatory NaCN responses. 
Experiments consisted of two series of intra-arterial NaCN solution (0.03%) boluses of 
incremental volumes (25, 50, and 75μL): the first series during pre-treatment conditions, and 
a second series after administration of NLX-101 (10nM or 100nM) or vehicle to the perfusate. 
For every respiratory/sympathetic output parameter, we calculated the change in each 
respiratory cycle during the first 20 seconds after NaCN administration (green bars) relative to 
its corresponding 60s baseline average (yellow bars). For each respiratory parameter, two 
types of NaCN response data were analysed: the ‘maximum response’, and the ‘delay to 
maximum response’. The ‘maximum response’ value is the greatest change from baseline 
observed in any of the respiratory cycles during the first 20s after NaCN administration. The 
‘delay to maximum response’ is the interval (s) between onset of NaCN bolus administration 
and the onset of the respiratory cycle in which the ‘maximum response’ value is observed. 
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Data acquisition, processing and analysis 
Data acquisition parameters and the hardware and software used are described in the 
General Methods (section 2.2.4). Data processing and analysis of sympatho-respiratory 
parameters was performed in Spike2 with the same custom script as described in section 
3.1.3. For every respiratory/sympathetic output parameter, we calculated the change in 
each respiratory cycle during the first 20 seconds after NaCN administration relative to its 
corresponding 60s baseline average (see Figure 3-3). For each respiratory parameter, two 
types of NaCN response data were analysed: the ‘maximum response’, and the ‘delay to 
maximum response’. The ‘maximum response’ value was the greatest change from 
baseline observed in any of the respiratory cycles during the first 20s after NaCN 
administration. The ‘delay to maximum response’ is the interval (s) between onset of 
NaCN bolus administration and the onset of the respiratory cycle in which the ‘maximum 
response’ value is observed. For each respiratory and sympathetic output parameter, 
statistical analysis was performed separately for pre-, vs. post-treatment peripheral 
chemoreflex responses. Statistical analysis was performed with a 2-way repeated 
measures ANOVA (α = 0.05) with Sidak correction for comparisons of either NLX-101 
group (10nM or 100nM) vs. Vehicle per NaCN bolus (25μL vs. 50μL vs. 75μL). Any effects 
of drugs (NLX-101 10nM or NLX-101 100nM) versus vehicle on the sympatho-respiratory 
response to peripheral chemoreceptor activation were expected to be revealed as a 
significant effect of drug versus vehicle in the post-treatment condition. As a 
supplementary analysis, the pre-treatment NaCN responses in all recordings (irrespective 
of drug treatment group) were quantified by comparison of pre-treatment baseline 
sample averages versus pre-treatment NaCN bolus (25μL, 50μL, or 75μL) maximum 
response values with a 2-way repeated measures ANOVA with Geisser-Greenhouse 
correction and Holm-Sidak correction for multiple comparisons (α =.05). 
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3.3.1 NLX-101 enhanced normocapnic respiratory drive in a concentration-
dependent manner 
Through simultaneous recordings of the PN, cVN, HN, and AbN we performed an 
assessment of the effects on respiratory motor output of systemic administration of 
selective 5-HT1A receptor agonist NLX-101 versus vehicle controls in incremental 
concentrations in the in situ WHBP of juvenile rats.  
Sample sizes and excluded recordings. 
For the NLX-101 treatment group in concentration-response experiments, eight in situ 
WHBP recordings were obtained that were stable throughout the duration of the 
recording protocol. In six of these in situ WHBP experiments, simultaneous recordings of 
the PN, HN, cVN, and AbN were performed. In the remaining two experiments, HN 
recordings were not obtained (tSN was recorded instead, data not shown). One AbN 
recording, one cVN recording, and one HN recording were excluded from analysis due to 
mechanical and electrical recording issues unrelated to in situ WHBP viability and stability 
(i.e. loss of nerve recording due to poor electrode fit, or baseline shifts due to drifts in seal 
resistance of that nerve). Thus, for the concentration response experiments, the resulting 
sample sizes per nerve in the NLX-101 treatment group were: PN n=8; HN n=5; cVN n=7; 
and AbN n=7.  For the vehicle treatment group, five in situ WHBP with recordings of PN, 
HN, cVN, and AbN were obtained.  
Pre-treatment discharge patterns of the PN, cVN, HN, and AbN in in situ WHBP reflect 
eupnoeic respiratory activity.  
In pre-treatment conditions, PN, HN, cVN, and AbN activities were identical to the typical 
eupnoeic respiratory activity (see section 1.2.1 for a detailed description of eupnoeic 
respiratory activity). Briefly, PN displayed a ramping burst pattern; HN displayed a similar 
pattern with onset slightly prior to inspiratory PN activity; cVN showed ramping 
inspiratory activity followed by decrementing post-I discharge that terminated at 
approximately two third of expiratory phase duration, and AbN showed low amplitude 
post-I discharge but no appreciable late-E activity (see figure 3-4A1/B1 for pre-treatment 
example traces).   
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Systemic administration of NLX-101 resulted in increased respiratory rate due to 
shortening of expiratory phase duration.  
Figure 3-5 shows concentration-response relationships for respiratory rhythm parameters in 
response to NLX-101 or vehicle. Table 3-1 can be referenced for the M and SEM values used 
to make the plots in figure 3-5.  
Systemic administration of NLX-101 results in a concentration-dependent increase of the 
respiratory rate (PN rate (bpm), see figure 3-5A1 and Table 3-1) with a statistically 
significant increase relative to vehicle controls at 1μM NLX-101 (36.60 ± 2.82 vs. 24.34 ± 
4.56, P=0.031; NLX-101 vs. vehicle group respectively). This increased respiratory rate 
appears to be mediated to a greater extent by shortening of expiratory phase duration 
(PN dur. E (s), see figure 3-5A3  and table 3-1) than by shortening of inspiratory phase 
duration phase (PN dur. I (s), see figure 3-5A2 and table 3-1) in the NLX-101 treatment 
group compared to vehicle controls. However, neither PN dur. E (s) and PN dur. I (s) were 
significantly altered in the NLX-101 treatment group relative to vehicle controls. The 
expiratory phase can be subdivided into duration of the Post-I phase (dur. PI), and 
duration of the second expiratory phase (dur. E2). Systemic administration of NLX-101 did 
not result in a significant reduction of cVN dur. PI (s) relative to vehicle controls (see figure 
3-5B1, and table 3-1). Ultimately, the Post-I duty cycle (cVN dur.PI : dur.E (%), see figure 
3-5B2, and table 3-1) was not significantly changed. This suggests that the duration of E2 
is reduced to a similar extent as the duration of Post-I.  
Systemic administration of NLX-101 resulted in a shortening of time to peak in the 
hypoglossal motor output. 
Both in the Phrenic nerve (PN Tpeak (s), figure 3-5A4  and table 3-1) and the HN nerve (HN 
Tpeak (s), figure 3-5C3 and table 3-1), the average Tpeak(s) value for (pre-)inspiratory 
burst activity appears shortened after administration of NLX-101 in a concentration 
dependent fashion. Statistically significant shortening of Tpeak (s) in the NLX-101 
treatment group vs vehicle controls is observed in the HN nerve at 100nM (NLX-101 vs. 
vehicle group M±SEM are 0.34 ± 0.05 vs. 0.71 ± 0.05, respectively; P=0.025), 500nM (NLX-
101 vs. vehicle group M±SEM are 0.24 ± 0.03 vs. 0.63 ± 0.04, respectively; P=0.019), and 
1μM (NLX-101 vs. vehicle group M±SEM are 0.22 ± 0.04 vs. 0.59 ± 0.05, respectively; 
P=0.029). The duration of pre-inspiratory activity in the HN burst was not significantly 
affected by NLX-101 relative to vehicle controls (HN dur. pre-I (s), figure 3-5C1 and table 
3-1). Similarly, HN pre-I duty cycle was not significantly affected by administration of NLX-
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101 (HN dur.pre-I : dur.I (%), See figure 3-5C2 and table 3-1). This suggests that the 
duration of HN burst activity during the inspiratory phase remained unchanged. 
Systemic administration of NLX-101 does not significantly increase the frequency of late-E 
activity  
The representative traces from the NLX-101 treatment group versus vehicle controls show 
that NLX-101 promoted the emergence of late-E activity in the abdominal nerve (see 
figure 3-4). Further, a large increase in mean AbN late-E activity (AbN late-E rate (bpm)) 
was seen in the NLX-101 treatment group compared to baseline (see figure 3-5D1, and 
table 3-1). Interestingly, this increase in AbN late-E rate in the NLX-101 treatment group 
was not significant when compared to vehicle controls.   
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Peripheral nerve recordings of 
the PN, cVN, HN, and AbN in two 
in situ WHBP illustrate the dose-
dependent effect of NLX-101 (A) 
vs. volume-matched vehicle 
(0.9% saline) administration (B) 
on respiratory motor nerve 
output. Activity in each nerve is 
represented by raw recording 
traces and integrated (∫) activity 
traces. The full time-course of a 
recording with NLX-101 is 
presented (A1), with red 
annotation to indicate 10s 
sections depicted in more detail 
below (A2-5)..NLX-101 
concentrations and vehicle 
volumes annotated on the 
figure describe the subsequent 
cumulative doses systemically 
applied via the perfusate as the 
recording progresses. NLX-101 
enhances respiratory drive in a 
dose-dependent manner 
compared to vehicle controls. 
This is apparent in the dose-
dependent increase of 
respiratory rate and the 
emergence of late-E discharges 
(black arrows) in the abdominal 
nerve in the NLX-101 treated in 
situ preparation (A1-5), when 
compared to the vehicle control 







Figure 3-4: representative traces of in situ WHBP respiratory response to systemic administrations of NLX-101 vs. vehicle.  
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Concentration-response relationships for respiratory 
rhythm parameters in response to NLX-101 or vehicle. 
Cumulative ascending NLX-101 concentrations were: 
pre-treatment (hollow symbols); 1nM; 10nM; 100nM; 
500nM; and 1μM. Vehicle was  volume-matched to NLX-
101. Plots show: respiratory rate, bpm (A1); duration of 
the inspiratory phase, s (A2); duration of the expiratory 
phase, s (A3); PN time to teak, s (A4); duration of the cVN 
post-inspiratory phase, s (B1); cVN post-inspiratory duty 
cycle, % (B2);  duration of pre-inspiration in HN, s (C1); 
HN pre-inspiratory duty cycle, % (C2), HN time to peak, s 
(C3); rate of AbN late-E busts, bpm (D1). Numbers are: 
NLX-101 n=8, Vehicle n=5 for A1-4;  NLX-101 n=7, Vehicle 
n=5) for B1-2;  show HN activity parameters (NLX-101 
n=5, Vehicle n=5) for C1-,3; and NLX-101 n=7, Vehicle n=5) 
for D1. Values are mean ± SEM. *= p <.05 in 2-WAY 
Repeated Measures ANOVA with Sidak correction for 
comparisons of NLX-101 group vs. vehicle control.  
Figure 3-5: Effects of NLX-101 on respiratory rhythms. 
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Table 3-1 Group means for concentration-response relationships of NLX-101 or vehicle on respiratory rhythms.  
Nerve parameter pre-treatment 1nM 10nM 100nM 500nM 1μM 
  NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle 
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Concentration-response relationships for respiratory pattern parameters in NLX-101 or 
vehicle. Cumulative NLX-101 concentrations were: pre-treatment (hollow symbols); 1nM; 
10nM; 100nM; 500nM; and 1μM. Vehicle was volume matched to NLX-101. Plots show: area 
under the curve of PN bursts, normalised to inspiratory phase duration in seconds (A1); PN 
burst peak amplitude (A2); area under the curve of HN bursts, normalised to inspiratory phase 
duration in seconds (B1); HN burst peak amplitude, μV (B2); cVN area under the curve during 
inspiration, normalised to inspiratory phase duration in seconds (C1); cVN area under the curve 
during Post-I, normalised to Post-I phase duration in seconds (C2); cVN burst peak amplitude 
during Post-I, μV (C3); AbN burst peak amplitude during Post-I, μV (D1); AbN late-E burst peak 
amplitude, μV (D2). Numbers are: NLX-101 n=8, Vehicle n=5 for A1-2; NLX-101 n=5, Vehicle n=5 
for B1-2; NLX-101 n=7, Vehicle n=5 for C1-3 and D1,2. Values are mean ± SEM. *= p <.05, • = p<.01 
in 2-WAY Repeated Measures ANOVA with Sidak correction for comparisons of NLX-101 group 
vs. vehicle control. 
Figure 3-6: Effects of NLX-101 on respiratory patterns. 







Nerve parameter pre-treatment 1nM 10nM 100nM 500nM 1μM 
  NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle NLX-101 vehicle 


































































































































































































































Table 3-2: Group means for concentration-response relationships of NLX-101 or vehicle on respiratory waveform patterns. 
 
Values are mean ± SEM values per treatment group. Significantly different group means (NLX-101 vs. vehicle controls, p<0.05) are annotated in bold red text. 
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Systemic administration of NLX-101 altered PN and AbN respiratory patterns  
Systemic administration of NLX-101 in the in situ WHBP resulted in altered PN and AbN 
respiratory patterns compared to vehicle controls. Peak amplitude of the PN inspiratory 
burst was increased compared to vehicle controls (PN amplitude I (μV), see figure 3-6A2 
and table 3-2), with statistically significant difference in NLX-101 vs. vehicle treatment 
group means at 1μM (NLX-101 vs. vehicle group, 16.18 ± 1.51 vs. 8.86 ± 2.20, respectively; 
p=0.034). Similarly, PN normalised AUC (see figure 3-6A1 and table 3-2) was increased 
after administration of NLX-101 with significant increase relative to vehicle controls at 
100nM (NLX-101 vs. vehicle group M±SEM are 13.05 ± 1.04 vs. 7.59 ± 1.32, respectively; 
p=0.014), 500nM (NLX-101 vs. vehicle group M±SEM are 13.39 (1.16) vs. 7.88 (1.46), 
respectively; p=0.013), and 1μM (M (NLX-101 vs. vehicle group M±SEM are 13.91 (1.22) 
vs. 7.73 (1.45), respectively; p=0.004).  
The average maximum amplitude of Post-I bursts in the cVN (cVN amplitude PI (μV), see 
figure 3-6C3 and table 3-2), was not significantly affected by NLX-101 administration 
relative to vehicle controls. Similarly, normalised AUC values in the cVN both during the 
inspiratory phase (cVN normalised AUC-I, see figure 3-6C1 and table 3-2), and during the 
post-inspiratory phase (cVN normalised AUC-PI, see figure 3-6C2 and table 3-2) were not 
significantly changed in the NLX-101 group relative to vehicle controls. 
Peak amplitudes of AbN activity during post-I phase (AbN amplitude PI (μV), see figure 3-
6D1 and table 3-2) and during late-E phase (AbN amplitude late-E (μV), see figure 3-6D1 
and table 3-2) were both significantly increased compared to vehicle controls at 1μM NLX-
101 (AbN amplitude PI (μV): NLX-101 vs. vehicle group 9.75 ±2.44 vs. 3.49 ±0.36, 
respectively, p=0.031. AbN amplitude late-E (μV): NLX-101 vs. vehicle group M±SEM are 
10.65 ± 2.63 vs. 3.35 ± 1.02, respectively, p=0.048). 
Hypoglossal nerve respiratory patterns did not change significantly. Both the peak 
amplitude (HN amplitude I (μV), see figure 3-6B2 and table 3-2) and normalised AUC 
values (HN normalised AUC I, see figure 3-6B2 and table 3-2) in the HN were not affected 
significantly after administration of NLX-101 relative to vehicle controls.  
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The eupnoeic three-phase respiratory pattern persisted after systemic administration of 
NLX-101  
Previous studies had reported inhibition of post-inspiratory neurones in response to 
systemic administration of 5-HT1A/7 agonist 8-OH-DPAT (Manzke et al., 2009, Shevtsova et 
al., 2011), which could result in a biphasic respiratory pattern. The biphasic respiratory 
pattern can be recognised in in situ WHBP peripheral nerve output patterns by the loss of 
cVN Post-I activity, and a square-wave (as opposed to ramping) discharge pattern in PN 
bursts. In none of the recordings in situ WHBP in the NLX-101 treatment group (n=8) did 
we observe a transition to a biphasic respiratory pattern. The typical response to NLX-101 
is illustrated in the representative traces in figure 3-4, which shows an increased 
respiratory rate, but without abolishing cVN Post-I activity, and with retention of the 
ramping PN burst shape. As addressed above, the NLX-101 treatment group average for 
cVN post-I phase duration (figure 3-5B1, and table 3-1) is not significantly reduced relative 
to the vehicle group average, and duty cycle is unchanged. Furthermore, the normalised 
AUC of the cVN Post-I burst is not reduced in the NLX-101 treatment group relative to 
vehicle controls (see figure 3-6C2, and table 3-2.  
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3.3.2 Effects of NLX-101 on sympatho-respiratory response to hypercapnia 
Through simultaneous recordings of the PN, cVN, AbN, and tSN we performed an 
assessment of the effects of systemic administration of 5-HT1AR agonist NLX-101 (10nM) 
or 5-HT1AR antagonist WAY-100635 (300nM) versus vehicle controls on the respiratory 
and sympathetic hypercapnic response in the in situ WHBP of juvenile rats.  
Sample sizes and excluded recordings 
The NLX-101 (10nM) treatment group in hypercapnic response experiments consisted of 
7 in situ WHBP experiments, where PN, AbN, and tSN were simultaneously recorded. 
Cervical vagus nerve recordings were also obtained in all in situ WHBP, with the exception 
of one recording. Thus, the sample sizes for the NLX-101 (10nM) treatment group in 
hypercapnic response experiments are: PN n=7; cVN n=6; AbN n=7; tSN n=7). The WAY-
100635 (300nM) treatment group in hypercapnic response experiments consisted of 7 in 
situ WHBP experiments in which only PN and AbN recordings were obtained. The vehicle 
control group in hypercapnic response experiments consisted of 7 in situ WHBP in which 
PN, cVN, AbN, and tSN were recorded. Of these, one PN recording and one AbN recording 
were excluded from analysis due to inadequate recording quality for reasons unrelated to 
viability and stability of the preparation (i.e. due to suboptimal seal of the electrode to 
the nerve). In addition to these recordings, an additional five in situ WHBP experiments 
were performed in which only PN and AbN were recorded. This results in the following 
sample sizes for the vehicle group in hypercapnia experiments: PN n=11; cVN n=7; AbN 
n=11; tSN n=7). For comparison of pre-treatment eucapnic and hypercapnic respiratory 
and sympathetic activity, recordings from all treatment groups were pooled. Sample sizes 
for this comparison were: PN n=25; cVN = 13; AbN n=25; tSN n=14) 
Pre-treatment hypercapnic rhythms and patterns of the PN, cVN, AbN, and tSN 
The hypercapnic response in in situ WHBP of juvenile rats has previously been described 
as an increase in respiratory rate and pattern, combined with the emergence of AbN and 
tSN late-E activity (Abdala et al., 2009, Marina et al., 2010, Molkov et al., 2011). The pre-
treatment hypercapnic response in recordings of the present chapter was consistent with 
this description (see representative traces in figure 3-7A1-2). Mean values of pre-
treatment baseline and pre-treatment hypercapnic respiratory and sympathetic activity, 
and statistical comparisons thereof, are reported in Supplementary Tables S1-S2 (See 
appendix: supplementary data).   
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Figure 3-7: Representative traces of effect of NLX-101 and WAY-100635 on the sympathetic 
and respiratory hypercapnic response. 
(A1-4) PN, cVN, AbN, and tSN raw and integrated (∫) traces obtained from a single in situ WHBP 
recording illustrate sympathetic and respiratory activity during: pre-treatment eucapnic 
conditions (5% CO2, O2-balanced) (A1); pre-treatment hypercapnic conditions (8% CO2, O2-
balanced) (A2); eucapnic conditions after systemic administration of NLX-101 (10nM) (A3); and 
hypercapnic conditions after administration of NLX-101 (10nM) (A4). Similarly, (B1-4) show PN 
and AbN raw and integrated (∫) traces obtained from an in situ WHBP recording under 
normocapnic and hypercapnic conditions, before and after systemic administration of WAY-
100635 (300nM). Arrows indicate AbN late-E bursts and concurrent augmented late-E tSN 
activity. Mean values and statistical comparisons of pre-treatment baseline vs. hypercapnic 
respiratory activities obtained from all recordings pooled are reported in Supplementary Table 
S1 (see appendix).  
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Systemic administration of NLX-101 did not affect the respiratory response to hypercapnia 
Figure 3-8 shows plots for pre-treatment and post-treatment respiratory hypercapnic 
rhythms between the different treatment groups. Mean values of changes from eucapnia 
pre- and post-treatment are provided for each treatment group (NLX-101 10nM; WAY-
100635 300nM; vehicle) in table 3-3.  
For none of the analysed respiratory rhythm parameters, and for neither post-, nor pre-
treatment comparisons, statistically significant differences in the mean hypercapnic 
response of the NLX-101 (10nM) treatment group or the WAY-100635 (300nM) treatment 
group were found when compared to vehicle controls (see figure 3-8 and table 3-3). 
Figure 3-9 shows plots for pre-treatment and post-treatment comparisons of the 
hypercapnic response in the drug treatment groups (NLX-101 10nM; WAY-100635 
(300nM)) vs. vehicle controls for PN, cVN, and AbN respiratory patterns (Δ normalised 
AUC and Δ maximum amplitude (μV), per respiratory phase, per motor nerve). 
Corresponding pre-, and post-treatment group means and SEM values for each 
hypercapnic response parameter are listed in table 3-4. No significant differences 
between the mean hypercapnic responses for the drug treatment groups vs. vehicle 
controls was observed in respiratory patterns. Thus, systemic administration of NLX-101 
or WAY-100635 did not affect the respiratory response to hypercapnia in in situ WHBP of 
juvenile rats. 
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Figure 3-8: NLX-101 did not affect hypercapnic 
respiratory rhythms. 
Hypercapnia-induced change in respiratory rhythms 
recorded before and after systemic administration of 
Vehicle, NLX-101 (10nM) or WAY-100635 (300nM). Plots 
show: change in respiratory rate, bpm (A1); change in 
duration of the inspiratory phase, s (A2); change in 
duration of the expiratory phase, s (A3); change in PN 
time to teak, s (A4); change in duration of the cVN post-
inspiratory phase, s (B1); change in cVN post-inspiratory 
duty cycle, % (B2);  change in rate of AbN late-E busts, 
bpm (C1). Numbers are: Vehicle n=11, NLX-101 n=7, 
WAY-100635 n=7 for A1-4 and C1; Vehicle n=6, NLX-101 
n=6 for B1-2. Values are mean ± SEM. 2-WAY Repeated 
Measures ANOVA with Sidak correction for comparisons 
of NLX-101 or WAY-100635 vs. vehicle group vs. vehicle 
per treatment condition (pre- vs. post-treatment) yields 
no significant results. Mean values and statistical 
comparisons of pre-treatment baseline vs. hypercapnic 
respiratory activities are reported in Supplementary 
Table S1 (see appendix).  
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Table 3-3 Group means for hypercapnic respiratory rhythm responses pre- and post-treatment 







































































































Values are mean ± SEM values per treatment group. NLX-101 (10nM) or WAY-100635 (300nM) 
group means are not significantly different from Vehicle group means.  
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Figure 3-9: NLX-101 did not affect hypercapnic respiratory patterns. 
Hypercapnia-induced change in respiratory patterns recorded before and after systemic 
administration of vehicle, NLX-101 (10nM) or WAY-100635 (300nM).Plots show: change in 
area under the curve of PN bursts, normalised to inspiratory phase duration in seconds (A1); 
change in PN burst peak amplitude (A2); change in cVN area under the curve during inspiration, 
normalised to inspiratory phase duration in seconds (B1); change in cVN area under the curve 
during Post-I, normalised to Post-I phase duration in seconds (B2); change in cVN burst peak 
amplitude during Post-I, μV (B3); change in AbN burst peak amplitude during Post-I, μV (D1); 
change in AbN E2 burst peak amplitude, μV (D2).Numbers are: Vehicle n=11, NLX-101 n=7, 
WAY-100635 n=7 for A1-2 and C1-2; Vehicle n=6, NLX-101 n=6 for B1-3. Values are mean ± SEM. 
2-WAY Repeated Measures ANOVA with Sidak correction for comparisons of NLX-101 or WAY-
100635 vs. vehicle group vs. vehicle per treatment condition (pre- vs. post-treatment) yields 
no significant results. Mean values and statistical comparisons of pre-treatment baseline vs. 





Chapter 3: Effects of 5-HT1A Transmission on Respiratory Motor and Sympathetic Network Output 
in Rat In Situ 
102 
 
Table 3-4: Group means for hypercapnic respiratory patterns pre- and post-treatment with NLX-








































































































Values are mean ± SEM values per treatment group. Values are mean ± SEM values per 
treatment group. NLX-101 (10nM) or WAY-100635 (300nM) group means are not significantly 
different from vehicle group means.  
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Systemic administration of NLX-101 did not affect the sympathetic response to 
hypercapnia 
Figure 3-10 shows the sympathetic hypercapnic responses as recorded from the tSN 
before (pre-treatment) and after (post-treatment) systemic administration of NLX-101 
(10nM) or vehicle. Changes in sympathetic activity in response to hypercapnia were 
analysed for each phase of the respiratory cycle (I, Post-I, and E2) for the following tSN 
parameters: peak amplitude (μV) (Δ tSN amplitude I (μV), Δ tSN amplitude PI (μV), Δ tSN 
amplitude E2 (μV)); trough amplitude (μV) (tSN Δ trough I (μV), tSN Δ  trough PI (μV), tSN 
Δ trough E2 (μV)); and normalised AUC values (tSN Δ normalised AUC I, tSN Δ  normalised 
AUC PI, tSN Δ normalised AUC E2). Mean and SEM for hypercapnic response values per 
treatment group (NLX-101 10nM vs. vehicle) are listed in table 3-5. Hypercapnia resulted 
in significantly increased sympathetic activity in all sympathetic activity parameters (see 
supplementary table S2 in appendix). Two-way repeated measures ANOVA with Sidak 
correction for comparisons of the NLX-101 (10nM) group versus vehicle controls (α = 
0.05), performed separately with pre-treatment and post-treatment hypercapnic 
response values, did not reveal significant treatment group differences in the mean 
hypercapnic response for each of the analysed sympathetic parameters. Thus, systemic 
administration of NLX-101 did not affect the sympathetic response to hypercapnia in in 
situ WHBP of juvenile rats.  
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Figure 3-10: NLX-101 did not affect sympathetic hypercapnic responses. 
Hypercapnia-induced changes in the sympatho-respiratory patterns from tSN traces recorded 
before and after systemic administration of Vehicle (n=7) or NLX-101 (10nM, n=7). Plots show 
A1-3 show change in peak amplitude (μV) during inspiration, post-inspiration, and E2. Plots B1-3 
show change in trough (minimum) amplitude (μV) during inspiration, post-inspiration, and E2). 
Plots C1-3 show change in area under the curve normalised by phase duration in seconds during 
inspiration, post-I, and E2. Values are mean ± SEM. 2-WAY Repeated Measures ANOVA with 
Sidak correction for comparisons of NLX-101 or WAY-100635 vs. vehicle group vs. vehicle per 
treatment condition (pre- vs. post-treatment) yields no significant results. Mean values and 
statistical comparisons of pre-treatment baseline vs. hypercapnic sympathetic activities are 
reported in Supplementary Table S2 (see appendix). 
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Table 3-5: Group means for sympathetic hypercapnic responses pre- and post-treatment with 
NLX-101 (10nM) or Vehicle. 
 
  
 pre-treatment post-treatment 






















































































Values are mean ± SEM values per treatment group. NLX-101 (10nM) group means are not 
significantly different from Vehicle group means. 
Chapter 3: Effects of 5-HT1A Transmission on Respiratory Motor and Sympathetic Network Output 
in Rat In Situ 
106 
 
3.3.3 NLX-101 did not affect sympatho-respiratory responses to peripheral 
chemoreflex stimulation 
Through simultaneous recordings of the PN, cVN, AbN, and tSN we performed an 
assessment of the effects of systemic administration of NLX-101 (10nM or 100nM) versus 
vehicle controls on the respiratory and sympathetic response to peripheral 
chemoreceptor activation with intra-arterial bolus administration (25, 50, or 75μL) of 
NaCN solution (0.03%) in in situ WHBP of juvenile rats.  
Sample sizes and excluded recordings 
The NLX-101 (10nM) treatment group in NaCN intra-arterial bolus response experiments 
consisted of 7 in situ WHBP experiments, in each of which PN, AbN, cVN and tSN were 
simultaneously recorded with no exclusions. The NLX-101 (100nM) treatment group 
consisted of 8 in situ WHBP experiments. In each of these experiments, PN, cVN, AbN, and 
tSN discharge was simultaneously recorded, with the exception of AbN activity in one 
recording. This AbN recording was excluded from analysis due to inadequate recording 
quality for reasons unrelated to viability and stability of the preparation (i.e. due to 
suboptimal seal of the electrode to the nerve). This resulted in the following sample sizes 
for the NLX-101 (100nM) treatment group in NaCN bolus response experiments: PN n=8 
cVN n=8; AbN n=7; tSN n=8). Finally, the vehicle control group in NaCN intra-arterial bolus 
response experiments consisted of 7 in situ WHBP experiments, in each of which PN, AbN, 
cVN and tSN were simultaneously recorded with no exclusions. For comparison of pre-
treatment baseline sympatho-respiratory activities vs. maximum sympatho-respiratory 
activities elicted by pre-treatment NaCN bolus adminsirations (25μL, 50μL, or 75μL), 
recordings from all treatment groups were pooled. Sample sizes for this comparison were: 
PN n=22; cVN = 22; AbN n=21; tSN n=22. 
Pre-treatment and post-treatment respiratory patterns of in response to NaCN 
In pre-treatment conditions, PN, cVN, AbN, and tSN respiratory and sympathetic response 
to peripheral chemoreceptor activation were as described in the previous literature 
(reviewed in General Introduction, section 1.5.1). That is, intra-arterial bolus injection (25, 
50, or 75μL) of NaCN solution (0.03% in saline) elicited a concentration dependent acute 
transient response (~10s) of increased respiratory rate, increased Post-I discharges in the 
cVN and AbN, sympatho-respiratory late-E activity in the AbN and tSN, and augmented 
I/post-I sympathetic activity in the tSN (see figure 3-12A1-3). Mean values of pre-treatment 
baseline respiratory and sympathetic activity and of maximum NaCN-elicited activities, 
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and statistical comparisons thereof, are reported in Supplementary Tables S3-S5 (See 
appendix: supplementary data).   
Systemic administration of NLX-101 altered respiratory rhythms elicited by intra-arterial 
NaCN bolus 
Potential treatment group differences in the respiratory response to NaCN bolus 
injections were quantified trough comparison of group mean values for the ‘maximum 
response’ for each analysed respiratory parameter (see figure -3-12 and section 3.2.5 for 
explanations of how ‘maximum response’ values are obtained). Statistical analysis was 
performed with a 2-way repeated measures ANOVA with Sidak correction for 
comparisons (α = 0.05) of either NLX-101 (10nM) or NLX-101 (100nM) vs. Vehicle per 
NaCN bolus (25μL vs. 50μL vs. 75μL). Any effects of drugs (NLX-101 10nM or NLX-101 
100nM) versus vehicle on the sympatho-respiratory response to peripheral 
chemoreceptor activation were expected to be revealed as a significant effect of drug 
versus vehicle in the post-treatment condition. 
Figure 3-11 and Table 3-6 show the mean maximum responses to NaCN intra-arterial 
bolus concentration (25, 50, or 75μL) per treatment group (NLX-101 10 nM; NLX-101 
100nM; vehicle). NaCN bolus injections caused a shortening of the PN inspiratory phase 
(see figure 3-11B1 and table 3-6), which did not differ significantly between pre-treatment 
groups. However, the shortening in PN inspiration to 25μL and 50μL NaCN was 
significantly attenuated after treatment with NLX-101 (100nM) versus vehicle (at post-
treatment 25μL NaCN, NLX-101 100nM vs vehicle group M±SEM is −0.06±0.01 vs. −0.20 ± 
0.06, respectively, p=0.044; at post-treatment 50μL NaCN, NLX-101 100nM vs vehicle 
group M±SEM is −0.06±0.02 vs. −20±.04, respectively, p=0.047) ( see figure 3-11B1-2 and 
table 3-6).  Duration of the PN expiratory phase (see figure 3-11C and table 3-6) was also 
shortened in response to NaCN bolus administrations, and this effect was significantly 
attenuated  by NLX-101 (10 nM) compared to vehicle at post-treatment 25μL and 50μL 
NaCN (at post-treatment 25μL NaCN bolus, NLX-101 10nM vs vehicle group M±SEM is 
−1.61 ± 0.31 vs. −0.64 ± 0.18, respectively, p=0.013; at post-treatment 50μL NaCN bolus, 
NLX-101 10nM vs vehicle group M±SEM is −1.54±0.32 vs. −0.62±0.14, respectively, 
p=0.020) (figure 3-11C2 and table 3-6). However, the expiratory duration response to 
50μL (NLX-101 100nM vs vehicle group M±SEM is −2.29±0.30 vs. −0.66±0.14, respectively, 
p=0.032) and 75μL NaCN (NLX-101 100nM vs vehicle group M±SEM is −2.40±0.53 vs. 
−0.82±0.19, respectively, p=0.041) was different pre-treatment with the higher 
concentration of NLX-101. The presence of pre-treatment group differences in this 
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parameter limits our ability to interpret the cognate post-treatment responses. The time 
to PN peak amplitude was significantly shortened in response to NaCN bolus 
administration (see figure 3-11D and table 3-6), and this response was not significantly 




Table 3-6: Group means for respiratory rhythms elicited by intra-arterial NaCN pre- and post-
treatment with NLX-101 (10nM, or 100nM) or Vehicle. 
  










































































































































































Values are mean ± SEM values per treatment group. Significantly different group means (NLX-
101 10nM or 100nM vs. vehicle controls, p<0.05) are annotated in bold red text. 
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Figure 3-11: NLX-101 alters 
respiratory rhythms elicited 
by  intra-arterial NaCN. 
Plots show greatest change-
from-baseline values in 
respiratory rhythm observed 
in the PN response to NaCN 
(25μL, 50μL, and 75μL) 
before and after systemic 
administration of Vehicle 
(n=7), NLX-101 (10nM, n=7) 
or NLX-101 (100nM, n=8). 
Plots A1,2 show greatest NaCN 
induced increase in 
respiratory rate (bpm) before 
(A1)  and after (A2) 
administration of NLX-101 or 
vehicle. Plots B1,2 show 
greatest NaCN induced 
shortening of inspiratory 
phase (s) before (B1)  and 
after (B2) administration of 
NLX-101 or vehicle. Plots C1,2 
show greatest NaCN induced 
shortening in expiratory 
phase duration (s) before (C1)  
and after (C2) administration 
of NLX-101 or vehicle. Plots 
D1,2 show greatest NaCN 
induced shortening of PN 
time to peak (s) before (D1)  
and after (D2) administration 
of NLX-101 or vehicle. Values 
are mean ± SEM.  *= p <.05 in 
2-WAY Repeated Measures 
ANOVA with Sidak correction 
for comparisons of NLX-101 
groups (10nM or 100nM) vs. 
vehicle control. Statistical 
analysis is performed 
separately for each NaCN (25 
μL, 50 μL, or 75μL) response. 
Mean values of pre-
treatment baseline 
respiratory rhythm responses 
and of maximum NaCN-
elicited rhythm responses, 
and statistical comparisons 
thereof, are reported in 
Supplementary Table S3 (See 
appendix).    






Nerve recordings of the PN, cVN, AbN, and tSN illustrating typical sympatho-respiratory responses to intra-arterial boluses of 25μL (A1) 50μL (A2) and 75μL (A3) of NaCN 
(0.03%) administered before, and after (B1,2,3) systemic NLX-101 (10nM) or vehicle. Black arrows indicate the maximum response observed in PN rate, relative to pre-
NaCN baseline. Red lines illustrate the delay to maximum response. Detailed descriptions for how ‘maximum response’ and ‘delay-to-maximum response’ values are 
obtained are provided in section 3.2.6.  
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Systemic administration of NLX-101 did not affect NaCN-elicited changes in burst 
amplitude and normalised burst envelopes in integrated respiratory motor nerve activities. 
Figure 3-13 shows plots for pre-treatment and post-treatment comparisons between the 
respiratory pattern changes in response to NaCN bolus administrations (25,50, and 75μL) 
observed in NLX-101 (10nM or 100nM) treatment groups vs. vehicle controls. The design 
of these plots is identical to the design described for NaCN responses observed in 
respiratory rhythm parameters. Pre-, and post-treatment group means and SEM values of 
the NaCN respiratory pattern responses are listed in table 3-7A-B.  
In the PN, the increase in the inspiratory burst amplitude (PN  Δ amplitude (μV), see figure 
3-13A1-2 and table 3-7A), as well as the increase in normalised inspiratory AUC (PN Δ 
normalised AUC I, see figure 3-13B1-2 and table 3-7A) in response to NaCN bolus injections 
were not significantly affected by systemic administration of NLX-101 (10nM or 100nM) 
compared to vehicle.  
In the cVN, NaCN bolus administrations resulted in an increase in the normalised AUC 
during inspiratory discharge (cVN Δ normalised AUC I, see figure 3-13E1-2 and table 3-7B). 
This response was found to be significantly increased pre-treatment relative to vehicle in 
the NLX-101 (100nM) group (at post-treatment 75μL NaCN bolus, NLX-101 100nM vs 
vehicle group M ± SEM is 2.83 ± 0.72 vs. 1.40 ± 0.29, respectively, p=0.022). However, no 
significant differences in cVN normalised AUC I in NaCN responses were observed 
between NLX-101 treatment groups (10nM or 100nM) vs. vehicle post-treatment. The 
amplitude of cVN post-inspiration burst was increased in response to NaCN bolus 
administrations (see figure 3-13F1-2 and table 3-7B). There were, however, no significant 
differences between NLX-101 treatment groups (10 nM or 100nM) versus the vehicle 
controls with regard to the increases in cVN post-I amplitude post-treatment (figure 
3-13F1-2 and table 3-7B). cVN trough (μV) values reflect baseline activity of the cVN nerve 
per respiratory cycle. NaCN bolus administrations resulted in an increase of cVN trough 
(μV) values (see figure 3-13G1-2 and table 3-7B).  No statistically significant differences 
were observed between NLX-101 treatment groups (10 nM or 100nM) versus the vehicle 
controls with regard to increase in cVN post-treatment (figure 3-13G1-2 and table 3-7B).  
In the AbN, the amplitude of post-I activity (see figure 3-13C1-2 and table 3-7A) and activity 
during E2 (see figure 3-13D1-2 and table 3-7A) in response to NacN bolus was not 
significantly altered after treatment with NLX-101 when compared to vehicle controls.
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Figure 3-13: NLX-101 did not affect respiratory 
patterns elicited by intra-arterial NaCN. 
Plots show greatest change-from-baseline values 
in respiratory patterns observed in the PN 
response to NaCN (25μL, 50μL, and 75μL) before 
and after systemic administration of Vehicle or 
NLX-101 (10nM, or 100nM). Plots A1,2 show 
greatest NaCN induced increase in PN burst 
amplitude (μV) before (A1)  and after (A2) 
administration of NLX-101 or vehicle. In a similar 
manner, plots B1,2-I1,2 describe the NaCN response 
greatest change-from-baseline values for the 
following nerves and parameters: (B1,2) PN burst 
area under the curve (AUC) normalised to 
inspiratory phase duration in seconds; (C1,2) AbN 
peak amplitude (μV) during post-I phase; (D1,2) 
AbN peak amplitude (μV)  during E2 phase ; (E1,2) 
cVN inspiratory AUC, normalised to inspiratory 
phase duration in seconds; (F1,2) peak amplitude 
of post-inspiratory cVN discharge; (G1,2) cVN 
trough (minimum) amplitude (μV)). Numbers are: 
Vehicle n=7, NLX-101 (10nM) n=7 , NLX-101 
(100nM) n=7, for C1,2 and D1,2; Vehicle n=7, NLX-
101 (10nM) n=7 , NLX-101 (100nM) n=8, for A1,2, 
B1,2, E1,2, F1,2, and G1,2.Values are mean ± SEM.  *= 
p <.05 in 2-WAY Repeated Measures ANOVA with 
Sidak correction for comparisons of NLX-101 
groups (10nM or 100nM) vs. vehicle control. 
Statistical analysis is performed separately for 
each NaCN (25 μL, 50 μL, or 75μL) response. Mean 
values of pre-treatment baseline respiratory 
patterns and of maximum NaCN-elicited patterns, 
and statistical comparisons thereof, are reported 
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Table 3-7A: Group means for respiratory patterns elicited by intra-arterial NaCN pre- and post-
treatment with NLX-101 (10nM, or 100nM) or Vehicle. 
 
Values are mean ± SEM per treatment group. Significantly different group means (NLX-101 
10nM or 100nM vs. Vehicle, p.05) are annotated in bold red text. Table is continued on next 
page (Table 3-7B). 
. 
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Table 3-7B Group means for respiratory patterns elicited by intra-arterial NaCN pre- and post-
treatment with NLX-101 (10nM, or 100nM) or Vehicle. 
 Continuation of Table 3-7A. Values are mean ± SEM per treatment group. Significantly different 
group means (NLX-101 10nM or 100nM vs. Vehicle, p.05) are annotated in bold red text.  
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Systemic administration of NLX-101 does not affect the onset of respiratory responses to 
intra-arterial NaCN bolus 
To assess whether 5-HT1AR agonism affected the onset of the respiratory response to 
peripheral chemoreceptor activation, we quantified the delay to the timepoint of 
maximum response (delay-to-max) for respiratory parameters of the PN response to each 
of three intra-arterial boluses (25μL, 50μL, and 75μL) with NaCN (0.03%) before and after 
systemic Vehicle, NLX-101 (10nM) or NLX-101 (100nM) in in situ WHBP from juvenile rats. 
See figure 3-12 and section 3.2.5 for a more detailed account of how ‘delay-to-max’ values 
are obtained. Figure 3-14 and table 3-8 provide delay-to-max mean and SEM  for the PN 
response to pre- and post-treatment 25, 50, or 75μL NaCN bolus injections for each 
treatment group (NLX-101 10nM, NLX-101 100nM, vehicle).  For each of the above 
respiratory parameters, no significant differences between NLX-101 treatment groups 
(10nM or 100nM) vs. vehicle controls were observed in the delay-to-max (s) values for 
respiratory responses to pre- , or post-treatment NaCN bolus injections. Thus, systemic 
administration of NLX-101 (10nM or 100nM) vs. vehicle controls did not affect the onset 
of the respiratory response to peripheral chemoreceptor activation with NaCN bolus 
injections.   
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Delay to the timepoint of maximum response (delay-to-max) values were obtained for 
respiratory parameters of the PN response to NaCN (25μL, 50μL, and 75μL) before and after 
systemic administration of Vehicle (n=7), NLX-101 (10nM, n=7), or NLX-101 (100nM, n=7). Plots 
A1,2 show the delay-to-max (s) for the change in PN rate in response to NaCN before (A1) and 
after (A2) administration of Vehicle or NLX-101 (10nM or 100nM). In identical fashion, the 
delay-to-max (s) values are provided for: the increase in burst amplitude (B1,2); the shortening 
of inspiratory phase duration (C1,2) ;and the shortening expiratory phase duration (D1,2). Values 
are mean ± SEM. 2-WAY Repeated Measures ANOVA with Sidak correction for comparisons of 
NLX-101 groups (10nM or 100nM) vs. vehicle control yielded no significant results. Statistical 
analysis is performed separately for each NaCN (25 μL, 50 μL, or 75μL) response. 
Figure 3-14: NLX-101 did not affect the delay to maximum PN respiratory response to intra-
arterial NaCN. 
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Table 3-8: Group means for the delay to maximum PN respiratory response to intra-arterial NaCN. 
Values are mean ± SEM for the delay to maximum PN responses (s) elicited by intra-arterial NaCN 
pre- and post-treatment with NLX-101 (10nM or 100nM) or vehicle. NLX-101 (10nM or 100nM) 
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Systemic administration of NLX-101 did not affect sympathetic response to intra-arterial 
NaCN 
Figure 3-15 shows plots for pre-treatment and post-treatment comparisons between the 
different treatment groups for the maximum response in tSN. The organisation of plots 
and design of statistical comparisons of treatment groups tests is identical to that 
previously described for maximum respiratory response values. Tables 3-10A-B list the 
maximum response mean and SEM values per NaCN (0.03%) intra-arterial bolus dose (25, 
50, or 75μL) and per treatment group (NLX-101 10 nM; NLX-101 100Nm; vehicle controls) 
for each of the above tSN parameters. 
NaCN bolus administration resulted in an increase of the maximum tSN amplitude (μV), 
trough value (μV), and normalised AUC values. Mean values of pre-treatment baseline vs. 
maximum NaCN-elicited sympathetic activities, and statistical comparisons thereof, are reported 
in Supplementary Tables S5A/B (see appendix). This increase in sympathetic activity in 
response to peripheral chemoreceptor activation is also illustrated in representative 
traces of the tSN (see figure 3-11). No significant differences between NLX-101 treatment 
groups (10nM or 100nM) vs. vehicle controls were observed in the tSN parameters for 
sympathetic responses to post-treatment NaCN bolus injections. Thus, systemic 
administration of NLX-101 (10nM or 100nM) vs. vehicle controls did not affect the 
sympathetic response to peripheral chemoreceptor activation as observed in maximum 
responses to intra-arterial bolus injections (25, 50, or 75μL) with NaCN solution (0.03%). 
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Figure 3-15: NLX-101 did not affect the thoracic Sympathetic nerve sympatho-respiratory response to intra-arterial administration of sodium cyanide. 
Plots show greatest change-from-baseline values observed in thoracic Sympathetic nerve (tSN) recordings of the sympatho-respiratory response to NaCN (25μL, 50μL, and 
75μL) before and after systemic administration of Vehicle (n=7), NLX-101 (10nM, n =8)) or NLX-101 (100nM, n=8). Plots A1,2 show the maximum NaCN induced increase in 
tSN burst amplitude during inspiration before (A1) and after (A2) systemic administration of Vehicle or NLX-101 (10nM or 100nM). In the same manner, plots B1,2 and C1,2 
show greatest NaCN induced changes in tSN burst amplitudes during post-inspiratory phase, and the second phase of expiration (E2), respectively. Plots D1,2 - F1,2, show 
the greatest NaCN induced increases in tSN trough values during inspiration (D1,2), during Post-I (E1,2), and during E2 (F1,2). Plots G1,2 show the maximum NaCN induced 
increase in tSN area under the curve during inspiration, normalized to inspiratory phase duration in seconds.  respiratory phase duration in seconds. Similarly, plots H1,2 
and I1,2 show normalised area under the curve for tSN activity during Post-I (H1,2,) and during E2 (I1,2). Values are mean ± SEM. 2-WAY Repeated Measures ANOVA with 
Sidak correction for comparisons of NLX-101 groups (10nM or 100nM) vs. vehicle control yielded no results. Statistical analysis is performed separately for each NaCN (25 
μL, 50 μL, or 75μL) response. Mean values of pre-treatment baseline vs. maximum NaCN-elicited sympathetic activities, and statistical comparisons thereof, are reported 
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Table 3-9A Means for maximum tSN response to intra-arterial NaCN pre- and post-treatment with 
NLX-101 (10nM or 100nM) or vehicle. 
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Values are mean ± SEM per treatment group. NLX-101 (10nM or 100nM) group means are not 
significantly different from Vehicle group means. Table is continued on next page (Table 3-9B). 
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Table 3-9B Means for maximum tSN response to intra-arterial NaCN pre- and post-treatment with 
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Continuation of Table 3-9A. Values are mean ± SEM per treatment group. NLX-101 (10nM or 100nM) 
group means are not significantly different from Vehicle group means.  
. 
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3.4 CHAPTER DISCUSSION 
3.4.1 Summary of results in the light of aims and hypotheses 
The aim of the present chapter was to assess the effects of systemic administration of 
selective 5-HT1A receptor agonist NLX-101 on restful respiratory activity (recorded at PN, 
HN, cVN, and AbN) in the in situ WHBP of juvenile rats. Further, we aimed to establish the 
respiratory response, as well as respiratory modulation of sympathetic activity (recorded 
at PN, cVN, AbN, and at the thoracic sympathetic chain), upon hypercapnia and upon 
peripheral chemoreceptor stimulation in the in situ WHBP.  
The work presented in this chapter provides unique contributions to our understanding 
of 5-HT1A transmission in respiratory control. Experiments in section 3.3.1 provide the first 
comprehensive assessment of effects of selective 5-HT1AR agonism on eupnoeic 
respiratory motor output from the intact and unanaesthetised respiratory network. In 
addition, experiments in this chapter provide the first comprehensive assessment of 
effects of selective 5-HT1A agonism on sympatho-respiratory responses to hypercapnia 
(section 3.3.2) and peripheral chemoreflex activation with NaCN (section 3.3.3) in the 
intact and unanaesthetised respiratory network.  
Systemic administration of 5-HT1AR agonist was hypothesised to result in increased 
respiratory rate, and in augmented amplitudes and burst envelopes of respiratory motor 
output under resting conditions. Our findings in concentration-response experiments 
with systemic administration NLX-101 vs. vehicle in in situ WHBP of juvenile rats (see 
section 3.3.1) are largely in line with this hypothesis. Systemic administration of NLX-101 
resulted in concentration-dependent increases in burst amplitudes and normalised burst 
envelopes of integrated motor outputs of the PN, and AbN compared to vehicle 
controls.No significant effects of NLX-101 on respiratory pattern were observed in 
integrated HN and cVN motor outputs (see Fig. 3-6, Table 3-2).  
With respect to respiratory rhythm, systemic administration of NLX-101 in in situ WHBP 
of rats resulted in a concentration-dependent increase in respiratory rate. This increased 
respiratory rate appears to be mediated to a greater extent by shortening of expiratory 
phase duration than by shortening of inspiratory phase duration. However, shortening of 
expiratory phase duration was not significant. This is surprising given the large effect sizes 
observed at higher doses (see PN dur. E (s) at 100μM, 500μM, and 1μM NLX-101 vs. 
vehicle control in figure 3-5A3  and table 3-1). The absence of statistical significance of this 
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effect may be due to the relatively low samples sizes in these experiments (NLX-101 n=7, 
vehicle n =5). Power analysis (InVivoStat, Bate & Clark (2014)) suggests that, assuming 
variance and an effect size equal to that observed for PN dur. E (s) at 1μM NLX-101 vs. 
vehicle in the present thesis, 70-92% power to detect this effect with α =.05 requires 
sample sizes of 6 to 10 recordings in each treatment group (see supplementary figure 
S1A). The expiratory phase comprises the Post-I phase, followed by the E2 phase. Post-I 
phase duration was not significantly shortened. Post-I duty cycle, i.e. the duration of Post-
I phase as a fraction of expiratory phase duration, was not significantly affected (see Fig. 
3-5B1). This suggests that the relative durations of Post-I and E2 phases were unaltered in 
the NLX-101 treatment group compared to vehicle controls. The respiratory rhythm 
remained tri-phasic throughout the full range of the NLX-101 dosing schedule (1nM-1μM).  
Non-hypothesised effects on respiratory rhythm in the NLX-101 treatment group vs. 
vehicle controls included a statistically significant shortening of the latency between onset 
and peak activity in the ∫HN (HN Tpeak(s)), as well as a concentration-dependent increase 
in late-E activity in the NLX-101 treatment group vs. vehicle controls. The latter effect is 
shown in a significant increase in late-E burst amplitude (see fig. 3-6D2, and table 3-2). 
AbN late-E rate (bpm) was not significantly increased in the NLX-101 treatment group 
compared to vehicle controls. The absence of statistical significance in the effect on late-
E rate is surprising, given its large effect size. Average occurrence of AbN late-E (bpm) in 
the NLX-101 treatment group increased from nearly non-occurring (pre-treatment, 
M±SEM are 1.65 ± 1.21) to occurring nearly every respiratory cycle (at 1μM NLX-101, 
M±SEM are 33.08 ± 3.64) (see Fig. 3-5D1, and table 3-1). In comparison, the mean and 
SEM late-E rate (bpm) at pre-treatment conditions in the vehicle control group was 7.93 
± 3.98, and increased to 19.80 ± 6.71 bpm at the highest concentration. This suggests that 
the absence of statistical significance is possibly due to high variability in the control 
group. Power analysis (InVivoStat, Bate and Clark (2014)) suggests that, assuming variance 
and an effect size equal to that observed for AbN late-E rate (bpm) at 1μM NLX-101 vs. vehicle in 
the present thesis, 69-91% power to detect this effect with α =.05 can be achieved with sample 
sizes from 11 to 19 recordings in each treatment group (see supplementary figure S1B). 
The respiratory and sympatho-respiratory hypercapnic response in the in situ WHBP of 
juvenile rats was hypothesised to be unaffected by systemic administration of 5-HT1A 
agonist NLX-101 (10nM), but to be augmented after systemic administration of 5-HT1A 
antagonist WAY-100635 (300nM), when compared to vehicle controls. This is because 
NLX-101 is postulated to be a 5-HT1A hetero-receptor biased agonist, whereas WAY-
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100635 is an antagonist of both hetero-receptors and auto-receptors without functional 
bias. We did not observe any significant changes in sympatho-respiratory hypercapnic 
response parameters in the NLX-101 treatment group or the WAY-100635 treatment 
group when compared to vehicle controls (section 3.3.2). 
The sympatho-respiratory response to stimulation of peripheral chemoreceptors through 
intra-arterial bolus injections (25, 50, or 75μL) with NaCN (0.03%) solution in in situ WHBP 
of juvenile rats was hypothesised to be attenuated by systemic administration of NLX-101 
(10nM or 100nM) when compared to vehicle controls. However, relative to vehicle 
controls, NLX-101 treatment groups did not display a significant change in sympatho-
respiratory response to NaCN intra-arterial bolus injections, both in magnitude and 
latency of maximum response. 
3.4.2 Technical considerations 
Technical consideration with regard to the use of the in situ working-heart-brainstem 
preparation 
The use of the in situ WHBP has a number of characteristics that make it more suitable for 
the present thesis’ objectives compared to in vivo animals or further reduced in situ or in 
vitro preparations of the respiratory CPG. However, the in situ WHBP also has its 
limitations which must be acknowledged and/or accounted for in experimental design 
and in the interpretation of data.  
A major advantage of the in situ WHBP over more reductive in vitro methods, is that the 
in situ WHBP has a near-intact respiratory network. This is important because any excision 
of network components is likely to affect the network interactions in the remaining 
circuitry. A further advantage is that the in situ WHBP enables simultaneous recordings of 
multiple peripheral nerves (used in chapter 3), which can be combined with single cell 
recordings in the brainstem (used in chapter 5). Simultaneous recordings of multiple 
peripheral nerves provides a comprehensive picture of respiratory network outputs. Such 
comprehensive assessment of network outputs can be used to optimally capitalize on 
known CPG network mechanisms to hypothesise the putative changes in the network that 
underlie the observed responses to experimental manipulations. In the in situ WHBP, the 
liver and kidneys are removed. This abolishes drug elimination and thereby stabilizes the 
concentration of drug present in the system throughout the duration of the experimental 
protocol. The preparation is transcardially perfused, which enables control over the 
metabolic state of the respiratory network through clamping of CO2 and O2 gases in the 
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perfusate. Transcardiac perfusion also supports selective stimulation of CB 
chemoreceptors through intra-arterial bolus injections of cyanide salt solutions upstream 
of the carotid bifurcation. 
Despite the above advantages of the in situ WHBP, there are a number of compromises 
to consider. Although the brainstem remains intact, there are two ways in which the 
respiratory network is reduced in the in situ WHBP. First, decerebration eliminates cortical 
descending inputs to the brainstem respiratory network. In the intact animal, the 
brainstem respiratory network receives cortical inputs involved in voluntary control of 
respiratory activity (e.g. during vocalization, mastication, defecation, etc) (Davies and 
Moores, 2010). Therefore, a decerebrated preparation is technically a reduction of the 
respiratory system and could be considered less favourable compared to the in vivo 
animal. However, the cortical inputs are irregular, perturbed under anaesthesia, and 
difficult to control for. Therefore, they could also be considered confounding factors when 
trying to methodically assess the effect and mechanisms of an experimental manipulation 
(e.g. drug administration). Also worth considering is that in vivo experiments with 
recordings of respiratory motor outputs typically require the use of opioid and/or 
barbiturate anaesthetics which are known to suppress respiratory neurones (Lee and 
Jones, 2018), and thereby introduce a confounding modulation of the respiratory CPG. 
The decerebrate in situ WHBP, on the other hand, allows for recordings and manipulations 
of the respiratory CPG without the requirement for anaesthetics.  
A second way in which the integrity of the respiratory CPG is compromised is trough 
removal of the lungs and sectioning of the vagal nerve. This eliminates pulmonary 
mechanoreceptor inputs to the respiratory CPG and constitutes elimination of the 
Herring-Breuer reflex (HBR) (see section 1.3.3). As a result, the eupnoeic respiratory rate 
is slightly reduced through elongation of inspiratory phase duration (Paton, 1996a). Loss 
of HBR feedback through vagotomisation is also reported to promote an increase in 
activity of inspiratory-to-expiratory phase spanning neurones in the PBc that are involved 
in the pontine medullary feedback loop (Molkov et al., 2013, Dick et al., 2008, Feldman 
and Gautier, 1976). It is possible that such increased activity of the pontine feedback loop 
acts to compensate for the loss of HBR feedback to drive inspiratory to expiratory phase 
transitioning (see section 1.3.3).  
In in situ WHBP recordings, perfusion pressure is upregulated with the use of AVP, which 
binds to V(1A) receptors on vascular smooth muscle cells to induce vasoconstriction 
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(Henderson and Byron, 2007). However, AVP also acts on V(1A) receptors in brainstem 
regions such as the area postrema (AP) and ventrolateral medulla, by which it can 
promote suppression of PN and HN respiratory activity in anaesthetised rats (Chuang et 
al., 2005, Chuang et al., 2003, Yang et al., 2006). In addition, AVP is thought to modulate 
sympathetic activity through excitatory influence on NTS barosensitive neurones (Hegarty 
and Felder, 1997), and through action at AVP V(1A) receptors in the RVLM (Kc et al., 2010). 
Endogenous AVP circulating in blood plasma does not cross the BBB in physiologically 
significant amounts (Landgraf, 1992). Therefore, arterial perfusion of AVP is not likely to 
affect respiratory or sympathetic nerve activity. However, through leakage of aCSF from 
blood vessels in the opened cranium, brainstem tissue in in situ WHBP becomes 
superfused with aCSF. This can result in diffusion of perfusate components (e.g. AVP) in 
brainstem tissue in a way that constitutes removal of the blood-brain barrier. Such 
diffusion of aCSF components is limited to peripheral areas of the brainstem only, and is 
not likely to affect deeper respiratory regions such as the ventrolateral medulla. We 
cannot exclude potential effects on respiratory and sympathetic activity as a result of 
diffusion of AVP in the most peripheral areas of the respiratory network, such as the area 
postrema or the commissural NTS. That said, the use of AVP in WHBP recordings in the 
present thesis was kept low (0.5-3 nM, compared to 27.7-461.2 μM microinjected in the 
NTS by Hegarty and Felder (1997)), and potential effects on the respiratory network are 
expected to be minimal. 
In situ WHBP have reduced temperature (30-32 °C), which is important to maintain 
preparation viability and stability for the long duration (>1hr) of experiments reported in 
this thesis. We cannot categorically exclude the possibility that hypothermia influences 
respiratory function in these preparations compared to in vivo. However, the functioning 
of the in situ WHBP brainstem respiratory network at rest, and in response to chronic and 
acute challenges (e.g. hypoxia, high blood pressure, lung inflation) is comparable to that 
observed in vivo (Braga et al., 2007, Dutschmann et al., 2009a, Zoccal et al., 2009a, Lemes 
et al., 2016a, Taxini et al., 2017) 
Pioneering experiments with in situ WHBP used aCSF solutions with high K+ 
concentrations (6.25mM) to enhance neural excitability in the preparation (Paton, 
1996b). It was later found that 6.25mM K+ concentrations are not required for function of 
the respiratory network in the in situ WHBP that is comparable to that observed in vivo 
(Lemes et al., 2016a, Dutschmann et al., 2009a, Taxini et al., 2017). The concentration of 
potassium in aCSF used in experiments reported here is 5.2 mM, which equates median 
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physiological concentrations in male Wistar rat serum (Boehm et al., 2007). Therefore, 
enhanced excitability due to high K+ concentrations is not a factor limiting translation of 
the present thesis’ in situ WHBP experiments to in vivo animals.  
Hyperoxic aCSF (92% or 95% O2) used in the present studies may lead to a reduction in 
baseline activity of O2 chemoreceptors. We acknowledge that this may result in different 
baseline respiratory activity compared to freely moving in vivo animals. However, freely 
moving animals do not permit the comprehensive recording of respiratory output from 
multiple motor nerves. And nerve recordings in anaesthetised animals in vivo are 
performed under similarly hyperoxic conditions, as animals are typically ventilated with 
100% O2 gas.   
Perhaps the greatest disadvantage of the in situ WHBP is that the preparation can 
deteriorate, for example, through the formation of embolisms induced by transcardiac 
perfusion. To control for deterioration of the preparation over the course of an 
experiment, recordings in which the eupnoeic respiratory pattern changes in pre-
treatment conditions are excluded from the dataset. Second, temporal controls are 
incorporated in the experimental design to control for changes in respiratory output over 
time that are not attributable to experimental manipulations.  
Technical consideration with regard to the use of NLX-101  
NLX-101 is a brain permeable high efficacy agonist with high selectivity (>1000-fold) at 5-
HT1A receptors compared to a wide range (>40) of other receptors, ion channels, or 
monoamine-transporters (Newman-Tancredi et al., 2009). The use of NLX-101 is an 
important feature of the present studies, notably because its selectivity for 5-HT1AR is not 
achieved by drugs used in previous pharmacological studies on the role of 5-HT1A 
transmission in respiratory control. NLX-101 is also reported to have biased agonist 
transmission properties. The consequences of the latter for effects of NLX-101 on distinct 
neural populations are not yet fully understood. This poses a limitation to the 
interpretation of our data.  
A biased agonist is a GPCR ligand that stabilises a specific active conformation of the 
receptor, leading to preferential activation of select receptor coupled intracellular 
pathways (Stott et al., 2016). In vitro, NLX-101 is reported to preferentially activate Gαi 
subunits over Gαo subunits at 5-HT1A receptors (Newman-Tancredi et al., 2009). NLX-101 
was also reported to have greater potency in phosphorylation of ERK1/2 relative to 
measures of other intracellular signaling mechanisms, such as: inhibition of cAMP 
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accumulation; receptor internalization; and Ca2+ mobilization in vitro (Newman-Tancredi 
et al., 2009, Sniecikowska et al., 2019a). The same in vitro experiments, revealed that 
other 5-HT1AR ligands (5-HT, buspirone; 8-OH-DPAT; and various 1-(1-benzoylpiperidin-4-
yl)methanamine derivates, a family of compounds to which NLX-101 also belongs) 
indiscriminately activated all signaling cascades. This suggests the results indicative of 
biased agonism by NLX-101 were not merely the result of differential amplification in the 
measures selected to represent various intracellular responses.  
Differences in host cell environment can determine which G-proteins interact with a G-
protein coupled receptor (GPCR). This can result in differential recruitment of intracellular 
responses in response to GPCR agonism across neural subpopulations (Mannoury la Cour 
et al., 2006). Based on In vivo and ex vivo experiments, it has been suggested that the 
biased agonist signaling properties of NLX-101 translate to differential potency of the drug 
in different brain regions. Systemic administration of NLX-101 results in phosphorylation 
of ERK1/2 and c-fos activation preferentially in the frontal cortex compared to raphe 
regions, as observed ex vivo (Newman-Tancredi et al., 2009). Further, microdialysis 
measurements of 5-HT release in the hippocampus – which is inhibited by auto-receptor 
activation - and dopamine (DA) release in the medial prefrontal cortex (mPFC) - which is 
disinhibited by 5-HT1A hetero-receptor mediated suppression of mPFC inhibitory 
interneurones - showed that systemic administration of NLX-101 affects the latter with 
greater potency compared to the former in anesthetized rats (Llado-Pelfort et al., 2010). 
Similarly, extracellular recordings of mPFC pyramidal cells and dorsal raphe neurons in 
anesthetized rats revealed that systemic administration of NLX-101 results in excitation 
of mPFC pyramidal cells at low concentrations, whereas higher concentrations were 
necessary to inhibit raphe neurons (Llado-Pelfort et al., 2010). The above in vivo effects 
were all abolished by prior administration of selective 5-HT1A antagonist (WAY-100635). 
The above findings have been interpreted by some to suggest preferential inhibition by 
NLX-101 of neurones with 5-HT1A hetero-receptors over those with auto-receptors. This 
notion is supported by a series of pharmacological magnetic resonance imaging (phMRI) 
and positron emission tomography (PET) studies in cats and rats, which show that 
systemic administration with NLX-101 exhibits a distinct profile of brain region targeting 
when compared to other 5-HT1A agonists (befiradol/NLX-112, F13714, and 8-OH-DPAT). 
Notably, NLX-101 produces anatomical patterns of energy metabolism that indicate 
activity in cortical regions is affected, whereas activity in dorsal raphe regions is not 
(Becker et al., 2016, Levigoureux et al., 2019, Vidal et al., 2018, Vidal et al., 2020). 
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However, the support for the hypothesis that NLX-101 biased agonism translates to 
preferential inhibition of neurones with hetero-receptors versus those with auto-
receptors has its limitations. Notably, the above mentioned in vivo and ex vivo studies 
(Llado-Pelfort et al., 2010, Newman-Tancredi et al., 2009) rely on direct comparison of 5-
HT1A hetero- versus auto-receptor mediated effects (DA release and neural activity in 
mPFC pyramidal cells, 5-HT release in the hippocampus, and neural activity in the dorsal 
raphe) that may be differentially amplified and subject to distinct network interferences. 
These experiments lack the necessary controls to account for such confounding 
differential amplification and interference. Therefore, the observed difference in 
sensitivity of the hetero-receptor versus auto-receptor mediated responses is not 
necessarily representative of differential potency of NLX-101 at raphe neurone auto-
receptors compared to hetero-receptors in the mPFC. Further, at the cellular level, 
differential responses to NLX-101 in neurones with auto-receptors vs. neurones with 
hetero-receptors could be mediated by differences in sensitivity or receptor reserve 
between these cell populations. The relative intrinsic efficacy of NLX-101 and other 
5-HT1AR agonists at auto- vs. hetero-receptor expressing populations remains to be 
experimentally established.  
In vitro studies indicate that NLX-101 preferably recruits Gαi over Gαo activation, and 
ERK1/2 pathway activation over other intracellular responses (Newman-Tancredi et al., 
2009, Sniecikowska et al., 2019a). It has been suggested that differential engagement of 
G protein subunits and intracellular signaling pathways in different neurone populations 
results in a translation of the above biased agonism to preferential inhibition of hetero-
receptor expressing neurons compared to auto-receptor expressing raphe neurones. This 
notion is supported by the above mentioned PET and phMRI studies which show that NLX-
101 produces anatomical patterns of energy metabolism that indicate activity in cortical 
regions is affected, whereas activity in dorsal raphe regions is not (Becker et al., 2016, 
Levigoureux et al., 2019, Vidal et al., 2018, Vidal et al., 2020).However, at present, the 
above notion is not established beyond reasonable doubt. Some key questions remain to 
be answered. First, do 5-HT1A R differentially couple with Gαi or Gαo subunits at auto 
receptors in raphe serotonergic neurones versus hetero-receptors elsewhere in the 
respiratory network? Second, what is the relative intrinsic efficacy of NLX-101 and other 
5-HT1AR agonists at auto- vs. hetero-receptor expressing respiratory populations? The lack 
of clarity regarding the potential for differential potency of NLX-101 at raphe serotonergic 
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neurones with 5-HT1A auto-receptors versus other populations in the respiratory network 
with hetero-receptors poses a limitation for the interpretation of our data.  
Technical considerations with regard to experimental design  
The dataset of peripheral chemoreflex experiments shows, for some parameters, 
significant differences between treatment group means in pre-treatment conditions. The 
presence of pre-treatment differences in treatment group means indicates presence of 
confounding group differences not related to the experimental manipulation. This could 
potentially be due to a flaw in the experimental design applied for this experiment. That 
is, animals from different batches were not distributed across drug vs. vehicle treatment 
groups evenly. However, the significant pre-treatment differences did not occur in groups 
that showed significant post-treatment differences; and vehicle responses remained 
consistent pre- and post-treatment. Therefore, significant effects observed are likely to 
be real. On the other hand, it is possible that some effects existed that were not found to 
be significant because they were masked by pre-treatment group differences. 
Optimal support for the notion that effects of NLX-101 in the present thesis are mediated 
by selective 5-HT1AR transmission requires experimental evidence that the effects of NLX-
101 are challenged by systemic co-administration of 5-HT1AR antagonist. In a small set of 
preliminary and experimental recordings with in situ WHBPs, I performed experiments in 
which systemic administration of NLX-101 was followed by co-administration of WAY-
100635. Effects observed in these recordings suggest that 5-HT1AR antagonism reverses 
effects of NLX-101 on respiratory activity (see figure 3-16). However, experimental 
protocols were not identical across these recordings (details on recording protocols are 
provided in legend to figure 3-16), and sample sizes were small (n=4). Therefore, these 
recordings cannot be used for statistical comparisons to provide categorical evidence that 
functional effects of NLX-101 observed in the present thesis are mediated selectively by 
5-HT1AR transmission. I acknowledge that the absence of such categorical evidence poses 
limitations to the degree of certainty with which I can attribute effects observed after 
administration of NLX-101 to selective 5-HT1AR agonism.  
That said, previous studies provide strong experimental support that effects of NLX-101 
in vitro and in vivo are mediated selectively by 5-HT1AR agonism.In vitro, NLX-101 has 
>1000-fold selectivity at 5-HT1A receptors compared to a wide range (>40) of other 
receptors, ion channels, or monoamine-transporters (Newman-Tancredi et al., 2009). 
Whole cell patch-clamp recordings show that NLX-101 (1μM) bath administration inhibits 
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dorsal raphe neurones in acute brain slices of rat, and this effect can be blocked with pre-
treatment with 5-HT1AR antagonist WAY-100635 (1μM) (Levitt et al., 2013). In vivo, effects 
of systemic NLX-101 (i.v.) on the discharge rate of pyramidal neurones in medial 
prefrontal cortex (mPFC) and on that of dorsal raphe 5-HT neurones were both reversed 
by the 5-HT1AR antagonist WAY-100635 in anaesthetised rats (Llado-Pelfort et al., 2010) 
(see section 3.4.2, pages 128-129). These findings, together with the in situ WHBP 
recordings reported in figure 3-16, suggest that functional effects of NLX-101 as described 
in this thesis are likely to be mediated selectively by 5-HT1AR transmission.  
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Figure 3-16: effects of NLX-101 on respiratory rhythm and pattern can be reversed by 
co-administration of 5-HT1A R antagonist WAY-100635.  
Peripheral nerve recordings of the PN, HN, cVN, and AbN in two in situ WHBP illustrate the 
effects of systemic NLX-101 on respiratory rhythm and pattern, and the full or partial reversal 
of these effects after subsequent systemic administration of 5-HT1AR antagonist WAY-100635. 
(A1) The full time-course of a concentration response recording with NLX-101 (1nM, 10nM, 
100nM, 500nM, and 1μM) and subsequent co-administration of WAY-100635 (2μM). Red 
annotation indicates 30s sections depicted in more detail below (A2-5)..Figures (B1-4) show 
excerpts of another NLX-101 concentration-response recording (1nM, 10nM, 100nM, 600nM, 
1μM NLX-101), followed by co-administration of WAY-100635 (2μM). Figures (C1-4) show 
excerpts of an NLX-101 concentration-response protocol (1nM, 10nM, 100nM NLX-101), 
followed by co-administration of WAY-100635 (200nM). In this recording, a two-minute 
hypercapnic stimulus (7% CO2, O2-balanced) was performed pre-treatment, and after each drug 
administration (not shown). Excerpts depicted here are sampled after recovery from each 
hypercapnic stimulus (>5 min after cessation of hypercapnic stimulus). Figures (D1-3) show 
excerpts of a recording with a (pre-treatment) hypercapnic stimulus (8% CO2, O2-balanced) (not 
shown), followed by NLX-101 (500nM), followed by co-administration of WAY-100635 (2μM). 
The pre-treatment excerpt depicted here is sampled after recovery from the hypercapnic 
stimulus (>9 min after cessation of hypercapnic stimulus).  
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3.4.3 Interpretation of data 
Systemic 5-HT1A transmission results in increased respiratory drive in resting conditions. 
The closest resemblance in previous literature to the concentration response experiments 
of section 3.3.1 is a series of studies on the effects of systemic administration of 5-HT1A/7 
receptor agonist (8-OH-DPAT) on respiratory rate and minute activity derived from 
recordings of the PN in in situ WHBP of rats. Minute PN activity (mPNA) was defined as 
the average PN motor burst envelope per minute, and can be considered a surrogate of 
minute ventilation. Systemic administration 8-OH-DPAT was reported to increase mPNA 
and significantly increase respiratory rate in in situ WHBP of juvenile rats in resting 
conditions (Corcoran et al., 2013, Manzke et al., 2009, Manzke et al., 2010). Conversely, 
systemic application 5-HT1Aantagonist (WAY-100635) resulted in depression of mPNA in 
in situ WHBP of rats (Manzke et al., 2009). Similarly, systemic administration of 
8-OH-DPAT (i.v.) resulted in increased respiratory rate and tidal volumes observed 
through plethysmography recordings in anesthetised rats (Szereda-Przestaszewska and 
Kaczynska, 2007, Valic et al., 2008, Manzke et al., 2009). These effects, too, were 
reversible by subsequent administration of 5-HT1A R antagonist (WAY-100635) (Valic et 
al., 2008, Manzke et al., 2009). Thus, systemic administration of 5-HT1A/7 R agonist (8-OH-
DPAT) resulted in increased respiratory rate and tidal volume, or physiological substrates 
thereof, in vivo and in situ. These findings are in line with the increased respiratory rate 
and increased PN burst amplitude and envelope observed after systemic administration 
of NLX-101 in in situ WHBP in concentration response experiments of the present chapter. 
Further, the significant increases in late-E amplitude also correspond to the increased tidal 
volume observed through plethysmography recordings, as forced expiration decreases 
lung volume below functional residual capacity so that the inspiratory volume of the 
subsequent breathing cycle can be increased. Overall, NLX-101 concentration-response 
experiments revealed similar effects on restful respiratory drive as has previously been 
reported after administration of 8-OH-DPAT. The NLX-101 concentration-response 
experiments in the present chapter offer direct experimental support for the hypothesis 
that network wide selective 5-HT1A agonism promotes increased respiratory drive. 
Discrepancies between effects of systemic NLX-101 on restful respiratory activitiy and 
previous literature on respiratory effects of systemic 5-HT1A transmission. 
Although findings from NLX-101 concentration-response experiments in this chapter are 
consistent with previous work that suggests 5-HT1A transmission results in increased 
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respiratory drive, the specific 5-HT1AR mediated changes in respiratory rhythm and 
pattern are distinct from findings and modelling hypotheses in the current literature.  
One finding regarding pattern changes in restful respiratory activity in response to NLX-
101 that is not consistent with previous reports is the lack of an effect on normalised burst 
envelope and peak amplitudes in integrated HN motor output. Besnard et al. (2007, 2012) 
reported that central injections (in the 4th ventricle) of 8-OH-DPAT promoted a significant 
increase in tonus of upper airway muscles involved in upper airway dilation and 
stabilization (genioglossus, geniohyoid, and digastric muscles) observed through 
electromyography recordings in anesthetised rats. The genioglossus and geniohyoid 
muscles are innervated by the HN, whereas the digastric muscle is innervated by the facial 
nerve (CN 7). Our recordings of the HN, however, did not reveal any changes in pattern 
(normalised burst envelope or peak amplitude) under resting conditions in response to 
systemic administration of NLX-101. It is currently not clear what could explain the 
discrepancy between these findings and the results observed in the present thesis. 
Differences between these studies include a difference in drug administration (injection 
in 4th ventricle vs. arterial perfusion), which could result in differential spread of 5-HT1AR 
agonist across the regions of the respiratory CPG. Further, the selectivity of the drugs used 
is different (5-HT1A/7R agonist 8-OH-DPAT vs. selective 5-HT1AR agonis NLX-101). Effects of 
5-HT7 transmission on respiratory network interactions are plausible as 73.9% of 
glycinergic (GlyT2 positive) cells in the pre-BötC are also 5-HT7 positive (Manzke et al., 
2009). Ultimately, the use of anaesthesia (urethane) could affect respiratory responses to 
the pharmacological manipulation. Although the anaesthetic used (urethane) affects 
cardiovascular and respiratory systems in rodents to a lesser extent than barbiturates and 
opioids (Lee and Jones, 2018) effect on respiratory function are still present, and urethane 
is reported to affect multiple neurotransmitter gated ion channels at approximately 
anaesthetic 50% effective concentration (Hara and Harris, 2002). Therefore, confounding 
effects of anaesthesia cannot be excluded.   
There are also some notable differences between our experimental findings and previous 
literature regarding respiratory rhythm changes in response to systemic 5-HT1AR 
transmission. Single cell recordings of expiratory neurones combined with PN recordings 
in anesthetised cats revealed that systemic administration of 8-OH-DPAT resulted in 
changes of the activity pattern of Post-I neurones (Manzke et al., 2009). Specifically, a low 
dose of 8-OH-DPAT (10 μg/kg -1) resulted in the receding of onset of bursting activity from 
the Post-I phase into the I phase. At a high dose of 8-OH-DPAT, Post-I neurone activity 
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became suppressed throughout most of the respiratory cycle via hyperpolarizing currents. 
Inspired by these recordings, a computational model was developed that described 
hypothetical 5-HT1AR mediated changes in interactions among expiratory and inspiratory 
neurone populations in the BötC and pre-BötC, respectively (Shevtsova et al., 2011). The 
specific putative effects of 5-HT1A R transmission at BötC and pre-BötC neurones, and how 
these are suggested to affect VRC network interactions, are beyond the scope of the 
present chapter but will be addressed in detail in chapter 5. Relevant with regard to the 
findings in the present chapter, however, is that both Manzke et al. (2009) and the 
subsequent modelling hypothesis (Shevtsova et al., 2011) assumed that the change in 
activity pattern observed in Post-I neurones can be extrapolated to the network level, and 
that systemic administration of a 5-HT1A agonist would result in a shift and, at higher 
concentrations, in suppression, of cVN Post-I activity. This was suggested to transform the 
tri-phasic eupnoeic respiratory rhythm to a two-phased oscillation between inspiratory 
and expiratory activity (without the Post-I phase). Although the NLX-101 concentration-
response experiment revealed a non-significant trend of shortening of cVN Post-I activity, 
we did not observe a phase shift, nor a loss of cVN Post-I activity. At all stages in the NLX-
101 concentration response curve, the tri-phasic rhythm remained intact. A number of 
factors could explain the discrepancy between our findings and the experimental findings 
by Manzke et al. (2009) and modelling hypothesis based thereon (Shevtsova et al., 2011). 
Manzke et al. (2009) used a non-selective 5-HT1A/7 R agonist (8-OH-DPAT), and single cell 
recordings of respiratory neurones are performed in pentobarbital anesthetised cats. One 
cannot exclude confounding effects of 5-HT7 transmission and/or barbiturate anaesthesia 
on the respiratory network. Further, the assumption that systemic stimulation of 5-HT1A 
transmission resulted in the complete loss of Post-I activity at the network level was never 
experimentally verified. This assumption was based on extrapolation of the responses to 
systemic administration of 8-OH-DPAT observed in 4 Post-I neurones, to the 
subpopulation of Post-I neurones at large. The limited sample size of these recordings 
does not permit such inference with confidence. Ultimately, the computational model by 
Shevtsova et al. (2011) relied on assumptions not experimentally verified with regard to 
the neuroanatomical  and biochemical properties of specific VRC respiratory functional 
subpopulations (e.g. Post-I neurones, Early-I neurones, etc), this topic will be addressed 
in more detail in chapter 5 (section 5.1.1).   
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Interpretation of putative mechanisms underlying effects of systemic NLX-101 inspired by 
lessons from the broader respiratory control literature.  
The effects of NLX-101 on resting state respiratory rhythm show interesting parallels with 
respiratory behaviours in health and disease that may contribute to a better 
understanding of how 5-HT1A affects the respiratory CPG.  
One such parallel can be found in research on the mechanism and treatment of 
respiratory dysrhythmia in Rett Syndrome (RTT). As addressed in the General Introduction 
(section 1.8.2), RTT is a neurological disorder most often caused by loss of function of 
transcriptional regulator MeCP2 (Chahrour et al., 2008, Percy, 2016, Young et al., 2005). 
Common features of disordered breathing in RTT include spontaneous central apnoea, 
active breath holding, and valsalva maneuvers (Ramirez et al., 2013, Bissonnette and 
Knopp, 2006, Weese-Mayer et al., 2006). These behaviours have been associated with 
overactivity of the laryngeal adductors that control expiratory airflow via closure of the 
glottis, and with overactivity of expiratory neural populations that ultimately drive these 
muscles (Abdala et al., 2014a, Ramirez et al., 2013). The respiratory phenotype of RTT 
syndrome is mimicked in MeCP2 deficient mice, which display respiratory rhythm 
variability and high incidence of spontaneous central apnoeas (Abdala et al., 2010, Levitt 
et al., 2013, Samaco et al., 2013, Schmid et al., 2012, Chao et al., 2007). In in situ WHBP 
of rats and mice, central apnoeas are characterized by enhanced activity and duration of 
Post-I activity in the cVN (Stettner et al., 2007, Abdala et al., 2010). Thus, exacerbated 
expiratory (Post-I) activity is a prominent feature of respiratory dysrhythmia in mouse 
models of RTT.  
Systemic administration of 5-HT1A/7R agonist (8-OH-DPAT) or 5-HT1AR agonist and D2 R 
antagonist (Sarizotan) can depress respiratory apnoea in unanaesthetised MeCP2 
deficient mice in vivo (Abdala et al., 2010), as well as in in situ WHBP of MeCP2 deficient 
mice (Abdala et al., 2010). Systemic administration of NLX-101 was found to reduce 
apnoea and improve breath irregularity in unanaesthetised MeCP2 deficient mice in vivo 
in a dose dependent manner (Levitt et al., 2013). Conversely, systemic administration 
5-HT1AR antagonist WAY-100635 induces periodic apnoeas in in situ WHBP of healthy WT 
mice (Dhingra et al., 2016). It is suggested that 5-HT1A transmission alleviates dysrhythmia 
in MeCP2 deficient mice through suppression of Post-I activity (Abdala et al., 2014a, 
Wittman et al., 2019). 
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In the present chapter, we observed that the increase in resting state respiratory rate 
after systemic administration of NLX-101 appears to be mediated predominantly through 
shortening of expiratory phase duration (PN TE(s)) (see  Fig. 3-5A3 and Table 3-1), that 
appears mediated to equal extent by shortening of Post-I and E2 phase durations (see  Fig. 
3-5B1,2 and Table 3-1). Although not statistically significant, the reduction in PN TE(s) had 
a large effect size. To conclude, findings in the present thesis suggest that the increased 
respiratory rate is mediated chiefly by shortening of expiratory phase duration. This is 
consistent with suppression of Post-I activity in response to systemic 5-HT1A agonism in 
MeCP2 deficient mice. It is conceivable that the stabilization of respiratory dysrhythmia 
in mouse models of RTT syndrome, and the increase in respiratory rate in in situ WHBP of 
rats in response to systemic 5-HT1A transmission are mediated by a shared mechanism. 
Further exploration of this notion benefits from data presented in subsequent chapters 
of the present thesis, and will therefore be addressed in the general discussion. 
Another interesting parallel that may help to elucidate putative mechanisms underlying 
the effect of systemic NLX-101 can be found in the similarities between the response to 
NLX-101 and the hypercapnic respiratory response. In in situ WHBP, the hypercapnic 
respiratory response was described as increased respiratory rate and pattern, combined 
with the emergence of late-E activity (Abdala et al., 2009, Marina et al., 2010). In vivo, a 
similar response was observed: increased tidal volume along with forced expiration 
through abdominal contraction (late-E) (Huckstepp et al., 2015, Falquetto et al., 2018). 
The network response to systemic administration of NLX-101 resembled the hypercapnic 
response: i.e. an increase in respiratory drive that included enhanced respiratory rate, 
increased pattern in PN and AbN respiratory motor outputs, and a (non-significant) 
increase in the incidence of late-E bursts. One noteworthy distinction is that late-E activity 
in response to hypercapnia is described as an all or nothing event, with similar amplitudes 
observed in all AbN late-E bursts (Abdala et al., 2009), whereas Late-E bursts in response 
to NLX-101 were a graded phenomenon, with dose-dependent increases in burst 
amplitude (see fig. 3-6D2). Under hypercapnic conditions, the increase in respiratory rate 
and pattern is thought to be mediated by enhanced excitatory drive from CO2 
chemoreceptors to respiratory neurones in the VRC, notably to inspiratory neurones in 
the pre-BötC (Bochorishvili et al., 2012, Mulkey et al., 2004, Guyenet et al., 2016) (see 
section 1.4.1). Similarly, the emergence of late-E activity under hypercapnic conditions 
was suggested to be mediated by enhanced excitatory chemoreceptor drive to late-E 
neurones of the expiratory oscillator in the pFRG  (Marina et al., 2010, Abbott et al., 2011) 
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(see section 1.4.4). Systemic NLX-101 and WAY-100635 did not affect the respiratory and 
sympathetic responses to hypercapnia or peripheral chemoreflex activation. Therefore, it 
is unlikely that systemic administration of NLX-101 or WAY-100635 resulted in increased 
chemoreceptor drive. An alternative mechanism via which systemic NLX-101 
administration could putatively promote the respiratory responses also observed under 
hypercapnic responses, is through disinhibition of mechanisms downstream of central 
chemoreceptors. Disinhibition of pFRG expiratory oscillator through focal co-
administration of GABAAR antagonist (bicuculline) and glycine receptor antagonist 
(strychnine) was reported to promote late-E activity in anesthetised rats (Huckstepp et 
al., 2015, Silva et al., 2019). Therefore, it is conceivable that systemic administration of 
NLX-101 promoted late-E activity through suppression of inhibitory afferents to the pFRG 
(i.e. disinhibition of the pFRG). Similarly, disinhibition of inspiratory VRC populations 
downstream of chemoreceptors could contribute to the observed increases in respiratory 
rate and pattern.  
Further discussion of putative mechanisms underlying the effects of systemic 
administration of NLX-101 on restful respiratory activity, as well as an interpretation of 
the absence of an effect on respiratory and sympatho-respiratory responses to 
hypercapnia and peripheral chemoreceptor activation, benefits from data presented in 
chapters 4 and 5. To this end, the general discussion will provide a comprehensive 
interpretation of the data presented across chapters of this thesis in the context of the 
relevant literature on respiratory behaviour in health and disease (e.g. the hypercapnic 
response, RTT syndrome, μOR-induced depression of respiratory activity). Topics 
addressed further in the general discussion include: putative mechanisms underlying [1] 
the increased respiratory rate and shortening of expiratory phase duration; [2] the 
emergence of late-E activity [3] the potentiation of respiratory pattern in some, but not 
all respiratory motor outputs; and [4] an interpretation of the absence of effects of NLX-
101 on chemoreflex responses.   
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Chapter 4: 5-HT1A RECEPTOR RNA DISTRIBUTION ACROSS 
BRAINSTEM REGIONS OF RESPIRATORY CONTROL. 
4.1 CHAPTER INTRODUCTION  
4.1.1 Identification of putative mechanisms underlying effects of 5-HT1A 
transmission requires an understanding of 5-HT1AR distribution among key 
regions of respiratory control. 
Chapter three provides a comprehensive account of the effects of selective 5-HT1A 
receptor agonism on the eupnoeic respiratory rhythm and pattern, and on the respiratory 
and sympathetic responses to peripheral and central chemoreflex activation. Previous 
experimental and modelling studies have suggested that 5-HT1A receptor agonism induces 
changes in respiratory rhythm and pattern chiefly due to inhibition of subpopulations of 
inhibitory respiratory interneurones in the VRC (Manzke et al., 2009, Manzke et al., 2010, 
Shevtsova et al., 2011) (see section 1.7.3). To determine whether differential anatomical 
distribution of 5-HT1AR could partly explain the agonism functional effects, I investigated 
the distribution of 5-HT1AR RNA transcripts over inhibitory and non-inhibitory neurones in 
key brainstem regions of respiratory control. 
There are multiple brainstem regions at which 5-HT1A transmission could hypothetically 
modulate respiratory network activity. The BötC and pre-BötC contain concentrations of 
respiratory neurones important for expiratory and inspiratory rhythm generation, 
respectively. Inhibitory interneurons in these regions are thought to be involved in the 
coordination of multiphase respiratory activity (Smith et al., 2013) (see section 1.2.3).The 
RVRG is thought to contain concentrations of respiratory neurons that contribute to 
respiratory pattern formation and relay rhythmic respiratory drives to (pre-)motor regions 
(Ezure et al., 1988, Alheid and McCrimmon, 2008) (see section 1.2.3). 5-HT1AR expression 
in motor neurones could suppress respiratory pattern, whereas 5-HT1AR expression in 
inhibitory pre-motor neurones could disinhibit motor neurones. Regions of the 
parabrachial complex are thought to contribute to inspiratory-to-expiratory phase 
transitioning (Alheid et al., 2004, Dutschmann and Dick, 2012) (see section 1.3). The NTS 
(Alheid et al., 2011) and the RTN (Guyenet et al., 2019) contain neurone populations 
involved in the respiratory and sympathetic peripheral and central chemoreflex responses 
(see sections 1.4.1, 1.5.2, and 1.6.2). Ultimately, the raphe nuclei contain serotonergic 
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neurones which modulate respiratory activity through 5-HT release, and of which 
subpopulations are reported to be involved the central chemoreflex responses (Brust et 
al., 2014, Hennessy et al., 2017) (see sections 1.4.2, 1.7.2, and 1.7.3). 
4.1.2 Current understanding of 5-HT1AR distribution in the respiratory CPG 
Histological-, in situ hybridization-, and PCR experiments indicate that 5-HT1AR are 
expressed in the BötC and pre-BötC (Manzke et al., 2009, Manzke et al., 2010), the  NTS 
(Vantrease et al., 2015), and in the dorsal and median raphe nuclei (Sotelo et al., 1990) of 
rats. Single cell recordings of neurones of the dorsal raphe in acute brain slices of mice 
suggested GIRK channel activation by NLX-101 (Levitt et al. 2013), which is consistent with 
the above histological evidence of 5-HT1AR in this region. Microdialysis of 5-HT1A/7R agonist 
(8-OH-DPAT) suggest that 5-HT1A receptors are also present in the raphe magnus and 
raphe pallidus (Li et al., 2006) (see section 1.7.3). Further, RT-PCR studies revealed 
presence of 5-HT1AR RNA in glomus cells isolated from carotid bodies of rat (Yokoyama et 
al., 2015). Thus, there is conclusive evidence for 5-HT1a R expression in the CB, BötC, pre-
BötC, NTS, and raphe nuclei of the pons (dorsal and median raphe), and there is 
pharmacological data that suggests there may be 5-HT1AR expression in caudal raphe 
nuclei (raphe magnus, raphe pallidus). 
A comprehensive mapping of 5-TH1A R expression throughout key regions of the 
respiratory CPG is still lacking. Furthermore, expression of 5-HT1A specifically in inhibitory 
(GlyT2 positive) neurones has, as yet, only been reported for the pre-BötC and not 
compared to other regions (Manzke et al., 2009, Manzke et al., 2010). Given the relatively 
well described and important role of inhibitory interneurons in respiratory rhythm and 
pattern formation, and their differential functional-anatomical distribution in the 
respiratory network, this study aimed to map and compare expression of 5-HT1AR 
transcripts in inhibitory neurone populations located in brainstem respiratory nuclei.  
4.1.3 Chapter aims and hypotheses 
Chapter Aim: The aim this chapter is to establish the distribution of 5-HT1AR RNA 
throughout key regions of the brainstem respiratory network, particularly in inhibitory 
neurone populations. 
Methodological approach: GABAergic and Glycinergic neurones were identified by 
expression of vesicular inhibitory amino-acid transporter (SLC32A1) RNA. Fluorescence in 
situ hybridization (FISH) of 5-HT1A RNA and SLC32A1 RNA was performed in key brainstem 
regions of respiratory control. Analyzed regions of the VRC are the BötC; the pre-BötC; 
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and the RVRG. Analyzed regions with (pre-)motor neurones are the nucleus ambiguus 
compactus (N. Amb. C., which contains hypoglossal and vagal (pre-)motor neurones 
(McGovern and Mazzone, 2010, Ezure, 1990)); the dorsal motor nucleus of the vagus 
(N10); the hypoglossal motor nucleus (N12); and a region dorsomedial to the N. Abm. C. 
that contains hypoglossal pre-motor neurones (XII pre-motor region) (Koizumi et al., 
2008). Analyzed regions of the PBc are the medial parabrachial nucleus (MPB); the 
internal, central, and external parts of the lateral parabrachial nucleus (LPBI, LBPC, and 
LPBE, respectively); and the Kölliker Fuse nucleus (KF). The ventral parafacial region where 
RTN neurones are located (pFV/RTN) and the commissural part of the NTS (NTScomm) are 
analyzed, both of which are important regions for chemoreceptor feedback mechanisms 
in respiratory control. And last, brainstem raphe nuclei are analyzed: raphe magnus 
(RMg); raphe obscurus (ROb); raphe pallidus (RPa), and the dorsal raphe nucleus. FISH 
was performed in fixed brain sections of adult rats.  
Hypotheses: Based on previous functional studies, I expected to find 5-HT1AR RNA in the 
NTS, median raphe, BötC , pre-BötC. I expected to find 5-HT1A R and Solute Carrier Family 
32 Member 1 (SLC32A1, a marker of glycinergic and GABAergic neurones) RNA 
(co-)expression in the pre-BötC. For other regions, the mapping of 5-HT1A R and SLC32A1 
(co-)expression is an exploratory effort.   
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4.2 CHAPTER METHODS 
4.2.1 Method description and justification 
To establish distribution of 5-HT1A R in various respiratory regions, and further identify the 
phenotype of 5-HT1AR expressing neurones, I used commercial fluorescence in situ 
hybridization (FISH) probes for labelling of rat 5HT1A receptor mRNA, Solute Carrier Family 
32 Member 1 mRNA (SLC32A1), and Peptidylprolyl Isomerase B mRNA (PPIB, an abundant 
housekeeping gene targeted as a positive control) with RNAscope® Fluorescent Multiplex 
assay (Advanced Cell Diagnostics Inc., Newark, USA). FISH enabled single molecule 
visualization of target mRNA in individual cells, while preserving tissue context. 
RNAscope® has improved selectivity and signal-to-noise ratio relative to conventional ISH 
methods (Wang et al., 2012). Furthermore, this proprietary platform facilitated 
simultaneous detection of multiple target mRNA’s (Wang et al., 2012). The method 
utilizes dual probes which bind to contiguous sequences of target RNA. Each probe 
consists of a (18-25 base) sequence complementary to a sequence of the target RNA, a 
spacer sequence, and a (14 base) tail sequence. This probe design is conceptualised as a 
‘Z-probe’. Of the two Z-probes binding to contiguous sequences of target RNA (double Z), 
the two ‘tail’ sequences are different, and together form a single (28-base) hybridization 
site for pre-amplifier molecules. Each pre-amplifier contains 20 binding sites for amplifier 
molecules, and each amplifier contains 20 binding sites to specific fluorescent label 
probes (for a schematic of this design, see figure 4-1). This design ensures minimal 
background noise because the 14-base tail sequence of a single z-probe will not bind the 
pre-amplifier with sufficient strength to result in successful signal amplification, and it is 
highly unlikely that a non-specific hybridization event will juxtapose a pair of z-probes 
along an off-target mRNA molecule to form the ‘double-z’ 28-base hybridization site for 
the preamplifier. Multiple distinct RNA sequences can be targeted simultaneously using 
distinct Z-probe pairs, each dual Z sequence targeted by a cognate set of pre-amplifiers, 
amplifiers, and fluorescent label probes.  
The strong and selective signal amplification with RNAscope® FISH means that individual 
hybridized RNA molecules are discernible as punctate dots with confocal imaging. 
Consequently, when FISH is combined with Nissl nucleic acid staining (labelling ribosomal 
RNA, and other accumulations of nucleic acid in the neurone), neural soma outlines can 
be established, and FISH labeled RNA (co-expression) levels can be counted per cell in a 
given neuro-anatomical structure. Additional DAPI staining was used for anatomical 
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referencing throughout the brainstem. Thus, FISH with RNAscope® Fluorescent Multiplex 
assay, combined with Nissl and DAPI staining, was used to perform a detailed analysis of 
5-HT1A receptor and SLC32A1 mRNA (co-)expression levels in individual neurones 
throughout key brainstem structures in respiratory control.  
 
 
4.2.2 Preparation of fixed brain sections for ISH labelling or Neutral red stain 
Brain section for RNAscope® ISH was acquired from four adult (~200g) male Wistar rats 
that were anesthetised with isoflurane until loss of hind paw pinch reflex, and 
subsequently euthanised with i.p. injection (10mL/kg) of Euthatal (200 mg/mL sodium 
pentobarbital; Merial, Harlow, United Kindgom). After euthanasia, the rat was 
transcardially perfused with 50mL 1x PBS, immediately followed by perfusion with 100mL 
4% PFA in 1x PBS. The brain was then carefully collected and stored in 4% PFA solution in 
1x PBS overnight at 4°C for postfixation. The brain was then transferred to 20% sucrose in 
1x PBS solution, and left in sucrose solution for 24 hours at 4°C for cryoprotection. Blocks 
of pontine and medullary brainstem tissue were then prepared and suspended in O.C.T. 
embedding media (Cellpath, Newtown, United Kingdom) and stored airtight at -80°C for 
a duration of up to two days until cryostat sectioning. 15 Micrometer coronal sections of 
RNAscope® Fluorescent Multiplex assay (Advanced Cell Diagnostics Inc., Newark, USA) 
enables single molecule visualization of target mRNA in individual cells, while preserving 
tissue context in PFA fixated brain slices (A). Multiple RNA sequences can be labelled 
simultaneously. For each targeted RNA, a distinct pair of ‘z-probes’ is designed to hybridize 
with contiguous sequences of that RNA, and form a ‘double-z’ probe pair (B). The combined 
tail sequences of the ‘double- z’ probe pair hybridize exclusively with cognate pre-amplifier 
molecules, to which exclusively cognate amplifiers and fluorescent label probes can bind (C). 
This ensures highly selective, yet powerfully amplified fluorescent labelling of the target RNA. 
Schematic is adapted from Wang et al. (2012). 
Figure 4-1: Schematic representation of RNAscope® Fluorescent Multiplex assay design. 
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the pons and sagittal sections of the lateral and medial medulla were prepared with a 
cryostat and mounted on Superfrost Plus slides (Thermo Scientific, Waltham, U.S.A.). 
When cutting and mounting sections, all slides were numbered in order of sectioning, and 
every fifth section was set aside for Neutral Red (1% in H2O) lysosomal staining for 
anatomical reference. The remaining sections were stored airtight at -80°C to be used for 
FISH labelling within 2 months from the day of euthanasia and PFA perfusion. The neutral 
red stained sections were evaluated for anatomical landmarks, based on which sections 
cut from immediately adjacent brain tissue were selected for FISH labelling. Except for 
O.C.T. embedding media, all solutions and materials in contact with brain tissue during 
this process were rendered RNAse free. 
4.2.3 Selection of sections for FISH labelling, and selection of anatomical 
structures for confocal imaging and image analysis 
From each of the four rat brains fixed and sectioned (see section 4.2.2), three sections 
were selected for FISH analysis of 5HT1AR RNA and SLC32A1 RNA (co-)expression in various 
brain regions of respiratory control. This selection of sections was guided by Paxinos and 
Watson (2007), and based on the presence of brainstem regions involved in respiratory 
control. A sagittal section of the lateral medulla (~ 2.1mm lateral from midline) was 
obtained from three out of four rats (in one of four rats I failed to obtain such a section). 
These sagittal lateral medulla sections were used for analysis of 5HT1AR and SLC32A1 
(co-)expression in the following brainstem regions: the ventral parafacial region, where 
RTN neurones are situated (pFV/RTN); the Bötzinger Complex (BötC); the pre-Bötzinger 
Complex (pre-BötC); the Rostroventral Respiratory Group (RVRG); Nucleus Ambiguus 
Compactus (N. Abm. C.); and a region with XII premotor neurones. Additionally, from each 
of the four rats, a sagittal section of the medial medulla (~ 0.1mm lateral from midline) 
was obtained for analysis of 5HT1A and SLC32A1 (co-)expression in: raphe Magnus (RMg); 
raphe Pallidus (RPa); raphe Obscurus (ROb); Dorsal Nucleus of the Vagus Nerve (N10); the 
hypoglossal motor nucleus (N12); and the commissural part of the Nucleus Tractus 
Solitarius (NTScomm). Finally, from each of the four rats, a coronal section was obtained 
of the pons (~8.88mm caudal from bregma) was obtained for analysis of 5HT1A and 
SLC32A1 (co-)expression in: the dorsal raphe, caudal part; the Medial Parabrachial 
Nucleus (MPB, bilaterally); the internal part of the Lateral Parabrachial Nucleus (LPBI, 
bilaterally); the central part of the Lateral Parabrachial Nucleus (LPBC, bilaterally); the 
external part of the Lateral Parabrachial Nucleus (LPBE, bilaterally); and the Kölliker Fuse 
Nucleus (KF, bilaterally). 
Chapter 4: 5-HT1A Receptor RNA Distribution Across Brainstem Regions of Respiratory Control. 
145 
 
To select the right sections for FISH, neutral red stained sections obtained during cryostat 
sectioning (see section 4.2.2) were imaged with a bright-field microscope, and evaluated 
relative to figures and images in the rat brain atlas by Paxinos and Watson (2007). Based 
on evaluation of anatomical landmarks in neutral red stained sections, and utilizing a 
numbering system applied when cryostat sectioning (see section 4.2.2), the appropriate 
sections were selected for FISH. Key anatomical landmarks for selection of lateral medulla 
sections were the presence of the facial nucleus, the nucleus ambiguous compactus, and 
the lateral reticular nucleus. Key anatomical landmarks for selection of the medial medulla 
sections were the principle-, medial-, and dorsal nuclei of the inferior olive, the 
hypoglossal nucleus, and the central canal. Key anatomical landmarks for selection of the 
pontine section were the shape of the fourth ventricle and the superior cerebellar 
peduncles. Figure 4-2 provides images of neutral red stained sections of the lateral 
medulla (sagittal) the medial medulla (sagittal), and the pons (coronal), each annotated 
with the key landmarks and brainstem regions selected for imaging and analysis of 5HT1A 
R and SLC32A1 (co-)expression.  
Figure 4-2: Sections of medulla and pons with annotation of brain regions in which FISH is 
quantified and analysed.  
Brightfield images of sagittal sections of the lateral meduula (~2.10 mm lateral from midline), 
(A) and medial medulla (~0.10 mm lateral from midline) (B), and a coronal section of the pons 
(~8.88mm caudal from bregma) (C). Sections were counterstained with neutral red stain for 
anatomical reference. Numbered blue boxes correspond to the regions in FISH treated sections 
that are imaged with a confocal microscope for subsequent RNA transcript counting and 
analysis. Pontine regions labelled with numbers 13 to 17 are imaged bilaterally. The numbers 
correspond to the following regions: 1 = ventral parafacial region (pFV) / retrotapezoid nucleus 
(RTN); 2 = Bötzinger Complex; 3 = pre-Bötzinger Complex; 4 = Rostroventral Respiratory Group; 
5 = Nucleus Ambiguus Compactus; 6 = region with XII premotor neurones; 7 = raphe Magnus; 
8 = raphe Pallidus; 9 = raphe Obscurus; 10 = Dorsal Nucleus of the Vagus Nerve; 11 = Nucleus 
Tractus Solitarius, commissural part; 12 = dorsal raphe, caudal part; 13 = Medial Parabrachial 
Nucleus; 14 = Lateral Parabrachial Nucleus, internal part;   15 = Lateral Parabrachial Nucleus, 
central part;   16 = Lateral Parabrachial Nucleus, external part; 17 = Kölliker Fuse Nucleus. 
Abbreviations: N7 = facial nucleus; N. Amb. C. = nucleus ambiguus compactus;  LRt = lateral 
reticular nucleus; inf. olive = inferior olive; N12 = hypoglossal nucleus; cc = central canal; 4V = 
fourth ventricle; scp = superior cerebellar peduncle. 
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4.2.4 Protocol for fluorescence in situ hybridization with DAPI and Nissl 
counterstaining  
The RNAscope® Fluorescent Multiplex assay (Advanced Cell Diagnostics Inc., Hayward, 
USA) protocol was performed as per manufacturer’s instructions, with additional NISSL 
and Dapi counterstaining for anatomical reference. This section provides a description 
and justification of the steps taken throughout the two-day protocol. The protocol was 
performed in a designated RNAse free zone, and all solutions and materials used were 
rendered RNAse free.  
Post fixation and dehydration of sections 
Upon collection from storage at -80°C, slides with selected sections were rinsed in PBS 
and placed in cold 4% PFA in PBS solution for 30 minutes for post fixation. Slides were 
then rinsed again with PBS and sections were dehydrated through three consecutive 5-
minute immersions in 50% EtOH, 75% EtOH, and 100% EtOH. This was followed by drying 
and baking the sections at 60°C for 30min. The baking step, along with subsequent warm 
(40°C) hybridization steps were performed with the use of a HybEZ hybridization oven 
(Advanced Cell Diagnostics Inc., Hayward, USA).  
Permeabilization and target retrieval 
Permeabilization of sections was performed by application of hydrogen peroxide (10 min 
at room temperature), and subsequently rinsed with distilled water (dH2O). A second 
permeabilization procedure performed was heat induced target retrieval (HITR), which 
facilitates target access and increases detection sensitivity of subsequent RNA 
hybridization steps through reversal of cross linking caused by PFA fixation. For HITR, 
slides were submerged in RNAscope® target retrieval reagent (provided in the RNAscope® 
Fluorescent Multiplex assay kit) for 2 minutes at 98-102 °C, and subsequently rinsed with 
dH2O and dehydrated through submersion in 100% EtOH for 3 minutes.  
Hybridization of z-probes to RNA 
Preceding RNA hybridization, amplification, and fluorophore binding steps, a hydrophobic 
barrier (0.75” * 0.75”) surrounding the section was drawn on each slide with a PAP 
hydrophobic barrier pen. To remove protein surrounding RNA strands, 
RNAscope®protease III solution (provided in the RNAscope® Fluorescent Multiplex assay 
kit) was applied to cover the section and allowed to incubate at 40°C for 15 minutes in a 
humified chamber, and subsequently removed and washed off with dH2O. For multiplex 
RNA hybridization, a mix of ISH probes targeting 5-HT1A R RNA (Rn-Htr1a, Advanced Cell 
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Diagnostics product code: 404801), PPIB RNA (Rn-Ppib, Advanced Cell Diagnostics product 
code: 320891), and SLC32A1 RNA (Rn-Slc32a1, Advanced Cell Diagnostics product code: 
424551-C3) was prepared as per manufacturer’s instructions. 120μL Probe mix was 
pipetted on each section and allowed to incubate at 40°C for 2 hours in a humified 
chamber. After hybridization, sections were washed in wash buffer (provided in the 
RNAscope® Fluorescent Multiplex assay kit) and stored overnight at room temperature in 
5x SSC (Sigma-Aldrich, Steinham, Germany) to resume with amplification and 
fluorophore binding steps the next day.  
Hybridization and amplification 
Hybridization of pre-amplifiers was performed with three distinct types of pre-amplifier, 
each type binding exclusively to one of the three RNA-binding probes. A solution 
containing a mix of all three pre-amplifiers (AMP1 solution, provided in the RNAscope® 
Fluorescent Multiplex assay kit) was applied on the sections and was left to incubate at 
40°C for 30 minutes in a humified chamber. This was followed with application and 
incubation (30 minutes at 40°C in a humidified chamber) of a mix of 3 amplifiers (AMP2 
solution, provided in the RNAscope® Fluorescent Multiplex assay kit), each binding 
exclusively to their cognate pre-amplifiers. Ultimately, a binding stabilizer (AMP3 
Solution, provided in the RNAscope® Fluorescent Multiplex assay kit) for the newly 
formed probe-pre-amplifier-amplifier complexes was applied and incubated at 40°C for 
15 min in a humidified chamber. Each of the three amplification steps (hybridization of 
pre-amplifiers, hybridization of amplifiers, and application of binding stabilizer) was 
preceded by washing with wash buffer.  
Hybridization of fluorescent label probes to amplifiers  
For Fluorescence signal development at hybridized target RNA’s, the RNAscope® 
Fluorescent Multiplex assay utilizes Tyramide Signal Amplification Plus (TSA Plus®) 
fluorophores (Perkin Elmer, Waltham, USA). TSA Plus® utilizes fluorescently labelled 
tyramide that can be converted to highly reactive free radicals that form covalent bonds 
with tyrosine residues near a probe. This conversion is catalysed by horseradish 
peroxidase (HRP). The TSA free radicals have a very short half-life and will form dimers 
that are subsequently washed away if they do not encounter a tyrosine residue. 
RNAscope® Multiplex assay signal development is performed through sequential 
fluorescent labelling of each of the three distinct amplifiers. The exact labelling design is 
undisclosed, but it involves incubation on the section (15 min at 40°C in a humidified 
chamber) of a reagent solution (HRP_C1 solution) that likely contains HRP conjugated to 
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tyrosine rich probes which bind selectively to one of the three distinct amplifier types 
(HRP_C2 solution and HRP_C3 solution could be used to selectively target each of the 
remaining two amplifier types, all HRP solutions were provided in the RNAscope® 
Fluorescent Multiplex assay kit). Subsequent incubation (30 minutes at 40°C in a 
humidified chamber) of TSA fluorophores will result in HRP-mediated deposition of 
fluorescently labelled tyramide at the probes bound to the target amplifier. An HRP 
blocker (RNAscope® Multiplex FLv2 HRP blocker, provided in the RNAscope® Fluorescent 
Multiplex assay kit) was applied (15 minutes at 40°C in a humidified chamber) to quench 
remaining HRP activity after TSA fluorescent probe deposition. All incubations were 
preceded and followed by washing steps with wash buffer. This fluorescent labelling 
sequence was first performed to bind TSA Plus Fluorescein dye (1:750 in TSA buffer, 
150μL) at amplifiers targeting 5-HT1A mRNA (using HRP_C1 solution), followed by TSA Plus 
Cyanine 3 dye (Cy3, 1:1500 in TSA buffer, 150μL) at amplifiers targeting PPIB mRNA (using 
HRP_C2 solution), and TSA Plus Cyanine 5 dye (Cy5 ,1:1500 in TSA buffer, 150μL) at 
amplifiers targeting SLC32A1 mRNA (using HRP_C3 solution). 
Nissl and DAPI counterstaining 
After completion of RNAscope® Multiplex assay signal development, sections were 
counterstained with fluorescent Nissl stain and DAPI. Sections were submerged in PBS 
with 0.1% Triton X-100 (10 min at room temperature), subsequently washed with PBS. 
Sections were covered with NeurotraceTM Blue Nissl stain (InvitrogenTM, Carlsbad, U.S.A.) 
solution (1:50 dilution in PBS) which was left to incubate (20 minutes at room 
temperature), followed by a wash (10 min at room temperature) with PBS with 0.1% 
Triton X-100. After additional washing steps with PBS (2x 5 minutes, 1x 2 hours at room 
temperature), DAPI was applied to each section and left to incubate for 1 minute at room 
temperature. Sections were washed with PBS for a final time (2x 2 minutes), and 
coverslipped with Prolong Gold Antifade Mounting medium. 
The concentrations of TSA Plus fluorescent dye solution, and optimization of Nissl and 
DAPI counterstaining were established through trial experiments with the use of a set of 
3-plex positive control probes which target RNA of genes expressed in all rat cells to 
varying degrees (RNAscope® 3-plex Positive Control Probe- Rn, Advanced Cell Diagnostics, 
product code: 320891). These positive control probes target RNA Polymerase II Subunit A 
(Polr2a) RNA (high expression), PPIB RNA (moderate-high expression), and Ubiquitin C 
(UBC) RNA (moderate-low expression). 
Chapter 4: 5-HT1A Receptor RNA Distribution Across Brainstem Regions of Respiratory Control. 
149 
 
4.2.5 Confocal Imaging 
Confocal images of brainstem regions involved in respiratory control were obtained with 
a Leica SP5-Acousto Optical Beam Splitter confocal laser scanning microscope, and with 
the use of Leica Application Suite AF image acquisition software (Leica, Newcastle Upon 
Tyne, UK). The imaging setup was equipped with a 50 mW diode laser (405nm), a 100 mW 
Argon laser (used for 488nm light), a 10 mW yellow laser (561 nm), and a 10 mW Red 
He/Ne laser (633 nm). Of each brainstem area, z-stack images (z-axis range = 10μm, step-
size = 2μm, 6 steps) of the fluorescein signal (FISH labelled 5HT1a R RNA), the Cy3 signal 
(FISH labelled PPIB RNA), the Cy5 signal (FISH labelled SLC32A1 RNA), and the DAPI signal 
pooled with the Neurotrace Blue signal (Nissl bodies and DNA for anatomical reference) 
were sequentially obtained with a 40x oil immersion lens (Leica HCX PL APO 40x/1.25). 
For clarity in future reference, the fluorescein, Cy3, and Cy5 signals will be referred as the 
5-HT1AR-, PPIB-, and SLC32A1 signals, respectively. The signal for DAPI pooled with 
Neurotrace Blue will be referred to as the ‘DAPI+Nissl’ signal. Imaging resolution was 1046 
x 1024 pixels, Airy Unit (A.U.) was set at 1, and images were obtained from a line average 
of 5 scans. Prior to obtaining each image, gain and laser power settings for each laser were 
optimized so that the pixel intensity extremes fitted just within the spectrum of image 
saturation according to the quick look up table (QLUT) image view. Table 4-1 displays 
details of excitation and emission wavelengths applied during imaging. Images were 
exported as .TIFF files for post-hoc image analysis.  








5HT1a R RNA Fluorescein 494 521 488 498-535 
PPIB RNA Cyanine 3 554 568 561 571-622 
SLC32A1 RNA Cyanine 5 649 666 633 643-720 
Nissl bodies Neurotrace Blue 405 455 405 415-485 
DNA DAPI 358 461 405 415-485 
The table lists the targets labelled with fluorophores, the peak emission (λem) and excitation (λex) 
wavelengths of fluorophores, and the wavelength used to excite fluorophores during imaging, 
and the wavelength filter settings for capturing light emitted by fluorophores during imaging. 
The Neutotrace Blue and DAPI signals were pooled and obtained simultaneously, as they served 
the same purpose (anatomical reference). 
 
Table 4-1: Confocal imaging emission and excitation wavelengths. 
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4.2.6 Post-Hoc image processing and analysis 
Post-hoc image analysis was performed with Volocity 6.3 imaging analysis software 
(Perkin Elmer, Waltham, USA). For each image, z-stacks were merged with a brightest 
point merge. Contrast settings were optimized with an automated contrast enhancement 
function. An automated protocol was set up to find objects in the DAPI+Nissl signal that 
represented cell somata. To avoid the identification of cell nuclei (labelled with DAPI) as 
cell somata, the minimum object size was set at 25μm2 and an object size guide parameter 
was set at 150μm2.  A medium filter was applied to remove noise from identified objects. 
Touching objects were separated and holes in objects were filled. Subsequently, regions 
of interest (ROI’s) were defined from the objects found in the DAPI+Nissl signal. FISH 
labelled RNA molecules were visible in the images as high contrast puncta. A Volocity 
function designed for the detection of high contrast spots was utilized to identify these 
puncta in 5-HT1AR-, PPIB-, and SLC32A1 signals separately. Ultimately, for each ROI (cell 
soma) in the image, the count of puncta (FISH labelled RNA) was calculated per signal 
(5-HT1AR, PPIB, SLC32A1). To avoid experimenter bias, determining ROI’s and counting 
puncta per signal per ROI was done through an automated procedure and was applied 
with identical parameter settings to all images. For clarity, an ROI derived from the 
DAPI+Nissl signal will henceforth be referred to as a ‘cell’, and the puncta count of an ROI 
will henceforth be referred to as its ‘transcript count’. 
Cells were assigned to phenotypes and expression level categories based on their 
transcript count observed in each imaging signal (5-HT1AR, PPIB, and SLC32A1). The 
expression level categories are: 0; 1 to 40 in bins of 2; and >40 transcripts per cell. Any 
cell with >0 transcripts observed in the 5-HT1AR, PPIB, or SLC32A1 signal was classified as 
5-HT1AR-, PPIB-, or SLC32A1-positive, respectively. Additionally, the population of cells 
that is 5-HT1AR positive (>0 transcripts per cell observed in the 5-HT1AR signal), is broken 
down into a subpopulation of cells that co-express 5HT1AR and SLC32A1 transcripts 
(5HT1aR+SLC32A1+) and a subpopulation of cells that are 5HT1AR positive and SLC32A1 
negative (5HT1AR+SLC32A1−). Similarly, the population of cells that is SLC32A1 positive 
(>0 transcripts per cell observed in the SLC32A1 signal), is subdivided into a SLC32A1 and 
5-HT1AR transcript co-expressing subpopulation (SLC32A1+5HT1aR+) and a subpopulation 
of cells that are SLC32A1 positive and 5-HT1AR negative (SLC32A1+5HT1AR−). Note that 
5HT1aR+SLC32A1+ and SLC32A1+5HT1aR+ describe the same population of 5-HT1AR and 
SLC32A1 co-expressing cells. The difference between these two definitions is that in the 
former group, each co-expressing cell is assigned to an expression level category based 
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on its 5HT1AR transcript count, whereas in the latter group each co-expressing cell is 
assigned to an expression level category based on its SLC32A1 transcript count. This allows 
for evaluation of the distribution of cells in the co-expressing population over various 5-
HT1AR expression levels, as well as over SLC32A1 expression levels. 
For each image of each brainstem region, the relative amount of PPIB-positive, 5-HT1AR 
positive (including subpopulations 5HT1aR+SLC32A1+ and 5HT1aR+SLC32A1−), and 
SLC32A1-positive (including subpopulations SLC32A1+5HT1AR+ and SLC32A1+5HT1AR−) 
cells per expression level category (1 to 40 in bins of 2; and >40 transcripts per cell) was 
expressed as the percentage of all cells in the image. Cumulative percentages in order of 
ascending expression level category (with exclusion of cells with zero transcripts) were 
also calculated for each phenotype. For brainstem regions imaged from lateral medulla 
sections (listed in figure 4.2A), the frequency (%) and cumulative frequency (%) values per 
expression level category were obtained from 4 images of sections from 4 different rats. 
The same applies for images of the dorsal raphe obtained from pontine sections (see 
figure 4.2C). For brainstem regions imaged on medial medulla sections (listed in figure 
4.2B), the frequency (%) and cumulative frequency (%) values per expression level 
category were obtained from 3 images of sections from 3 different rats. Brain regions of 
the parabrachial complex in pontine sections from 4 different rats were imaged 
bilaterally, resulting in 8 images for each region (See figure 4.2C). For every brainstem 
region, averages and standard deviations were calculated of the frequency (%) and 
cumulative frequency (%) of cells assigned to each expression level category (1 to 40 in 
bins of 2; and >40 transcripts per cell) per phenotype (PPIB+, 5-HT1A+, 5HT1aR+SLC32A1+ 
5HT1aR+SLC32A−, PPIB+, SLC32A1+, SLC32A1+5HT1aR+, and SLC32A1+5HT1AR−). For each 
brain region, figures plotted expression level categories against the average frequencies 
(%) and average cumulative frequencies (%) of cells of a certain phenotype assigned to 
each expression level category. These figures give an indication of the prevalence of 
various phenotypes in each brain region (i.e., the cumulative frequency of a phenotype at 
>40 transcripts per cell), but also of the distribution of cells with a certain RNA phenotype 
over various RNA expression levels within that region. Plots were made with GraphPad 
Prism (GraphPad Software Inc., La Jolla, USA).   
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4.3 CHAPTER RESULTS 
By multiplex FISH, and subsequent automated quantification of hybridized transcripts per 
cell, I determined the distribution of 5-HT1A receptor RNA (5HT1AR), vesicular inhibitory 
amino acid transporter RNA (SLC32A1), and housekeeping gene Cyclophylin B RNA (PPIB) 
transcripts in a series of brainstem nuclei involved in respiratory control. The brainstem 
regions in which FISH and quantification was performed are listed on annotated sections 
of the pons and medulla in (see section 4.2.3, figure 4.2). Figures 4-3 to 4-20 display 
representative images and plots that illustrate the average frequency (%) of cells 
categorised by their quantity of PPIB, 5HT1AR, and SLC32A1 transcripts in each of the 
brainstem regions. The make-up of figures 4-3 to 4-20 is identical, and to reduce 
repetition, it is described in a general legend in textbox 1. A summary of FISH 
quantification results is provided in table 4-2. 
 
  




Textbox 1: general legend for figures 4-3 to 4-20.  
Figures 4-3 to 4-20 show representative images and plots that illustrate fluorescence in situ 
hybridization (FISH) data, each figure describes a different brain region. RNA Transcripts 
labelled with FISH are 5-HT1a receptor RNA (5HT1AR), vesicular inhibitory amino acid 
transporter RNA (SLC32A1), and Cyclophilin B (PPIB) RNA. PPIB is a housekeeping gene and 
serves as a positive control. A combination of DAPI and Nissl counterstain (DAPI+Nissl) is used 
to determine cell outlines through automated analysis. (A1) Shows a representative image of 
the relevant brain region with 5HT1AR, SLC32A1, PPIB, and DAPI+Nissl labelling. Individual FISH 
labelled transcripts show as punctate dots. White arrows, if present, mark examples of cells 
that contain both 5HT1AR and SLC32A1 RNA transcripts. (A2) Shows the same image with only 
5HT1AR labelling in view. Dotted white lines mark the cell outlines derived from the DAPI+Nissl 
signal. (A3) Is similar to A2 but shows SLC32A1 labelling and cell outlines. (B) Within each cell 
outline, hybridized transcripts are counted, and for each transcript type (PPIB, 5HT1AR, 
SLC32A1) cells are assigned to categories based on their transcript count (categories are: 0; 1 
to 40 in bins of 2; and >40 transcripts/cell).  In figure (B1), the various transcript count categories 
(excluding the category of cells with zero transcripts) are plotted against the cumulative 
frequency (% of all analysed cells in image) of cells that fit each category. Figure B2 is as figure 
B1 but plots the transcript count categories against the (non-cumulative) frequency (%) of cells 
that fit these categories. Combined, the plots B1 and B2 give an indication of the prevalence of 
5HT1AR, SLC32A1, or PPIB RNA transcript expressing cells (i.e. the cumulative frequency at >40 
transcripts per cell, annotated to the right of each curve), but also of the distribution of 
transcript expressing cells over various expression levels (i.e. the frequency at any given 
transcript count category). Figure (C) shows the cumulative frequencies (%) (C1), and 
frequencies (%) (C2) of cells that fit the various transcript count categories for PPIB and 5HT1AR, 
and for subpopulations of 5HT1AR positive cells that do (5HT1AR+SLC32A1+) or do not 
(5HT1aR+SLC32A1−) co-express SLC32A1. Figure D shows the cumulative frequencies (%) (D1) 
and frequencies (%) (D2) of cells that fit the various transcript count categories for PPIB and 
SLC32A1, and for subpopulations of SLC32A1 positive cells that do (SLC32A1+5HT1AR+) or do 
not (SLC32A1+5HT1AR−) co-express 5HT1AR. Note that, although the 5HT1AR+SLC32A1+ 
population in figures C1,2 and the SLC32A1+5HT1AR+ population in figures D1,2 are in effect the 
same population of cells, C1,2 and D1,2 differ in the way in which the cells of that population are 
distributed over various transcript-count categories. In C1,2, 5HT1AR+SLC32A1+ cells are 
assigned to transcript count categories by their 5HT1AR count. In D1,2, SLC32A1+5HT1AR+ cells 
are assigned to transcript count categories by their SLC32A1 count. Plotted values are averages 
of 4 images from 4 rats, unless stated otherwise in the individual figure legends. Error bars are 
SD. 
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4.3.1 Distribution of 5-HT1A receptor RNA and vesicular inhibitory amino acid 
transporter RNA in the ventral respiratory column: BötC, pre-BötC, and 
RVRG. 
Figures 4-3, 4-4 and 4-5 describe the frequency and distribution of cells with PPIB, 
5HT1AR, and SLC32A1 transcripts in the BötC, pre- BötC, and RVRG, respectively. All values 
described in these figures are averages derived from 3 images from 3 rats for each region.  
In the BötC images, the average cumulative frequency of cells in which any transcripts are 
observed is 98.9% for PPIB transcripts, 42.6% for 5HT1AR transcripts, and 37% for 
SLC32A1 transcripts (figure 4-3B1). Figure 4-3B2 shows that the 5HT1AR or SLC32A1 
transcripts presented mostly with lower transcript counts relative to the transcript counts 
for PPIB RNA. Figure 4-3C1 breaks down the population of 5HT1AR cells into 5HT1AR 
expressing cells that do (5HT1AR+SLC32A1+) or do not (5HT1AR+SLC32A1−) co-express 
SLC32A1. On average, 26.2% of the analysed cells in the BötC were 5HT1AR+SLC32A1+, 
whereas 16.3% were 5HT1AR+SLC32A1−. Figure 4-3D2 shows that 10.7% of all cells in the 
BötC samples were SLC32A1+5HT1AR−. This means that 61.5% of 5HT1AR positive cells co-
expressed SLC32A1, and 70.8% of SLC32A1 positive cells co-expressed 5HT1AR.  The 
average number of cells analysed in the BötC was 243.3 ±  11.6. 
In the pre-BötC images, the average cumulative frequency of cells in which any count of 
transcripts was observed is 98.7% for PPIB transcripts, 46.6% for 5HT1AR transcripts, and 
46.4% for SLC32A1 transcripts (figure 4-4B1). On average, 32.7% of the analysed cells in 
the pre-BötC images were 5HT1AR+SLC32A1+, whereas 13.9% of the total amount of cells 
in the pre-BötC images were 5HT1AR+SLC32A1− (figure 4-4C1). 13.7% of analysed cells in 
the pre-BötC were SLC32A1+5HT1AR− (figure 4-4D1). As such, in the pre-BötC, 70.2% of 
5HT1AR positive cells co-expressed SLC32A1, and 70.5% of SLC32A1 positive cells co-
expressed 5HT1AR. The average total cell count in the pre-BötC images used for these 
plots was 252.7± 8.1. 
In the RVRG (figure 4-5), the average cumulative frequency of cells in which transcripts 
are observed is 99.1% for PPIB transcripts, 34.9% for 5HT1AR transcripts, and 31.8% for 
SLC32A1 transcripts (figure 4-5B1). On average, 19.4% of analysed cells in the RVRG were 
5HT1AR+SLC32A1+, and 15.5% of analysed cells in the pre-RVRG were 5HT1AR+SLC32A1− 
(figure 4-5C1). 12.5% of analysed cells in the RVRG samples were SLC32A1+5HT1AR− 
(figure 4-5D1). Of all 5HT1AR positive cells in the RVRG, 55.6% co-expressed SLC32A1, and 
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61% of SLC32A1 positive cells co-expressed 5HT1AR. The average analysed cell count in 
the RVRG images used for these plots was 231.7 ± 16.1. 
Comparison of BötC, pre- BötC, and RVRG averages shows that cells that express 5HT1AR, 
SLC32A1, or both are present in all three regions. The frequency of cells with 5HT1AR 
transcripts was highest in the pre- BötC images (pre-BötC 46.6%; BötC 42.6%; RVRG 
34.9%). The same is true for the frequency of cells with SLC32A1 transcripts (pre-BötC 
46.4%; BötC 37%; RVRG 31.8%), and for cells with both 5HT1AR and SLC32A1 transcripts 
(pre- BötC 32.7%; BötC 26.2%; RVRG 19.4%). These findings are consistent with the notion 
that observed functional effects of systemic NLX-101 on respiratory rhythm and pattern 
may be mediated by modulation of activity of inspiratory and/or expiratory rhythmogenic 
populations in the BotC and pre-BotC, and of respiratory neurones in VRC transmission 
circuits. 
 




Figure 4-3: Fluorescence in situ 
hybridization (FISH) of 5-HT1a receptor 
RNA (5HT1AR), vesicular inhibitory 
amino acid transporter RNA (SLC32A1), 
and cyclophilin B RNA (PPIB) in the 
Bötzinger Complex (BötC).  
 (A1,2,3) Representative image of the 
BötC region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
White arrows mark examples of 
5HT1AR+SLC32A1+ cells. (B1,2 C1,2 D1,2) 
Cells that expressed PPIB, 5HT1AR, 
and/or SLC32A1 were categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 3 
images from 3 rats. Error bars are SD. 
See textbox 1 for a detailed 
description of figures.  
1
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Figure 4-4: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter 
RNA (SLC32A1), and cyclophilin B 
RNA (PPIB) in the pre-Bötzinger 
Complex (pre-BötC). 
 (A1,2,3) Representative image of the 
pre-BötC region. Individual FISH 
labelled transcripts show as 
punctate dots, a combination of 
DAPI and Nissl counterstain 
(DAPI+Nissl) was used to determine 
cell outlines (dotted lines). White 
arrows mark examples of 
5HT1AR+SLC32A1+ cells.  (B1,2 C1,2 
D1,2) Cells that express PPIB, 
5HT1AR, and/or SLC32A1 are 
categorized by their transcript 
count. Plots show the frequencies 
(%), and cumulative frequencies (%) 
of cells assigned to each transcript 
count category. Cells with 0 
transcripts are excluded from plots. 
All values are averages of 3 images 
from 3 rats. Error bars are SD. See 
textbox 1 for a detailed description 








Figure 4-5: Fluorescence in situ 
hybridization (FISH) of 5-HT1a receptor 
RNA (5HT1AR), vesicular inhibitory 
amino acid transporter RNA (SLC32A1), 
and cyclophilin B RNA (PPIB) in the 
Rostroventral Respiratory Group 
(RVRG). 
(A1,2,3) Representative image of the 
RVRG region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used 
to determine cell outlines (dotted 
lines). White arrows mark examples 
of 5HT1AR+SLC32A1+ cells. (B1,2 C1,2 
D1,2) Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 3 
images from 3 rats. Error bars are SD. 
See textbox 1 for a detailed 




Chapter 4: 5-HT1A Receptor RNA Distribution Across Brainstem Regions of Respiratory Control. 
159 
 
4.3.2 Distribution of 5-HT1A receptor RNA and vesicular inhibitory amino acid 
transporter RNA in respiratory motor and pre-motor nuclei: Nucleus 
Ambiguus Compactus, N10, N12, and XII premotor neurones. 
Figures 4-6, 4-7, 4-8, and 4-9 describe the frequency and distribution of cells with PPIB, 
5HT1AR, and SLC32A1 transcripts in the Nucleus Ambiguus Compactus (N. Amb. C.), the 
Dorsal Nucleus of the Vagus Nerve (N10), the Hypoglossal Nucleus (N12), and a region 
with Hypoglossal premotor neurones (XII premotor), respectively. All values in plots 
describing N. Amb. C. (figure 4-6), N10 (figure 4-7), and XII premotor neurones (figure 4-
9) are averages derived from 3 images from 3 rats. Values in plots describing N12 (figure 
4-8) are averages derived from 4 images from 4 rats. 
In the N. Amb. C., the average cumulative frequency of cells in which any transcripts were 
present is 98.5% for PPIB transcripts, 38.3% for 5HT1AR transcripts, and 38.4% for 
SLC32A1 transcripts (figure 4-6B1). 20% Of the total amount of analysed cells in the N. 
Amb. C. images were 5HT1AR+SLC32A1+ (figure 4-6C1). This means that for both the 
population of cells with 5HT1AR transcripts and the population with SLC32A1 transcripts, 
approximately half of the cells were co-expressing. 18.3% Of the analysed cells in the N. 
Amb. C. were 5HT1AR+SLC32A1− (figure 4-6C1). Figure 4-6D1 shows that 18.4% of all cells 
in the N. Amb. C. region were SLC32A1+5HT1AR- The average total cell count in the N. 
Amb. C. images used for these plots was 115.7 ±11.9. 
In the N10 images, the average ultimate cumulative frequency of cells in which any count 
of transcripts was observed is 98.7% for PPIB transcripts, 29.6% for 5HT1AR transcripts, 
and 47.2% for SLC32A1 transcripts (figure 4-7B1). On average, 21.7% of the analysed  cells 
in the N10 region were 5HT1AR+SLC32A1+. Relatively few cells in the N10, 7.9% of the 
analysed cells in the region, were 5HT1AR+SLC32A1− (figure 4-7C1). 25.5% Of analysed 
cells in the N10 region were SLC32A1+5HT1AR- (figure 4-7D1). From the above it follows 
that, in the N10, 46% of 5HT1AR positive cells co-expressed SLC32A1, and 73.3% of 
SLC32A1 positive cells co-expressed 5HT1AR. The average total cell count in the N10 
images used for these plots was 97 ±46.8. 
In the N12 region (figure 4-8), the average cumulative frequency of cells in which 
transcripts were observed is 99.2% for PPIB transcripts, 30.3% for 5HT1AR transcripts, and 
15.8% for SLC32A1 transcripts (figure 4-8B1). Figure 4-8B2 shows that the 5HT1AR or 
SLC32A1 transcripts were present mostly in cells with low transcript counts. A relatively 
low amount (8.9%) of analysed cells in the N12 region was 5HT1AR+SLC32A1+, the 
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remainder of the 5HTAR1 positive population (5HT1AR+SLC32A1− cells) was 21.3% of 
analysed cells in the N12 images (figure 4-8C1). This means that, in the N12, the population 
of 5HT1AR+SLC32A1+ cells comprised of 29.4% of all 5HT1AR+ cells, and of 56.3% all 
SLC32A1+ cells. 12.5% Of analysed cells in the N12 images were SLC32A1+ 5HT1AR- (figure 
4-8D1). The average total cell count in the RVRG images used for these plots was 200.8 
±41. 
In the region with XII premotor neurones, the average ultimate cumulative frequency of 
cells in which any transcripts were observed is 97.6% for PPIB transcripts, 50.8% for 
5HT1AR transcripts, and 55.3% for SLC32A1 transcripts (figure 4-9B1,2). On average, 35.4% 
of all analysed cells in the XII premotor images were 5HT1AR+SLC32A1+, whereas 15.4% of 
analysed cells in the images was 5HT1AR+SLC32A1− (figure 4-9C1,2). It follows that 69.7% 
of 5HT1AR positive cells co-express SLC32A1, and 64% of SLC32A1 positive cells co-express 
5HT1AR. Figure 4-9D1,2 shows that 19.9% of analysed cells in the XII premotor images were 
SLC32A1+5HT1AR-. The average total cell count in the images used for these plots was 
249.3 ±3.1. 
When reviewing the analysed respiratory (pre)motor regions together, it is noteworthy 
that the frequency of cells with 5HT1AR transcripts in the XII premotor region (50.8%) 
exceeded that in the other (pre)motor nuclei analysed (N. Amb. C. 38.3%, N10 29.6%, and 
N12 30.3%). The N10 and XII premotor region images showed high frequencies of cells 
with SLC32A1 transcripts as well (47.2% and 55.3%, respectively). This indicates that some 
level of local disinhibition may play a role in observed 5-HT1AR agonist functional effects 
on respiratory pattern. Finally, in both N10 and N12, populations with 5HT1AR transcripts 
consisted largely of cells with a low transcript count. That is, 92% (in N10) 91% (in N12) of 
5HT1AR+ cells had 6 or fewer 5HT1AR transcripts.  
 




Figure 4-6: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter 
RNA (SLC32A1), and cyclophilin B 
RNA (PPIB) in the Nucleus Ambiguus 
Compactus (N. Amb. C.). 
(A1,2,3) Representative image of the N. 
Amb. C. region. Individual FISH 
labelled transcripts show as punctate 
dots, a combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
ISH data analysis was restricted to 
cells within the white box. (B1,2 C1,2 
D1,2) Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 3 
images from 3 rats. Error bars are SD. 
See textbox 1 for a detailed 








Figure 4-7:Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter RNA 
(SLC32A1), and cyclophilin B RNA 
(PPIB) in the Dorsal Nucleus of the 
Vagus Nerve (N10). 
 (A1,2,3) Representative image of the 
N10 region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
ISH data analysis was restricted to cells 
within the white box. White arrows 
mark examples of  5HT1AR+SLC32A1+ 
cells. (B1,2 C1,2 D1,2) Cells that express 
PPIB, 5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 3 images from 3 rats. Error 
bars are SD. See textbox 1 for a more 









Figure 4-8: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter RNA 
(SLC32A1), and cyclophilin B RNA 
(PPIB) in the Hypoglossal Nucleus 
(N12). 
(A1,2,3) Representative image of the 
N12 region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
White arrows mark examples of  
5HT1AR+SLC32A1+ cells. (B1,2 C1,2 D1,2) 
Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 4 
images from 4 rats. Error bars are SD. 
See textbox 1 for a detailed description 









Figure 4-9: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter 
RNA (SLC32A1), and cyclophilin B 
RNA (PPIB) in XII premotor neurones 
(XII premotor). 
 (A1,2,3) Representative image of the 
XII premotor region. Individual FISH 
labelled transcripts show as punctate 
dots, a combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
White arrows mark examples of  
5HT1AR+SLC32A1+ cells. (B1,2 C1,2 D1,2) 
Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 3 
images from 3 rats. Error bars are SD. 
See textbox 1 for a detailed 
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4.3.3 Distribution of 5-HT1A receptor RNA and vesicular inhibitory amino acid 
transporter RNA in the parabrachial complex. 
The present section describes the frequency and distribution of cells with PPIB, 5HT1AR, 
and SLC32A1 transcripts in the Kölliker Fuse (KF) (figure 4-10), Medial Parabrachial (MBP) 
region (figure 4-11), the internal part of the Lateral Parabrachial (LPBI) region (figure 4-
12), the central part of the Lateral Parabrachial region (LPBC) (figure 4-13), and the 
external part of the Later Parabrachial region (LPBE) (figure 4-14). All values described in 
figures 4-10 to 4-14 are averages derived from 8 images from 4 rats for each region 
(regions are imaged bilaterally).  
In the KF, the average ultimate cumulative frequency of cells in which any transcripts are 
present was 99.3% for PPIB transcripts, 43.1% for 5HT1AR transcripts, and 13.8% for 
SLC32A1 transcripts (figure 4-10B1). The average frequency of SLC32A1+5HT1AR+ cells was 
7.4% of all analysed cells in images of this region (figure 4-10C1/D1). From these 
percentages, it follows that these co-expressing cells constitute 17.2% of 5-HT1AR+ cells, 
and 53.6% of SLC32A1+ cells. (figure 4-10C1). 35.7% Of all analysed cells in the KF was 
5HT1AR+SLC32A1− (figure 4-10C1), and 6.4% of all cells were SLC32A1+5HT1AR- (figure 
4-10D1). The average total cell count in the KF images used for these plots is 266.4 ± 15.6. 
In images of the MPB, 48.9% of analysed cells were 5HT1AR positive, 23.3% of cells were 
SLC32A1 positive, and 98.9% of cells in the MPB images contained transcripts of PPIB 
(figure 4-11B1). On average, 14.2% of the total amount of analysed cells in the MPB was 
5HT1AR+SLC32A1+, whereas 34.7% of analysed cells was 5HT1AR+SLC32A1− (figure 4-
11C1). 9.2% Of analysed MPB cells were SLC32A1+ 5HT1AR - (figure 4-11D1). This means 
that 29% of 5HT1AR positive cells in the MPB also contained SLC32A1, and 60.9% of 
SLC32A1 positive cells also had 5HT1AR transcripts. The average total cell count in the 
MPB images used for these plots was 259.5 ± 18.9. 
In the LPBI region, the average cumulative frequency of cells in which transcripts were 
observed is 99.1% for PPIB transcripts, 36.6% for 5HT1AR transcripts, and 22.6% for 
SLC32A1 transcripts (figure 4-12B1). 12.6% Of cells in the LPBI images was 
5HT1AR+SLC32A1+, and the remainder of the 5HTAR1 positive population 
(5HT1AR+SLC32A1− cells) comprised 21.3% of all cells analysed (figure 4-12C1). Thus, in the 
LPBI, the population of cells that co-expressed 5HT1AR and SLC32A1 RNA comprised 
34.4% of all 5HT1AR positive cells, and 55.8% of all SLC32A1 positive cells. 12.6% Of all 
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cells in the LPBI images were SLC32A1+5HT1AR- (figure 4-12D1). The average total cell 
count in the images used for these plots is 270.9 ± 25.4. 
In the LPBC, cells with PPIB transcripts comprised 99.2% of all cells, 5HT1AR positive cells 
comprised 41.6% of all cells, and cells with SLC32A1 transcripts comprised 20.5% of all 
analyzed cells in the images (figure 4-13B1). On average, 11.8% of analyzed cells in the 
LPBC images were 5HT1AR+SLC32A1+, whereas 29.8% of cells were 5HT1AR+SLC32A1− 
(figure 4-13C1). 8.7% Of all analysed cells in the LPBC images were SLC32A1+5HT1AR- 
(figure 4-13D1). It follows that 29% of 5HT1AR positive cells in the LPBC co-expressed 
SLC32A1, and that this population of co-expressing cells makes up 57.6% of the SLC32A1 
positive population. The average total cell count in the images used for these plots is 286 
± 28.6. 
The final parabrachial region for which 5HT1AR and SLC32A1 transcripts were quantified, 
was the LPBE. In this region, the average cumulative frequency of cells in which any 
transcripts are observed was 98.7% for PPIB transcripts, 31.5% for 5HT1AR transcripts, 
and 32.5% for SLC32A1 transcripts (figure 4-14B1,2). The average prevalence of 
5HT1AR+SLC32A1+ cells is 12% of all analysed cells in the LPBE. 19.5% analysed cells was 
5HT1AR+SLC32A1− (figure 4-14C1,2). Derived from the above, is that 5HT1AR+SLC32A1+ 
cells makes up 38.1% of 5HT1AR positive cells, and 36.9% of SLC32A1 positive cells. figure 
4-14D1,2 shows that 20.5% of all analysed cells in the LPBE regions were 
SLC32A1+5HT1AR-. The average total cell count in the LPBE images used for these plots is 
276 ± 26.5. 
When comparing the PBc regions, prevalence of cells with 5HT1AR transcripts is highest 
in the MPB (48.9%), followed by the KF (43.1%), and the LPBC(41.6). In the LPBI and LPBE 
images, cells that have 5HT1AR transcripts are less prevalent (36.6% and 31.5% of all cells, 
respectively). The highest prevalence of cells with SLC32A1 transcripts was observed in 
the LPBE images (32.5%). In the KF, MPB, LPBI, and LPBC regions, prevalence of cells with 
SLC32A1 transcripts ranged from 13.8% to 23.3%. In all analysed regions of the 
parabrachial complex, prevalence of cells with both 5HT1AR and SLC32A1 transcripts was 
relatively low, ranging from 7.4% (KF) to 14.2% (LPBI). Regions of the parabrachial 
complex are thought to contribute to inspiratory-to-expiratory phase transitioning by 
providing excitatory drive to Post-I neurones (Alheid 2004; Dutschman & Dick 2012); 
Abdala et al. 2016; Barnett et al. 2018) (see section 1.3). The present FISH findings are 
consistent with the possibility that 5-HT1A transmission in excitatory respiratory neurones 
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of the PBc may contribute to changes in respiratory rhythm observed after systemic 5-
HT1AR agonist (see section 3.3.1) 
 
 




Figure 4-10: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter 
RNA (SLC32A1), and cyclophilin B 
RNA (PPIB) in the Kölliker Fuse (KF) 
 (A1,2,3) Representative image of the 
KF region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used 
to determine cell outlines (dotted 
lines).  White arrow marks an 
example 5HT1AR+SLC32A1+ cell. 
(B1,2 C1,2 D1,2) Cells that express PPIB, 
5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 8 images from 4 rats. 
Error bars are SD. See textbox 1 for a 
detailed description of figures.  
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Figure 4-11: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter 
RNA (SLC32A1), and cyclophilin B RNA 
(PPIB) in the Medial Parabrachial 
(MPB) region. 
 (A1,2,3) Representative image of the 
MPB region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
White arrows mark examples of  
5HT1AR+SLC32A1+ cells. (B1,2 C1,2 D1,2) 
Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 8 
images from 4 rats. Error bars are SD. 
See textbox 1 for a detailed 
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v Figure 4-12: Fluorescence in situ 
hybridization (FISH) of 5-HT1a receptor 
RNA (5HT1AR), vesicular inhibitory 
amino acid transporter RNA (SLC32A1), 
and cyclophilin B RNA (PPIB) in the 
internal part of the Lateral 
Parabrachial (LPBI) region. 
 (A1,2,3) Representative image of the 
LPBI region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
(B1,2 C1,2 D1,2) Cells that express PPIB, 
5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 8 images from 4 rats. Error 
bars are SD. See textbox 1 for a 
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 Figure 4-13: Fluorenscence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter RNA 
(SLC32A1), and cyclophilin B RNA 
(PPIB) in the central part of the Lateral 
Parabrachial (LPBC) region. 
(A1,2,3) Representative image of the 
LPBC region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
(B1,2 C1,2 D1,2) Cells that express PPIB, 
5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 8 images from 4 rats. Error 
bars are SD. See textbox 1 for a 
detailed description of figures.  
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Figure 4-14: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter 
RNA (SLC32A1), and cyclophilin B 
RNA (PPIB) in the external part of the 
Lateral Parabrachial (LPBE) region. 
(A1,2,3) Representative image of the 
LPBE region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used 
to determine cell outlines (dotted 
lines). White arrow marks an 
exemplary 5HT1AR+SLC32A1+ cell. 
(B1,2 C1,2 D1,2) Cells that express PPIB, 
5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 8 images from 4 rats. 
Error bars are SD. See textbox 1 for a 
detailed description of figures.  
1
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4.3.4 Distribution of 5-HT1A receptor RNA and vesicular inhibitory amino acid 
transporter RNA in the commissural part of the Nucleus Tractus Solitarius, 
and in the Retrotrapezoid Nucleus region. 
Figure 4-15 describes the frequency and distribution of cells with PPIB, 5HT1AR, and 
SLC32A1 transcripts in the commissural part of the Nucleus Tractus Solitarius (NTScomm). 
Similarly, figure 4-16 describes the ventral parafacial region where RTN neurones are 
located. (pFV/RTN). All values in the plots describing the NTScomm are averages derived 
from 4 images of 4 rats. All values in the plots describing the pFV/RTN region are averages 
derived from 3 images of 3 rats.  
In the NTScomm, a population of cells with 5HT1AR transcripts was observed that 
comprised 55.9% of all analysed cells in the image. The population of cells with SLC32A1 
transcripts comprised 44.5% of analysed cells, and 98.7% of cells in the NTS images 
contained transcripts of PPIB (figure 4-15B1). On average, 28.3% of the total amount of 
cells in the NTS images was 5HT1AR+SLC32A1+, whereas 27.6% of the total amount of cells 
was 5HT1AR+SLC32A1− (figure 4-15C1). 16.2% Of all cells in the NTScomm were 
SLC32A1+5HT1AR- (figure 4-15D1). Thus, 50.6% of 5HT1AR positive cells in the NTScomm 
also contained SLC32A1, and 63.6% of SLC32A1 positive cells also have 5HT1AR 
transcripts. The average total cell count in the NTScomm images used for these plots is 
159.5 ± 34.5. 
In the pFV/RTN region, the average cumulative frequency of cells in which transcripts were 
observed is 99.4% for PPIB transcripts, 19.4% for 5HT1AR transcripts, and 17.3% for 
SLC32A1 transcripts (figure 4-16B1). 9.1% Of analysed cells in the pFV/RTN images were 
5HT1AR+SLC32A1+ and the remainder of the 5HTAR1 positive population 
(5HT1AR+SLC32A1− cells) comprised 10.2% of all cells analysed (figure 4-16C1). This means 
that, in the pFV/RTN, the population of 5HT1AR+SLC32A1- cells comprised 46.9% of all 
5HT1AR positive cells, and 52.6% of all SLC32A1 positive cells. 8.2% Of analysed cells were 
SLC32A1+5HT1AR- (figure 4-16D1). The average total cell count in the images used for 
these plots is 276 ± 26.5. Compared to other regions analysed in this chapter, there are 
relatively few 5HT1AR+ (19.4%) cells in the pFV/RTN (see table 4-2). This, combined with 
the absence of an effect of systemic 5-HT1AR agonist (NLX-101) or antagonist (WAY-
100635) on the central chemoreflex response (see section 3.3.2), suggests that 5-HT1A 
transmission may not affect central chemoreceptor activity.  
 




Figure 4-15: Fluorescence in situ 
hybridization (FISH) of 5-HT1a receptor 
RNA (5HT1AR), vesicular inhibitory 
amino acid transporter RNA 
(SLC32A1), and cyclophilin B RNA 
(PPIB) in the commissural part of the 
Nucleus Tractus Solitarius (NTS-
comm). 
(A1,2,3) Representative image of the 
NTS-comm region. Individual FISH 
labelled transcripts show as punctate 
dots, a combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
ISH data analysis was restricted to cells 
within the white box. White arrows 
mark examples of  5HT1AR+SLC32A1+ 
cells. (B1,2 C1,2 D1,2) Cells that express 
PPIB, 5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 4 images from 4 rats. Error 
bars are SD. See textbox 1 for a 









Figure 4-16: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter RNA 
(SLC32A1), and cyclophilin B RNA 
(PPIB) in the ventral parafacial region 
(pFV) where retrotrapezoid nucleus 
(RTN) neurones are located. 
(A1,2,3) Representative image of the 
pFV/RTN. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used 
to determine cell outlines (dotted 
lines). (B1,2 C1,2 D1,2) Cells that express 
PPIB, 5HT1AR, and/or SLC32A1 are 
categorized by their transcript 
count. Plots show the frequencies 
(%), and cumulative frequencies (%) 
of cells assigned to each transcript 
count category. Cells with 0 
transcripts are excluded from plots. 
All values are averages of 3 images 
from 3 rats. Error bars are SD. See 
textbox 1 for a detailed description 
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4.3.5 Distribution of 5-HT1A receptor RNA and vesicular inhibitory amino acid 
transporter RNA in raphe nuclei: raphe Magnus, raphe Obscurus, raphe 
Pallidus, and the caudal part of the dorsal raphe. 
Figures 4-17, 4-18, 4-19, and 4-20 describe the frequency and distribution of cells with 
PPIB, 5HT1AR, and SLC32A1 transcripts in the raphe Magnus (RMg) region, raphe 
Obscurus (Rob) region, the raphe Pallidus (RPa) region, and the dorsal raphe (DR), 
respectively. All values in plots that describe the RMg, ROb, and RPa are averages derived 
from 4 images from 4 rats. Plots that describe the DR are made with averages derived 
from 2 images from 2 rats.  
In the RMg region, the average cumulative frequency of cells in which transcripts are 
observed is 99% for PPIB transcripts, 54% for 5HT1AR transcripts, and 44.6% for SLC32A1 
transcripts (figure 4-17B1). 31.4% Of all analysed cells in the RMg images were 
5HT1AR+SLC32A1+, and the remainder of the 5HTAR1 positive population 
(5HT1AR+SLC32A1− cells) comprised 22.5% of analysed cells (figure 4-17C1). From this one 
can derive that, in the RMg images, the population of 5HT1AR+SLC32A1- co-expressing 
cells comprises 58.1% of all 5HT1AR positive cells, and 70.4% of all SLC32A1 positive cells. 
13.2% Of all cells in the RMg images were SLC32A1+5HT1AR− (figure 4-17D1). The 
population of 5HT1AR+SLC32A1− cells and the population of SLC32A1+5HT1AR− were both 
largely comprised of cells with low transcript counts for 5HT1AR and SLC32A1, 
respectively. The average total cell count in the images used for these plots is 261 ± 25.2. 
In the ROb, cells with PPIB transcripts comprised 98.3% of all analysed cells, 5HT1AR 
positive cells comprised 48% of all cells, and cells with SLC32A1 transcripts comprised 
23.1% of analysed cells in the images (figure 4-18B1). On average, 17.2% of cells in the 
ROb images were 5HT1AR+SLC32A1+, whereas 30.8% of the cells were 5HT1AR+SLC32A1− 
(figure 4-18C1). 5.9% Of all analysed cells in the ROb images were SLC32A1+5HT1AR- 
(figure 4-18D1). It follows that 35.8% of 5HT1AR positive cells in the RMg region co-
expressed SLC32A1, and that this population of co-expressing cells comprises 74.5% of 
the SLC32A1 positive population. The population of SLC32A1+5HT1AR− cells is largely 
comprised of cells with low transcript counts. The average total cell count in the images 
used for these plots is 247 ± 30.1.  
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In the RPa, a population of cells with 5HT1AR transcripts was observed that comprised 
41.1% of all analysed cells in the image. The population of cells with SLC32A1 transcripts 
comprised 39.8% of all cells, and 99.1% of all analysed cells in the RPa images contained 
transcripts of PPIB (figure 4-19B1). On average, 20.8% of cells in the RPa images were 
5HT1AR+SLC32A1+, whereas 20.3% of the total amount of cells were 5HT1AR+SLC32A1− 
(figure 4-19C1). 19% Of analysed cells in the RPa were SLC32A1+5HT1AR- (figure 4-19D1). 
This means that 50.6% of 5HT1AR positive cells in the RPa also contained SLC32A1, and 
52.3% of SLC32A1 positive cells also had 5HT1AR transcripts. The average total cell count 
in the MPB images used for these plots is 185 ± 102.2. 
The final raphe nucleus for which 5HT1AR and SLC32A1 transcripts were quantified, is the 
dorsal raphe (DR) (figure 4-201). In this region, the average cumulative frequency of cells 
in which any transcripts are observed was 99.6% for PPIB transcripts, 73.6% for 5HT1AR 
transcripts, and 45.6% for SLC32A1 transcripts (figure 4-20B1,2). On average, 35.1% of the 
total amount of analysed cells in the DR images were 5HT1AR+SLC32A1+, whereas 38.5% 
of the total amount of cells were 5HT1AR+SLC32A1− (figure 4-20C1,2). From these numbers, 
it follows that 5HT1AR+SLC32A1+ cells made up 47.7% of 5HT1AR positive cells, and 77% 
of SLC32A1 positive cells. Figure 4-20D1,2 shows that 10.5% of all analysed cells in the DR 
regions were SLC32A1+5HT1AR-. The average total cell count in the DR images is 120 ± 
11.3. 
Comparison of the analysed raphe nuclei reveals that the relative size of the 5HT1AR 
positive cell population was largest in the DR (73.6%), followed by the RMg (54%), then 
the ROb (48%), and ultimately the RPa (41.1%). The same order was observed when 
comparing the populations of 5HT1AR and SLC32A1 co-expressing cells. In the DR, 35.1% 
of all analysed cells were co-expressing (5HT1AR+SLC32A1+), followed by the RMg (31.4%), 
and then the RPa and ROb (20.8% and 17.2%, respectively). The SLC32A1 positive 
population, too, was most prevalent in the DR (45.8%). This was closely followed by the 
SLC32A1 positive population in RMg (44.6%), then that in the RPa (39.8), and last that in 
the ROb (23.1%). These findings indicate that 5-HT1AR expression is highly prevalent in 
GABAergic and/or glycinergic, and other raphe neurones. 
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Table 4-2: Overview of the brainstem regions in which FISH is quantified, and the corresponding 
average percentages of cells that meet various 5HT1AR and SLC32A1 expression profiles. 
  
















BötC   42.6 16.3 26.2 37 10.7 46.8 
pre-BötC 46.6 13.9 32.7 46.4 13.7 39.7 
RVRG 34.9 15.5 19.4 31.8 12.5 52.6 
       
N. Amb. C. 38.3 18.3 20 38.4 18.4 43.3 
N10 29.6 7.9 21.7 47.2 25.5 44.9 
N12 30.3 21.3 8.9 15.8 6.9 62.9 
XII premotor 50.8 15.4 35.4 55.3 19.9 29.3 
       
KF 43.1 35.7 7.4 13.8 6.4 50.5 
MPB 48.9 34.7 14.2 23.3 9.2 41.9 
LPBI 36.6 24 12.6 22.5 9.9 53.5 
LPBC 41.6 29.8 11.8 20.5 8.7 49.7 
LPBE 31.5 19.5 12 32.5 20.5 48 
       
NTScomm 55.9 27.6 28.3 44.5 16.2 27.9 
pFV/RTN 19.3 10.2 9.1 17.3 8.2 72.5 
       
RMg 54 22.5 31.4 44.6 13.2 32.9 
ROb 48 30.8 17.2 23.1 5.9 46.1 
RPa 41.1 20.3 20.8 39.8 19 39.9 
dorsal raphe 73.6 38.5 35.1 45.6 10.5 15.9 
Summary of FISH data presented in figures 4-3 to 4-20. For each of the brainstem regions of 
which images after FISH are analysed, the average prevalence (% of all analysed cells in image) 
is provided of cells that meet one of the 4 possible 5HT1AR and SLC32A1 expression profiles. The 
5HT1AR and SLC32A1 expression profiles are: 5HT1AR positive and SLC32A1 negative 
(5HT1aR+SLC32A1−); 5HT1AR positive and SLC32A1 positive (5HT1AR+SLC32A1+); 5HT1AR 
negative and SLC32A1 positive (5HT1AR−SLC32A1+); and 5HT1AR negative and SLC32A1 negative 
(5HT1AR−SLC32A1−). 




Figure 4-17: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibitory amino acid transporter RNA 
(SLC32A1), and cyclophilin B RNA 
(PPIB) in the raphe Magnus (RMg). 
(A1,2,3). Representative image of the 
RMg region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
White arrows mark examples of  
5HT1AR+SLC32A1+ cells. (B1,2 C1,2 D1,2) 
Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 4 
images from 4 rats. Error bars are SD. 
See textbox 1 for a detailed description 
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 Figure 4-18: Fluorescence in situ 
hybridization (FISH) of 5-HT1a receptor 
RNA (5HT1AR), vesicular inhibitory 
amino acid transporter RNA (SLC32A1), 
and cyclophilin B RNA (PPIB) in the 
raphe Obscurus (ROb). 
(A1,2,3) Representative image of the 
RMg region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
White arrows mark examples of  
5HT1AR+SLC32A1+ cells. (B1,2 C1,2 D1,2) 
Cells that express PPIB, 5HT1AR, 
and/or SLC32A1 are categorized by 
their transcript count. Plots show the 
frequencies (%), and cumulative 
frequencies (%) of cells assigned to 
each transcript count category. Cells 
with 0 transcripts are excluded from 
plots. All values are averages of 4 
images from 4 rats. Error bars are SD. 
See textbox 1 for a detailed description 









Figure 4-19: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibi-tory amino acid trans- porter 
RNA (SLC32A1), and cyclophilin B RNA 
(PPIB) in the Raphe Pallidus (RPa). 
(A1,2,3) Representative image of the 
RPa region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
(B1,2 C1,2 D1,2) Cells that express PPIB, 
5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 4 images from 4 rats. Error 
bars are SD. See textbox 1 for a 









Figure 4-20: Fluorescence in situ 
hybridization (FISH) of 5-HT1a 
receptor RNA (5HT1AR), vesicular 
inhibi-tory amino acid trans- porter 
RNA (SLC32A1), and cyclophilin B RNA 
(PPIB) in the caudal part of the Dorsal 
Raphe (DR). 
(A1,2,3) Representative image of the DR 
region. Individual FISH labelled 
transcripts show as punctate dots, a 
combination of DAPI and Nissl 
counterstain (DAPI+Nissl) was used to 
determine cell outlines (dotted lines). 
ISH data analysis was restricted to cells 
within the white box. White arrow 
marks an exemplary 5HT1AR+SLC32A1+ 
cell. (B1,2 C1,2 D1,2) Cells that express 
PPIB, 5HT1AR, and/or SLC32A1 are 
categorized by their transcript count. 
Plots show the frequencies (%), and 
cumulative frequencies (%) of cells 
assigned to each transcript count 
category. Cells with 0 transcripts are 
excluded from plots. All values are 
averages of 2 images from 2 rats. Error 
bars are SD. See textbox 1 for a 
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4.4 CHAPTER DISCUSSION 
4.4.1 Summary of results in light of aims and hypotheses 
Because the existing literature does not provide a comprehensive description of 5-HT1AR 
expression in the brainstem respiratory CPG network, and because little is known about 
the chemical phenotype of 5-HT1AR expressing brainstem neurones, I mapped the 
distribution of 5-HT1AR RNA as well as SLC32A1 RNA in key brainstem regions of 
respiratory control. Previous histological-, in situ hybridization-, and PCR experiments 
indicated that 5-HT1AR are expressed in the BötC and pre-BötC (Manzke et al., 2009, 
Manzke et al., 2010), the  NTS (Vantrease et al., 2015); the carotid bodies (Yokoyama et 
al. 2015); and in the dorsal and median raphe nuclei (Sotelo et al., 1990) of rats. Data in 
the present chapter expands knowledge of 5-HT1AR distribution in the respiratory CPG 
through classification of cells by their 5-HT1AR RNA and/or SLC32A1 RNA expression 
profile, as well as through quantification of the amount of 5-HT1AR RNA and/or SLC32A1 
RNA transcripts present per cell, in each of the following regions: respiratory regions of 
the VRC (BotC, pre-BotC, and RVRG), respiratory (pre-)motor regions (N. Ambiguus 
Compactus, XII pre-motor neurones, N10, N12), pontine respiratory nuclei of the PB 
complex (KF, LBPI, LPBC, LBPE, MBP), the pFv/RTN region, the commissural part of the 
NTS, and brainstem raphe nuclei (raphe Magnus, raphe Obscurus, raphe Pallidus, and the 
caudal part of the dorsal raphe). Tissue morphology in coronal and sagittal brainstem 
sections was maintained, and RNA expression levels were quantified per individual 
neurone in each of the brainstem regions listed above. As such, the present studies 
provide the first comprehensive and high-resolution mapping of 5-HT1AR RNA expression 
combined with mapping of SLC32A1 RNA co-expression throughout key brainstem regions 
of respiratory control.  
Final paragraphs of results subsections in this chapter provide brief written summaries of 
5-HT1AR RNA and SLC32A1 RNA distribution in the VRC (section 4.3.1), the PB complex 
(section 4.3.2), in (pre-)motor regions (section 4.3.3), and in raphe nuclei (section 4.3.5). 
Additionally, table 4-2 provides a summary of the relative amounts of cells of all possible 
5-HT1A R and SLC32A1 RNA expression profiles within each analyzed brainstem region.  A 
selection of notable findings is discussed here. 
5-HT1A R RNA was observed in both SLC32A1 positive (glycinergic and/or GABAergic) cells 
and SLC32A1 negative cells in all imaged brainstem regions involved in respiratory control. 
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Among these regions, the highest prevalence of cells with 5-HT1AR RNA was observed in 
the following areas: the BötC (on average, 42.6% of all analyzed cells in BötC images 
contained 5-HT1AR RNA) and the pre-BötC (46.6%) in the VRC; the KF (43.1%), MPB 
(48.9%), and LPBC (41.6%) in the PB complex; a region with XII pre-motor neurons dorsal 
to the nucleus ambiguus (50.8%); the commissural part of the NTS (55.9%); and raphe 
nuclei. Among raphe nuclei, the percentage of cells with 5-HT1AR RNA was highest in the 
dorsal raphe (73.6%), followed by the RMg (54%), the ROb (48%), and the RPa (41.1%). 
Lowest relative amounts of 5-HT1aR RNA positive cells (19.3%) were observed in images 
of the pFV/RTN. The highest percentages of 5-HT1AR RNA and SLC32A1 RNA co-expressing 
cells per region were observed in the pre-BotC (32.7%), the NTS commissural (28.3%), in 
XII premotor region (35.4%), the RMg (31.4%), and the dorsal raphe (35.1%). Also 
noteworthy, the prevalence of cells with co-expression was low in regions of the PBc (KF 
(7.4%), MPB (25.3%), LBPI (12.6%) , LPBC (11.8%), LPBE (12%). Finally, 5-HT1AR positive 
populations in the N10 and N12 regions consisted primarily of cells with a low 5-HT1AR 
RNA transcript count. That is, 92% of 5-HT1AR RNA positive cells in images of N10, and 91% 
of 5-HT1a R RNA positive cells in images of N12, have 6 or fewer 5HT1AR transcripts.  
4.4.2 Technical considerations 
Considerations regarding the use of the Nissl+DAPI signal for determining cell outlines 
5-HT1AR-, SLC32A1-, and PPIB RNA sequences were fluorescently labeled with the use of 
RNAscope® fluorescence in situ hybridization (FISH). This labelling technique was 
described in detail in section 4.2.1. The main advantages of the use of this technique are: 
[1] improved selectivity and signal-to-noise ratio relative to conventional ISH methods; [2] 
simultaneous detection of multiple target mRNA’s; and [3] high signal amplification 
results in individually discernible hybridized RNA molecules (Wang et al., 2012). In the 
present study, RNAscope® FISH was combined with Nissl and DAPI staining for anatomical 
reference and visualisation of outlines of cell somata. As a result, hybridized RNA strands 
could be counted per cell soma in any given neuro-anatomical structure. This allowed for 
quantification of both the number of cells with 5-HT1A R RNA and/or SLC32A1 RNA per 
anatomical region, as well as the RNA counts within each cell. Despite these advantages, 
the use of RNAscope® in combination with Nissl and DAPI staining does have its 
limitations.  
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First, there are limitations to the selectivity of structures in which RNA is counted in the 
present analysis. In neurones, RNA translation does not exclusively occur in cell bodies, 
RNA can also be found in dendrites (Middleton et al., 2019) and axons (Piper and Holt, 
2004). Further, expression of VIAAT RNA (Echigo and Moriyama, 2004) and 5-HT1aR RNA 
(Miyazaki et al., 2013) also occurs in glial cells. Similarly, Nissl bodies are most abundant 
in neural soma, but are also present in neural dendrites and synaptic terminals, and glial 
cells (Garcia-Cabezas et al., 2016). I used NeuroTraceTM Nissl dye in low concentrations 
(1:50 dilution), consistent with manufacturer instructions for selective neuronal labelling. 
However, I cannot exclude the possibility that Nissl+DAPI staining labels structures other 
than neural soma.  
As described in section 4.3.2, an automated analysis protocol was set up to find objects in 
the DAPI+Nissl signal that represented cell soma. In this protocol, the minimum object 
size was set at 25μm2 and an object size guide parameter was set at 150μm2. This size cut-
off prevents identification of cell nuclei (labelled with DAPI) as cell soma, but also serves 
to prevent Nissl+DAPI staining of fibres and synaptic terminals to be misrepresented as 
cell soma. However, this method does not exclude from count RNA in fibres overlapping 
Nissl+DAPI stained soma, nor does it allow to distinguish neurones from glial cells. I 
acknowledge that limitations to the ability to distinguish neurones from glial cells in the 
present chapter limits interpretation of this data. To ensure optimal selectivity of neural 
soma versus glial cells in FISH data analysis, follow up studies could include an RNAScope® 
FISH probe for a neurone-selective marker such as NeuN (neuronal nuclei) RNA (Rn-
Rbfox3n, Advanced Cell Diagnostics product code: 436351). Although a select subset of 
neurone populations is known to be NeuN negative (for an overview of NeuN negative 
neurones, see: Wolf et al. (1996); Mullen et al. (1992)), these populations are not present 
in the regions analysed in this chapter. Because all neurones (but not other cell types) in 
regions analysed in this chapter express NeuN, co-labelling of NeuN RNA with 5HT1AR and 
SLC32A1 RNA would enable analysis of the distribution of the latter two selectively in 
neurones.  
A Second limitation to the use of RNAscope® in combination with Nissl and DAPI staining, 
is that the DAPI+Nissl signal provides an approximation of the outlines of soma, but not 
an exact outline. Visual inspection revealed that the far extremities of soma were 
sometimes inadequately labelled. This could result in an underestimation of the size of 
neural soma, and consequently, in a failure to include labelled RNA strands in the 
peripheries of cell somas. Further, small ‘gaps’ or other imperfections in the labelling 
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could result in an overestimation of the number of cell soma. That is, in image processing, 
suboptimal Nissl+DAPI labelling could occasionally result in the identification of two or 
more objects to represent what is in fact a single soma. Here too, the use of a minimum 
object size (25μm2) as well as an object size guide parameter (150μm2) helped to reduce 
the occurrence of false positives and to improve the signal-to-noise ratio. Despite the 
above limitations, misrepresentations of RNA counts can be expected to be minimal. 
Furthermore, since experimental conditions and quantification methods were automated 
procedures, it can be inferred that the error rate in RNA counts is similar for neurones 
across all imaged regions. Therefore, the image analysis produced quantification of RNA 
count with adequate accuracy for comparisons of relative RNA expression levels across 
the imaged regions. 
Positive and negative controls for RNA hybridization with RNAscopeTM 
In separate experiments with sections from the ventrolateral medulla, I used probes 
targeting DapB RNA of Bacillus subtilis bacteria (RNAscope® 3-plex Negative Control 
Probe, Advanced Cell Diagnostics product code: 320871) as negative controls, and 
observed absence of labelling (data not shown). This indicates absence of non-selective 
RNA hybridization and fluorescent label binding in the assay. I used PPIB (housekeeping 
gene) RNA as a positive control. Across all analysed regions, PPIB was observed in nearly 
all cells, distributed over a wide range of expression levels categories. This indicates that 
RNA scope protocol was able to label RNA with high sensitivity. The broad distribution 
across expression level categories can be expected with variability in size of analysed cell 
soma. High levels of 5HT1AR RNA labelling in the dorsal raphe (73.6% of all analysed soma) 
is consistent with previous ISH experiments that report high 5-HT1AR RNA levels in this 
region in rat (Zhang et al., 2000). Similarly, high levels of SLC32A1 RNA labelling in the pre-
BötC (46.4% of all analysed soma) is consistent with previous reports that approximately 
half of pre-BötC neurones are immunoreactive for glycinergic and/or GABA-ergic markers 
(most are glycinergic) (Winter et al., 2009, Koizumi et al., 2013, Manzke et al., 2009). These 
findings suggest high sensitivity of the 5HT1AR and SLC32A1 ISH probes, and suggests that 
findings of low expression elsewhere are valid.  
Considerations regarding the anatomical locations of imaged regions. 
Anatomical regions were imaged from sections on a single anatomical plane. Caudal raphe 
regions (RMg, RPa, ROb) and N10, N12, and NTScomm were imaged on sagittal sections 
of the medial medulla, at the lateral edge of the central canal. Therefore, the medial most 
anatomical structures (RMg, RPa, ROb, NTScomm), images were obtained at their lateral 
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edge, and more lateral structures (N12, N10) were imaged at their medial edge. Of the 
regions imaged from sagittal sections of the lateral medulla (BotC, pre-BotC, RVRG, N 
Amb., XII premotor neurons, pFV/RTN), it should be noted that images of region with XII 
premotor neurones show the lateral edge of the anatomical region where XII premotor 
neurons are located. Further, the pFV/RTN region shows a caudal, ventromedial part of 
the parafacial region. This means the pFV/RTN images cover the anatomical regions where 
RTN neurons are located, but not the region where the pFRG expiratory oscillator has 
been most recently located; i.e. at the rostro-lateral edge of the facial nucleus (Huckstepp 
et al., 2015, Zoccal et al., 2018). Further, regarding the RTN it should be noted that this 
structure consists of a small population of neurons interspersed in the region imaged, and 
it is primarily defined by phenotype (see section 1.4.1 for the exact phenotype definition 
of RTN neurones). Therefore, the distribution of 5-HT1AR and SLC32A1 RNA in images of 
the pFV/RTN region should be considered as descriptive of the region in which RTN 
neurons are located, rather than as descriptive of RTN neurones exclusively. This is 
reflected in the presence of some SLC32A1 RNA positive neurons in the imaged region, 
whereas RTN neurons have been described as lacking in markers of GABAergic and 
glycinergic neurons (Guyenet et al., 2019).  
4.4.3 Interpretation of findings   
Systemic 5-HT1A R transmission appears to induce specific effects on respiratory control 
that are suggestive of inhibitory action or disinhibition at select brainstem regions and 
mechanisms. Therefore, one would expect the selectivity of functional effects is reflected 
in the distribution of 5-HT1AR RNA over key brainstem regions in respiratory control. 
Considering this, it is suprising to see that none of the imaged respiratory regions were 
exempt of 5-HT1AR-expressing neurones. The presence of 5-HT1AR RNA positive cells in all 
imaged regions precludes exclusion of any regions and mechanisms as candidate 
contributors to the nett respiratory effects of 5-HT1A agonism. Therefore, the dissection 
of the neural mechanisms underlying the effects of systemic 5-HT1A transmission on 
respiratory function cannot be guided simply by the distribution of 5-HT1AR. Further 
knowledge of the phenotype, connectivity, and function in respiratory control of 5-HT1A R 
expressing cells is required to understand the mechanisms underlying effects of 5-HT1A 
transmission in respiratory control.  




Despite the above, some regional differences in levels of (co-)expression of 5-HT1AR and 
SLC32A1 RNA provide cues for hypothetical mechanisms underlying the network effect of 
systemic 5-HT1AR transmission. The FISH data in the present chapter will be incorporated 
in a discussion of putative mechanisms that could underlie the observed effects of 
systemic administration of NLX-101 on respiratory rhythm and pattern in restful breathing 
and in the respiratory and sympatho-respiratory responses to hypercapnia and peripheral 
chemoreceptor activation. Because this discussion is based on converging evidence 
presented across chapters of this thesis, as well as in the literature, it will be presented in 
the general discussion (chapter 6).  
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Chapter 5: 5-HT1A RECEPTOR DISTRIBUTION ACROSS 
FUNCTIONAL SUBPOPULATIONS OF RESPIRATORY NEURONES 
IN THE VENTRAL RESPIRATORY COLUMN 
5.1 CHAPTER INTRODUCTION  
To help identify the mechanism underlying the effects of systemic administration of 
selective 5-HT1AR agonist (NLX-101) on respiratory control (see Chapter 3), I established 
the distribution of 5-HT1AR and SLC32A1 RNA in key regions of the respiratory CPG (see 
Chapter 4). In addition to biochemical phenotype, anatomical location, and connectivity, 
neurones of the respiratory CPG can be described in terms of their functional phenotype 
(i.e. activity pattern relative to the respiratory cycle). The functional phenotypes of 
respiratory neurones ultimately shape network activity of the respiratory CPG, yet the 
distinct functional phenotypes of respiratory neurones are rarely exclusively associated 
with a biochemical marker. To further aid identification of mechanisms underlying the 
effects of 5-HT1A transmission on respiratory control, I investigated the distribution of 5-
HT1A receptors in specific functional subpopulations of CPG respiratory neurones.  
5.1.1 Current understanding of 5-HT1AR distribution among CPG respiratory 
neurone functional subpopulations 
Pioneering studies aimed at identifying the effect of 5-HT1AR transmission at the level of 
functional subpopulations of respiratory neurones have reported hyperpolarization of 
expiratory (Aug-E) neurones after systemic application or iontophoresis application at the 
individual neurones in the VRC of anesthetised cats (Richter et al., 1997, Lalley et al., 
1994). In these studies, respiratory neurones were recorded intracellularly under voltage 
or current clamp, and their functional subtype was identified by their discharge pattern 
relative to PN motor output. Later, using a similar approach, Manzke et al. (2009) 
recorded 4 Post-I/Dec-E neurones in which, after systemic administration of low doses of 
8-OH-DPAT, they registered a release from Early-I inhibitory input. The loss of early-I 
inhibitory input caused the recorded Post-I neurones to advance onset of their bursting 
activity into the inspiratory phase. At higher concentrations (8-OH-DPAT 10-50 μg-kg-1), 
this effect was combined with a hyperpolarizing K+ current which resulted in a silencing of 
the Post-I neurones throughout most of the respiratory cycle (with only brief bursting 
activity during late inspiration). At the network level, the authors observed an increase in 
respiratory rate due to a shortening of inspiratory and expiratory phase durations 
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recorded from the PN. From the shortening of expiratory phase duration, along with the 
loss of bursting activity during the Post-I phase recorded from (what under control 
conditions were) Post-I neurones, the authors inferred that systemic administration of 8-
OH-DPAT resulted in a complete loss of post-I activity at the network level, and a transition 
from a tri-phasic respiratory pattern (I, Post-I, E2) to a bi-phasic respiratory pattern (I, E2) 
(see section 1.7.3).  
Ways in which 5-HT1AR transmission can affect target cells include: inhibition of 
intracellular mechanisms mediated by the CA-cAMP-PKA pathway; GIRK channel 
activation; and activation of voltage gated Ca2+ channels (Richter et al., 2003) (see section 
1.7.3, Figure 1-9). 5-HT1AR transmission is also to reported have neuromodulatory effects, 
as it augmented glycine-activated inhibitory Cl- currents in HEK293 cells co-expressing 
5-HT1AR and Glyα3 receptors (Manzke et al., 2010). In in situ WHBP of juvenile rats, the 
augmented PN rate in response to 8-OH-DPAT was abolished when glycine receptors were 
blocked by systemic application of strychnine before or after administration of 8-OH-DPAT 
(Manzke et al., 2010, Manzke et al., 2009). Furthermore, IHC labelling showed that Glyɑ3R 
was expressed in glycinergic neurones in both the BötC and pre-BötC, and 5-HT1AR 
expression was observed on glycinergic neurones of the pre-BötC (Manzke et al., 2010, 
Manzke et al., 2009). On the basis of these findings, it has been suggested that network 
effects of systemic 8-OH-DPAT administration may be shaped not only by 5-HT1AR 
activated inhibitory K+ channels, but to a large extend by 5-HT1AR mediated modulation of 
Glyɑ3 receptors, resulting in potentiation of glycine activated inhibitory chloride currents 
in select populations of respiratory neurones in the VRC (Manzke et al., 2009, Manzke et 
al., 2010, Shevtsova et al., 2011).  
Computational modelling simulations (Shevtsova et al., 2011) suggested that the effect of 
systemic 8-OH-DPAT administration on respiratory control is largely mediated by 5-HT1AR-
dependent potentiation of glycinergic currents in Early-I neurones and Aug-E neurones at 
low doses, in combination with hyperpolarizing K+ currents in Early-I and Post-I neurones 
due to activation of GIRK channels at higher doses. The augmented glycinergic inhibition 
at glycinergic Early-I neurones was suggested to result in a loss of inspiratory post-synaptic 
inhibition at Post-I neurones, resulting in the advanced onset of bursting activity in Post-I 
neurones. The augmented glycinergic inhibition at Early-I neurones, as well as augmented 
glycinergic inhibition at GABAergic and glycinergic Aug-E neurones was suggested to 
underlie a shortening of I and E2 phases, respectively. This model was able to reproduce 
the effects of systemic administration of 8-OH-DPAT on Post-I neurones and at network 
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level as observed in the experimental single cell and PN recordings by Manzke et al. 
(2009). The model was also able to reproduce the previously reported hyperpolarization 
and inhibition of a VRC Aug-E neurones after systemic administration of 8-OH-DPAT in 
anesthetised cats (Lalley et al., 1994). Furthermore, the model predicted 5-HT1AR-induced 
loss of Post-I activity at the network level, an effect inferred from the loss of activity 
recorded in Post-I neurones by Manzke et al. (2009). 
Gaps in understanding of the effect of 5-HT1AR agonism on the VRC respiratory network  
The above model provided the most comprehensive working hypothesis currently 
available to describe putative mechanisms underlying the effect of systemic 5-HT1A 
receptor agonism on respiratory control. However, it relied on several assumptions not 
supported by experimental verification, some of which have already been pointed out in 
the discussion of chapter 3 (section 3.4.3). First, the model attributed effects of 5-HT1A/7R 
agonism exclusively to mechanisms mediated by 5-HT1A R. Second, effects of anaesthesia 
in the experimental findings on which the model was based (Manzke et al., 2009) cannot 
be excluded. Third, the model extrapolated the effects of systemic 8-OH-DPAT 
administration experimentally observed in a small set of single cell recordings of VRC Post-
I neurones (n = 4 neurones) (Manzke et al., 2009) to network level responses (i.e. changes 
in cVN Post-I activity). (Manzke et al., 2009). The limited sample size of Post-I neurone 
recordings does not permit such inference with confidence. In fact, experimental findings 
presented in Chapter 3 of this thesis do not support a phase shift or abolition of Post-I 
activity at the network level in response to systemic administration of a selective 5HT1AR 
agonist (NLX-101) (see section 3.4.3).  
It is possible that the discrepancy between experimental observations at the network 
level, and observations at the level of individual neurones is due to a certain degree of 
heterogeneity in the response to systemic 5-HT1AR agonism among the population of 
neurones with a Post-I discharge pattern. This could be due to heterogeneity of 5-HT1AR 
and/or Glyɑ3R (co-)expression in the population of Post-I neurones themselves, but also 
due to heterogeneity within populations of neurones that project to Post-I neurones 
(notably, Early-I neurones). This remains to be verified experimentally.  
The fourth point is that the model made assumptions with regard to the distribution of 5-
HT1A R, as well as Glyɑ3R (co-)expression over functionally distinct subpopulations of 
respiratory neurones in the VRC (e.g. Aug-E neurones, Post-I neurones, Early-I neurones, 
etc). Although co-expression of both receptor types is anatomically confirmed in VRC 
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respiratory regions in which the relevant neurone populations are concentrated (i.e. the 
BötC and pre-BötC), experimental data on 5-HT1A expression at specific functional 
subtypes of respiratory neurones is limited to a small number of expiratory (Post-I/Dec-E 
and Aug-E) neurones. Furthermore, in only one of these recordings 8-OH-DPAT was 
administered juxta-cellularly to (Aug-E) neurone via iontophoresis (reported in Lalley et 
al. (1994)). In all other recordings, 8-OH-DPAT was administered systemically, and one 
cannot exclude that effects on the recorded neurone were induced by indirect network 
interactions rather than by direct effects at 5-HT1AR of the recorded cell.  
5.1.2 Chapter Aims and Hypotheses 
Chapter aim: The aim of this chapter is to establish which functionally defined 
subpopulations of respiratory neurones respond to 5-HT1AR agonist, allowing inference of 
5-HT1AR expression. Functional phenotypes of respiratory neurones are defined by their 
discharge pattern relative to the respiratory cycle. Previous literature, along with the 
results presented in chapters 3 and 4 of this thesis, suggest that 5-HT1A transmission likely 
affects respiratory control at multiple sites in the respiratory network (e.g. the VRC and 
the PBc). However, the theoretical framework for network interactions that shape the 
respiratory rhythm, and the putative mechanisms by which 5-HT1A transmission may 
affect these interactions, is best developed for the VRC. Therefore, to capitalize on the 
currently existing body of knowledge, I focused on VRC respiratory neurones. 
Experiment: To infer 5-HT1AR expression at functionally defined respiratory neurones 
of the VRC, I performed extracellular single unit recordings combined with juxta-cellular 
pico-ejections of 5-HT1AR selective agonist NLX-101, combined with recordings of the PN 
in in situ WHBP of juvenile rats.  
Hypothesis: Based on previous literature, I expect 5-HT1AR expression predominantly 
in VRC respiratory neurones with an Early-I discharge pattern, as well as in VRC neurones 
with an Aug-E discharge pattern. Experimental findings also suggest presence of 5-HT1A 
receptors in Post-I neurones.   
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5.2 CHAPTER METHODS. 
5.2.1 Description and justification of extracellular recordings combined with juxta-
cellular pico-ejection of drugs 
Extracellular single unit recordings in the in situ WHBP allow for the identification of 
respiratory neurone functional subtypes through evaluation of the recorded neurones 
burst pattern and its phase relation with simultaneously recorded PN activity. With the 
use of a multi-barrel microelectrode, extracellular single unit recordings can be combined 
with juxtacellular drug pico-ejections. This enables us to infer receptor expression at 
individual functionally identified neurones in the in situ WHBP. I can exclude wider 
network effects induced by drug pico-ejection through monitoring peripheral nerve 
respiratory output. While I cannot exclude possible effect on neighbouring cells, a high 
multi-barrel micro-electrode tip resistance (15-20MΩ) ensures volumes of drug pico-
ejected from the pipette are almost insignificant, and diffusion is minimal. I know from 
experience that if any sizable volume of drug solution is ejected, the recorded cell dies or 
is pushed away. Therefore, the stability of the recording during pico-ejection can be used 
as a control to ensure minimal volumes of drug solution are pico-ejected and possible 
effects on neighbouring cells are unlikely. Pico-ejection of GABA or Glutamate can be used 
as a positive control to verify effective drug delivery. Because I use in situ WHBP, there is 
no need for the use of anaesthetics, and their potential confounding effects can be 
excluded. Thus, peripheral nerve recordings in the in situ WHBP, combined with 
extracellular single unit recordings and juxtacellular pico-ejectons of 5-HT1A agonist (NLX-
101), GABA, or glutamate enable us to establish expression of 5-HT1A receptors in 
functionally identified respiratory neurone subtypes. 
5.2.2 Additional surgical procedures for extracellular recordings in in situ WHBP 
In situ WHBP were prepared as described in the General Methods (section 2.2.2), only the 
PN was exposed and cut for nerve recordings. Additional surgical procedures were 
performed to enable a dorsal approach of the brainstem with multi-barrel electrodes for 
extracellular recordings combined with juxtacellular pico-ejection. For exposing the dorsal 
surface of the medulla, all muscle and connective tissue surrounding dorsal and lateral 
regions of the atlanto-occipital joint were removed. The exoccipital bones and atlanto-
occipital membrane were carefully cut, and the occipital bone was removed to expose the 
dorsal surface of the brainstem and cerebellum. Subsequently, the meninges covering the 
cerebellum were removed and the cerebellar peduncles were cut, after which, the 
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cerebellum was lifted and removed. This enabled unobstructed access to the dorsal 
surface of the medulla. The preparation was placed in prone position in the recording 
chamber with head fixed in ear bars and an incisor bar, set up so that the medulla was 
oriented horizontally. Prior to each descend with multi-barrel electrodes into the 
medullary tissue, the pia was carefully punctured and removed from the site of entrance. 
This prevented the breaking of electrode tips upon descending into medullary brain 
tissue.  
5.2.3 Multibarrel electrodes for extracellular recording and drug pico-ejection 
Multibarrel micro-electrodes for combined extracellular single unit recordings combined 
with juxtacellular drug pico-ejection were custom made by fastening together 3 
borosilicate glass capillaries (GC150-F10, Harvard Apparatus, Kent, United Kingdom). 
These were twisted to conjoin under heat and pulled to a single tip with a pipette puller 
(PE-2 8405, Narisighe, Tokyo, Japan). One of three barrels of the multibarrel electrodes 
was filled with NLX-101 solution (1mM, pH 7.3), and a second barrel was filled with GABA 
solution (500mM, pH 7.3), Glycine solution (10Nm, pH 7.3), or Glutamic acid solution 
(10mM, pH 7.3). Positive air pressure for pico-ejection was applied to each barrel 
independently from a pico-pressure device (Picospritzer III, Intracel Ltd., Shepreth, United 
Kingdom). The third barrel of the multibarrel electrode was filled with NaCl (3M, pH 7.3) 
solution and fitted a recording electrode for extracellular recordings. The multibarrel 
electrode tip was broken to obtain a resistance of 15-20 MΩ. A reference electrode was 
suspended in the perfusate filled cranial cavity of the decerebrated preparation, in 
proximity of the brainstem. The multibarrel electrode was mounted on a hydraulic 
micromanipulator (MO-10, Narishige International LTD, London, United Kingdom) which 
was placed on a 3D mechanical micromanipulator (SM-11 11020, Narishige International 
LTD, London, United Kingdom)  
5.2.4 Solutions and Pharmacological Agents 
NLX-101 fumarate (Neurolixis Inc. Dana Point, USA) solution (1mM) for pico-ejections was 
made up with aCSF (Harvard Apparatus, Holliston, U.S.A.). Glycine solution (10mM) 
(ab120050, Abcam, Cambridge, UK) for pico-ejection was made up with aCSF. GABA (A-
5835, Merck & Co, Kenilworth, U.S.A.) solution (500mM) for pico-ejections was made up 
with saline (0.9%). L-Glutamic Acid solution (10mM) (G-1626, Merck & Co, Kenilworth, 
U.S.A.) for pico-ejections was made up with saline (0.9%). pH Recording electrodes were 
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filled with saline (3M). All solutions were adjusted to pH 7.3 with NaOH and HCl solution 
in H2O.  
5.2.5 Experimental protocols, data acquisition, processing, and analysis  
Experimental protocols 
For extracellular single unit recordings of medullary respiratory neurones, combined with 
drug (NLX-101, GABA, or glutamate) pico-ejections, combined with PN recordings, in situ 
WHBP of juvenile (50-90g) male rats were made as described in General Methods (section 
1.2.2) with additional surgical procedures as described in section 4.1.2. When an eupnoeic 
ramping pattern was established of the PN, a multi-barrel electrode was slowly descended 
vertically and unilaterally into the medullary VRC region into the medulla (coordinates 
from Obex Callimus Scriptorius: AP = + 0.6 - 1.8mm; L = ± 1.4−2.0 mm; V = -1.8-2.7mm) 
(Fong and Potts, 2006). Once an extracellular recording of a VRC respiratory neurone was 
obtained, the cell was exposed to pico-ejection of NLX-101 (1mM). Pico-ejection pressure 
started at 5-PSI, and was sequentially increased to maximally 45 PSI in 10 PSI increments, 
whereby each incremental step had a duration of three to five respiratory cycles. If, at any 
step during this pico-ejection sequence, a notable change of action potential (AP) 
frequency was observed by the experimenter, pico-ejection was stopped after completion 
of that ejection step. If no change of AP frequency during pico-ejection was observed, 
pico-ejection was stopped after the final step of the sequence, at maximum pico-ejection 
pressure (50 PSI). Recovery from any response to drug pico-ejection was near 
instantaneous, suggesting that only the minimally required volume of drug was ejected 
juxta-cellular to the recorded neurone to elicit a response. After a brief interval, this pico-
ejection sequence was repeated with GABA (500mM), Glycine (10mM), or Glutamate 
(10mM) pico-ejection as a positive control. 
Data acquisition 
Data acquisition parameters and the hardware and software used for PN recordings are 
described in the General Methods (section 2.2.4). Single unit electrophysiological 
recordings were amplified (20K) and bandpass filtered (60 Hz to 3 kHz) (Model 1800 
Microelectrode AC amplifier, A-M systems, Sequim, USA). 50 Hz Electrical interference 
was eliminated with the use of a Humbug noise eliminator (AM-systems, Sequim, USA). 
A-D conversion was performed using a Micro 1401 data-acquisition unit (Cambridge 
Electronic Design Ltd, Cambridge, UK) and Spike2 data acquisition and analysis software 
(Cambridge Electronic Design Ltd., Cambridge, UK). 
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Data processing and analysis 
From the PN recording, timepoints of onset of each respiratory cycle, and respiratory cycle 
durations were obtained with a custom script (Abdala Sheikh, 2020) in Spike2 data 
analysis software (Cambridge Electronic Design Ltd., Cambridge, UK). In the extracellular 
single unit recording, a waveform analysis function built in Spike2 was applied to enhance 
the action potential (AP) signal-to-noise ratio. That is, representative AP waveforms were 
manually selected to construct an AP waveform template, which was then used to 
automatically search the extracellular recording for matching waveforms. The resulting 
selection of AP waveforms was manually checked. AP waveforms and match inclusion 
parameters were such that AP’s should remain detectable if the AP signal were slightly 
depressed due to mechanical displacement during pico-ejection. On the other hand, 
waveforms of a different shape (e.g. ECG or other noise) would not match the AP template 
waveform.  
The timepoint of onset of each selected AP waveform was marked to establish the 
normalised burst rate per respiratory cycle of the recorded neurone (AP-count per 
respiratory cycle: respiratory cycle duration (s)). Additionally, burst pattern histograms 
were made with AP count per 0.05s bin (AP/.05s). AP/.05s histogram data relative to PN 
activity was used to categorise the respiratory neurone among known functional 
subtypes. These functional subtypes are: neurones with a pre-inspiratory and inspiratory 
phase spanning ramping burst pattern (Pre-I/I); Early-inspiratory (early-I) neurones with a 
decrementing burst patter spanning the inspiratory phase; neurones with an 
incrementing (ramping) burst pattern spanning the inspiratory phase (Ramp-I); Neurones 
with a decrementing burst pattern spanning the expiratory (Dec-E neurones) or post-
inspiratory phase (Post-I neurones); and neurones that have an incrementing 
(augmenting) burst pattern occurring during the expiratory phase, with termination at 
onset of the inspiratory phase (Aug-E). Both Post-I and Dec-E neurones are most found in 
BötC, presenting with a decrementing burst pattern through expiration, and both are 
important for inspiratory to expiratory phase transitioning. Depending on physiological 
conditions, the activity pattern of these two functional subtypes of respiratory neurones 
can overlap, and they cannot conclusively be distinguished by their burst pattern relative 
to PN activity. Therefore, Post-I and Dec-E neurones were pooled (Post-I/Dec-E) in the 
classifications applied here.  
For each drug pico-ejection, a sample of five consecutive respiratory cycles immediately 
preceding that pico-ejection was selected, and their firing frequencies (AP/s) per 
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respiratory cycle were used to establish firing frequency baseline averages and standard 
deviation (SD) values. Firing frequency (AP/s) values of two respiratory cycles during pico-
ejection at the final and highest pico-ejection pressure were selected to calculate the 
average firing frequency (AP/s) during drug exposure. Any change in activity of the 
recorded cell during drug pico-ejection was expressed as the percentage change in 
average firing frequency during pico-ejection relative to the baseline average firing 
frequency (ΔAP/s % = ((pico-ejection average AP/s - baseline average AP/s)/baseline 
average AP/s )*100). Cells were classified as responsive to NLX-101, GABA, or Glycine if 
the reduction in average firing frequency (AP/s) during pico-ejection was equal to or 
greater than two times the SD of the average firing frequency (AP/s) of the baseline 
sample. Similarly, cells were classified as responsive to glutamate if the increase in 
average firing frequency (AP/s) during pico-ejection was equal to or greater than two 
times the SD of the average firing frequency (AP/s) of the baseline sample. There were 
two single unit recordings for which sample sizes are different than described above. The 
first is a Pre-I/I neurone recording (NLX-101 pico ejection: baseline = 2 respiratory cycles, 
pico-ejection = 1 respiratory cycle. Glutamate pico-ejection: baseline = 3 respiratory 
cycles; pico-ejection = 1 respiratory cycle), and the second is a Post-I/Dec-E neurone 
recording (NLX-101 pico ejection: baseline = 5 respiratory cycles, pico-ejection = 2 
respiratory cycles. GABA pico-ejection: baseline = 2 respiratory cycles; pico-ejection =2 
respiratory cycles).  
Extracellular recordings were excluded from the dataset if cells were classified non-
responsive to NLX-101 pico-ejection, as well as non-responsive to pico-ejection of 
Glutamate, GABA, or Glycine. The lack of response to positive control pico-ejections 
indicated a likely failure of drug administration (e.g. electrode tip was too far from the 
cell). Cells were also excluded if pico-ejection resulted in a significant loss of AP amplitude. 
This suggested that the pico-ejection volume was too high due to a damaged micro-
electrode tip. If this was observed, the electrode was retracted and replaced. These 
criteria resulted in exclusion of 3 recordings from analysis (two Post-I/Dec-E recordings, 
and one Aug-E recording).  
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5.3 CHAPTER RESULTS 
I performed PN recordings, combined with single unit extracellular recordings of 
respiratory neurones of the ventral respiratory column, combined with juxtacellular pico-
ejection of NLX-101 solution (1mM in aCSF, pH  7.3) and pico-ejection of GABA (500mM 
in saline, pH = 7.3), Glycine (10mM in aCSF, pH = 7.3), or glutamic acid (10mM in saline 
(0.9%), pH = 7.3) in the in situ WHBP of juvenile rats. Via this approach I identified 
functional subtypes of respiratory neurones in the VRC that were responsive to the 
selective 5-HT1AR agonist, NLX-101 (i.e. functional subtypes that express 5-HT1A 
receptors).  
5.3.1 Overall responsiveness of respiratory neurones to juxtacellular pico-ejection of 
NLX-101 
Figure 5-1A shows the relative and absolute quantities of neurones that are classified as 
responsive to juxtacellular pico-ejection of NLX-101. In total, 46 single unit recordings of 
VRC neurones were included in analysis, of which 25 (54%) neurones were inhibited by 
NLX-101. 
5.3.2 Responsiveness of Ramp-I respiratory neurones to juxtacellular pico-ejection of 
NLX-101 
Ramp-I neurons were identified by their incrementing inspiratory burst pattern (see figure 
5-2A for representative traces of a Ramp-I neurone and simultaneously recorded PN 
activity). Figure 5-2A1 shows the response of that neurone to pico-ejection of NLX-101, 
whereas Figure 5-2A2 shows the response of that same neurone to subsequent GABA 
pico-ejection. Twenty-two Ramp-I neurones were identified in recordings from in situ 
WHBP of 11 different rats. In 21 of these recordings, NLX-101 pico-ejections were paired 
with a subsequent pico-ejection of inhibitory amino acid (GABA or glycine). The remaining 
Ramp-I recording did not have a positive control but was inhibited by NLX-101. Fifteen out 
of the 22 (67%) recorded Ramp-I respiratory neurones of the VRC were inhibited by NLX-
101. (see figure 5-1A). Figure 5-1B shows the average effect sizes of inhibition in response 
to juxtacellular pico-ejection of NLX-101 inhibition (or lack thereof), as well as the average 
effect sizes of inhibition in response to juxta-cellular pico-ejection of GABA or Glycine 
(pooled) for the recorded samples of NLX-101 responsive, and non-responsive Ramp-I 
neurones. Of the 15 NLX-101 responsive Ramp-I neurons, the average firing frequency 
(AP/s) was reduced by 63% upon juxtacellular NLX-101 pico-ejection. In the subset of this 
population of cells in which juxtacellular pico ejection of GABA or glycine was performed, 
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this resulted in a reduction of the average firing frequency (AP/s) by 94% (Figure 5-1B). Of 
the 7 Ramp-I neurons classified as NLX-101 non-responsive, the average firing frequency 
(AP/s) was increased by 4% upon juxtacellular NLX-101 pico-ejection. In the same 
population of cells, juxtacellular pico ejection of GABA or Glycine resulted in a reduction 







Figure 5-1: Responses of functional subpopulations of VRC respiratory neurones to juxta-cellular 
pico-ejection of NLX-101 
Figure A shows, for each functionally identified group of respiratory neurones, percentages and 
counts of neurones that are inhibited by NLX-101. Neurones were classified as NLX-101 
responsive if change from baseline in AP/s during NLX-101 pico-ejection was greater than twice 
the SD of the baseline sample. (B) Percentage change in average firing frequency (AP/s) during 
NLX-101 and inhibitory amino-acid pico-ejection relative to baseline average firing frequencies 
(AP/s) for all NLX-101 responsive and non-responsive Ramp-I neurones. n = 22 neurones from 11 
rats. One of the plotted neurones did not have a positive control (GABA,glycine,or L-glutamic 
acid) pico-ejection, but was inhibited by NLX-101. (C) Percentage change in average firing 
frequency (AP/s) during NLX-101 and inhibitory amino-acid pico-ejection relative to baseline 
average firing frequencies (AP/s) for all NLX-101 responsive and non-responsive Post-I/Dec-E 
neurones. n = 16 neurones from 11 rats. In one recording NLX-101 pico-ejection was paired with 
subsequent pico-ejection of L-Glutamic acid (not shown). One of the plotted Post-I/Dec-E 
recordings did not have a positive control but was inhibited by NLX-101.  
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5.3.3 Responsiveness of Post-I/Dec-E respiratory neurones to juxtacellular 
pico-ejection of NLX-101 
Post-Inspiratory and decrementing expiratory (Post-I/Dec-E) neurons were identified by 
their decrementing burst pattern during expiration, with onset immediately after 
termination of the inspiratory phase. Figure 5-2B shows representative traces of a Post-
I/Dec-E neurone and simultaneously recorded PN activity. Figure 5-2B1 shows the 
response of that neurone to pico-ejection of NLX-101, whereas figure 5-2B2 shows the 
response of the same neurone to subsequent GABA pico-ejection. 16 Recordings of Post-
I or Dec-E neurones were obtained from 11 rats. In 14 of these recordings, NLX-101 pico-
ejections were paired with a subsequent pico-ejection of GABA. In one recording NLX-101 
pico-ejection was paired with subsequent pico-ejection of L-Glutamic acid. The remaining 
Post-I/Dec-E recording did not have a positive control but was inhibited by NLX-101. Eight 
of the 16 (50%) recorded Post-I/Dec-E respiratory neurones of the VRC were inhibited by 
NLX-101 (see figure 5-1A). Figure 5-1C shows the average effect sizes of inhibition (or lack 
thereof) in response to juxtacellular pico-ejection of NLX-101, as well as the average effect 
sizes of inhibition in response to juxtacellular pico-ejection of GABA (if obtained) for the 
recorded samples of NLX-101 responsive, and NLX-101 non-responsive Post-I/Dec-E 
neurones. Of the 8 NLX-101 responsive Post-I/Dec-E neurons, the average firing frequency 
(AP/s) was reduced by 84% upon juxta-cellular NLX-101 pico-ejection. In the subset of this 
population of cells in which juxta-cellular pico ejection of GABA was performed, this 
resulted in a reduction of the average firing frequency (AP/s) by 96% (figure 5-1C). Of the 
8 Post-I/Dec-E neurones classified as NLX-101 non-responsive, the average firing 
frequency (AP/s) was decreased by 11% upon juxta-cellular NLX-101 pico-ejection. In the 
subset of this population of cells in which juxta-cellular pico ejection of GABA was 
performed, this resulted in a reduction of the average firing frequency (AP/s) by 96% 
(figure 5-1C). 
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A Shows representative traces of extracellular recordings (Cell), histograms with extracellularly 
recorded action potentials per 0.05s bin (AP/.05s), and integrated phrenic nerve activity (∫PN). 
A1 Shows activity of a Ramp-I neurone during baseline, pico-ejection of NLX-101 (22% reduction 
in average firing frequency (AP/s) relative to baseline), and recovery. A2 shows the activity of 
the same cell in response to GABA pico-ejection (83% reduction in average firing frequency 
(AP/s) relative to baseline).  B1 and B2 are representative traces from a Post-I/Dec-E neurone in 
the same way as A1 and A2. During pico-ejection of NLX-101 and GABA, reduction of firing 
frequencies (AP/s) compared to the corresponding baseline averages is 41% and 81%, 
respectively. Both neurones shown in A1,2 and B1,2 are classified as NLX-101 responsive.    
 
Figure 5-2: Representative traces of extracellular recordings of a Ramp-I, and a Post-I/Dec-E 
neurone with pico-ejections of NLX-101 and GABA. 
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5.3.4 Responsiveness of Aug-E respiratory neurones to juxtacellular pico-ejection of 
NLX-101 
Augmenting expiratory (Aug-E) neurons were identified by their augmenting burst pattern 
with onset during the expiratory phase and termination of burst activity at the onset of 
the inspiratory phase. Figure 5-3C shows representative traces of an Aug-E neurone and 
simultaneously recorded PN activity. Figure 5-3C1 shows the response of that neurone to 
pico-ejection of NLX-101, whereas figure 5-3C 2 shows the response of the same neurone 
to subsequent GABA pico-ejection. Four Recordings of Aug-E neurones were obtained 
from in situ WHBP of 4 rats. None of these recorded neurones were classified as 
responsive to juxta-cellular NLX-101 pico-ejections (see figure 5-1A), while all were 
responsive to a subsequent pico-ejection of GABA. 
5.3.5 Responsiveness of Pre-I/I respiratory neurones to juxtacellular pico-ejection of 
NLX-101 
Pre-inspiratory and inspiratory (Pre-I/I) neurones were identified by their incrementing 
burst pattern during inspiration, with onset slightly prior to onset of the inspiratory phase. 
Figure 5-3A shows representative traces of a Pre-I/I neurone and simultaneously recorded 
PN activity. Figure 5-3A1 shows the response of a Pre-I/I neurone to pico-ejection of NLX-
101, whereas figure 5-3A2 shows the response of that same neurone to subsequent L-
glutamic acid pico-ejection. Two recordings of Pre-I/I neurones were obtained from in situ 
WHBP of two rats. One of the two recordings was responsive to juxtacellular pico-ejection 
of NLX-101 (see figure 5.1A), which was paired with a subsequent pico-ejection of L-
glutamate (see figure 5-3A). In the other recording NLX-101 pico-ejection was paired with 
subsequent pico-ejection of glycine.  
5.3.6 Responsiveness of Early-I respiratory neurones to juxtacellular pico-ejection of 
NLX-101 
Early inspiratory (Early-I) neurones were identified by their decrementing burst pattern 
during inspiration. See figure 5-3B for representative traces of an Early-I neurone and 
simultaneously recorded PN activity. Figure 5-3B1 shows the (lack of) response of an Early-
I neurone to pico-ejection of NLX-101, whereas figure 5-3B2 shows the response of that 
same neurone to subsequent juxtacellular pico-ejection of GABA. Two recordings of Early-
I neurones were obtained from in situ WHBP of two rats. One of the two recordings was 
responsive to juxtacellular pico-ejection of NLX-101 (see figure 5-1A). The other recording 
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was not responsive to juxtacellular pico-ejection of NLX-101, but was inhibited by 
subsequent pico-ejection of GABA.   
Figure 5-3: Representative traces of extracellular recordings of a Pre-I, an Early-I, and an Aug-
E VRC neurone with pico-ejections of NLX-101, L-glutamic acid, and GABA. 
Representative traces of extracellular recordings (Cell), histograms with extracellularly 
recorded action potentials per 0.05s bin (AP/.05s), and integrated phrenic nerve activity 
(∫PN).Figure caption is continued on the next page. 
Chapter 5: 5-HT1A Receptor Distribution Across Functional Subpopulations of Respiratory 
Neurones in the Ventral Respiratory Column 
204 
 
5.4 CHAPTER DISCUSSION 
5.4.1 Summary and review of results in light of aims and hypotheses 
To help identify mechanisms underlying the effects of systemic 5-HT1A transmission on 
respiratory control, the present chapter presents an exploratory investigation of 5-HT1AR 
expression (inferred from agonist-mediated inhibition) at functionally identified individual 
respiratory neurones in the intact, unanaesthetised respiratory network in in situ WHBP 
of rat. Fluorescence ISH evidence of 5-HT1AR RNA and SLC32A1 RNA in the BötC, pre-BötC, 
and RVRG (chapter 4) as well as IHC evidence of 5-HT1AR and GlyT2 expression in the pre-
BötC (Manzke et al., 2009, Manzke et al., 2010) suggest that 5-HT1AR are present in 
inhibitory neurones of the VRC. Previously published experiments with iontophoresis of 
5-HT1A/7R agonist (8-OH-DPAT) and single cell recordings at individual VRC neurones in 
anesthetised cats suggested that 5-HT1AR are expressed in Aug-E neurones of cats (Richter 
et al., 1997, Lalley et al., 1994). Other experimental evidence with systemic administration 
of 8-OH-DPAT and single cell recordings of Post-I neurones in the VRC of anesthetised cats 
suggest that 5-HT1A may also be expressed in inhibitory inspiratory neurones that project 
to Post-I neurones, as well as in Post-I neurones themselves (Manzke et al., 2009).   
Figure 5-3, caption continued from previous page: Representative traces of extracellular 
recordings (Cell), histograms with extracellularly recorded action potentials per 0.05s bin 
(AP/.05s), and integrated phrenic nerve activity (∫PN). A1 Shows activity of one of two recorded 
Pre-I/I neurones during baseline, pico-ejection of NLX-101 (39% reduction in average firing 
frequency (AP/s) relative to the baseline average), and recovery. A2 shows the activity of the 
same cell in response to pico-ejection of L-glutamic acid (44% increase in average firing 
frequency (AP/s) relative to the baseline average).  In the same fashion, B1,2 shows 
representative traces from one of two recorded Early-I neurones. B1, shows a 4% increase in 
average firing frequency (AP/s) relative to the baseline average. B2 Shows full inhibition in 
response to GABA pico-ejection in the same cell. This cell is classified as an NLX-101 non-
responsive neurone. C1,2 Shows representative traces from one of four recorded Aug-E 
neurones. C1, shows a 13% reduction in average firing frequency during (AP/s) NLX-101 pico-
ejection relative to the baseline average. C2 Shows strong inhibition (95% reduction in average 
firing frequency (AP/s)relative to the baseline average) in response to GABA pico-ejection in 
the same cell. This cell is classified as an NLX-101 non-responsive neurone.  
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The present study is the first to establish 5-HT1A transmission at functionally identified 
individual respiratory neurones of the VRC in rat, and the first to do so in an 
unanaesthetised intact respiratory CPG network. In total 46 respiratory neurones were 
recorded, distributed across 5 distinct functional subtypes defined by their discharge 
pattern relative to the respiratory cycle. Prior to the present experiments, 5-HT1AR 
transmission was established in a single Aug-E neurone recording combined with 
juxtacellular iontophoresis of 8-OH-DPAT in anesthetised cat (Lalley et al., 1994). As such, 
the present work offers a substantial expansion of the existing knowledge of 5-HT1AR 
distribution across functional phenotypes of respiratory neurones in the VRC. 
Recordings of the PN, combined with extracellular recordings of VRC respiratory 
neurones, and with juxtacellular pico-ejection of NLX-101 in the in situ WHBP, revealed 
that 5-HT1AR are expressed in subsets of the following functional subpopulations: Ramp-I 
neurones (15 out of 22 neurones were inhibited by NLX-101); Post-I/Dec-E neurones (8 
out of 16 neurones inhibited); Pre-I/I neurones (1 out of 2 neurones inhibited); and Early-
I neurones (1 out of 2 neurones inhibited). An additional four augmenting expiratory 
neurones (Aug-E) were recorded that were all non-responsive to juxtacellular pico-
ejection of NLX-101. All respiratory neurones that were non-responsive to pico-ejection 
of NLX-101, were responsive to pico-ejection of glycine, GABA, and/or glutamic acid. This 
suggests that the absence of a response to NLX-101 pico-ejection is likely not due to 
failure of drug delivery, but rather absence of 5-HT1AR at the recorded neurone.  
To summarize, data in the present chapter demonstrate that: [1] 5-HT1AR presence is 
established among Ramp-I, Post-I/Dec-E, Pre-I, and Early-I respiratory neurones in the 
VRC; and [2] functional subpopulations of respiratory neurones as defined per discharge 
pattern appear heterogeneous regarding 5-HT1AR expression. I hypothesised that 5-HT1A 
R were predominantly expressed in Early-I, Post-I and Aug-E neurones (see section 5.1). 
Although our findings indicate presence of 5-HT1A R expression in Early-I, Post-I and Aug-
E neurones, 5-HT1A R are not exclusively present in these subpopulations, and there is thus 
far no indication of increased 5-HT1A R expression in any specific functional phenotype 
relative to others in the VRC.  
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5.4.2 Technical considerations 
Potential indirect effects of drug pico-ejection on the recorded neurones. 
An important consideration in the present chapter’s experiments is the question whether 
the pharmacological manipulations are selective of the recorded neurone, or whether 
neighbouring cells may also be exposed to pico-ejection of drugs. The latter could result 
in confounding indirect manipulations of the recorded neurone via network interactions. 
Drug pico-ejection on neighbouring cells cannot be excluded, but they are unlikely to 
occur. The volumes that come out of the  pipette are almost insignificant and diffusion 
would be minimal. This is reflected in the near-immediate cessation of any drug induced 
effect on the recorded cell when turning off the positive air pressure on the ejection 
pipette, as well as in the absence of systemic effects. I know from experience that if any 
sizable volume comes out, the cell being recorded dies or is pushed away. I use the 
stability of the recording during pico-ejection as a control. Wider network effects can be 
excluded through monitoring of PN activity during pico-ejections.  
Limitations to the classification of respiratory neurone functional subtypes by discharge 
pattern relative to PN activity.  
Discharge pattern relative to the respiratory cycle is a valuable classification by which to 
assess the distribution of 5-HT1AR across subpopulations of respiratory neurones, in part 
because no biochemical markers are known by which functional phenotypes of VRC 
respiratory neurones could be identified. Nevertheless, the interpretation of the present 
chapter’s findings is limited by the restrictions to what can be said about a respiratory 
neurone, and its physiological function, based on its discharge pattern alone.  
First, because only PN recordings were performed for reference to the network 
respiratory output, Post-I neurons and Dec-E neurons (both described in section 1.2.1) 
could not be reliably distinguished as there is no accurate cVN/RLN recording to 
determine the duration of the Post-I phase. 
Second neurones of the same functional phenotype likely have shared or similar afferent 
projections but may differ in their efferent projections. Additional information on 
projection targets of recorded neurones can help to classify recorded neurones in more 
detail, and potentially reveal distinctions among subpopulations with shared discharge 
patterns. One way to attain information on efferent projections of a recorded neurone is 
by performing electrical stimulations at potential projection sites of VRC neurones, 
combined with action potential collision tests at the recorded neurone. In a collision test 
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(Lipski, 1981), constant latency action potentials in response to electrical stimulation are 
occluded when the stimulus was delivered within a critical interval following a 
spontaneous spike. Such occlusion suggests that axons of the recorded neurones travel 
to or through the site of electrical stimulation, as orthodromic synaptic action potentials 
appear to have collided with antidromic spikes along the axon.  
In respiratory research, spike collision tests have been used to identify bulbospinal pre-
motor (Richter et al., 1991, Schwarzacher et al., 1991, Moraes et al., 2014b, Zheng et al., 
1991, Fortuna et al., 2008) or pre-sympathetic (Moraes et al., 2013) neurones through 
stimulation of contralateral segments of the spinal cord. Cranial motor neurones can be 
identified through antidromic stimulations of various cranial nerves (e.g. the hypoglossal 
nerve, glossopharyngeal nerve, facial nerve, and pharyngeal and laryngeal branches of the 
vagal nerve) (Bianchi et al., 1995, Song et al., 2015, Schwarzacher et al., 1991, Moraes et 
al., 2014b, Zheng et al., 1991, Moraes and Machado, 2015). If antidromic stimulation is 
applied comprehensively at each of these sites, absence of an antidromic response in the 
recorded neurone suggests that it is propriobulbar. If propriobulbar neurones have 
contralateral projections, these could be identified by contralateral stimulations in 
brainstem regions (Guyenet and Wang, 2001, Saether et al., 1987). However, 
opportunities for identification of propriobulbar projection sites are limited as low 
stimulation intensity will recruit axons in only a limited range from the stimulation site, 
whereas stronger stimulation intensities can lesion parts of the CPG. Further, the insertion 
of an additional (stimulating) electrode in the respiratory CPG could result in mechanical 
damage of the CPG and could therefore only be performed at regions distal from the site 
of the recording electrode (i.e. not elsewhere in the ipsilateral VRC). Therefore, 
antidromic stimulation can be applied only in a limited set of regions to which recorded 
neurones could project. Further, one cannot exclude the possibility that a recorded 
neurone with a positive collision test has axons passing through, but not terminating at, 
the site of electrical stimulation.   
Third, for many functional phenotypes, it remains unknown whether the recorded 
neurones are inhibitory or excitatory. One possible approach to discern inhibitory from 
excitatory neurones among recorded VRC neurones is to inject viral vectors for excitatory 
opsin (e.g. ChR2) transgene expression under a VGLUT1 (to target glutamatergic 
neurones, (Zhang et al., 2011a), GAD67 (to target GABAergic neurones (Rasmussen et al., 
2007)) or GlyT2 (to target glycinergic neurones (Moraes et al., 2014a) promoter in VRC 
regions of rat. Recordings and pico-ejections as described in the present chapter could be 
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followed up by light stimulation after systemic administration of pharmacological synaptic 
blockers (e.g. CNQX, AP5, strychnine, and bicuculline). If a recorded neurone responds to 
light stimulation under conditions of synaptic blockade, this suggests presence of ChR2 in 
that neurone from which one can infer whether it is glutamatergic, glycinergic or 
GABAergic (depending on the promoter used to drive ChR2 expression). Disadvantages of 
this approach include the possibility of less than perfect efficacy and selectivity of viral 
vector mediated opsin expression. Additional histological experiments would have to be 
performed to verify efficacy and selectivity of transgene expression with the viral vectors 
used. Further, after systemic administration of synaptic blockers, a preparation would no 
longer be usable for recordings of other respiratory neurones or network activity.  
Histological control experiments would have to be performed to verify efficacy and 
selectivity of the promoters used.  
The above limitations likely underlie the observed heterogeneity of 5-HT1AR phenotypes 
within neurone populations of a similar discharge pattern. Antidromic mapping strategies 
and/or optogenetic excitation could provide additional information on the connectivity 
and phenotype of recorded neurones that could help to classify neurones of a similar 
discharge pattern in more detail. However, these experimental approaches have their 
limitations (addressed above), are technically challenging, and would come at the expense 
of reduction of animal use and/or numbers of recorded neurones. 
5.4.3 Interpretation of data 
Effects of systemic 5-HT1AR transmission on respiration likely emerge as a network effect 
from multiple distinct respiratory neurone populations in the respiratory CPG.  
In the present chapter, neurones with an Aug-E discharge pattern were the only functional 
subpopulations in which no response to NLX-101 pico-ejection was observed. All other 
known functional subpopulations of VRC respiratory neurones contained cells responsive 
to NLX-101 pico-ejection (Pre-I, Early-I, Ramp-I, Post-I/Dec-E). One previously reported 
study with juxtacellular administration of 5-HT1AR agonist (8-OH-DPAT) suggests that 5-
HT1AR expression can occur in Aug-E neurones also (Lalley et al. 1994). Thus, collectively, 
experiments with single cell recordings combined with juxtacellular pico-ejection of 
5-HT1AR agonist indicate that 5-HT1AR are expressed across VRC neurone populations of 
all functional phenotypes. Further, data from the present thesis, combined with that of 
Lalley et al. (1994), give no indication of greater 5-HT1AR expression in any specific 
functional phenotype relative to others in the VRC. Regarding the latter, it should be 
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noted that sample sizes are small, and patterns in the distribution may yet emerge with 
greater sample sizes.  
One noteworthy finding in the present thesis is the high prevalence of NLX-101 mediated 
inhibition of Ramp-I neurones. Ramp-I neurones are thought to be excitatory bulbospinal 
pre-motor neurones that project to spinal PN motor neurones innervating the diaphragm 
(Smith et al., 2013, Alheid and McCrimmon, 2008). Therefore, 5-HT1AR mediated inhibition 
of Ramp-I neurones appears contradictory to the increase in pattern parameters 
(increased amplitude and normalised burst envelopes) observed in integrated PN output 
after systemic NLX-101 administration in in situ WHBP (see section 3.3.1). Two factors 
may contribute to this discrepancy.  
First, recorded Ramp-I neurones were heterogenous with regard to 5-HT1AR expression. 
The majority of recorded Ramp-I neurones (15 out of 22) was NLX-101 responsive. 
However, there are limitations to the certainty with which one can extrapolate the 
relative distribution of NLX-101 responsive and non-responsive neurones observed 
among the sampled Ramp-I neurones to the population of Ramp-I neurones at large. This 
is in part a result of the limited sample size in the present chapter. In addition, there may 
be a sampling bias for larger cells in extracellular single cell recordings. Larger neurones 
have greater field potentials relative to smaller cells and can therefore be recorded from 
a greater distance. Smaller cells are more likely to incur damage when an electrode comes 
in close enough proximity to record. As a result, I cannot exclude the possibility that 
smaller neurones are underrepresented in the present dataset of single unit recordings.  
Second, given the broad expression of 5-HT1AR across key regions of the respiratory CPG 
(see Chapter 4), as well as among respiratory neurone functional subtypes in the VRC 
(present chapter), multiple candidate mechanisms could contribute to the network effect 
of systemic 5-HT1AR agonism with NLX-101. Therefore, direct 5-HT1AR mediated inhibition 
of Ramp-I neurones may be overcome by disinhibition and enhanced excitatory network 
inputs to these neurones as a result of 5-HT1AR agonism elsewhere (a topic explored 
further in Chapter 6).  
To conclude, the current understanding of distribution of 5-HT1AR among VRC neural 
populations with distinct discharge patterns does not, by itself, suggest a predominant 
role of 5-HT1AR agonism at any specific subsets of VRC populations in the network 
response to systemic 5-HT1AR agonism. No VRC functional subpopulations can be excluded 
as putative contributors to the effects of systemic 5-HT1A transmission on respiratory 
Chapter 5: 5-HT1A Receptor Distribution Across Functional Subpopulations of Respiratory 
Neurones in the Ventral Respiratory Column 
210 
 
control. Therefore, it is likely that that effects of systemic 5-HT1AR activation on 
respiratory motor output (see chapter 3) emerged as a network effect from multiple 
distinct respiratory neurone populations in the respiratory CPG.  
Distinct biochemical characteristics of 5-HT1AR expressing respiratory neurones may 
mediate differential contributions of neural subpopulations to the respiratory CPG 
network response to systemic 5-HT1AR agonism. 
The specific functional effects of systemic 5-HT1A agonist (chapter 3) appear not reflected 
in a selective distribution of 5-HT1A R across anatomical regions (chapter 4), nor in a 
selective distribution of 5-HT1A R across functional subpopulations of respiratory neurones 
(present chapter). An additional level of organization by which broad 5-HT1AR expression 
in the respiratory network could underlie selective responses to systemic 5-HT1A 
transmission, is through differential recruitment of intracellular and neuromodulatory 
mechanisms across subpopulations of 5-HT1AR expressing respiratory neurones.  
One such intracellular mechanism that may contribute to differentiation of respiratory 
neurons by their responses to 5-HT1AR agonism is activation of G-protein coupled inward 
rectifying potassium (GIRK) channels. GIRK activation hyperpolarizes neurones and 
inhibits neuronal firing. (Clarke et al., 1987). GIRK channel activation in response to 5-
HT1AR agonism is mediated by G protein βγ subunits (Richter et al., 2003, Polter and Li, 
2010, Clarke et al., 1987). Voltage clamp recordings revealed that Post-I neurones 
demonstrated hyperpolarizing currents consistent with GIRK channel activation after 
systemic administration of 8-OH-DPAT in anesthetized cats (Manzke et al., 2009). It is 
plausible that the response to 5-HT1AR activation at respiratory neurones can differ across 
respiratory neurone populations, depending on co-expression levels of GIRK channels. 
Differential responses to 5-HT1AR agonism on the basis of distinct 5-HT1AR and GIRK 
channel co-expression profiles between respiratory subpopulations is a feature of 
multiple computational modelling studies that explore potential mechanisms underlying 
the network responses to systemic 5-HT1A (Shevtsova et al., 2011, Wittman et al., 2019). 
However, the distribution of 5-HT1AR and GIRK channels across neurons of distinct 
functional subpopulations is yet to be experimentally established. 
A second mechanism that may contribute to differential responses to 5-HT1AR agonism 
across respiratory subpopulations is potentiation of Glyɑ3R inhibitory currents. 5-HT1A 
agonism is reported to augment glycine-activated inhibitory Cl- currents in HEK293 cells 
co-expressing 5-HT1AR and Glyα3 receptors (Manzke et al., 2010). Pharmacological 
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evidence for the involvement of glycinergic transmission in the respiratory response to 5-
HT1A transmission (Manzke et al., 2009, Manzke et al., 2010), as well as histological 
evidence for the presence of Glyα3R in the VRC  (Manzke et al., 2009, Manzke et al., 2010) 
has been addressed in the introduction to this chapter (section 5.1.1). It is plausible that 
neuromodulatory effects of 5-HT1AR transmission can result in enhanced glycinergic 
inhibition at select respiratory subpopulations, depending on 5-HT1AR and Glyα3R co-
expression and the nature of afferent glycinergic innervation. The pattern of enhanced 
inhibition in response to 5-HT1AR agonism would be dependent on the pattern of glycine 
release from afferent projections to the co-expressing neurons. Differential responses to 
5-HT1AR agonism based on distinct 5-HT1AR and Glyα3R channel co-expression profiles, as 
well as distinct patterns of glycinergic afferent input, has previously been suggested as an 
important mediator of inhibition of select respiratory subpopulations in response to 
systemic 5-HT1AR agonism (Shevtsova et al., 2011). However, the distribution of 5-HT1AR 
and Glyα3R co-expression across respiratory subpopulations, as well as the pattern of pre-
synaptic glycine release in co-expressing neurons, is yet to be experimentally established. 
The third mechanism involves 5-HT1AR mediated modulation of voltage gated Ca2+ 
currents, thereby modulating a neurone’s discharge properties. Influx of Ca2+ can 
depolarize the neurone and promote burst activity. However, Ca2+ also influences multiple 
calcium-dependent intracellular processes, and elevated internal concentration of Ca2+ 
triggers second messenger cascades that act as a negative feedback loop and promote 
reduction of Ca2+ influx, Ca2+ efflux, and Ca2+ buffering. The consequent decline in 
intracellular Ca2+ concentrations promotes a periodic refractory cessation of burst activity 
(Catterall, 2011). 5-HT1AR transmission can inhibit voltage gated Ca2+ channel activity 
mediated by G protein βγ subunit (Bayliss et al., 1997b, Chen and Penington, 1996). In 
hypoglossal motorneurones in acute brainstem slices of neonatal mice, activation of 
5HT1A receptors with 8-OH-DPAT substantially down-regulated voltage evoked Ca2+ 
signals without a significant impact on basal Ca2+ concentrations (Ladewig et al., 2004). 
High-voltage activated Ca2+ and Ca2+ dependent K+ currents are suggested to be important 
mediators of intrinsic adaptive properties (incrementing and decrementing burst 
patterns) of respiratory neurones in the VRC, notably the Aug-E, Post-I and Early-I 
subpopulations (Molkov et al., 2010, Rubin et al., 2009, Rybak et al., 2007, Smith et al., 
2007). It is conceivable that 5-HT1AR mediated inhibition of voltage gated calcium currents 
can affect adaptive properties of respiratory neurones, likely promoting neural excitation 
at small currents, followed by cessation of activity (i.e. shortening of burst duration) at 
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larger currents. 5-HT1AR transmission may evoke Ca2+ responses and corresponding 
changes in excitability that are different across subpopulations of respiratory neurones, 
as a function of differential co-expression levels of 5-HT1AR and voltage gated Ca2+ 
channels across subpopulations. Additionally, emergent network drives can result in 
differential susceptibility to 5-HT1AR mediated changes in Ca2+ signalling between neurone 
subpopulations. For example, in some populations, early suppression of burst activity by 
inhibitory input can pre-empt potential effects of Ca2+ signalling, whereas populations 
with longer burst durations may be more susceptible to changes in excitability due to 
effects of 5-HT1AR transmission on Ca2+ signalling.  
To conclude, differential recruitment of each of the three mechanisms discussed above 
can potentially differentiate respiratory neurone subpopulations and their responses to 
5-HT1AR agonism in ways not reflected by 5-HT1AR distribution alone. To the best of my 
knowledge, the potential for differentiation of respiratory subpopulations by distinct 
recruitment of each of the above mechanisms in response to 5-HT1A agonism remains to 
be experimentally explored. 
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Chapter 6: GENERAL DISCUSSION 
6.1 OVERARCHING THESIS AIMS, HYPOTHESES, AND RESULTS 
6.1.1 Thesis aims and hypotheses 
The overarching aim of this thesis is to establish the effects of systemic administration of 
selective 5-HT1AR agonist (NLX-101) on eupnoeic respiratory activity, as well as on 
modulation of respiratory and sympathetic activity in response to activation of 
homeostatic respiratory reflexes, as established in the intact respiratory CPG network in 
in situ WHBP of juvenile rats. In addition, this thesis aims to contribute to establishing the 
network interactions that underlie the respiratory and sympathetic responses to systemic 
administration of 5-HT1AR agonist NLX-101. The overarching hypothesis was that systemic 
administration of selective 5-HT1AR agonist would result in net enhanced respiratory 
drives that are determinant of ventilation. The homeostatic respiratory reflexes 
investigated were the responses to hypercapnia, as well as the responses to peripheral 
chemoreceptor activation by intra-arterial bolus administration of NaCN solution. 
Although systemic 5-HT1AR agonism was thought to attenuate the hypercapnic response, 
respiratory and sympathetic hypercapnic responses were hypothesised to be unaffected 
by systemic administration of NLX-101. This was because the attenuation of the 
hypercapnic response was thought to be mediated by 5-HT1AR auto-receptor 
transmission, and NLX-101 is thought to exert functional bias for hetero-receptors (see 
section 1.3.2). Systemic 5-HT1AR antagonist WAY-100635 was hypothesised to potentiate 
the respiratory and sympathetic hypercapnic responses. Respiratory and sympathetic 
responses to activation of peripheral chemoreceptors were hypothesised to be 
attenuated by systemic administration of NLX-101. Descriptive mapping of the 
distribution of 5-HT1A R RNA and SLC32A1 RNA (co-)expression was performed throughout 
key regions of the respiratory CPG. In addition, responsiveness to juxtacellular pico-
ejection of NLX-101 was established at the level of individual neurones to explore the 
distribution of 5-HT1AR across functionally defined subpopulations of respiratory 
neurones in the VRC.  
6.1.2 Thesis results 
Data presented in this thesis revealed that systemic administration of 5-HT1AR agonist 
NLX-101 in in situ WHBP of rats resulted in a significant increase in respiratory rate, 
chiefly due to a shortening to equal extent of Post-I and E2 phase durations. This effect 
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on respiratory rhythm can be interpreted as reduced activity of expiratory-, relative to 
inspiratory rhythmogenic neurone populations. In addition, systemic NLX-101 promoted 
enhanced late-E activity under eucapnic normoxic conditions, reflected in a significant 
increase in AbN late-E amplitude (μV).  
Respiratory pattern parameters (normalised burst envelopes and peak amplitudes of 
integrated activity) were significantly increased in motor output obtained from the PN 
and AbN, but not in cVN and HN motor output. Respiratory and sympathetic responses 
to hypercapnia were unaffected by systemic administration of NLX-101 or 5-HT1AR 
antagonist WAY-100635 compared to vehicle controls. Similarly, respiratory, and 
sympathetic responses to peripheral chemoreceptor activation were unaffected by 
systemic administration of NLX-101 compared to vehicle controls.  
Anatomical mapping of 5-HT1AR RNA and SLC32A1 RNA in key brainstem regions of 
respiratory control in rat revealed that 5-HT1AR expression occured in both SLC32A1 RNA 
positive (i.e. glycinergic and/or GABAergic) and SLC32A1 negative neurones across all 
imaged respiratory regions of the brainstem. Extracellular recordings of functionally 
identified respiratory neurones of the VRC, combined with juxtacellular pico-ejection of 
NLX-101 indicated that most of the recorded respiratory subpopulations contained 5-
HT1AR expressing neurones. Specifically, NLX-101 responsive neurones were observed 
among VRC populations with Ramp-I, Post-I/Dec-E, Pre-I/I, and Early-I discharge 
patterns. Four Aug-E neurones were recorded of which none were responsive to NLX-
101 pico-ejection. However previous studies with anesthetised cats had shown that 
juxtacellular electrophoresis of 5-HT1A/7 agonist 8-OH-DPAT in anesthetised cats resulted 
in inhibition of these neurones too (Lalley et al., 1994). Therefore, 5-HT1AR expression is 
likely not selective to neurones of any specific functional phenotypes as identified by 
discharge pattern relative to the respiratory cycle. 
6.2 PUTATIVE MECHANISMS CONTRIBUTING TO NETWORK EFFECTS OF SYSTEMIC 
5-HT1AR  AGONISM 
The present section will present hypotheses, along with further considerations, regarding 
mechanisms putatively contributing to the network response to systemic 5-HT1AR 
transmission. 
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6.2.1 General considerations regarding mechanisms contributing to the network 
response to systemic 5-HT1AR transmission.  
When considering candidate mechanisms that could underlie the net effect of systemic 
5-HT1A transmission on respiratory control, there are a few things one must keep in mind. 
First, respiratory subpopulations of the CPG are thought to be interconnected in the 
fashion of a half-centre oscillator, with reciprocal inhibitory functional relationships 
between neural populations associated to each respiratory phase (see section 1.2.3) 
(Rybak et al., 2007, Smith et al., 2007, Rubin et al., 2009, Molkov et al., 2010). Enhanced 
inspiratory activity is paired with suppression of Post-I and Aug-E activity, and vice versa. 
Therefore, a relative reduction of expiratory activity, as observed in the present thesis, 
could be mediated by both excitation or disinhibition of inspiratory neurones (an indirect 
effect of 5-HT1AR agonism), as well as by inhibition or reduced excitation of expiratory 
neurones (a direct effect of 5-HT1A transmission). Second, at the cellular level, the effect 
of 5-HT1AR activation on neural excitability can differ among distinct populations, 
depending on the extent to which various intracellular mechanisms are recruited upon 
receptor activation. The (co-)expression levels of 5-HT1AR with GIRK channels, with voltage 
gated Ca2+ channels, and with Glyα3R are notable factors by which the cellular response 
to 5-HT1AR agonism may differ among various neurone populations (see section 5.4.3). 
Third, given the broad expression of 5-HT1AR across key regions of the respiratory CPG, as 
well as among respiratory neurone functional subtypes in the VRC, multiple candidate 
mechanisms could contribute to the network effect of systemic 5-HT1AR agonism with 
NLX-101. The observed network effect of systemic administration of NLX-101 is likely 
mediated by simultaneous recruitment of multiple mechanisms that have both direct and 
indirect effects within the network. The multitude of possible effects at the cellular level, 
as well as at the circuit level, underscores the value of exploring and refining hypotheses 
in the network context through computational modelling simulations. Therefore, 
hypotheses presented in the subsequent sections could be evaluated and refined in the 
more comprehensive network context of the inhibitory ring model in future collaborative 
in silico studies. 
6.2.2 Putative mechanisms contributing to augmented respiratory rate through 
shortening of expiratory phase duration.  
Increased respiratory rate combined with a trend of reduced expiratory phase duration 
suggests a reduction in activity of expiratory VRC neurone populations (concentrated in 
the BötC) relative to inspiratory VRC neurone populations (concentrated in the pre-BötC). 
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Absence of changes in cVN Post-I duty cycle indicates that the shortening of expiratory 
phase duration is mediated by shortening of Post-I and E2 phase durations to roughly 
equal extent. Under the half-centre oscillator paradigm (see section 1.2), this corresponds 
to a reduction in activity of Post-I and Aug-E neurones relative to inspiratory neurones. 
Although inspiratory and expiratory rhythmogenic neurone populations are thought to be 
concentrated in the BötC and pre-BötC of the VRC, they are (often reciprocally) connected 
with respiratory neurones in other brainstem regions. Important sources of inhibitory and 
excitatory drive to the VRC include neurones in the PBc, the pFRG expiratory oscillator, 
central chemoreceptors (in the RTN and raphe nuclei), and peripheral chemoreceptors 
(relayed via the NTS) (see sections 1.2 -1.5) (Koizumi et al., 2013, Smith et al., 2007). Thus, 
the balance between expiratory and inspiratory activity is shaped by VRC microcircuitry 
interactions, but also by inputs from other populations in the CPG to the VRC. The present 
section proposes two mechanisms that may contribute to changes in drive to VRC 
subpopulations in a manner consistent with the increased respiratory rate and shortening 
of expiratory phase durations observed in response to systemic 5-HT1AR transmission.  
Enhanced respiratory drive through disinhibition of inspiratory populations 
The first mechanism suggested to contribute to an enhanced respiratory rate and a 
shortening of expiratory phase duration in response to systemic 5-HT1A transmission 
involves disinhibition of inspiratory neurones in the pre-BötC that receive central 
chemoreceptor drive. As addressed in the discussion of chapter 3 (section 3.4.3), the 
respiratory behaviour in response to systemic NLX-101 resembles respiratory activity 
under hypercapnic conditions. The similarities include the increase in respiratory rate and 
pattern, along with the emergence of late-E (Abdala et al., 2009, Marina et al., 2010). In 
the hypercapnic response, increased respiratory rate and pattern is thought to be 
mediated by enhanced excitatory drive from RTN chemoreceptor neurones to inspiratory 
neurones in the pre-BötC (Yang et al., 2020, Huckstepp et al., 2015, Zoccal et al., 2018, 
Ikeda et al., 2019, Guyenet et al., 2019). NLX-101 does not affect the hypercapnic 
response. Therefore, increase in rate and pattern in restful respiratory activity observed 
after systemic administration is likely not mediated by modulation of chemoreceptor 
neurones. However, it is possible that NLX-101 promotes increased respiratory rate and 
pattern through disinhibition of pre-BötC inspiratory neurones downstream of central 
chemoreceptors. This scenario would be consistent with the resemblance of the response 
to NLX-101 to the hypercapnic response in the absence of changes in chemoreceptor 
output. Given the relative reduction of expiratory activity observed in the present thesis, 
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along with the high levels of 5-HT1A RNA and SLC32A1 RNA co-expressing neurones in the 
BötC (26.2% of analysed neurones in region) and pre-BötC (32.7%), I propose that 5-HT1AR 
mediated suppression of expiratory populations in the VRC is a plausible contributor to 
disinhibition of inspiratory neurones downstream from chemoreceptors. Whether 
systemic administration of 5-HT1AR agonist does indeed promote disinhibition of 
inspiratory neurones downstream of central chemoreceptors, and whether this is 
mediated by inhibition of GABAergic and/or glycinergic expiratory populations, remains 
to be experimentally verified.  
The notion of enhanced respiratory drive through inhibition of expiratory activity is also 
consistent with the finding that 5-HT1A transmission can counteract opioid induced 
respiratory depression. Systemic administration of opioids can result in suppression of 
respiratory activity (Dahan et al., 2018). (see section 1.8.1). This respiratory suppression 
is thought to be mediated by μ-opioid receptor (μOR) mediated inhibition of inspiratory 
neurone populations in the pre-BötC (Gray et al., 1999, Montandon et al., 2011, Manzke 
et al., 2003, Varga et al., 2020) (Gray 1999, Montandon 2011, Manzke 2003, Varga 2020) 
and the KF (Levitt, 2020, Levitt et al., 2015, Varga et al., 2020). 5-HT1AR agonism is 
observed to rescue respiratory activity that was suppressed by μOR agonism in rats 
(Manzke et al., 2009, Shevtsova et al., 2011, Guenther et al., 2012, Ren et al., 2015). This 
suggests that 5-HT1A can restore the balance between inspiratory- and expiratory activity 
after initial suppression of inspiratory activity. Given that in our experiments, the increase 
in respiratory rate appears largely mediated by a shortening of expiratory phase duration, 
it is possible that inhibition of expiratory populations contributes to disinhibition of 
inspiratory populations and thereby counteracts μOR induced respiratory depression. 
Thus, 5-HT1AR mediated recovery from μOR induced respiratory depression is consistent 
with the notion of 5-HT1A mediated increases in respiratory drive through inhibition of 
expiratory activity, and consequent disinhibition of inspiratory activity.   
Inhibition of BötC Post-I neurones through 5-HT1a mediated suppression of KF neurones. 
A second hypothetical mechanism that could contribute to increased respiratory rate 
through shortening of expiratory phase durations in response to systemic 5-HT1AR 
agonism involves reduction of excitatory drive from KF neurones to glycinergic BötC Post-
I neurones.  
Periodic apnoeas In Rett syndrome are associated with exacerbation of Post-I activity 
(Stettner et al., 2007, Abdala et al., 2010). Systemic administration of 5-HT1AR agonists can 
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alleviate respiratory dysrhythmia in MeCP2 deficient mouse models of Rett syndrome, 
and it has been suggested to do so through corrective suppression of Post-I activity 
(Abdala et al., 2014a, Wittman et al., 2019) (see sections 1.8.2 and 3.4.3). In the discussion 
of Chapter 3 (section 3.4.3), it was suggested that the increased respiratory rate through 
shortening of expiratory phase duration after systemic administration of NLX-101 may be 
in part mediated by 5-HT1AR-mediated suppression of Post-I activity. Post-I activity is 
thought to depend on excitatory drive from the KF to BötC Post-I neurones (Song et al., 
2015, Molkov et al., 2013) (see section 1.3.2). Post-I activity can be prolonged through 
pharmacological excitation or disinhibition of neurones in the KF (Abdala et al., 2016, 
Barnett et al., 2018, Bonis et al., 2013, Dutschmann and Herbert, 2006) and suppressed 
through pharmacological inhibition of the KF (Dutschmann and Herbert, 2006, Jenkin et 
al., 2017, Levitt et al., 2015). Exacerbated Post-I activity in RTT syndrome has been 
suggested to be caused, at least in part, by deficits in synaptic inhibition in the KF (Abdala 
et al., 2016). Indeed, focal administration of 5-HT1AR agonist in the KF (Abdala et al., 
2014b) depressed respiratory apnoea in in situ WHBP of MeCP2 deficient mice. 
Conversely, systemic administration of 5-HT1AR antagonist (WAY-100635) promoted 
central apnoeas in in situ WHBP of WT mice, and this effect is recapitulated by focal 
administration of WAY-100635 in the KF (Dhingra et al. 2016). These findings suggest that 
5-HT1A transmission in the KF mediates Post-I activity in MeCP2 deficient and WT mice, 
presumably through attenuation of excitatory drive from the KF to BötC Post-I neurones 
(Abdala et al., 2014a, Wittman et al., 2019). 
In the present thesis, I observed significant increases in respiratory rate, mediated to 
equal extent by a shortening of Post-I and E2 phase durations, after systemic 
administration of 5-HT1AR agonist NLX-101. Chapter 4 shows relatively high expression of 
5-HT1AR RNA (43.1% of all analysed neurones) in neurones of the KF, the majority of which 
are SLC32A1 negative (not GABAergic, nor glycinergic) neurones (35.7% of all analysed 
neurones, 82.8% of 5-HT1A R RNA positive neurones). These findings are consistent with 
the notion that 5-HT1AR mediated suppression of the KF results in inhibition of Post-I 
activity. I propose that 5-HT1AR mediated suppression of neurones in the KF results in a 
reduction of excitatory drive from the KF to BötC Post-I neurones, and that this 
mechanism contributes to the enhancement of respiratory rate through shortening of 
expiratory phase duration observed after systemic administration of NLX-101. 
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6.2.3 Putative mechanisms contributing to the emergence of late-E 
Systemic administration of 5-HT1AR agonist NLX-101 promoted enhanced late-E activity 
under eucapnic normoxic conditions, reflected in a significant increase in AbN late-E 
amplitude (μV). Emergence of AbN (and tSN) late-E bursts is driven by a release from 
inhibition of late-E neurones in the pFRG expiratory oscillator. In hypercapnic conditions, 
AbN and tSN late-E is thought to emerge as a result of enhanced excitatory 
chemoreceptor drive to the pFRG, by which pFRG late-E neurones can overcome their 
inhibitory inputs. Based on the absence of effects on chemoreflex responses, I assume 
that systemic administration of NLX-101 does not affect chemoreceptor output. The pFRG 
contains glutamatergic neurons (Onimaru et al., 2008) and lacks inhibitory neurons 
(Ellenberger, 1999, Stornetta and Guyenet, 1999, Tanaka et al., 2003). Therefore, I 
propose that the emergence of AbN late-E activity in response to NLX-101 is likely 
mediated by 5-HT1AR mediated suppression of distal inhibitory inputs to the pFRG, rather 
than through enhanced chemoreceptor drive (see section 3.4.3) or through suppression 
of local inhibitory interneurons.  
Injection of retrograde tracers at the pFRG expiratory oscillator resulted in labelling of 
GABAergic and 5-HT neurones in the RMg and ROb (Silva et al., 2020). Selective lesioning 
of 5-HT neurones in the RMg or ROb through local micro-injections with Saporin did not 
affect the hypercapnic late-E response observed at abdominal EMG (AbdEMG) recordings 
in anesthetised rats. Subsequent focal administration of GABAA agonist (muscimol) 
potentiated the amplitude of AbdEMG late-E activity under hypercapnic conditions (Silva et 
al., 2019). The hypercapnic stimulus applied was strong (9-10% CO2) and resulted in late-
E activity at every respiratory cycle, this saturation of the late-E rate meant that potential 
increases in late-E rate could not be established. Nevertheless, these findings indicate that 
GABAergic neurones in the RMg and ROb project to the pFRG expiratory oscillator, and 
that their inhibition results in disinhibition of abdominal late-E activity.  
A similar set of experiments revealed that GABAergic neurones in the commissural part 
of the NTS (NTScomm) also project to the pFRG expiratory oscillator. Inhibition of these 
neurones resulted in a tonic increase in AbdEMG activity in anesthetised rats (Silva et al., 
2019). FISH experiments in the present thesis (Chapter 4) show that 5-HT1AR RNA was 
expressed in SLC32A1 RNA positive (GABAergic and/or glycinergic) neurones of the RMg 
(22.5% of all analysed RMg neurones), the ROb (30.8%), as well as the NTScomm (27.6%). 
It is possible that systemic 5-HT1A transmission promoted disinhibition of the pFRG 
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through inhibition of the RMg, ROb, and/or NTScomm GABAergic neurones described in 
Silva et al. (2020,2019).  
A fourth source of inhibitory drive to the pFRG are glycinergic Post-I neurones in the BötC. 
Optogenetic inhibition, via selective expression of a light-sensitive inhibitory Cl- channel 
(eNpHR3.0) at glycinergic neurones of the BötC, during the post-I phase, evoked 
generation of late-E abdominal nerve activity in in situ WHBP of rats. In contrast, 
optogenetic excitation of glycinergic BötC neurones via a light-sensitive cation channel 
(ChETA) during the post-I phase suppressed late-E abdominal nerve activity in hypercapnic 
conditions (Moraes et al., 2014a). In the same in situ preparations, intracellular recordings 
of pFRG late-E neurones confirmed that inhibitory input during the post-I phase prevents 
generation of late-E neurone activity under eucapnic conditions (Moraes et al., 2014a). 
Given the evidence in support of 5-HT1A mediated suppression of Post-I activity (see 
section 6.2.2), it is possible that systemic administration of NLX-101 promotes 
suppression of Post-I activity, which in turn results in disinhibition of the pFRG, and 
thereby promotes emergence of late-E activity.  
Going one step further, given the role of 5-HT1A transmission in the KF in the emergence 
of Post-I activity as evidenced by RTT research (see section 6.2.2), it is plausible that 
suppression of the KF is one mechanism by which systemic administration of NLX-101 can 
promote disinhibition of late-E activity. The notion of such interactions between the KF, 
BötC Post-I neurones, and the-pFRG expiratory oscillator is supported by pharmacological 
evidence that suppression of the KF promotes both suppression of Post-I activity and 
emergence of late-E activity (Jenkin et al., 2017). Conversely, pharmacological 
disinhibition of the KF increases cVN Post-I activity and suppresses the emergence of late-
e activity under hypercapnic conditions (Barnett et al., 2018) (see section 1.4.4, figure 1-
5). Thus, 5-HT1A mediated suppression of Post-I activity can suppress inhibitory input from 
glycinergic post-I neurones to the pFRG expiratory oscillator and thereby promote late-E 
activity. This hypothesis is in line with mechanisms previously suggested to contribute to 
enhanced respiratory rate through suppression of expiratory (Post-I) activity in response 
to systemic 5-HT1A transmission (section 6.2.2).  
6.2.4 Putative mechanisms contributing to augmented respiratory pattern in 
select motor nerves 
The respiratory pattern was significantly augmented in PN, and AbN motor outputs.  
Cervical vagus nerve and HN motor output, on the other hand, remained unaffected. 
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Further, respiratory pattern was increased throughout all respiratory phases, even if 
phase durations were suppressed. Given that respiratory pattern was augmented in only 
a subset of motor nerves (PN and AbN) yet throughout all respiratory phases and 
irrespective of changes in rhythm, the pattern enhancement may be predominantly 
mediated at the level of PN and AbN pre-motor and motor regions rather than in 
rhythmogenic circuitry. The mechanism by which Inhibitory 5-HT1A transmission could 
hypothetically induce augmented pattern in motor outputs would be disinhibition of 
motor or (excitatory) pre-motor neurones.  
To the best of my knowledge, there is presently little evidence to test the notion of 5-HT1A 
disinhibition of PN or AbN (pre-)motor neurones. However, Silva et al. (2019) revealed 
that suppression of GABAergic projections from the NTS to the pFRG promoted tonic 
excitation of AbN output. This is potentially reflective of disinhibition of excitatory AbN 
pre-motor neurones. FISH experiments in the present thesis (chapter 4) do not exclude 
the possibility of 5-HT1A mediated disinhibition of (pre-)motor neurones, as there is 5-
HT1AR RNA and SLC32A1 co-expression throughout all imaged brainstem regions involved 
in respiratory control (including: (pre-)motor respiratory regions (N10, N12, N. Amb. C., 
XII premotor neurones); VRC transmission cicuits (RVRG); and the NTS). It must be noted 
that the distribution of 5-HT1AR RNA and SLC32A1 RNA specifically in PN and AbN motor 
nuclei is, to the best of my knowledge, not yet established. Nonetheless, given that 
systemic administration of NLX-101 resulted in increased peak amplitudes and burst 
envelopes in the integrated respiratory motor output of some, but not all nerves, and in 
a fashion irrespective of respiratory phases, it is conceivable that systemic 5-HT1A 
transmission promoted enhanced pattern through disinhibition of (pre-)motor activity. 
Whether this is the case remains to be experimentally verified.  
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6.2.5 Interpretation of absence of effect on chemoreflex responses 
Activity of central chemoreceptors is likely not affected by systemic 5-HT1AR agonism.  
I did not see an effect of systemic NLX-101 or WAY-100635 on the respiratory and 
sympathetic response to hypercapnia. These findings contrast with previous studies in 
which systemic administration of 5-HT1A/7R agonist (8-OH-DPAT) results in a loss of the 
hypercapnic respiratory response in in situ WHBP of juvenile rats (Corcoran et al., 2013). 
Further, focal administration of 8-OH-DPAT in the RPa or RMg attenuated the hypercapnic 
response in conscious rats (Li et al., 2006), yet focal administration of 5-HT1AR antagonist 
and D4 receptor agonist (WAY-100635) in the LC also attenuated the hypercapnic 
response in anesthetised rats (de Souza Moreno et al., 2010). The latter studies suggest 
physiologically antagonistic contributions of 5-HT1AR transmission in distinct brainstem 
regions to the hypercapnic response.  
Differences in the animal models and experimental designs used (anesthetised rats in vivo 
vs. unanaesthetised in situ WHBP of rats; focal administration vs. systemic administration; 
5HT1A/7R agonism vs. 5-HT1AR agonism) do not permit direct comparisons between the 
above studies and experiments in the present thesis. I cannot exclude the possibility of 
simultaneous recruitment of physiologically antagonistic mechanisms that cancel out 
potential effects of 5-HT1AR transmission on the hypercapnic network response. However, 
compensatory effects downstream of central chemoreceptor effects can be expected to 
selectively modulate certain hypercapnic response activities and leave others unaffected. 
In light of this, the absence of effects after systemic selective 5-HT1AR agonist (NLX-101) 
as well as after systemic 5-HT1AR antagonist (WAY-100635), observed in all analysed 
hypercapnic respiratory and sympathetic activities of unanaesthetised in situ WHPB of 
rats, suggests that output of central chemoreceptors is not affected by systemic 5-HT1A 
transmission.  
Absence of effect of NLX on the hypercapnic response can be attributed to biased 
agonism, and/or to absence of 5-HT1AR at central chemoreceptors. 
Previous studies suggest that raphe serotonergic neurons with intrinsic CO2 
chemosensitivity are exclusively expressed in Erg2-Pet1 neurones from rhombomeric 
lineage r3 and r5, the anatomical location of these populations corresponds to the caudal 
part of the dorsal raphe, and the caudal parts of raphe magnus and raphe pallidus nuclei 
(Brust et al., 2014). A population of (presumed not intrinsically) CO2 chemosensitive 5-HT 
neurons that also contributes to hypercapnic respiratory response was identified in the 
Raphe Obscurus (Hennessy et al., 2017) (see section 1.4.2). RTN neurones are also thought 
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to act as CO2 chemoreceptors (Guyenet et al., 2019) (see section 1.4.1). FISH experiments 
presented in Chapter 4 show that 5-HT1AR RNA positive neurones were present in each of 
the above anatomical regions (54% of RMg, 48% of RPa, 41.1% of Rob, and 19.3% of 
pFV/RTN neurons were 5-HT1AR RNA positive). The 5-HT1AR RNA positive neurones were 
not functionally or biochemically identified as chemoreceptors, but the possibility of 
5-HT1AR expression in CO2 chemoreceptor neurones cannot be excluded based on the 
anatomical distribution of 5-HT1AR RNA alone. Of further note, previous studies reported 
that 5-HT1AR RNA is present in cytosol of isolated glomus cells from CB’s of rats (Yokoyama 
et al., 2015). These glomus cells were responsive to reductions in pO2. Given that glomus 
cells are thought to specialize in either CO2 or O2 sensitivity (Lu et al., 2013) (see section 
1.5.1), it is plausible that the 5-HT1A expressing cells reported in this study are not CO2 
chemoreceptors.  
It is possible that 5-HT1AR are present as auto-receptors in raphe chemoreceptor or 
chemosensitive neurones, but that these are not potently recruited by NLX-101 due to its 
potential functional bias for hetero-receptors over auto-receptors. One indication that 
NLX-101 might inhibit raphe serotonergic neurones comes from (Levitt et al., 2013), who 
report that bath application of NLX-101 (1μM) hyperpolarizes dorsal raphe neurones in a 
manner consistent with GIRK channel activation as observed through whole cell 
recordings in acute brain slices of mice. FISH experiments in the present thesis showed 
that 5-HT1AR expressing neurones were highly prevalent in the dorsal raphe (73.6% of all 
analysed neurones, see section 4.3.5). The phenotype of neurones recorded by Levitt et 
al. was not verified, but it is possible that the recorded neurones were serotonergic, and 
that 1μM NLX-101 can indeed hyperpolarize raphe serotonergic neurones via activation 
of 5-HT1A auto-receptors. However, the dose use by Levitt et al. (2013) was high (1μM), 
given that NLX-101 is active at nanomolar range in vitro (Newman-Tancredi et al., 2009), 
and the presumed functional hetero-receptor bias of NLX-101 is dependent on 
concentration (Llado-Pelfort et al., 2010). It is therefore possible that NLX-101 stimulates 
5-HT1A auto-receptors at 1μM, but not at the dose applied in hypercapnic response 
experiments of the present thesis (10nM). 
To conclude, absence of effect on the hypercapnic response after systemic NLX-101 could 
be attributed to absence of expression of 5-HT1AR at chemoreceptor populations, in raphe 
regions as well as in the RTN and CB’s and/or to failure of NLX-101 (10nM) to inhibit raphe 
serotonergic chemoreceptor neurones because of functional hetero-receptor bias. 
However, either possibility remains to be experimentally verified.   
Chapter 6: General Discussion 
224 
 
Effects of 5-HT1AR transmission on peripheral chemoreflex sympatho-respiratory 
responses 
Based on previous reports of 5-HT1AR RNA in cytosol of O2 chemosensitive isolated glomus 
cells from rats (Yokoyama et al., 2015), I hypothesized that the peripheral chemoreceptor 
response would be attenuated after systemic administration of NLX-101 in in situ WHBP. 
One explanation for the absence of effect is that the effects of 5-HT1A transmission on 
intracellular mechanisms in these cells does not substantially change responsiveness to 
reductions in pO2 in these cells. However, here too, I cannot exclude the possibility that 
that O2 chemoreceptor responses are indeed affected, but that compensatory 
mechanisms occur downstream of the glomus cells. For instance, disinhibition of second 
order chemosensitive neurones of the NTS could theoretically compensate for the 
reduced activity of CB chemoreceptor neurons. FISH experiments in chapter 4 showed 
that 55.9% of all analysed cells in the commissural part of the NTS express 5-HT1AR, 
indicating that inhibition of second order peripheral chemoreceptor neurones in the NTS 
is a possibility. Effects of 5-HT1AR transmission at brainstem respiratory neurones involved 
in the peripheral chemoreflex responses remain to be experimentally established.   
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6.3 CONCLUSIONS  
Based on converging evidence from the present thesis, research on the respiratory 
hypercapnic response, RTT research, and research on μOR induced respiratory 
depression, I propose that the network effect of systemic 5-HT1A transmission constitutes 
a shift in the balance between activity of inspiratory and expiratory neural populations in 
favour of the former. The broad expression of 5-HT1AR across respiratory regions and 
functional subpopulations of VRC respiratory neurones indicates that the effect of 
systemic 5-HT1A transmission on respiratory activity is likely not mediated by a single 
subset of neurones and mechanisms. Rather, the effect is an emergent network effect 
mediated by action at multiple neurone populations and mechanisms throughout the 
respiratory network. I propose that the following mechanisms provide key contributions 
to the effect of systemic 5-HT1A transmission. First, systemic 5-HT1A transmission 
promotes enhanced respiratory rate and pattern via disinhibition of inspiratory VRC 
populations downstream of chemoreceptors. Second, systemic 5-HT1A transmission 
suppresses expiratory activity via attenuation of excitatory drive from the KF to BötC Post-
I neurones. Third, systemic 5-HT1A transmission promotes emergence of late-E activity via 
attenuation of inhibitory drive to the pFRG expiratory oscillator. Ultimately, based on the 
absence of effect of systemic administration of NLX-101 on chemoreflex responses, I 
hypothesise that systemic administration of NLX-101 does not affect central and 
peripheral chemoreceptor function.  
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6.4 FUTURE DIRECTIONS  
6.4.1 Multilevel computational modelling can aid formulation of hypotheses and 
determine optimal strategy for future experimental studies. 
The multitude of possible responses to systemic administration of NLX-101 at the cellular 
level, as well as at the circuit level, illustrates the importance of exploring and refining 
hypotheses in the network context through computational modelling simulations. 
Therefore, hypotheses presented in this thesis are best refined and evaluated in silico in 
a context that incorporates possible direct and indirect effects at the cellular and circuit 
level.  
Currently, the most comprehensive theory of respiratory CPG network architecture is 
presented in the inhibitory ring model. This is a multilevel computational model that 
incorporates detailed biophysical properties and ion channel kinetics of individual 
neurones (modelled in Hodgkin-Huxley style) as well as population dynamics (each 
population represented by 20 to 50 neurones) (Molkov et al., 2010, Rubin et al., 2009, 
Rybak et al., 2007, Smith et al., 2007). The inhibitory ring model is able to reproduce in 
silico experimental observations of the eupnoeic three-phase respiratory rhythm, 
respiratory reflex responses, and specific experimental manipulations (e.g. transections 
and pharmacological manipulations) (Molkov et al., 2010, Rubin et al., 2009, Rybak et al., 
2007, Smith et al., 2007, Barnett et al., 2016, Barnett et al., 2018). The major weakness of 
any computational model is that it relies on assumptions to fill in the gaps of knowledge. 
I do not know the full connectivity and phenotype characteristics of 5-HT1AR expressing 
neurones, nor do I know whether and how 5-HT1AR transmission differentially affects 
intracellular mechanisms across distinct neural populations. It is likely that multiple 
configurations of the model can reproduce in silico the results of systemic 5-HT1AR 
transmission described in the present thesis. Nonetheless, computational modelling 
simulations can help to guide the focus for future experimental efforts aimed at 
experimental verification of such gaps in knowledge. 
With the ultimate aim to experimentally establish the key mechanisms underlying 
network effects of systemic 5-HT1A transmission, the next step will be an in silico 
evaluation of the hypotheses presented in the present thesis in the context of the 
inhibitory ring model.  
  
Chapter 6: General Discussion 
227 
 
6.4.1 Experimental strategies for testing of thesis and modelling hypotheses  
Based on the previous literature, one can ascribe specific functional contributions of 
neurone populations in distinct anatomical brainstem regions to the generation of 
respiratory activities. For example, expiratory neurone populations (Post-I/Dec-E, Aug-E) 
are concentrated in the BötC, whereas inspiratory neurones (Pre-I/I, Early-I, Ramp-I) are 
concentrated in the pre-BötC (see section 1.2.3). Further, activity of auto-rhythmic 
excitatory neurones in the pFRG drives AbN and tSN late-E activity (Pagliardini et al., 2011, 
Abdala et al., 2009, Huckstepp et al., 2015). Inhibitory neural populations in the NTS (Silva 
et al., 2019), the RMg and ROb (Silva et al., 2020), and the BötC (Moraes et al., 2014a) are 
thought to modulate to late-E activity via projections to the pFRG. Excitatory neurones in 
the KF region are thought to project to inhibitory Post-I neurones in the BötC, and to 
indirectly modulate the latter’s inhibitory drive to pFRG late-E activity (see section 6.2.3). 
These findings facilitate experimental strategies to test hypotheses on the contributions 
of 5-HT1AR transmission in specific functional-anatomical regions to the network response 
to systemic 5-HT1AR transmission. 
One such experimental strategy is to perform focal micro-injections of 5-HT1AR agonist 
(NLX-101) in specific brainstem regions of respiratory control and monitor respiratory 
motor outputs via electrophysiological recordings of peripheral nerves and neural 
populations in in situ WHBP of rats. For example, the hypothesis that 5-HT1AR mediated 
inhibition of expiratory BötC neurones promotes enhanced respiratory rate (see section 
6.2.2) and late-E activity (see section 6.2.3) could be experimentally tested by focal 
microinjection of NLX-101 in the BötC while monitoring respiratory motor outputs (e.g. in 
PN, cVN, and AbN). Similarly, the hypotheses that 5-HT1AR agonism at (non-serotonergic) 
neurones of the RMg and RPa, at neurones in the NTS, and/or at KF neurones contributes 
to disinhibition of late-E activity can be tested via focal micro-injection of NLX-101 in 
either of these regions. Such experiments could be performed under normocapnia, or 
under differing degrees of hypercapnia to gradually increase excitatory chemoreceptor 
drive to the pFRG and reduce the threshold for putative 5-HT1AR mediated disinhibition of 
late-E activity to become discernible. Effects of these manipulations can be monitored 
with electrophysiological recordings of PN and AbN respiratory activities, and with local 
field potential recordings of late-E neurones in the pFRG. To demonstrate that effects of 
NLX-101 are mediated selectively by 5-HT1AR agonism, effects of NLX-101 micro-injections 
must be reversible by co-administration of 5-HT1AR antagonist (WAY-100635). 
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An alternative experimental approach to assess the contributions of the above 
functional-anatomical regions to the network response to systemic 5-HT1AR agonist (NLX-
101) is to compare the network response to systemic NLX-101 to the network response 
to systemic NLX-101 after focal microinjections of 5-HT1AR antagonist (WAY-100635) in 
one of the above regions. The advantage of this approach compared to micro-injections 
of 5-HT1AR agonist is that contributions of 5-HT1AR transmission in specific regions can be 
evaluated against a background of systemic 5-HT1AR agonism. This adds a control for 
5-HT1A mediated changes to the wider respiratory network that likely contribute to effects 
of systemic NLX-101 as observed in the present thesis. In all micro-injection experiments, 
drugs must be co-injected with dye for post-hoc anatomical verification of injection sites.  
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Values are mean ± SEM for baseline and hypercapnic PN, cVN, and AbN activity. The dataset 
consists of pooled recordings of the pre-treatment hypercapnic response in all treatment 
groups (vehicle; NLX-101 10nM; NLX-101 100nM) (see section 3.3.2). Repeated measures t-
test indicates that hypercapnic sympathetic responses in bold red text are significantly 
different compared to baseline (p < .05). PN n=25; cVN n=13; AbN n=25  
 
Supplementary Table 1: Means for baseline and hypercapnic respiratory rhythms and patterns.  
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Values are mean ± SEM for tSN baseline and hypercapnic activity. The dataset consists of 
pooled recordings of the pre-treatment hypercapnic response in all treatment groups 
(vehicle; NLX-101 10nM; NLX-101 100nM) (see section 3.3.2). Repeated measures t-test 
indicates that hypercapnic sympathetic responses in bold red text are significantly 
different compared to baseline (p < .05). n=14  
 

















































































Values are mean ± SEM for PN baseline, and for PN greatest rhythm response to intra-arterial 
NaCN bolus administrations (25μL, 50μL, 75μL). The dataset consists of pooled recordings of 
pre-treatment NaCN bolus administrations in all treatment groups (vehicle; NLX-101 10nM; 
NLX-101 100nM) (see section 3.3.3). Two-way repeated measures ANOVA with Geisser-
Greenhouse correction and Sidak’s multiple comparisons test indicates that NaCN response 
values annotated in bold red text are significantly different compared to baseline (p < .05). 
n=22 
 
Supplementary Table 3: Means for baseline respiratory rhythms and respiratory rhythms 






































































































































Values are mean ± SEM for 
PN, AbN, and cVN baseline 
patterns, and for PN, AbN, 
and cVN greatest pattern 
response to intra-arterial 
NaCN bolus 
administrations (25μL, 
50μL, 75μL). The dataset 
consists of pooled 
recordings of pre-
treatment NaCN bolus 
administrations in all 
treatment groups (vehicle; 
NLX-101 10nM; NLX-101 
100nM) (see section 3.3.3). 
Two-way repeated 
measures ANOVA with 
Geisser-Greenhouse 
correction and Sidak’s 
multiple comparisons test 
indicates that NaCN 
response values annotated 
in bold red text are 
significantly different 
compared to baseline (p < 
.05). PN n=22; AbN n=21; 
cVN n=21 
.  
Supplementary Table 4: 
Means for baseline 
respiratory patterns and 
respiratory patterns 



















































































































Values are mean ± SEM for 
tSN baseline activity, and 
for tSN greatest response 
to intra-arterial NaCN bolus 
administrations (25μL, 
50μL, 75μL). The dataset 
consists of pooled 
recordings of pre-
treatment NaCN bolus 
administrations in all 
treatment groups (vehicle; 
NLX-101 10nM; NLX-101 
100nM) (see section 3.3.3). 
Two-way repeated 
measures ANOVA with 
Geisser-Greenhouse 
correction and Sidak’s 
multiple comparisons test 
indicates that NaCN 
response values annotated 
in bold red text are 
significantly different 
compared to baseline (p < 
.05). tSN n=22. Table is 
continued on next page 
(Supplementary Table 5B). 
 
Supplementary Table 5A: 
Means for baseline 
sympathetic activity and 
sympathetic activity elicited 
by intra-arterial NaCN bolus 
administration.  
 






























































Continuation of Supplementary Table 5A. Values are mean ± SEM for tSN baseline activity, and 
for tSN greatest response to intra-arterial NaCN bolus administrations (25μL, 50μL, 75μL). The 
dataset consists of pooled recordings of pre-treatment NaCN bolus administrations in all 
treatment groups (vehicle; NLX-101 10nM; NLX-101 100nM) (see section 3.3.3). Two-way 
repeated measures ANOVA with Geisser-Greenhouse correction and Sidak’s multiple 
comparisons test indicates that NaCN response values annotated in bold red text are 
significantly different compared to baseline (p < .05). tSN n=22. 
 
Supplementary Table 6B: Means for baseline sympathetic activity and sympathetic activity 
elicited by intra-arterial NaCN bolus administration.  
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Power analysis plots for comparison of means based on respiratory responses to 1μM NLX-101 
(n=7) vs. vehicle controls (n=5) as observed in the present thesis (see section 3.3.1). (A) The 
absolute change in PN dur. E (s) at 1μM NLX-101 vs. vehicle controls was a shortening of 
expiratory phase duration by 0.9563 s. Assuming α = .05, and variance equal to that observed 
in the present thesis, 70-92% power to detect an absolute change of 0.9563 requires sample 
sizes of 6 to 10 recordings in each treatment group. (B) The absolute change in AbN late-E rate 
(bpm) at 1μM NLX-101 vs. vehicle controls was an increase in late-E rate by 13.28 bpm. 
Assuming α = .05, and variance equal to that observed in the present thesis, 69-91% power to 
detect an absolute change of 13.28 requires sample sizes of 11 to 19 recordings in each 
treatment group. 
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